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Thesis summary – Leanne Grimes 
P2X receptors and pannexins (Panx) are eukaryotic ion channels that are implicated in a 
range of diseases and conditions including cancer, inflammation and pain sensation and 
as a result, are important therapeutic targets. Deducing their 3D-structures would 
enable the use of structure-based drug design to identify novel agonists or antagonists. 
However, solving eukaryotic membrane protein structures is a significant challenge due 
to the requirement for high yields of purified folded, functional protein, which are not 
readily obtainable with conventional over-expression systems. By using P2X receptors 
and pannexins as model ion channel targets, this thesis aims to test Drosophila 
melanogaster as a system for the over-expression and functional analysis of eukaryotic 
ion channels. A number of epitope-tagged P2X and Panx protein constructs were 
generated and first expressed in HEK-293 cells (rat P2X2-GFP, human P2X4-GFP, rat 
Panx1-GFP and human P2X4-int-CBD (chitin binding domain)) to allow their expression, 
glycosylation and oligomeric states to be investigated as markers of protein folding and 
quality. Subsequently, rat P2X2-GFP and rat Panx1-GFP constructs were successfully 
expressed in the photoreceptor cells of Drosophila melanogaster, where the 
photoreceptive membrane in the visual system is organised into a densely packed brush 
of microvilli, the rhabdomere. This system provides a large surface area of membrane 
for protein expression. Although the yields of purified protein were lower than 
expected, rat Panx1-GFP was successfully purified and used for low resolution structural 
studies with transmission electron microscopy. Rat P2X2-GFP was also expressed in the 
nervous system of Drosophila under control of a pan-neural, C155-Gal4 driver and was 
shown to be functional by measuring ATP-evoked action potentials using 
electrophysiological recordings of the Drosophila taste sensilla. This system was also 
used to test the activity of an adenosine nucleotide library of 80 compounds. Three 
nucleotides were identified that elicited responses similar to ATP; these were 2F-ATP, 
ATPαS and ATPγS. 
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Chapter 1 - Introduction 
1.1  Membrane proteins 
1.1.1  Classes of membrane proteins  
Membrane proteins are embedded within or interact with the membrane lipid bilayer and are 
responsible for mediating many interactions between the cytoplasm of the cell and the 
extracellular environment. There are two main classes of membrane proteins; integral and 
peripheral proteins. Integral membrane proteins are embedded within the lipid bilayer, and 
are only displaced from the bilayer by the action of membrane-disrupting agents such as 
detergents (see section 1.2.1). Within the class of integral membrane proteins are the sub-
classes of monotopic (partially embedded), bitopic (one transmembrane-spanning domain 
(TM) and polytopic (more than one TM) membrane proteins. Peripheral membrane proteins 
are not directly associated with the bilayer but interact with other membrane proteins (Lodish 
et al, 2000). There are many different types of membrane proteins including ion channels 
which gate the flow of ions across the membrane (Gadsby, 2009), G-protein coupled receptors 
(GPCRs) which activate intracellular signalling cascades in response to extracellular messages 
(Neer, 1995), receptor tyrosine kinases which respond to many growth factors and hormones 
(Lemmon and Schlessinger, 2010) and the Na+/K+ ATPase which pumps potassium and sodium 
ions into and out of the cell respectively by active transport (Morth et al, 2007). The variety in 
types and structures of ion channels reflects their involvement in almost all key cellular 
processes. 
1.1.2  Membrane proteins as drug targets 
Due to the importance of membrane proteins at the interface of the cell and the extracellular 
environment, they have many physiological roles in the body, impacting on a huge number of 
conditions including pain sensation (Tsuda et al, 2003), rheumatoid arthritis (Ardissone et al, 
2011), cystic fibrosis (Taylor et al, 1999) and cancer (Di Virgilio et al, 2009; Arinaminpathy et al, 
2009; Inoue et al, 2005; North and Jarvis, 2013). Therefore they are key therapeutic targets, 
representing over 60% of current drug targets (Arinaminpathy et al, 2009).  
1.1.3  The use of structure based drug design 
Many drugs have been developed against membrane proteins using high-throughput screening 
approaches, but this is expensive and time-consuming. The recent advances in membrane 
protein structure determination have opened up the possibility of using structure based drug 
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design (SBDD). 3D crystal structures of membrane proteins are vitally important for assisting 
SBDD. One of the first examples of the use of SBDD was the design of an inhibitor of the 
protease of human immunodeficiency virus type-1 (HIV-1) which was based on the 3D 
symmetry of the HIV-1 protease active site (Erickson et al, 1990). Three years later, in 1993, 
two potent inhibitors of influenza virus sialidase were designed based on its crystal structure 
(von Itzstein et al, 1993). More recently, drug discovery has vastly increased due to the 
development of docking tools and computer-aided resources that aide the rational design of 
drugs based on crystal structures (Mandal et al, 2009; Muller, 2009). The structure of AmpC β-
lactamase was used in 2001 to design inhibitors useful for targeting antibiotic resistance (Tondi 
et al, 2001). In 2012, potent, selective antagonists of the adenosine A2A receptor were 
identified using SBDD to target molecules in the orthosteric binding cavity of the crystal 
structure for the potential treatment of Parkinson’s disease (Congreve et al, 2012). 
Additionally, in 2014, the chromone antagonists of the adenosine A2A receptor were designed. 
Antagonists of A2A receptors may provide potential therapies for central nervous system 
(CNS) disorders (Andrews et al, 2014). These are just a small number of examples which 
represent the recent progress of drug discovery using SBDD. 
 
It is clear that structure determination is necessary for SBDD but for membrane proteins this 
has proven to be difficult for a number of reasons. One significant problem is that when 
integral membrane proteins are removed from the membrane they often get degraded, 
misfold or aggregate due to their instability and the formation of hydrophobic interactions. To 
overcome these problems, membrane proteins must be solubilised in detergent (see section 
1.2.1) (Carpenter et al, 2008). Additionally, conventional expression systems only enable 
membrane proteins to be expressed at low levels (see section 1.2.2) making obtaining a high 
enough yield of protein for 3D-crystallisation time-consuming and costly (Wuu and Swartz, 
2008). This explains why membrane protein structures only account for approximately 2% of 
known protein structures (RCSB Protein Data Bank, accessed 12/05/14, Protein Data Bank of 
Transmembrane Proteins, accessed 12/05/14) despite accounting for 20 - 30% of all proteins in 
an organism (Stevens and Arkin, 2000).  
1.1.4  Ion channels 
Ion channels are an important class of integral membrane proteins that form pores and allow 
the passage of large numbers of specific ions across the membrane by passive diffusion along 
their electrochemical gradient. Ion channels can be opened by various means including 
changes in voltage, binding of ligands or by post-translational modifications (Alberts et al, 
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2002). In addition their expression at the membrane can be strictly regulated. Ion channels 
play major roles in the control of electrical excitability by regulating the flow of ions across the 
membrane of cells such as epithelial and secretory cells (Jentsch et al, 2004). Additionally, 
intracellular ion channels are responsible for calcium release from intracellular stores which 
can lead to various downstream signalling cascades important in cellular processes. 
Impairment of ion channel function can have extreme consequences leading to phenotypes 
such as hypertension, cardiac arrhythmias and neurological diseases (Jentsch et al, 2004).  
 
Advancements in expression systems, crystal screening and data acquisition technology has 
led to a significant recent growth in publication of ion channel 3D-structures. Some of the 
published crystal structures include the CLC chloride channel from Salmonella typhimurium (3 
Å – Protein Data Bank (PDB) 1KPL) (Dutzler et al, 2002) and E. coli (2.51 Å – PDB 1OTS) (Dutzler 
et al, 2003), the Torpedo nicotinic acetylcholine receptor (4 Å – PDB 2BG9) (Unwin, 2005) and 
the closed and open state structures of P2X4 from the zebrafish, Danio rerio at 2.9 and 2.8 Å 
respectively from sf9 cells (Hattori and Gouaux, 2012). More recently, a number of mammalian 
ion channel structures have been solved including the rat GluN1/GluN2B heterotetrameric 
NMDA (N-methyl-d-aspartate) receptor ion channel at a resolution of 4 Å from sf9 insect cells 
(PDB – 4TLL/4TLM) (Karakas and Furukawa, 2014), and the mouse serotonin 5-HT3 receptor at 
a resolution of 3.5 Å from the human T-Rex-293 cell line (PDB – 4PIR) (Hassaine et al, 2014). 
Thus the field of ion channel structure is rapidly growing due to their huge importance as 
targets for therapeutic drugs. 
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1.2  Challenges encountered in membrane protein 
structure determination 
1.2.1  Solubilisation of membrane proteins 
The membrane bilayer phospholipids are arranged with their polar head groups exposed to 
the cytoplasm and extracellular space, while the hydrophobic lipid chains fill the inside of the 
bilayer (Bretscher 1972). Membrane proteins comprise of hydrophobic transmembrane 
regions and hydrophilic intracellular and extracellular domains (Rees et al, 1989). Their unique 
protein topology makes them particularly difficult to solubilise due to aggregation of the 
hydrophobic regions in solution, thus membrane proteins must be successfully reconstituted 
in detergent in order for solubilisation to occur when they are removed from their native 
membrane environment (Garavito and Ferguson-Miller, 2001). Detergents are amphipathic 
molecules consisting of a polar head group and a hydrophobic carbon tail which form micelles 
in solution so that only polar residues are exposed to the aqueous environment. Their 
amphipathicity makes them ideal for membrane protein solubilisation as the non-polar tails 
surround the transmembrane protein regions, with the polar head groups exposed to the 
aqueous environment, see Fig 1.1 (Seddon et al, 2004). However, finding a detergent that can 
efficiently remove the protein of interest from the membrane and retain its native structure 
can prove challenging. 
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1.2.2  Membrane protein expression systems 
The majority of membrane proteins are only expressed at low levels in their endogenous 
environment, making it essential to overexpress these proteins in other systems to gain a high 
yield of protein. For example, the serotonin transporter (SERT) was overexpressed in both 
baculovirus systems and mammalian cells where expression levels did not exceed 250,000 
copies/cell (Tate, 2001). Many of the membrane protein structures solved to date were 
successful, at least in part, due to their specialised, natural abundance in the membrane. For 
example, the structure of rhodopsin, which is naturally present at high levels in the eye 
(rhodopsin levels in mouse photoreceptor cells estimated to be approximately 8 x 107 – 1.6 x 
108 molecules per cell (Palczewski, 2006) and in Drosophila photoreceptor cells about 2 x 108 
molecules per cell (Johnson and Pak, 1986)) was solved to 2.8 Å in 2000 (Palczewski et al, 
2000). In addition, the first membrane protein structure solved was the photosynthetic 
reaction centre from Rhodopseudomonas viridis at 3Å resolution in 1985. The reaction centre 
Figure 1.1 – Detergent solubilisation of membrane protein. (Top) Membrane proteins within 
the phospholipid bilayer of the membrane. Upon incubation with a concentration of 
detergent above the critical micelle concentration (CMC), the detergent disrupts the 
membrane and the hydrophobic detergent tails surround the hydrophobic regions of the 
protein, enabling solubilisation (bottom). Excess detergent forms pure detergent micelles and 
mixed lipid micelles.  
Detergent 
Membrane 
bilayer 
Membrane proteins 
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was naturally expressed at high levels and was purple in colour due to the presence of co-
factors. The coloured nature of the protein not only assisted in purification procedures but was 
also useful in tracking protein quality; any changes in protein colour would have provided 
information on the cofactor environment of the protein and thus protein quality (Deisenhofer 
et al, 1985). 
E. coli, yeast, insect cells and mammalian cells are commonly used systems for membrane 
protein over-expression. However there is no single system available which is suitable for the 
expression of all membrane proteins; each system has a number of limitations for membrane 
protein expression. Overexpression of membrane protein can often lead to protein 
aggregation, making it difficult to produce high levels of functional, folded protein in many 
systems (Mus-Veteau, 2010).  
1.2.2.1  E. coli 
Prokaryotic hosts such as E. coli are often used for exogenous protein expression due to their 
short generation time, simplicity and low maintenance costs. However, membrane proteins 
over-expressed in E. coli can encounter problems with protein folding and membrane 
targeting. A high level of heterologous membrane protein expression in E. coli frequently leads 
to the formation of inclusion bodies, which consist of highly aggregated protein. The unfolded, 
aggregated protein cannot be used directly for structural or functional experiments without 
complex refolding techniques (Palmer and Wingfield, 2004). 
Inclusion bodies predominantly consist of recombinant protein (99%), chaperones and 
membrane fragments. An advantage to the formation of inclusion bodies is that these 
complexes can contain very high levels of membrane protein at high purity that would 
otherwise cause toxicity to the host. The aggregates can be separated from the cell using 
centrifugation and the protein is protected from proteolysis and degradation. High 
concentrations of a denaturing agent (e.g. urea) can be used to recover the recombinant 
protein and theoretically, specialised refolding methods can be used to refold the protein to 
make functional, folded protein for structural studies (Mus-Veteau et al, 2010). There are a 
small number of cases where mammalian membrane protein structures have been solved by 
over-expression in E. coli such as the integral membrane protein fatty acid amide hydrolase at 
a resolution of 2.8 Å (PDB – 1MT5) (Bracey et al, 2002) and human 5-lipooxygenase-activating 
protein with 2 leukotriene biosynthesis inhibitors at 4.0 and 4.2 Å resolution respectively (PDB 
– 2Q7M and 2Q7R) (Ferguson et al, 2007). However there has been no success with 
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determination of eukaryotic membrane protein structures refolded from inclusion bodies to 
date. 
1.2.2.2  Yeast 
Yeast (e.g. Saccharomyces cerevisiae, Pichia pastoris) is a eukaryotic host used for the 
exogenous expression of membrane proteins. An advantage of using yeast as an expression 
system is the capacity to implement many of the post-translational modifications native to 
eukaryotic membrane proteins, such as glycosylation. Furthermore, large volumes of yeast can 
be grown in a short period of time and is relatively cheap to culture. However, unlike 
mammalian membranes, yeast membranes contain ergosterol instead of cholesterol; this may 
have an effect on the correct trafficking and stability of membrane proteins (Baumann et al, 
2011). Proteolytic degradation is also a common problem faced with yeast protein expression 
(Macauley-Patrick et al, 2005). Very few (3 – 4) mammalian membrane protein structures have 
been solved using the S. cerevisae expression system. Expression in P. pastoris has been 
slightly more successful with approximately 18-20 structures solved (Membrane Proteins of 
Known 3D Structure database, accessed 22/06/14). Some of the structures solved using yeast 
overexpression include human liver monoamine oxidase B (3 Å in P. pastoris) (Binda et al, 
2002) and human liver monoamine oxidase B with bound Isatin (1.7 Å in P. pastoris) (Binda et 
al, 2003), rat monoamine oxidase A (3.2 Å in S. cerevisiae) (Ma et al, 2004), and the human 
AQP2 aquaporin kidney channel at 2.75Å (Frick et al, 2014).  
1.2.2.3  Insect cells 
Insect cells are widely used for eukaryotic protein expression due to their improved ability to 
express eukaryotic proteins, this is partially attributable to their similar codon usage to 
mammalian proteins, when compared with bacteria or yeast (Bernaudat et al, 2011). Insect 
cells are also cheaper, easier to maintain, culture and amplify compared with mammalian cells 
making them a rational choice for protein over-expression. However, insect cell membranes 
possess a lower level of cholesterol than mammalian cells which may interfere with the correct 
expression and localisation of mammalian membrane proteins. Additionally, they are capable 
of the post-translational modification of proteins; this is particularly important when studying 
membrane proteins. However, the modifications which take place in insect cells do not directly 
replicate what occurs in mammalian cells, for example complex glycosylation is rarely noted in 
insects (Bernaudat et al, 2011). Nevertheless, this can be considered to be advantageous for 
crystallisation due to the improved homogeneity of protein samples which lack complex glycan 
chains (see Section 1.2.3). Insect cells are commonly used for membrane protein expression as 
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they offer more comparable protein-processing machinery and membrane composition to 
mammalian cells than yeast or E. coli whilst they are much cheaper to culture and easier to 
maintain than mammalian cells (Mus-veteau, 2010). Fall armyworm, Spodoptera frugiperda, 
insect cells have been used for the expression and structure determination of approximately 
60 membrane proteins including GPCRs and ion channels (Membrane Protein of Known 3D 
Structure databank, accessed 22/06/14). Some examples of structures solved following 
expression in sf insect cell lines include an AMPA-(α-amino-3-hydroxy-5-methyl-4-
isoxasolepropionic acid) subtype glutamate receptor, rat GluA2 that was solved to a resolution 
of 3.6 Å (PDB – 3KG2) (Sobolevsky et al, 2009), connexin 26 gap junction channel that was 
solved at a resolution of 3.5 Å (PDB – 2ZW3) (Maeda et al, 2009) and zfP2X4.1 receptors in the 
apo, closed and ATP bound states at 2.9 and 2.8 Å respectively (PDB 4DW0 and 4DW1) (Hattori 
and Gouaux, 2012). 
1.2.2.4  Mammalian cells 
Although mammalian cells provide the most native environment for mammalian proteins, they 
also have many limitations in terms of their cost to maintain and low yield of protein 
production. To obtain enough protein for crystallisation and structural studies is very 
expensive and requires a large amount of labour-intensive work. Additionally, mammalian cells 
tend to produce a very heterogeneous population of protein. Heterogeneity of proteins can 
cause problems during crystallisation as a result of disorder and quality of crystals. Additionally 
the presence of certain glycan chains may hinder the formation of favourable crystal contacts 
(Grueninger-Leitch, 1996; Mus-veteau, 2010).  There are some recent examples of membrane 
protein structures that have been solved using mammalian expression systems, for example, 
human ammonia transporter, Rh C glycoprotein (RhCG) was expressed and purified from HEK-
293S GnTI- cells (GnTI- HEK-293 cell lines lack GnTI and thus cannot perform complex 
glycosylation) and the structure was solved at a resolution of 2.1 Å (Gruswitz et al, 2010). The 
Xenopus laevis GLuN1-GluN2B NMDA receptor was also expressed and purified from GnTI- 
HEK-293S cells; the structure was solved at a resolution of 3.7 Å (Lee et al, 2014). The crystal 
structure of a human β3 GABAA receptor was solved at a resolution of 3 Å, following 
expression and purification from GnTI- HEK-293S cells (Miller and Aricescu, 2014). The recent 
progression in the use of GnTI- cells for structure determination demonstrates the importance 
of obtaining homogeneous protein populations for crystallisation.  
Due to the limitations of many of the currently available protein expression systems described 
above, a new membrane protein expression system that overcomes some of these problems 
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and enables the production of a high yield of homogeneous, quality protein would be very 
useful. 
1.2.3  Post translational modifications 
Post-translational modifications are extremely important for the correct expression and 
function of many proteins. In eukaryotes these modifications include the addition of methyl 
groups (methylation), phosphate groups (phosphorylation), ubiquitin groups (ubiquitination) 
and sugar groups (glycosylation). In summary, the addition of a methyl group to a protein from 
S-adenosylmethionine can be either reversible or irreversible and results in the formation of 
protein-protein interactions that may be important for processes such as protein repair, 
transport, differentiation and transcriptional regulation (Clarke, 1993; Willemsem et al, 2006). 
Ubiquitination is important for protein degradation thereby regulating protein turnover; the 
addition of a ubiquitin group to a protein causes the protein to be moved to the proteasome 
where it will be degraded (Lecker et al, 2006). Protein phosphorylation is the most widespread 
post-translational modification and is responsible for activating and deactivating proteins via 
protein kinases and phosphatases for phosphorylation and dephosphorylation respectively 
(Cielsa et al, 2011). Phosphorylation is important for many basic cell processes including cell 
division, cell growth, membrane transport and metabolism (Cielsa et al, 2011). Post-
translational modifications are less extensive but still present in prokaryotes. There is some 
evidence for the existence of N-glycosylation and O-glycosylation in bacteria (Abu-Qarn et al, 
2008). Additionally protein acetylation has been shown to happen in both gram-negative and 
gram-positive bacteria (Hayden et al, 2013). Although ubiquitination has not been established 
in prokaryotes, they have simpler versions of proteasome targeting systems that contain 
similar proteins labelled ‘ubiquitin-like proteins’ (Burroughs et al, 2012).  
Protein glycosylation, the addition of sugar molecules to synthesised proteins, is an important 
post-translational modification that occurs ubiquitously in eukaryotes, predominantly to 
secreted and membrane-targeted proteins (Devasahayam, 2007). The added glycan structures 
can have essential roles in protein folding and targeting as well as in quality control (ensuring 
misfolded or aggregated proteins are targeted for degradation) (Moremen et al, 2012). N-
linked glycosylation involves the attachment of an oligosaccharide to a nitrogen atom of an 
asparagine or arginine amino acid side chain. Dolichol phosphate acts as a membrane anchor 
for the formation of Glc3Man9GlcNAc2 before the glycan is transferred to a developing amino 
acid chain in the ER (Burda and Aebi, 1999). N-linked oligosaccharides are often quite large 
with extensive chains (with a minimum of 5 sugar residues) and always contain mannose 
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residues, an N-acetylglucosamine residue as well as other sugar residues. O-linked 
glycosylation involves the addition of sugar residues to the hydroxyl group of hydroxylysine via 
galactose or a serine or threonine residue via N-acetylgalactosamine. O-linked saccharides 
tend to be short consisting of only one to four sugar residues (Freeman, 2000). 
The majority of membrane proteins and secreted proteins are translated and processed in the 
endoplasmic reticulum (ER) and many of them are consequently N-linked glycoproteins. 
Problems are encountered during membrane protein structure determination due to the large 
number of N-linked glycans. The glycan chains take form in a variety of conformations, 
chemical structures and can be mobile; therefore in conventional expression systems, 
glycosylated membrane proteins are often very heterogeneous making X-ray crystallography 
particularly difficult as a result of disorder and quality of crystals (Grueninger-Leitch, 1996; 
Mus-veteau, 2010). As a result of this, the majority of protein structures obtained using x-ray 
crystallography have their glycosylation sites removed using site directed mutagenesis or are 
treated with deglycosylases (Nagae and Yamaguchi, 2012). 
1.2.4  N-linked glycosylation in vertebrates 
In vertebrates, the sequence of events that occur during glycosylation is highly complex 
leading to a mixture of high mannose, hybrid and complex N-glycosylated proteins (Fig 1.2). 
High mannose glycoproteins have 3 or more mannose residues attached to the chitobiose core 
which consists of 2 N-acetylglucosamine (GlcNAc2) molecules. Complex glycoproteins have a 
mixture of other glycans such as fucose and galactose attached to the initial 3 mannose 
residues in the chain and have no terminal mannose residues, whereas hybrid glycoproteins 
are complex glycoproteins with one or more terminal mannose residues (Fig 1.2) (Freeman, 
2000). In eukaryotes, the transfer of an assembled Glc3Man9GlcNAc2 saccharide to the 
asparagine residue of an Asn-X-Ser, Asn-X-Cys or Asn-X-Thr motif to initiate glycosylation is 
relatively well conserved (Katoh and Tiemeyer, 2012; Burda and Aebi, 1999). 
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Animal systems contain approximately 200 glycosyltransferases, the enzymes involved in 
extending the glycan chain; local enzyme availability is equally as important as the abundance 
and localisation of glycoprotein substrates and sugar donors during glycosylation (Moreman et 
al, 2012). 
The first step of N-linked glycosylation is the transfer of a Glc3Man9GlcNAc2 glycan to the 
emerging amino acid chain in the ER. Subsequently 2 of the Glc residues are removed resulting 
in a GlcMan9GlcNAc2 structure, which acts as a substrate for the lectin chaperones, calnexin 
and calreticulin (Helenius and Aebi, 2004). Calnexin and calreticulin are linked to another 
protein, ERp57, which together protect developing polypeptide chains from hydrophobic 
aggregation and misfolding (Lederkremer, 2009). Correctly folded proteins that pass quality 
control dissociate from the lectins and the final Glc is cleaved, they are sent for export to the 
Golgi apparatus where further glycan processing may take place (Fig 1.3) (Moremen et al, 
Figure 1.2 – Glycosylation. Representations of the core oligosaccharide (Glc3Man9GlcNAc2) 
and high mannose, hybrid and complex glycosylated proteins. See key for individual symbols. 
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2012). In the Golgi, several trimming steps occur by α-mannosidase I to generate an 
intermediate (Man5GlcNAc2). At this stage, the high mannose-type glycoprotein can be 
converted to a hybrid type glycoprotein via the action of N-acetylglucosaminyl transferase I 
(GnTI). Hybrid glycans can then be remodeled further by a number of enzymes to form 
complex N-glycans. These processes that occur in the Golgi can vary in nature and can result in 
the addition of large numbers of sugar residues to the protein which add significant mass. In 
addition, these processes can result in the formation of a very heterogeneous protein 
population causing great problems for crystallization as described above (Nagae and 
Yamaguchi, 2012). Ideally these processes should be avoided in order to help achieve protein 
crystallization. 
In vertebrate differentiated cells, very few glycoproteins at the high mannose stage can 
successfully reach the cell surface and require further modification in the Golgi apparatus. This 
is in contrast to what occurs in stem cells where cell surface glycoproteins appeared to consist 
mostly of the high mannose type (An et al, 2012). 
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1.2.5  Glycosylation in insect cells 
The process of glycosylation in insects is markedly different from that in vertebrates. There is 
some evidence to suggest that mannose containing O-glycans are present in insect species 
although only one has been described, the dystroglycan protein in D. melanogaster (Ichimiya 
et al, 2004). It is well established that the majority of glycoproteins synthesised are 
paucimannosidic or oligomannosidic N-linked glycan structures (Rendic et al, 2008) whereas 
complex and hybrid N-linked glycoproteins are uncommon in insects. This was initially 
accredited to the fact that either no or very low levels of appropriate glycosyltransferase 
activity needed for the production of complex glycans were present. However, more recently a 
β-N-acetylglucosaminidase enzyme (fused lobes) involved in removing the terminal GlcNAc 
structure from a polypeptide chain was identified. Removal of the GlcNAc residue thereby 
blocks further elongation of the chain, suggesting that the production of hybrid and complex 
glycoproteins in insects is impeded (Rendic et al, 2008). Despite the activity of fused lobes, 
Figure 1.3 – N-glycsoylation and quality control of proteins. Schematic showing the post-
translational events that occur in the cell to form mature functional, folded proteins. 
Reprinted by permission from Macmillan Publishers Ltd: [Nature] (Moremen et al), 
copyright (2012). 
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there is evidence of primary production of a complex glycoprotein on the bee venom 
phospholipase A, which contains 2 fucose residues linked to the proximal GlcNAc residue. In 
addition, it contains an additional GlcNAc residue linked to a fucose residue and a GalNAc 
residue (Fig 1.4) (Rendic et al, 2008). This was the first indication of the initial phases of 
complex-type glcyosylation occuring in insects. 
 
 
 
 
 
 
Therefore, although insect cells are commonly used as expression systems for mammalian 
proteins due to their ability to perform eukaryotic post-translational modifications, the specific 
modifications that take place may differ considerably from the modifications that occur in 
native systems. However these differences can be advantageous in terms of membrane 
protein structure determination. When a mammalian protein is expressed in an insect system, 
the protein can still be glycosylated which is important for protein function and quality control. 
However the nature of the glycosylation that will occur in an insect system will be different to 
that occurring in mammalian cells as they will be less likely to contain long, heterogeneous 
complex sugar chains (Rendic et al, 2008). This is beneficial as expressing proteins in insect 
systems will reduce the large degree of protein heterogeneity acquired with other systems and 
this will have less of an impact on crystal formation. For this reason, a novel insect expression 
system would be particularly valuable for eukaryotic membrane protein studies and 
biologically relevant ion channels. 
1.3  Purinergic receptors 
1.3.1  Purinergic signalling – summary 
Purinergic signalling may be defined as cell-signalling activity induced by the action of 
adenosine and purine nucleotides such as adenosine diphosphate (ADP) and adenosine 
triphosphate (ATP). Three families of purinergic receptors have been identified in mammals, 
Figure 1.4 – Complex glycosylation-like moiety observed in insects. Lewis-like structure 
observed on phospholipase A represents the initial stages of complex glycosylation, indicating 
that insects have some of the enzymes required to perform complex glycosylation. 
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the adenosine P1 receptors (GPCRs), P2Y receptors (GPCRs) and P2X receptors (ligand gated 
ion channels -LGICs) (Burnstock 2006). P1 adenosine receptors are activated by adenosine, P2X 
receptors by ATP and P2Y receptors by ADP, ATP and a variety of other nucleotide-based 
ligands (Table 1.1). ATP is released by gentle mechanical stress such as an increase in fluid flow 
(Bodin and Burnstock, 2001; Jensen et al, 2007), at synapses, and at sites of cell damage, injury 
and inflammation where it activates P2X and P2Y receptors. Subsequently the ATP is broken 
down by a family of ectonucleotidase enzymes to form ADP, adenosine monophosphate (AMP) 
and adenosine, which can in turn act on P2Y and adenosine receptors accordingly (see Table 
1.1 for summary) (Zimmermann, 2000). Each receptor family now has a representative crystal 
structure(s), which has been instrumental in the interpretation of structure-function data, but, 
at least in the case of P2X receptors, not without its limitations. 
1.3.2  Brief history of purinergic signalling 
ATP was first postulated to act as a neurotransmitter in 1953 (Holton, 1953) and in 1954 it was 
shown that ATP injection caused a similar effect on vasodilatation of the rabbit ear artery as 
that induced by antidromic stimulation of the nerves supplying it. This led to the hypothesis 
that stimulation of nerves causes release of ATP, resulting in vasodilatation of the ear (Holton 
and Holton, 1954). Further work in 1959 demonstrated that ATP does indeed act as a 
neurotransmitter where Holton showed that ATP is released upon stimulation of the great 
auricular nerve (Holton, 1959). 
In the early 1960s, a novel component of the autonomic nervous system was acknowledged 
that was both nonadrenergic and noncholinergic (Eccles, 1964). This component was later 
termed ‘purinergic’ by Burnstock who suggested that ATP was the substance released from 
these nerves (Burnstock et al, 1970). In 1978, two types of purinergic receptors (termed P1 
and P2) activated by adenosine and ADP/ATP respectively were distinguished according to a 
number of criteria: (i) the agonist potency of adenosine, AMP, ADP and ATP; (ii) antagonist 
action e.g. methylxanthines which inhibit adenosine actions; (iii) changes in intracellular cAMP 
levels in response to adenosine and (iv) the induction of prostaglandin synthesis by ATP 
(Burnstock and Kennedy, 1985). This P1/P2 classification of receptors is now well-established 
and is widely used.  
P2 receptors were further reclassified into two distinct subtypes – the P2X and the P2Y 
receptors. Burnstock and Kennedy discriminated between the two classes by their differential 
response profiles to a range of ATP analogs and antagonists (Burnstock and Kennedy, 1985). 
P2X and P2Y receptors can also be discriminated by their transduction mechanisms. P2X 
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receptors form a cation selective ion channel permeable to Na+, Ca2+ and K+ (Benham and 
Tsien, 1987) whereas P2Y receptors are G-protein coupled receptors (Abbrachio and 
Burnstock, 1994). The first P2X receptor was subsequently cloned from the rat vas deferens 
and characterised in mammalian cells and Xenopus oocytes where it was shown to be a cation-
selective ion channel with high calcium permeability (Valera et al, 1994).  
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Receptor Receptor type Ligand(s) No. 
mammalian 
subtypes 
Crystal structure 
P1 G-protein 
coupled 
receptor 
Adenosine 4 Human A2A receptor bound 
to ZM241385 – PDB 3EML 
(Jaakola et al, 2008) and 
adenosine – PDB 2YDO 
(Lebon et al, 2011) 
P2Y G-protein 
coupled 
receptor 
ADP 
ATP 
UDP 
UDP-glucose 
UTP 
8 P2Y12 in complex with 
2MeSADP – PDB 4PXZ 
P2Y12 in complex with 
2MeSATP – PDB 4PY0 
(Zhang et al, 2014) 
P2X Ligand gated 
ion channel 
ATP 7 zfP2X4.1 closed state – PDB 
4DW0 
zfP2X4.1 open state – PDB 
4DW1 (Hattori and Gouaux, 
2012) 
1.3.3  P2X receptors - Expression and topology 
P2X receptors are a family of ligand-gated ion channels that open when ATP binds to the 
extracellular domain resulting in the non-selective influx of cations including sodium and 
calcium. This ion flow plays a key part in many signalling pathways due to changes in 
membrane potential and local ion concentrations (Khakh and North, 2006; Young MT, 2009).  
P2X receptors have been identified in a large range of species from the slime mold, 
Dictyostelium discoideum, to more complex organisms such as the rat, Rattus norvegicus and 
humans, Homo sapiens. However they are absent from the genomes of insects such as the 
fruit fly, Drosophila melanogaster and the nematode, Caenorhabditis elegans (North, 2002; 
Fountain and Burnstock, 2009). Seven subtypes have been identified in mammals that vary 
considerably in length; P2X4 is the shortest (388 amino acids) and P2X7 the longest, with a 
long intracellular C-terminal domain (approximately 240 amino acids in length; total protein 
length 595 amino acids) (Khakh and North, 2006). Each P2X subunit consists of 2 
Table 1.1 – Summary of purinergic receptor types and associated ligands (Khakh and 
North, 2006). 
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transmembrane, hydrophobic α-helical domains, intracellular N and C termini and a large 
extracellular domain (Fig 1.5) (Khakh and North, 2006).   
 
 
 
 
 
Functional P2X channels are formed from 3 subunits, which move relative to one-another 
upon ATP binding, resulting in the opening of a lateral portal just above the transmembrane 
domains and cation influx through the transmembrane domains (see Section 1.3.8) (Hattori 
and Gouaux, 2012). Channels can be either homomeric (made up of 1 subtype) or heteromeric 
(made up of 2 subtypes) depending on the particular subtype/s involved. In addition, a 
heteromeric receptor made up of 3 subtypes (P2X2/4/6) has also been suggested to form 
according to co-immunoprecipiation and atomic force microscopy (AFM) imaging experiments 
in tsa-201 cells (Antonio et al, 2014). 
P2X6 cannot form homomeric channels but can form functional heteromeric channels with 
P2X2 or P2X4 (Barrera et al, 2005; Barrera et al, 2007). The remaining subtypes (with the 
exception of human P2X5 – hP2X5) are able to form functional homomeric channels at the cell 
surface. The full-length hP2X5 protein is able to traffic to the cell surface; however the 
majority of hP2X5 contains a deletion of exon 10 (Δ328 – 349) and lacks part of the TM2 and 
pre-TM2 domains (Le et al, 1997; Duckwitz et al, 2006). As a result the majority of the protein 
appeared to be retained in the ER (Bo et al, 2003; Kotnis et al, 2010). Conversely, more 
recently, a functional role has been identified for this hP2X5 splice variant. Abramowski and 
TM1 TM2 
Extracellular 
Intracellular 
C-terminus 
N-terminus 
Extracellular 
domain 
S1 S2 
S3 
P2X2 P2X3 
P2X3 
Figure 1.5 – Schematic representations of a P2X receptor. (A) Schematic showing topology of a 
single P2X subunit with intracellular N- and C- termini, 2 transmembrane domains (TM1 and 
TM2) and large extracellular domain. (B) Schematic showing the clustering of 3 subunits to 
form a functional channel in the membrane (S=subunit) where ATP would bind at the 
intersubunit interface. (C) Schematic showing an example of a heterotrimer, in this case a 
P2X2/3 heteromer made up of two P2X3 (green) subunits and one P2X2 (red) subunit. TM = 
transmembrane domain. S = subunit. 
A B C 
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colleagues showed that hP2X5 gene expression in human T lymphocytes was upregulated and 
receptors were trafficked to the cell membrane during activation of CD4+ T cells. In addition, in 
hP2X5 knockdown cells, there was a two-fold higher production of IL-10 indicating that the 
hP2X5 variant might play a role in T-cell activation and thus immunoregulation (Abramowski et 
al, 2014). 
1.3.4  P2X receptors – N-linked glycosylation 
All P2X receptors studied so far undergo N-linked glycosylation, however the number of 
glycosylation sites varies between subtypes. Each P2X monomer contains a minimum of 2 N-
glycosylation consensus sequences (Asn, X, Ser/Thr, where X denotes any amino acid except 
proline), all of which are relatively well conserved across species (North, 2002). The number of 
glycosylation sites in the various subtypes can be referred to in Table 1.2.  
 
 
P2X 
Subtype 
No. of consensus 
sequences 
Effects of mutagenesis of glycan sites 
1 5 Increases/decreases in channel function. Reduction in 
ATP potency. Abolition of channel function upon 
mutation of 3 sites (Rettinger et al, 2000b). 
2 3 Effects on channel function and trafficking to the 
surface (Newbolt et al, 1998). 
3 4 Effects on channel function, trimer formation and 
trafficking to the membrane (Vacca et al, 2011). 
4 6 Abolition of P2X4 resistance to degradation in 
lysosomes. Effects on cell surface trafficking (Qureshi 
et al, 2007). 
5 2 Not studied 
6 3 Not studied 
7 5 Effects on channel function, pore formation and cell 
surface trafficking (Lenertz et al, 2010). 
 
Four of the five glycosylation sites in rat P2X1 (rP2X1) undergo glycosylation when expressed in 
Xenopus oocytes. However, only one of these sites (N300) acquires complex glycosylation. 
Table 1.2 – Summary table showing the number of glycosylation sites in each P2X receptor 
subtype and the effects caused by mutagenesis of these sites. 
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Removal of the N210 site using site-directed-mutagenesis significantly altered channel 
function. Electrophysiological recordings demonstrated that mutation at this site resulted in 
increased channel currents, but a threefold decrease in potency for ATP. In contrast, 
elimination of N153 resulted in a 30% decrease in the current response to ATP. If more than 2 
of the glycan sites were eliminated, rP2X1 channel formation was severely affected or 
completely abolished. Therefore rP2X1 glycosylation is implicated in both channel function and 
trafficking (Rettinger et al, 2000b).  
N-linked glycosylation has been well studied in rat P2X2 (rP2X2), which contains 3 consensus 
sequences (N182S, N239S, and N298S). Mutagenesis studies show that all three of these sites 
undergo glycosylation in the wild type receptor (Newbolt et al, 1998). Additionally, 
glycosylation of 2 sites gave a fully functional channel that was successfully trafficked to the 
cell membrane. However upon removal of 2 of the sites by mutagenesis or tunicamycin 
treatment, which inhibits GlcNAc phosphotransferase (GPT) (Doroghazi, et al, 2011), very low 
levels of protein reached the membrane and currents in response to ATP were almost 
undetectable. Removal of all three consensus sites resulted in a non-functional channel (Torres 
et al, 1998; Newbolt et al, 1998). In addition, cysteine substitution of residues Arg304, Leu306, 
Lys308 and Ile312 in the N-terminal half of the pre-TM2 led to channels with a loss of function 
due to the loss of complex glycosylation at Asn298. This work suggested that the glycosylation 
site at Asn298 has an important role in sensing receptor conformational changes in this pre-
TM2 region, which was shown to be important for the correct conformation of the receptor at 
the extracellular face of the membrane (Young et al, 2008). 
A minimum of 2 successfully glycosylated consensus sites was shown to be required for cell-
surface trafficking of P2X1, P2X3 and P2X7 subtypes (Kaczmarek-Hajek et al, 2012). The N170 
glycosylation site in P2X3, located close to the ATP binding site, is the most well conserved, 
this may be due to its critical role in receptor function (Vacca et al, 2011). Mutation of this 
P2X3 consensus site resulted in a loss of P2X3 cell surface expression, an inability to form 
trimeric complexes and a loss of inward currents detected in response to ATP in HEK-293 cells 
(Vacca et al, 2011).   
Experiments with chick P2X4 (cP2X4) demonstrated that only the glycosylated form of cP2X4 
was detectable at the cell surface (Hu et al, 2002). Furthermore, Endoglycosidase-H (Endo-H) 
digestion experiments showed that rP2X4 underwent complex glycosylation, with partial 
resistance to Endo-H digestion. Removing the N-glycans from the 6 glycosylation sites by 
incubation with DMJ (an inhibitor of Golgi α-mannosidase I) followed by Endo H did not affect 
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protein trafficking to lysosomes. However the receptors were rapidly degraded in the 
lysosomes, suggesting that glycosylation of P2X4 plays an important role in receptor resistance 
to degradation (Qureshi et al, 2007). Additionally Valente and colleagues published work 
showing that each of the 6 glycosylation sites in hP2X4 underwent N-linked glycosylation in 
HEK cells, where abolition of any one site had no effect on channel function (Valente et al, 
2011).  
P2X5 receptors contain 3 N-glycosylation sites in the extracellular domain, 2 of which undergo 
complex glycosylation and 1 that undergoes high mannose glycosylation (Duckwitz et al, 2006). 
P2X6 receptors are unable to form functional homomeric receptors at the cell surface. 
However data by Jones and colleagues showed that there was an increased level of 
glycosylation of P2X6 in functional HEK-293 cells expressing P2X6 receptors compared to non-
functional cells suggesting that the glycosylation state of the protein is essential in the 
production of functional P2X6 channels (Jones et al, 2004). 
Human P2X7 contains 5 N-linked glycosylation consensus sequences and Lenertz and 
colleagues showed that the wild type receptor is glycosylated at all 5 sites (N187, N202, N213, 
N241 and N284) using site directed mutagenesis; when each site was mutated to alanine, a 
reduction in molecular weight was observed using sodium dodecyl sulphate (SDS)-PAGE. 
Mutation of N187 had a significant effect on downstream channel function, cell surface 
expression and pore formation. Furthermore this glycan site is conserved across six of the 
seven P2X subtypes, suggesting that it is vitally important to P2X channel function (Lenertz et 
al, 2010).  
These results highlight the importance of glycosylation for P2X receptor trafficking which in 
turn is necessary for protein function. However, whether or not glycosylation itself is necessary 
for P2X protein function has not been determined, thus those channels that reach the 
membrane may be fully functional. 
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1.3.5  P2X receptors - Trafficking 
P2X receptors undergo core N-linked glycosylation in the endoplasmic reticulum, where they 
assemble into trimeric complexes (see below). Subsequently they are transported to the Golgi 
complex for further modification and packaging before transportation to the cell membrane. 
Depending on the P2X subtype, the receptors may be internalised and returned to the cell 
surface via endosomes or may be targeted for degradation in lysosomes (Robinson and 
Murrell-Lagnado, 2013). A non-canonical, conserved YXXXK trafficking motif present in the C-
terminus of all P2X receptor subtypes was shown to be responsible for the regulation of cell 
surface expression. Mutation of this motif resulted in a decrease of cell surface expression of 
all P2X subtypes; furthermore it increased internalisation of P2X2 receptors (Chaumont et al, 
2004).  
The only P2X subtype that is fully retained within the ER and unable to form functional 
homomeric channels is P2X6 (Ormand et al, 2006). However, P2X6 was shown to be able to 
form functional heterotrimers with P2X2 or P2X4 (Bobanovik et al, 2002). The heteromeric 
receptor complexes were successfully trafficked to the cell surface and their localisation 
resembled that of homomeric P2X2 or P2X4 receptors respectively (Robinson and Murrell-
Lagnado, 2013). The transportation of P2X6 to the cell surface from the ER only in assembly 
with other subunits indicates that the assembly of trimeric complexes takes place in the ER. 
P2X2 channels often appear to be localised mostly within intracellular compartments in 
heterologous expression systems, due to the slow progression of P2X2 through the secretory 
pathway (Bobanovik et al, 2002). However upon reaching the cell membrane, P2X2 is stably 
expressed at the surface. P2X7 shows a similar expression pattern to P2X2, experiencing slow 
but stable accumulation of expression at the cell surface. However the trafficking of P2X7 
receptors is cell-type specific and localisation can vary from being largely within the cell 
(monocytes and lymphocytes) to being largely at the plasma membrane (macrophages) (Gu et 
al, 2000; Gudipaty et al, 2001). 
P2X4 is principally located in intracellular organelles, in a distinct punctate pattern surrounding 
endosomes and lysosomes. A small level of expression can also be seen at the periphery of the 
cell (Fig 1.6) (Bobanovik et al, 2002). Upon further investigation, it was found that the majority 
of P2X4 protein co-localised with the early endosomal marker, EEA-1, suggesting it is recycled 
to and from the cell surface. Localisation to the membrane is largely influenced by the 
extracellular concentration of ATP; an increase in extracellular ATP caused increased 
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internalisation of P2X4 receptors. This is in contrast to P2X2, which did not undergo any 
changes in protein internalisation upon ATP application (Bobonavik et al, 2002).  
 
 
 
 
 
 
 
 
 
 
 
 
Co-expression of a dominant negative form of dynamin-1 (K44A), which is responsible for the 
inhibition of dynamin-dependent endocytosis, resulted in a P2X4 distribution similar to that of 
P2X2 i.e. a uniform distribution at the cell surface. These results imply that P2X4 
internalisation is a dynamin-1 dependent mechanism (Bobanovik et al, 2002). Furthermore, 
two endocytic motifs were identified in the P2X4 C-terminus. The first is a non-canonical 
tyrosine based sorting C-terminal YXXGL motif (where X is any amino acid). Mutation of this 
motif resulted in a dramatic increase in P2X4 expression at the cell membrane due to a 
decrease in both constitutive and agonist-induced internalisation. The YXXGL motif is 
conserved across all mammalian P2X4 receptors, however it is not present in the C-terminus of 
any other P2X subtype (Royle et al, 2002). The second C-terminal motif is the canonical YXXØ 
(where X is any amino acid and Ø is an amino acid with a bulky hydrophobic side chain) motif, 
but this motif appears to be less accessible to AP2, the clathrin adaptor complex responsible 
for receptor inclusion into clathrin-coated vesicles. Hence internalisation is predominantly 
mediated by the YXXGL motif (Royle et al, 2005). Lysosomal targeting of P2X4 is further 
determined by a dileucine motif located in the N-terminus (Quereshi et al, 2007). 
Figure 1.6 – P2X2 and P2X4 localisation in HEK-293 cells. (A,C) Expression of P2X4 and P2X4-
GFP in HEK-293 cells. Confocal images show that the majority P2X4 clusters are intracellular. 
(B,D) Expression of P2X2 and P2X2-GFP in HEK-293 cells. P2X2 is localised predominantly at 
the cell membrane. Cells expressing untagged P2X2 and P2X4 were visualised using Anti 
P2X2/Cy3 or Anti P2X4/Cy5 respectively (Figure reused with permission, Bobanovik et al, 
2002). GFP tagging of protein had little or no effect on protein localisation. Scale bar: 10 µM. 
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P2X3 also undergoes constitutive internalisation and re-insertion into the membrane and 
contains a C-terminal dileucine motif with a DSGØXS (where X is any amino acid and Ø is an 
amino acid with a bulky hydrophobic side chain) ubiquitination consensus sequence, which has 
been suggested to be partly responsible for its internalisation and degradation. However, it 
does not share any of the described trafficking motifs associated with P2X4 (Vacca et al¸ 2009).  
The trafficking pathways of each of the P2X subtypes is summarised in Fig 1.7.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3.6  P2X receptors - Expression, distribution and roles in health 
and disease 
ATP plays a definitive role in excitatory transmission at synapses within many areas of the CNS 
via activation of P2X receptors (Holton, 1959). P2X receptors are largely involved with 
neuropathic pain; this can be partially attributed to their abundant expression in neurons and 
glial cells of the nervous system (North, 2002; Rubio and Soto, 2001). Specifically P2X2, P2X4 
and P2X6 are the most widely expressed in neurons. P2X2 and P2X4 were identified at the 
Figure 1.7 – Summary of the trafficking pathways of P2X receptors. P2X1 is internalised and 
stored in endosomes and recycled to the cell surface. P2X2 and P2X7 are stably expressed at 
the cell membrane and are not recycled. P2X3 can be internalised by endosomes and is sent 
to lysosomes for degradation. P2X4 is rapidly internalised by endosomes and lysosomes, but 
resists degradation and is recycled to the cell surface. The majority of P2X5 and P2X6 
receptors are retained in the endoplasmic reticulum and do not form functional homomers. 
However P2X6 can form various heteromers with other subtypes. These heteromers will 
acquire the trafficking properties of the second subtype. 
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edge of the postsynaptic membrane of excitatory synapses of the brain, indicating that ATP 
release into synapses during stints of action potential firing may activate the receptors (Rubio 
and Soto, 2001).  
Further evidence has also implicated P2X receptors with a function at the presynaptic 
membrane as well as the postsynaptic membrane. For example, P2X receptors are expressed 
on the presynaptic membrane of dorsal root ganglion (DRG) neurons. Upon activation at these 
synapses, action potentials were evoked that resulted in glutamate release and downstream 
signalling, which may lead to pain sensation (Gu and MacDermott, 1997).  
1.3.6.1  P2X receptors in pain  
P2X2 homomers and P2X2/P2X3 heteromers are critical mediators of pain sensation. Both 
P2X2-/- and P2X2/P2X3 (dbl-/-) mice experienced a reduction in pain-response behaviour 
following formalin injection, an established method for assessing nociception in mice 
(Cockayne et al, 2005; Hunskaar and Hole, 1987). P2X4 receptors are also largely implicated in 
nociception. Wild type mice experienced tactile allodynia following peripheral nerve damage. 
Upon reducing P2X4 protein expression levels by intraspinal administration of P2X4 antisense 
oligodeoxynucleotide, the tactile allodynia response was reversed (Tsuda et al, 2003). This 
data highlighted the importance of P2X receptors in pain sensation, and their therapeutic 
potential for anti-analgesic drugs. 
1.3.6.2   P2X receptors in blood pressure 
Vigorous exercise or changes in environmental conditions can influence changes in blood flow 
through the body (Hudlicka et al, 1992). These changes in conditions are sensed by endothelial 
cells, which in turn respond by releasing vasodilators such as nitric oxide (NO) (Davies et al, 
1995). P2X4 is expressed on these endothelial cells and has a significant role in the dilation of 
blood vessels. Endothelial cells of P2X4 (-/-) mice did not experience calcium influx or 
subsequent NO release in response to changes in blood flow, contrary to wild type mice. 
Consequently, vessel dilation was substantially reduced in response to increases in blood flow 
and this caused an increase in blood pressure. This data suggested that P2X4 plays a significant 
role in the mechanisms involved in regulating blood pressure and vascular remodelling 
(Yamamoto et al, 2006). 
1.3.6.3  P2X receptors in inflammation 
P2X7 receptors are largely involved in the inflammatory response. P2X7 activation is 
implicated in the release of the pro-inflammatory cytokine, interleukin - 1β (IL-1β). Le Feuvre 
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and colleagues demonstrated that prolonged ATP and lipopolysaccharide (LPS) stimulation of 
macrophages isolated from wild type mice led to IL-1β release. However cells obtained from 
P2X7 (-/-) mice (Pfizer) did not release IL-1β (Le Feuvre et al, 2002). The inflammatory 
response of wild-type and P2X7 (-/-) mice was investigated in response to the induction of 
monoclonal anti-collagen-induced arthritis. Wild type mice suffered from severely inflamed 
and swollen paws, collagen degradation products and lesions on joint cartilage following 
lipopolysaccharide stimulation. However P2X7 deficient mice showed a much lower level of 
response with the disease severity markedly reduced (Labasi et al, 2002). This data implicated 
P2X7 receptors as important mediators of pain and inflammation, serving them as possible 
targets for anti-inflammatory drugs and anti-arthritic drugs.  
P2X2, P2X3 and P2X4 channels are also important mediators of inflammation. Inflammation 
was induced in rats via hindpore injection with Freund’s adjuvant (CFA). ATP responses in DRG 
neurons isolated from the rats were examined. CFA-induced inflammation caused an increase 
in ATP-activated currents and an increase in expression of P2X2 and P2X3 receptors. As a result 
of the increased ATP responses, large depolarisations were elicited and action potentials were 
fired in DRG neurons. The increase in P2X receptor expression following inflammatory injuries 
may account for the high levels of pain responses experienced (Xu and Huang, 2002). P2X4 
inhibition was shown to affect the development of arthritis in a collagen-induced arthritis (CIA) 
mouse model. Inhibition of P2X4 using P2X4 antisense oligonucleotide reduced the clinical 
score of CIA of mice, inhibited joint inflammation and suppressed inflammasome activation (Li 
et al, 2014). 
1.3.6.4  P2X receptors in taste sensation 
In 2005, ATP was identified as the key neurotransmitter involved in the transduction of 
information from taste receptor cells to taste nerves (Finger et al, 2005). Furthermore P2X2 
and P2X3 are expressed in taste nerves and were recognised as the receptors involved in the 
taste transmission pathway. P2X2/P2X3 (dbl-/-) mice showed abolition of any taste evoked 
neural responses following chemical stimulation in the taste nerves of the oral cavity. However 
responses to touch, temperature and menthol were unaffected. In a further experiment it was 
shown that P2X-knockout mice also have reduced behavioural responses to specific taste 
substances including sweeteners and bitter compounds using bottle preference tests. Single 
knockouts of either P2X2 or P2X3 in mice resulted in a slight decrease in taste behavioural 
responses, but these changes were moderate in comparison to those experienced by double 
knockout mice (Finger et al, 2005). More recently, it was shown that in P2X2/P2X3 (-/-) mice, 
27 
 
stimulation by tastants still mobilises calcium ions in taste receptor cells but their taste cells do 
not release ATP when stimulated (Huang et al, 2011). 
1.3.6.5  P2X receptors in cancer 
P2X receptors have been associated with a variety of cancer types, which is unsurprising 
considering their importance in many biological processes. P2X receptors are not only 
expressed in excitable cells such as neurons and smooth muscle, but have also been identified 
in tissues such as the lungs, skin, kidneys and endothelium (White and Burnstock, 2006). Upon 
prolonged application of a high concentration of ATP to P2X7 receptors, a large pore is formed, 
possibly via interactions with other proteins such as Pannexin (Panx) 1, which allows the 
passage of both cations and small molecules up to 900 daltons (Ralevic and Burnstock, 1998). 
Opening of P2X7 and this large pore leads to intracellular potassium efflux which is associated 
with activation of the inflammasome and caspase 1. However the mechanisms underlying 
these processes are not fully understood. Potassium efflux is dependent upon pore formation 
and IL-1β processing is dependent upon this potassium efflux (Wewers and Sarkar, 2009). 
Caspase 1 cleaves pro-IL-1β to form mature IL-1β which is subsequently released from the cell. 
IL-1β activates immune cells and contributes to the induction of cell apoptosis (Fig 1.8) 
(Pelegrin and Surprenant, 2007). Targeting mediators of apoptosis is a keen area of research 
for the development of new cancer therapies. Furthermore, P2X7 receptors are expressed and 
functional in many different cancer types including human melanoma cancers and non-
melanoma skin cancers (White et al, 2005; Greig et al, 2003). Incubation of malignant 
melanoma cells with a highly potent  and partially selective P2X7 agonist, BzATP, led to a 
reduction in cell number whereas antagonism of P2X7 activation using KN-62 (1-N,O-bis-[5-
isoquinoline-sulfonyl]-N-methyl-L-tyrosyl)-4-phenyl-piperazine) caused a reverse in this cell 
reduction (White et al, 2005). This data indicates that P2X7 may be a key anti-cancer 
therapeutic target. 
P2X5 is expressed in a variety of tissues such as the skin, bladder and skeletal muscle, and has 
roles in cell differentiation and the inhibition of cell proliferation making them attractive 
targets for anti-cancer drugs. Additionally P2X5 receptors have been identified in skin 
carcinomas and prostate cancers. Application of ATP and ATPγS (P2X5 agonists) to these 
carcinogenic cells caused a decrease in cell number (Greig et al, 2003). 
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1.3.6.6  P2X receptors in platelet aggregation 
Platelets express 3 P2 subtypes – P2Y1, P2Y12 and P2X1. Experiments have been done both in 
vivo and in vitro to study the role of P2X1 receptors in platelet function. In vitro, selective 
activation of P2X1Rs led to a fast, reversible change in platelet shape, temporary centralisation 
of secretory granules and low level activation of αIIbβ3 integrin that led to weak platelet 
aggregation (Rolf et al, 2001; Toth-Zsamboki et al, 2003; Erhardt et al, 2003). Additionally in a 
mouse model with acute vascular occlusion where mice were injected with adrenaline and 
collagen, P2X1 (-/-) mice displayed a lower level of thrombus formation compared to wild type 
mice. The loss of P2X1 caused a 50% reduction in the number of mice deaths as a result of 
blocked pulmonary circulation (Hechler et al, 2003; Mahaut-Smith et al, 2011). The calcium 
influx via P2X1 receptors was shown to amplify the P2Y1-evoked calcium response in platelets 
whereby activation of P2X1 alone did not cause significant platelet aggregation but co-
Figure 1.8 – Implications of P2X receptors in the cell cycle and apoptotic pathways. P2X5 is 
involved in regulation of the cell cycle, affecting the proliferative ability of cancer cells upon 
application of P2X5 agonists (Greig et al, 2005). Upon P2X7 activation, potassium ions are 
exported from the cell; the decrease in intracellular potassium concentration induces 
activation of the inflammasome and IL-1β release, thereby mediating apoptosis. Panx1 
channels, speculated to form the large pore associated with P2X7, releases ATP which acts as 
a ‘find-me’ signal for apoptotic machinery. At high concentrations this ATP can reactivate 
P2X7 in a feed-forward mechanism (Pelegrin and Surprenant, 2007; Wewers and Sakar, 2009). 
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stimulation of both P2X1 and P2Y1 increased the aggregation response (Jones et al, 2014). 
P2X1 is promising as a potential new drug target to reduce thrombotic events in diseases such 
as atherosclerosis.  
1.3.6.7  P2X receptors in hearing loss 
P2X2 receptors are expressed in the sensory and supporting cells of the cochlea. A P2X2 
mutation (V60L) was identified in inherited, progressive sensorineural hearing loss in families 
studied over six generations. The mutation was associated with fully penetrant hearing loss in 
two families and was absent from controls. The V60L mutation was shown to abolish the P2X2 
ATP-evoked inward current response and ATP stimulated macropore permeability. In addition, 
P2X2-null mice acquired severe progressive hearing loss (Yan et al, 2013). 
1.3.6.8  P2X receptors in mood disorders 
A number of single nucleotide polymorphisms (SNPs) have been identified in P2X7 receptors 
that have been associated with affective mood disorders. For example, a strong association 
was observed in families with bipolar disorder and the SNP E13A (P value = 0.000708) (Barden 
et al, 2006). P2X7 SNPs have also been associated with other mood disorders such as major 
depressive disorder and anxiety disorder (Lucae et al, 2006; Hejjas et al, 2009; Erhardt et al, 
2007). In a study by Roger and colleagues, twelve P2X7 SNPs that have been linked with mood 
disorders were tested for function in HEK-293 cells. Eleven of the mutations had a significant 
effect on channel function and pore formation. Using a P2X7 structural model (based on the 
zfP2X4.1 crystal structure), it was suggested that the functional effects of the SNPs are caused 
by changes in agonist binding, channel gating and subunit interactions (Roger et al, 2010). In 
addition, more recently, it was shown that the changes in protein function of P2X7 are 
associated with changes in protein expression levels (Ursu et al, 2014). 
1.3.6.9  P2X receptors in CNS diseases 
Recent evidence has implicated P2X7 receptors in CNS diseases such as stroke, epilepsy, 
Alzhiemer’s disease and Parkinson’s disease. Genetic deletion or antagonism of P2X7 receptors 
led to changes in the responsiveness of animal models of neurological diseases. For example, 
in animal models with induced epileptic like seizures, BzATP was shown to prolong the activity 
of brain neurons caused by seizures whereas P2X7 antagonists were shown to have 
neuroprotective effects (Jimenez-Pacheco et al, 2013). The β-amyloid peptide (Aβ) present at 
high concentrations in the plaques found in the brains of Alzheimer’s patients, was shown to 
generate a rise in intracellular calcium, ATP release and interleukin-1 β release in wild-type but 
not P2X7(-/-) mice indicating that Aβ initiates a purinergic activation loop involving P2X7 
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receptors. In addition, inhibition of P2X7 in mice expressing mutant human amyloid precursor 
protein resulted in a decrease in the number of plaques (Sanz et al, 2009; Diaz-Hernandez et 
al, 2012). 
1.3.6.10  P2X receptors in male fertility 
P2X1 receptors are expressed in the vas deferens smooth muscle cells where they play a role 
in the contractile response of the vas deferens to nerve stimulation. This response is essential 
for propelling sperm into the ejaculate and is largely mediated by P2X receptors. It has been 
shown that a P2X1 mutation with a targeted deletion causes a reduction in fertility in male 
mice by 90% due to a reduction in sperm in the ejaculate, whereas female mice were 
unaffected. Responses to P2XR agonists were abolished in these mice and contraction of the 
vas deferens in response to nerve stimulation was dramatically reduced. Due to the role of 
P2X1 receptors in male infertility, selective antagonists may provide potential therapies in the 
development of a male contraceptive pill (Mulryan et al, 2000). In addition, more recently a 
study by White et al showed that α1A- adrenoceptor and P2X1 double knockout mice 
experienced 100% infertility without affecting sexual behaviour or function (White et al, 2013).  
1.3.6.11  P2X receptors in health and disease: Summary 
With critical roles in many conditions including pain sensation, blood pressure, cancer, 
rheumatoid arthritis, mood disorders, male fertility and atherosclerosis, finding selective 
agonists and antagonists for P2X receptors will be greatly beneficial for future drug 
development against a range of conditions. However, as many of the receptors are implicated 
in more than one disorder, problems may arise when using the receptors as drug targets. For 
example, development of a selective P2X7 agonist as a therapeutic agent against cancer may 
have implications for inflammation in patients. Similarly, using a selective P2X7 antagonist to 
target inflammation for a condition such as rheumatoid arthritis may cause affect the patients’ 
mood causing anxiety or depression. P2X4 was shown to be implicated in blood pressure and a 
selective agonist may be useful for reducing blood pressure. However, like P2X7, P2X4 agonists 
may cause problems with both pain and inflammation in patients. P2X2/3 receptors have been 
shown to be involved in pain sensation and antagonists may act as anti-analgesics; however 
they may also affect the patients’ tastant responses and hearing. P2X1 receptors were shown 
to be involved in platelet aggregation and antagonists were thus suggested to be used to 
reduce thrombotic effects. However they may have an effect on the fertility of the male 
patients. These results show that although P2X receptors are key drug targets, there are many 
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factors that need to be considered for agonists or antagonists to be used as therapeutic 
agents. 
1.3.7  P2X receptors - agonists and antagonists 
1.3.7.1  Agonists 
Although all P2X receptors are activated by ATP, their sensitivity to ATP and the kinetics of the 
current passing through the channel varies considerably for each subtype. The order of 
channel sensitivity to ATP is: P2X1R = P2X3R < P2X2R < P2X4R = P2X5R < P2X6R << P2X7R 
(Zemkova et al, 2004). 
P2X1 and P2X3 undergo rapid desensitisation following application of 30 µM ATP (Fig 1.8), 
while P2X2 and P2X4 desensitise at a much slower rate. P2X5 does not desensitise (Ralevic and 
Burnstock, 1998). P2X7 requires a higher concentration of ATP for activation compared with 
other subtypes, experiencing full activation at 1mM ATP (North, 2002). Fig 1.9 illustrates the 
differing responses elicited by each homomeric receptor.  
 
 
 
 
 
 
 
 
 
 
 
 
As well as exhibiting differing responses to ATP, the subtypes display variable sensitivities to a 
number of other compounds. Many P2X subtypes are activated by ATP analogues; however 
the exact activation profile is subtype-specific.   
Figure 1.9 – Comparison of fast (top) and slow (bottom) desensitisation of homomeric rat 
P2X receptors transfected in HEK-293 cells, in response to 30 µM ATP (1mM for P2X7).  Fast 
desensitisation is observed for P2X1 and P2X3 in response to a 2 second application of ATP. 
Slow desensitisation is observed for P2X2 and P2X4 in response to a 60 second application of 
ATP. P2X7 transfected cells experienced a 2 minute pre-application of ATP before the recorded 
application shown (Image: North, 2002). 
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P2X1, P2X3 and P2X5 subtypes are activated by the synthetic ATP analogue, αβ-methylene ATP 
(αβ-meATP). Their sensitivity to low micromolar concentrations of αβ-meATP distinguishes 
P2X1, P2X3 and P2X5 from the remaining homomeric receptors that are activated by 
significantly higher concentrations of αβ-meATP (Waldron and Sawynok, 2004, North, 2002). 
αβ-meATP and ATP are equally potent at human P2X1, with an EC50 in HEK-293 cells of 0.8- 1 
µM (Evans et al, 1995).  
2'(3')-O-(4-Benzoylbenzoyl)adenosine-5'-triphosphate (BzATP) is an ATP analogue with the 
addition of a benzoyl-benzoyl group to either the 2’- or 3’-position of the ribose moiety. BzATP 
acts as an agonist at all P2X subtypes with the exception of P2X3 and is highly potent at human 
P2X1 and P2X2 receptors (EC50 – 1-2 µM and 6 µM respectively) (Evans et al, 1995; Lynch et al, 
1999). However it is much less effective at rat P2X1 and P2X2 receptors (EC50 - 24 µM and 23 
µM respectively) (Wildman et al, 1999; Kew and Davies, 2010). BzATP is also active at human 
P2X4 (EC50 – 9.4 µM) and at human and rat P2X5 (EC50 – 1.3 µM and 5.7 µM respectively). 
Importantly, P2X7 is considerably more sensitive to BzATP (EC50 - 7 µM) than ATP (EC50 - 
2.62mM) (Surprenant et al, 1996). 
Adenosine 5'-O-(3 thiotriphosphate) (ATPγS) contains a sulphide group attached to the gamma 
phosphate group of ATP and is active at P2X1, P2X2, P2X3 and P2X5 receptors with variable 
potency (EC50 ranging from 0.29 µM [rP2X5] to 8 µM [rP2X2]) (Wildman et al, 2002; Evans et 
al, 1995; Lynch et al, 1999; Liu et al, 2001).  
βƳ-methylene-ATP (βγmeATP) is an ATP derivative with a methyl group substitution for the 
oxygen between the β and ϒ phosphate groups. This compound is relatively insensitive at 
P2X2, P2X3 and P2X4 receptors. However it displays a relatively high potency at P2X1 (EC50 - 2 - 
8.7 µM) and P2X5 (EC50 - 11.8 µM) (Evans et al, 1995; Wildman et al, 2002; Liu et al, 2000; 
Garcia-Guzman, 1997; Chen et al, 1995; Coddou et al, 2011).  
2-Methylthioadenosine triphosphate (2MeSATP) contains a methylthio group attached to the 
adenosine ring of ATP. 2MeSATP is a full agonist of P2X1 and P2X2 (EC50 = 0.1 - 8 µM 
respectively) expressed in Xenopus oocytes (Evans et al, 1995; Lynch et al, 1999; Wildman et 
al, 2002). Additionally it activates P2X3, P2X4, P2X5 and P2X7 (EC50 – 0.3 µM, 10-100 µM, 0.44 
µM and 200 µM respectively) (Garcia Guzman, 1997; Liu et al, 2001; Coddou et al, 2011; 
Wildman et al, 2002; Surprenant et al, 1996). 
A summary of agonist activity of the compounds mentioned above and other agonists at all 
P2X subtypes can be referred to in Table 1.3. 
33 
 
 
 
Compound P2X1 P2X2 P2X3 P2X4 P2X5 P2X7 
ATP 0.8 µM (human) (Evans et 
al, 1995) 0.1 -0.3 µM (rat) 
(Wildman et al, 1999) 
8 µM (rat) (Grubb and 
Evans, 1999) 
0.8 µM (human) (Garcia-
Guzman, 1997) 1.2 µM 
(rat) (Chen et al, 1995) 
10 µM (rat) (Buell et al, 
1996) 5.5 µM (human) 
(Jones et al, 2000) 
0.44 µM (rat) (Wildman 
et al, 2002) 4 µM 
(human) (Bo et al, 
2003) 
2.62 mM (mouse), 
3.89 mM (rat), 4.13 
mM (human) 
(Surprenant, 1996) 
αβ-methylene ATP 1 µM (human) (Evans et 
al, 1995), 3 µM (rat) 
(Wildman et al, 2002) 
Inactive (rat) (Liu et al, 
2001) 
2.5 µM (human) (Garcia-
Guzman, 1997) 1 -2 µM 
(rat) (Lewis et al, 1995) 
Inactive (human) 
Norenberg and Illes, 
2000) Acts as an 
antagonist IC50 – 4.6 
(rat) (Jones et al, 2000) 
1.1 µM (rat) (Wildman 
et al, 2002) 12.2 µM 
(human) (Kotnis et al, 
2010) 
- 
BzATP 1-2 µM (human) [Evans et 
al, 1995, 24 µM (rat) 
(Wildman et al, 1999)  
6 µM (human) (Lynch et 
al, 1999) 23 µM (rat) 
(Kew and Davies, 2010) 
Not determined (Coddou 
et al, 2011) 
9.4 µM (human) (Stokes 
et al, 2011) 
1.3 µM (rat) (Wildman 
et al, 2002) 5.7 µM 
(human) (Bo et al, 
2003) 
7 µM (rat) 
(Surprenant et al, 
1996),  
ATPƳS 1 µM (human) (Evans et 
al, 1995) 0.6 µM (rat) 
(Wildman et al, 2002) 
6 µM (human) (Lynch et 
al, 1999) 8 µM (rat) (Liu 
et al, 2001) 
1.5 µM (rat) Liu et al, 
2001 
- 0.29 µM (rat) (Wildman 
et al, 2002)  
- 
βƳ-methylene-ATP 2 µM (human) (Evans et 
al, 1995) 8.7 µM (rat) 
Wildman et al, 2002) 
>300 µM (rat) (Liu et al, 
2000) 
> 100 µM (human) 
(Garcia-Guzman, 1997) 
>300 µM (rat) (Chen et 
al, 1995) 
> 300 µM (rat and 
human) (Coddou et al, 
2011) 
11.8 µM (rat) (Wildman 
et al, 2002) 
- 
2-meSATP 0.8 µM (human) (Evans et 
al, 1995), 0.1 µM (rat) 
(Wildman et al, 2002) 
1 µM (human) (Lynch et 
al, 1999) 8 µM (rat) 
(Grubb and Evans, 1999) 
0.3 µM (human) (Garcia-
Guzman, 1997) 0.3 µM 
(rat) (Liu et al, 2001)  
10 – 100 µM (Coddou et 
al, 2011) 
0.44 µM (rat) (Wildman 
et al, 2002) 
200 µM (rat) 
(Surprenant et al, 
1996) 
Other agonists Ap3A, Ap4A, Ap5A, Ap6A 
(rat) – >100, 0.04, 0.9, 
0.72  µM respectively 
(Wildman et al, 1999) 
Ap4A - 15 µM (rat) (Pintor 
et al, 1996)) 
Ap3A, Ap4A, Ap5A, Ap6A 
(rat) – 1, 0.8, 1.3, 1.6  µM 
respectively (Wildman et 
al, 1999) 
Ap4A, Ap6A (rat) – 3, 
>100 µM respectively 
(Wildman et al, 1999) 
ADP – 3.6 µM (rat), UTP 
– 8.2 µM (rat), Ap3A, 
Ap4A, Ap5A, Ap6A – 5, 
0.3, 0.69, 5 µM 
respectively (Wildman 
et al, 2002) 
- 
Table 1.3 – P2X receptor agonists. Values given represent approximate EC50 values for compound at each subtype. 
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1.3.7.2  Antagonists 
Pyridoxal-phosphate-6-azophenyl-2',4'-disulfonic acid (PPADS) and suramin are non-selective 
P2 receptor antagonists (Lambrecht et al, 1992). PPADS is relatively potent at P2X1, P2X2, 
P2X3 and P2X5 with an IC50 in the low micromolar range. It is also effective at blocking P2X7 
with a slightly higher IC50 of 45-60 µM. However PPADS has no effect on P2X4 receptors. 
Similarly suramin is highly potent at P2X1-3 and P2X5 and is inactive at P2X4. Suramin exhibits 
a variable potency at the different mammalian P2X7 receptors (IC50 at rat P2X7 = 285 µM, IC50 
at human P2X7 = 52 µM); these differences are likely to be caused by small variations in 
channel structure. The insensitivity of P2X4 to PPADS and suramin distinguishes P2X4 from the 
rest of the P2XR subtypes (Wildman et al, 2002; Evans et al, 1995; Lynch et al, 1999; Lewis et 
al, 1995; Buell et al, 1996; Bo et al, 2003; Surprenant et al, 1996) 
8,8 - carbonylbis imino- 4,1-phenylenecarbonylimino-4,1-phenylenecarbonylimino.bis 1,3,5-
naphthalenetrisulfonic acid (NF279), a suramin-related compound, is a potent antagonist at 
P2X1 receptors (IC50 – 19-50 nM). It is also active at P2X2, P2X3 and P2X7 receptors, but is 
inactive at P2X4 receptors (Damer et al, 1998; Rettinger et al, 2000a]; Klapperstuck et al, 
2000). Brilliant Blue-G (BBG) shows potent antagonist effects at P2X7 (IC50 – 10 – 200nM) and 
also blocks P2X4 and P2X5 receptors. However it is less effective at the other P2X subtypes 
(Jiang et al, 2000a). 2'(3')-O-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate (TNP-ATP) is a 
potent antagonist at all P2X subtypes (IC50 at P2X1 – 1-6 nM, IC50 at P2X7 - 30 µM). (Virginio et 
al, 1998; Wildman et al, 2002). These antagonists and other P2X antagonists can be referred to 
in more detail in table 1.4.  
Despite the many non-selective P2 antagonists described here, there are still relatively few 
selective antagonists available for specific P2X subtypes, including P2X4 and P2X2, which are 
key drug targets in pain and inflammation. N-(benzyloxycarbonyl)phenoxazine (PSB-12054) is a 
recently developed selective hP2X4 antagonist. PSB-12054 (IC50 – 0.189 µM) was identified 
following a screen of N-substituted phenoxazine and acridone derivates in hP2X4 stably 
transfected 1321N1 astrocytoma cells. However, although PSB-12054 significantly reduced 
P2X4 channel activation, it did not completely block the response. Additionally, more potent 
compounds are still required for use as therapeutic agents against P2X4 (Hernandez-Olmos et 
al, 2012).  
A series of anthraquinone derivatives were screened in Xenopus oocytes expressing rP2X2 in a 
search for selective P2X2 antagonists. Two potent P2X2 antagonists were identified. Sodium 1-
amino-4-[3-(4,6-dichloro[1,3,5]triazine-2-ylamino)phenylamino]-9,10-dioxo-9,10-
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dihydroanthracene-2-sulfonate (PSB-10211) displayed an IC50 of 86nM. Disodium 1-amino-4-
[3-(4,6-dichloro[1,3,5]triazine-2-ylamino)-4-sulfophenylamino]-9,10-dioxo-9,10-
dihydroanthracene-2-sulfonate (PSB-1011) displayed an IC50 of 79nM. However the latter was 
only 5-fold more selective at P2X2 compared with P2X1 and P2X3 (Baqi et al, 2011). The search 
for potent and selective P2X2 and P2X4 antagonists is still ongoing. 
4,4’,4”,4”’-(carbonylbis(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakis-benzene-1,3-
disulfonic acid (NF449) is a suramin analogue which is a highly potent antagonist at P2X1 
receptors (IC50 – 0.05nM) with significant selectivity of human P2X1 over human P2X7, rP2X2, 
rP2X3 or rP2X4 receptors (IC50 – 40 µM, 47 µM, 1.82 µM and >300 µM respectively) (Braun et 
al, 2001; Hulsmann et al, 2003; Rettinger et al, 2005). 
A number of selective P2X7 antagonists have been identified. Nelson and colleagues tested a 
series of disubstituted tetrazole compounds for P2X7 antagonist activity and identified 3-((5-
(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methyl pyridine (A-438079) as a reversible and 
competitive blocker at rat and human P2X7 receptors (IC50 of 100 and 300 nM respectively). 
Additionally it appeared to have little activity at other P2 receptor types (Nelson et al, 2006). 
N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-
dimethoxyohenyl)acetamide (A-740003) is also a cyanoguinidine compound shown to have 
highly specific antagonistic activity at  rat and human P2X7 receptors (IC50 of 18 and 40 nM 
respectively) (Honore et al, 2006). 
A-317491 is a potent antagonist of P2X3 and P2X2/3 receptors (IC50 – 22 – 92 nM) and was 
shown to be highly selective over other P2 receptors. However A-317419 is not selective of 
P2X3 over P2X2/3 receptors (Jarvis et al, 2004). Similarly, Spinorphin, an endogenous 
antinociceptive peptide (LVVYPWT), which is a potent P2X3 antagonist (IC50 – 8.3 pM), does not 
distinguish between the two receptor complexes (Jung et al, 2007). More recently reports of a 
selective and potent P2X3 antagonist, RO-85, have been published (rat P2X3 IC50 = 31 – 32 nM, 
human P2X3 IC50 =0.4 µM) which is selective for P2X3 homozygous receptors over other P2X 
receptors tested (IC50 > 10 µM) (Brotherton-Pleiss et al, 2010). 
The chemical structures of a selection of P2X antagonists are shown in Fig 1.10 for reference 
and show the diversity between the structures.  
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Figure 1.10 – Chemical structures of P2X antagonists. Non-selective P2X antagonists – 
TNP-ATP, Suramin, PPADS, BBG. P2X2/3 antagonist - A-317491. P2X7 selective antagonist – 
A-438079. P2X2 selective antagonists – PSB-10211, PSB-1011. P2X4 selective antagonist – 
PSB-12054. 
TNP-ATP Suramin PPADS
BBG A-317491 A-438079
PSB-10211 PSB-1011 PSB-12054
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Compound P2X1 P2X2 P2X3 P2X4 P2X5 P2X7 
PPADS 0.12 µM (Rat) 
(Wildman et al, 2002) 
1-6 µM (human and rat) (Evans 
et al, 1995, Lynch et al, 1999) 
0.2 - 1.5 µM (rat) (Lewis 
et al, 1995, Liu et al, 
2001) 
Insensitive (Buell et al, 
1996) 
0.2 µM (rat and 
human) (Wildman et 
al, 2002; Bo et al, 
2003) 
45 - 60 µM (rat) 
(Surprenant et al, 1996) 
Suramin 1.7 µM (Rat) (Wildman 
et al, 2002) 
1-5 µM (human and rat) (Evans 
et al, 1995; Lynch et al, 1999) 
3 -4 µM (rat) (Lewis et 
al, 1995, Liu et al, 2001) 
Insensitive (Buell et al, 
1996) 
1.5 µM (rat) (Wildman 
et al, 2002) 2.9 µM 
(human) Bo et al, 
2003) 
70 µM (human) (Chessel 
et al, 1998)  
NF279 (Suramin 
analogue) 
50 nm (human) 
(Klapperstuck et al, 
2000) 19 nm (with pre-
incubation) (rat) 
(Rettinger et al, 2000a) 
0.76 µM (rat) (Rettinger et al, 
2000a) 
1.62 µM (with pre-
incubation) (rat) 
(Rettinger et al, 2000a) 
Insensitive (Rettinger et 
al, 2000a) 
- 4.8 µM  (mouse),2.8 µM 
(human) (Klapperstuck 
et al, 2000) <4 µM (rat) 
(Donnelly-Roberts et al, 
2009) 
BBG - - - >10 µM (rat), 3.2 µM 
(human) (Jiang et al, 
2000a) 
0.53 µM (human) (Bo 
et al, 2003) 
10 nm (rat), 200nm 
(human) (Jiang et al, 
2000a) 
TNP-ATP 1 nM (Rat) (Wildman et 
al, 2002b) 6 nM 
(human) (Virginio et al, 
1998) 
1-2 µM (rat) (Virginio et al, 
1998, Liu et al, 2001) 
0.9 µM (rat) (Virginio et 
al, 1998) 
15 µM (rat/human) 
(Virginio et al, 1998) 
0.45 µM (Rat) 
(Wildman et al, 2002) 
>30 µM (rat) (Virginio et 
al, 1998) 
RB-2 2.3 µM (Rat) (Wildman 
et al, 2002) 
0.4 µM (rat) (Liu et al, 2001) - - 18.3 µM (Rat) 
(Wildman et al, 2002) 
- 
IP5I 0.003 µM (Rat) ( King 
et al, 1999) 
Insensitive (King et al, 1999) 2.8 µM (rat) (King et al, 
1999) 
0.002 µM (rat) (King et 
al, 1999) 
>30 µM (Rat) 
(Wildman et al, 2002) 
- 
Other 
antagonists 
NF449 (0.05 nM) 
(human) (Hulsmann et 
al, 2003), IP4I (0.56 
µM) (rat) (King et al, 
1999) NF023 (0.24 µM, 
0.21 µM) (rat, human) 
(Soto et al, 1999) 
NF770, NF776, NF778 (19 nM, 
97 nM, 1.4 µM respectively) 
(rat) (Wolf et al, 2011) 
PSB1011, PSB10211 (79 nM, 
86 nm respectively) (rat) (Baqi 
et al, 2011) 
A-317491 (20 nM) 
(Jarvis et al, 2002) IP4I 
(1 µM) (King et al, 
1999) RO-85 (6.4-7.5 
nM) (Brotherton-Pleiss 
et al, 2010) 
Spindorphin (8.3 pM) 
(Jung et al, 2006) 
PSB-12054 (0.189 µM) 
(Hernandex-Olmos et al, 
2012) 5-BDBD (0.5 µM) 
(Donnelly-Roberts et al, 
2008) IP4I (1.69 µM) 
(King et al, 1999) 
- KN-62 (12.7 
nM)(Gargett and Wiley, 
1997), o-ATP (Di Virgilio, 
2003), AZ11645373 
(90nM) (human) (Stokes 
et al, 2006) A-438079 
(100nM and 300nM at 
rat and human) (Nelson 
et al, 2006) A-740003 
(18-40nM at rat and 
human) (Honore et al, 
2006) 
Table 1.4 – P2X receptor antagonists. Values given represent approximate IC50 values for compound at each subtype. 
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1.3.8  P2X receptors – Structure 
The first crystal structure of a P2X receptor was solved in 2009 by Kawate et al at a 
resolution of 3.1 Å. This structure represented the closed state of zfP2X4.1. Additionally, 
in 2012, the ATP bound structure was solved at a resolution of 2.8 Å and the apo, closed 
structure was corrected and solved to a resolution of 2.9 Å (Hattori and Gouaux, 2012). 
zfP2X4.1 shares significant sequence similarity with mammalian P2X receptors. It is most 
similar to hP2X4 with 59% sequence identity and least similar to hP2X6 with 40% 
sequence identity (Fig 1.11; sequence alignment). 
1.3.8.1  Zebrafish P2X receptors  
Nine P2X receptor genes have been identified in the zebrafish, Danio rerio, 6 of which 
are orthologs of mammalian P2X subtypes – zfP2X1, zfP2X2, zfP2X3.1, zfP2X4.1, zfP2X5 
and zfP2X7. Two of the other identified receptors correspond to zfP2X3.1 and zfP2X4.1 
paralogs (zfP2X3.2 and zfP2X4.2 respectively), the final receptor has not been classified 
(Kucenas et al, 2003). zfP2X4.1 displays significant sequence similarity to the 
mammalian P2X4 receptors, with an amino acid identity of 59% with rat P2X4 (rP2X4) 
and 58% with human P2X4 (hP2X4) (Figure 1.11). Additionally zfP2X4.1 is able to form 
functional homomeric channels, with properties comparable to the respective 
mammalian orthologs (Diaz-Hernandez et al, 2002).  
When expressed in HEK-293 cells, zfP2X4.1 channels display a similar 
electrophysiological and pharmacological profile to rP2X4 (North, 2002), exhibiting a 
slow, incomplete desensitisation in response to ATP, and little or no response to the ATP 
derivatives 2'(3')-O-(4-Benzoylbenzoyl) adenosine-5'-triphosphate (BzATP) and α,β-
Methylene adenosine 5′-triphosphate (αβmeATP). Additionally, zfP2X4.1 is not inhibited 
by the non-selective P2X antagonists, pyridoxalphosphate-6-azophenyl-2',4'-disulfonic 
acid (PPADS) and suramin, which are also ineffective at mammalian P2X4 receptors 
(Diaz-Hernandez et al, 2002; Buell et al, 1996). However, ATP is significantly less potent 
at zfP2X4.1 (EC50 = 275 – 800 µM [4, 22]) compared with the equivalent mammalian 
channels (rP2X4 EC50 = 10 µM (Buell et al, 1996; Khakh et al, 2001a); hP2X4 EC50 = 5.5 
µM (Jones et al, 2000)). 
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zfP2X4.1    ----------MSESVGCCDSVSQCFFDYYTSKILIIRSKKVGTLNRFTQALVIAYVIGYV 50 
hP2X4 (58)  -------------MAGCCAALAAFLFEYDTPRIVLIRSRKVGLMNRAVQLLILAYVIGWV 47 
rP2X4 (59)  -------------MAGCCSVLGSFLFEYDTPRIVLIRSRKVGLMNRAVQLLILAYVIGWV 47 
hP2X1 (43)  ------------MARRFQEELAAFLFEYDTPRMVLVRNKKVGVIFRLIQLVVLVYVIGWV 48 
hP2X2 (44)  MAAAQPKYPAGATARRLARGCWSALWDYETPKVIVVRNRRLGVLYRAVQLLILLYFVWYV 60 
rP2X2 (45)  ------------MVRRLARGCWSAFWDYETPKVIVVRNRRLGFVHRMVQLLILLYFVWYV 48 
hP2X3 (45)  ------------------MNCISDFFTYETTKSVVVKSWTIGIINRVVQLLIISYFVGWV 42 
hP2X5 (49)  ------------MGQAGCKGLCLSLFDYKTEKYVIAKNKKVGLLYRLLQASILAYLVVWV 48 
hP2X7 (44)  -------------MPACCS--CSDVFQYETNKVTRIQSMNYGTIKWFFHVIIFSYV-CFA 44 
                                    .: * * :    :.   * :    :  :: *.  :. 
 
 
zfP2X4      CVYNKGYQDTDTV-LSSVSTKVKGIALTN-------TSELGERIWDVADYIIPPQEDGSF 102 
hP2X4       FVWEKGYQETDSV-VSSVTTKVKGVAVTN-------TSKLGFRIWDVADYVIPAQEENSL 99 
rP2X4       FVWEKGYQETDSV-VSSVTTKAKGVAVTN-------TSQLGFRIWDVADYVIPAQEENSL 99 
hP2X1       FLYEKGYQTSSGL-ISSVSVKLKGLAVTQ-------LPGLGPQVWDVADYVFPAQGDNSF 100 
hP2X2       FIVQKSYQESETGPESSIITKVKGITTSE------------HKVWDVEEYVKPPEGGSVF 108 
rP2X2       FIVQKSYQDSETGPESSIITKVKGITMSE------------DKVWDVEEYVKPPEGGSVV 96 
hP2X3       FLHEKAYQVRDTAIESSVVTKVKGSGLYA------------NRVMDVSDYVTPPQGTSVF 90 
hP2X5       FLIKKGYQDVDTSLQSAVITKVKGVAFTN-------TSDLGQRIWDVADYVIPAQGENVF 101 
hP2X7       LVSDKLYQRKEPV-ISSVHTKVKGIAEVKEEIVENGVKKLVHSVFDTADYTFPLQG-NSF 102 
             : .* **  .    *:: .* **                   : *. :*  * :    . 
 
zfP2X4      FVLTNMIITTNQTQSKCAENPT-PASTCTSHRDCKRGFNDARGDGVRTGRCVSYSA-SVK 160 
hP2X4       FVMTNVILTMNQTQGLCPEIPD-ATTVCKSDASCTAGSAGTHSNGVSTGRCVAFNG-SVK 157 
rP2X4       FIMTNMIVTVNQTQSTCPEIPD-KTSICNSDADCTPGSVDTHSSGVATGRCVPFNE-SVK 157 
hP2X1       VVMTNFIVTPKQTQGYCAEHPE-G-GICKEDSGCTPGKAKRKAQGIRTGKCVAFND-TVK 157 
hP2X2       SIITRVEATHSQTQGTCPESIRVHNATCLSDADCVAGELDMLGNGLRTGRCVPYYQGPSK 168 
rP2X2       SIITRIEVTPSQTLGTCPESMRVHSSTCHSDDDCIAGQLDMQGNGIRTGHCVPYYHGDSK 156 
hP2X3       VIITKMIVTENQMQGFCPESEE--KYRCVSDSQC--GPERLPGGGILTGRCVNYS-SVLR 145 
hP2X5       FVVTNLIVTPNQRQNVCAENEGIPDGACSKDSDCHAGEAVTAGNGVKTGRCLRRENLARG 161 
hP2X7       FVMTNFLKTEGQEQRLCPEYPT-RRTLCSSDRGCKKGWMDPQSKGIQTGRCVVYEG-NQK 160 
             ::*..  *  *    * *        * ..  *  *     . *: **:*:         
 
zfP2X4      TCEVLSWCPLEKIVDPPNPPLLADAENFTVLIKNNIRYPKFNFNKRNILPNINSSYLTHC 220 
hP2X4       TCEVAAWCPVEDDTHVPQPAFLKAAENFTLLVKNNIWYPKFNFSKRNILPNITTTYLKSC 217 
rP2X4       TCEVAAWCPVENDVGVPTPAFLKAAENFTLLVKNNIWYPKFNFSKRNILPNITTSYLKSC 217 
hP2X1       TCEIFGWCPVEVDDDIPRPALLREAENFTLFIKNSISFPRFKVNRRNLVEEVNAAHMKTC 217 
hP2X2       TCEVFGWCPVEDGA-SVSQFLGTMAPNFTILIKNSIHYPKFHFSKGNIADR-TDGYLKRC 226 
rP2X2       TCEVSAWCPVEDGT-SDNHFLGKMAPNFTILIKNSIHYPKFKFSKGNIASQ-KSDYLKHC 214 
hP2X3       TCEIQGWCPTEVDT-VETPI-MMEAENFTIFIKNSIRFPLFNFEKGNLLPNLTARDMKTC 203 
hP2X5       TCEIFAWCPLETSS-RPEEPFLKEAEDFTIFIKNHIRFPKFNFSKSNVMDVKDRSFLKSC 220 
hP2X7       TCEVSAWCPIEAVEEAPRPALLNSAENFTVLIKNNIDFPGHNYTTRNILPGLNI----TC 216 
            ***: .*** *             * :**:::** * :* ..    *:           * 
 
zfP2X4      VFSRKTDPDCPIFRLGDIVGEAEEDFQIMAVHGGVMGVQIRWDCDLDMPQSWCVPRYTFR 280 
hP2X4       IYDAKTDPFCPIFRLGKIVENAGHSFQDMAVEGGIMGIQVNWDCNLDRAASLCLPRYSFR 277 
rP2X4       IYNAQTDPFCPIFRLGTIVGDAGHSFQEMAVEGGIMGIQIKWDCNLDRAASLCLPRYSFR 277 
hP2X1       LFHKTLHPLCPVFQLGYVVQESGQNFSTLAEKGGVVGITIDWHCDLDWHVRHCRPIYEFH 277 
hP2X2       TFHEASDLYCPIFKLGFIVEKAGESFTELAHKGGVIGVIINWDCDLDLPASECNPKYSFR 286 
rP2X2       TFDQDSDPYCPIFRLGFIVEKAGENFTELAHKGGVIGVIINWNCDLDLSESECNPKYSFR 274 
hP2X3       RFHPDKDPFCPILRVGDVVKFAGQDFAKLARTGGVLGIKIGWVCDLDKAWDQCIPKYSFT 263 
hP2X5       HFGPK-NHYCPIFRLGSVIRWAGSDFQDIALEGGVIGINIEWNCDLDKAASECHPHYSFS 279 
hP2X7       TFHKTQNPQCPIFRLGDIFRETGDNFSDVAIQGGIMGIEIYWDCNLDRWFHHCRPKYSFR 276 
             :    .  **::::* :.  :  .*  :*  **::*: : * *:**     * * * *  
 
zfP2X4      RLDNKDPDNNVAPGYNFRFAKYYKNSDGTETRTLIKGYGIRFDVMVFGQAGKFNIIPTLL 340 
hP2X4       RLDTRDVEHNVSPGYNFRFAKYYRDLAGNEQRTLIKAYGIRFDIIVFGKAGKFDIIPTMI 337 
rP2X4       RLDTRDLEHNVSPGYNFRFAKYYRDLAGKEQRTLTKAYGIRFDIIVFGKAGKFDIIPTMI 337 
hP2X1       GLY---EEKNLSPGFNFRFARHFVE-NGTNYRHLFKVFGIRFDILVDGKAGKFDIIPTMT 333 
hP2X2       RLDPKH--VPASSGYNFRFAKYYKINGTT-TRTLIKAYGIRIDVIVHGQAGKFSLIPTII 343 
rP2X2       RLDPKY--DPASSGYNFRFAKYYKINGTTTTRTLIKAYGIRIDVIVHGQAGKFSLIPTII 332 
hP2X3       RLDSVSEKSSVSPGYNFRFAKYYKMENGSEYRTLLKAFGIRFDVLVYGNAGKFNIIPTII 323 
hP2X5       RLDNK-LSKSVSSGYNFRFARYYRDAAGVEFRTLMKAYGIRFDVMVNGKG---------- 328 
TM1 
TM1 
TM2 
Start of model 
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hP2X7       RLDDKTTNVSLYPGYNFRYAKYYKE-NNVEKRTLIKVFGIRFDILVFGTGGKFDIIQLVV 335 
             *           *:***:*:::        * * * :***:*::* * .           
 
 
zfP2X4      NIGAGLALLGLVNVICDWIVLT-------------------FMKRKQHYKEQKYTYVDD- 380 
hP2X4       NIGSGLALLGMATVLCDIIVLY-------------------CMKKRLYYREKKYKYVED- 377 
rP2X4       NVGSGLALLGVATVLCDVIVLY-------------------CMKKKYYYRDKKYKYVED- 377 
hP2X1       TIGSGIGIFGVATVLCDLLLLH-------------------ILPKRHYYKQKKFKYAED- 373 
hP2X2       NLATALTSVGVGSFLCDWILLT-------------------FMNKNKVYSHKKFDKVCTP 384 
rP2X2       NLATALTSIGVGSFLCDWILLT-------------------FMNKNKLYSHKKFDKVRTP 373 
hP2X3       SSVAAFTSVGVGTVLCDIILLN-------------------FLKGADQYKAKKFEEVNET 364 
hP2X5       ------------AFFCDLVLIY-------------------LIKKREFYRDKKYEEVRG- 356 
hP2X7       YIGSTLSYFGLAAVFIDFLIDTYSSNCCRSHIYPWCKCCQPCVVNEYYYRKKCESIVEPK 395 
                         .: * ::                      :     *  :    .    
 
 
zfP2X4      --------FGLLHNEDK------------------------------------------- 389 
hP2X4       --------YEQGLASELDQ----------------------------------------- 388 
rP2X4       --------YEQGLSGEMNQ----------------------------------------- 388 
hP2X1       --------MGPGAAERDLAAT--------------SST------LGLQENMRTS------ 399 
hP2X2       SH-PSGSW----------P-------------------------VTLARVLGQAPPEPGH 408 
rP2X2       KH-PSSRW----------P-------------------------VTLALVLGQIPPPPSH 397 
hP2X3       TL-KIAA------------------------------------------LT--NPVYPSD 379 
hP2X5       --------LEDSSQEAEDE----------------ASG------LGLSEQLTSGPGLLGM 386 
hP2X7       PTLKYVSFVDESHIRMVNQQLLGRSLQDVKGQEVPRPAMDFTDLSRLPLALHDTPPIPGQ 455 
                                                                         
 
1.3.8.2  Zebrafish P2X4.1 crystal constructs 
zfP2X4.1 was chosen for structural studies following a screen of 35 different green fluorescent 
protein (GFP)-tagged P2X receptor homologs using fluorescence size exclusion 
chromatography (FSEC) following transient transfection in HEK-293 cells. The screen showed 
that zfP2X4.1 was capable of forming stable trimers in detergent and displayed a sharp, 
symmetrical elution profile following FSEC, which favoured it as a candidate for further 
structural studies. However, the addition of a GFP tag to the C-terminus of zfP2X4.1 had a 
significant effect on receptor function. According to Kawate et al the EC50 of ATP at wild type 
zfP2X4.1 was 800 µM, while the EC50 at zfP2X4.1-GFP was increased to 1.73 mM (Kawate et al, 
2009). 
TM2 End of model 
Figure 1.11. Sequence alignment of selected mammalian P2X receptors with zfP2X4.1. The 
start and the end of the zfP2X4.1 sequence present in the crystal structure (PDB ID 3H9V) are 
indicated with red arrows. The percentage amino-acid identities are indicated by the numbers 
in brackets next to the sequence names at the start of the alignment. TM1 and TM2 are 
indicated by green and blue double-headed arrows respectively. The ten conserved cysteine 
residues in the extracellular domain are indicated in green, the amino-acids which contribute to 
the ATP binding site are indicated in yellow, the amino-acids contributing to the channel pore 
are indicated in cyan, and the conserved lysine which contributes to both ATP binding and 
channel gating is indicated in red. The long C-terminal domains of P2X2 and P2X7, for which 
there is no structural information, are omitted. 
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To improve the crystallisation behaviour of zfP2X4.1, a number of modifications were made to 
the wild-type receptor. Firstly the N- and C-termini were truncated; 26 and 8 residue segments 
were removed from the N- and C-termini respectively to yield a crystal structure solved by 
single-wavelength anomalous diffraction in the presence of gadolinium (zfP2X4.1-A), which 
diffracted to 3.5 Å resolution (PDB ID - 3I5D). Additionally, 3 further point mutations (C51F, 
N78K and N187R) were introduced to the extracellular domain to reduce both non-native 
disulphide bond formation and heterogeneity due to glycosylation (zfP2X4.1-B). The structure 
of zfP2X4.1-B was solved by molecular replacement, yielding crystals that diffracted to 3.1 Å 
resolution (PDB ID - 3H9V). Although the mutated receptors were still responsive to ATP, the 
peak current amplitude was markedly reduced (by approximately 95% and 99% for zfP2X4.1-A 
and zfP2X4.1-B respectively) (Fig 1.12) when compared to the wild type GFP-tagged channel. 
Additionally, the agonist sensitivity was markedly increased with reported EC50 values of 27.4 
µM and 3.4 µM for zfP2X4.1-A-GFP and zfP2X4.1-B-GFP respectively. The return of current to 
baseline on washout of agonist was significantly delayed in both crystal constructs (Kawate et 
al, 2009). These observations demonstrate that there are large differences in channel function 
between the wild-type and crystal constructs.  
 
 
 
 
 
 
 
 
 
To solve the ATP bound structure of zfP2X4.1, additional mutagenesis of the receptor was 
required to improve crystallisation behaviour. Further truncation of the C-terminus (zfP2X4.1 
final model, residues 36 – 359) and reversal of the initial C51F mutation gave rise to P2X4.1-C, 
which also gave a sharp, symmetrical elution profile following FSEC. The P2X4.1-C structure 
was solved by molecular replacement, using P2X4.1-B as a search probe, at a resolution of 2.8 
Figure 1.12 – Peak current amplitude in response to ATP for wild type zfP2X4 (a), zfP2X4.1-A 
(b) and zfP2X4.1-B (c) constructs. The peak current amplitude is reduced by approximately 
95% for zfP2X4.1-A and 99% for P2X4.1-B compared to wild type. Reprinted by permission 
from Macmillan Publishers Ltd: [Nature] (Kawate et al), copyright (2009). 
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Å (PDB ID - 4DW1; Fig 1.13B,D). Furthermore the structure of the apo-state zfP2X4.1-B 
construct was re-solved using new crystals which diffracted to a higher resolution of 2.9 Å 
(referred to as zfP2X4.1-B2; PDB ID 4DW0; Fig 1.13A,C) (Hattori and Gouaux, 2012). Electron 
density maps from the new apo-state structure (PDB ID 4DW0) showed an incorrect 
assignment of electron density in the region encompassing residues 88 – 97 in the previously 
published structures (PDB IDs 3H9V and 3I5D). The functional properties of GFP-tagged 
zfP2X4.1-C were measured using two-electrode voltage clamp of Xenopus oocytes; the authors 
stated that the functional properties of this receptor were similar to that recorded for wild-
type zfP2X4.1, yet their EC50 value was significantly different (2.1 µM compared to 1.73 mM for 
the wild-type GFP-tagged construct (Hattori and Gouaux, 2012)). They did not report peak 
current values for wild-type zfP2X4.1 in their experiments, so it is not known how much peak 
current amplitudes were impaired by the introduced mutations, but it is clear from the current 
traces that zfP2X4.1-C also displayed delayed return of current to baseline values on washout 
of agonist, so from this evidence it is reasonable to assume that the function of zfP2X4.1-C was 
impaired in a similar fashion to the zfP2X4.1-A and zfP2X4.1-B crystal constructs. While the 
crystal structure derived from the zfP2X4.1-C construct clearly represents an ATP-bound 
structure, because of the impairment of function, it may well represent an artificially stabilised 
open state for the channel (because of the delayed return of current to baseline on washout of 
agonist). 
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1.3.8.3  The ATP binding site 
Preceding determination of the crystal structure of zfP2X4.1, mutagenesis and functional 
experiments were used to ascertain key residues involved in ATP binding of P2X receptors. P2X 
receptors do not contain any of the previously identified ATP binding motifs associated with 
other ATP binding proteins, such as the Walker motif (Walker et al, 1982). It was hypothesized 
that polar and positive amino acids conserved across P2X subtypes may play a role in ATP 
binding and activity. Site-directed mutagenesis has been used to assess the function of some 
of these highly conserved residues at a number of P2X subtypes. 
Residues thought to contribute to the ATP binding pocket have been identified in hP2X1, 
rP2X2, hP2X3 and rP2X4. An alanine-scanning mutagenesis study in rP2X2 performed by Jiang 
et al identified Lys-69, Lys-71 and Lys-308 as critical residues for ATP binding. K69A and K308A 
A    
C    
B    
D    
Figure 1.13 - Representation of the crystal structures of zfP2X4.1. The apo-, closed state 
zfP2X4-B2 (PDB ID - 4DW0) crystal structure viewed from the side (A) and the top 
(extracellular side) (C). The ATP bound, open state zfP2X4-C (PDB ID - 4DW1) crystal structure 
viewed from the side (B) and the top (extracellular side) (D). Each subunit is represented by a 
different colour. ATP in the binding pocket between 2 adjacent subunits is shown in cyan. 
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mutations in rP2X2 gave rise to non-functional channels, K71C channels experienced a marked 
reduction in function, with a 1000-fold reduction in affinity for ATP (Jiang et al, 2000b). 
Additionally, Leu-186 was shown to be involved in the binding of the adenine base of ATP 
(Jiang et al, 2011). 
Similarly Ennion et al studied the effect of mutating 11 conserved positive residues in the 
extracellular loop of hP2X1. K69A and K308A (rP2X2 numbering) mutations led to a dramatic 
reduction (< 1,400 fold) in ATP potency. Upon mutation of Lys-308 to arginine, another 
positively charged amino acid, the channel was 25 fold less sensitive to ATP. These results 
indicate the individual chemical properties of the amino acid, as well as the charge, contribute 
to the binding of ATP. Lys-71 and Arg-290 were also proposed to contribute to the ATP binding 
pocket of hP2X1 (Ennion et al, 2000).  
The conserved Lys-69 and Lys-71 residues have been shown to be highly important for ATP 
recognition in hP2X1, hP2X2, rP2X2, hP2X3, rP2X4 homomers and rP2X2/P2X4 heteromers 
(Roberts et al, 2008; Jiang et al, 2000b; Allsopp et al, 2011; Bodnar et al, 2011; Wilkinson et al, 
2006). Lys-188 and Lys-308 have also been implicated in agonist recognition in hP2X1, hP2X2, 
rP2X2, hP2X3, rP2X4 and hP2X7 receptors (Ennion et al, 2000; Roberts and Evans, 2007; 
Roberts et al, 2008; Bodnar et al, 2011; Jiang et al, 2000b]; Worthington et al, 2002). Arg-290 is 
also understood to interact with the phosphate group of ATP in hP2X1, rP2X2, hP2X3 and 
rP2X4 receptors (Ennion et al, 2000; Jiang et al, 2000b; Fischer et al, 2007; Zemkova et al, 
2007). 
ATP was proposed to bind at the interface between 2 adjacent subunits, as opposed to within 
one subunit, using a disulphide cross-linking approach in hP2X1. Mutation of Lys-69 and Phe-
289 to cysteine residues leads to cross-linking between neighbouring subunits, indicating them 
to be in close proximity between 2 adjacent subunits. Furthermore these channels showed a 
reduction in ATP potency. However upon application of dithiothreitol (DTT), which disrupts 
disulphide bond formation, these currents were increased 60 fold, indicating an inter-subunit 
ATP binding site at hP2X1 receptors (Marquez-Klaka et al, 2007). These results were later 
replicated with P2X2 receptors. However cross-linking between equivalent residues was less 
efficient in P2X3 and P2X4 receptors, signifying one of these residues may not play a role in 
ATP binding in these subtypes (Marquez-Klaka et al, 2009). 
In zfP2X4.1, the ATP binding site is embedded in the receptor between the upper body domain 
of subunit A and the lower body and dorsal fin of subunit B (Fig 1.14A) (Hattori and Gouaux, 
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2012). The site is lined by a number of positively charged residues that form extensive 
hydrophilic interactions with ATP. ATP assumes a U-shaped conformation in the binding 
pocket; the phosphate groups form salt bridges and hydrogen bonds with surrounding polar 
and basic amino acids. In agreement with previous data, Lys-69 is shown to have a crucial role 
in ATP binding, forming critical interactions with all 3 phosphate groups. Additionally Asn-288 
and Lys-308 form further contacts with the β-phosphate. The γ phosphate further interacts 
with Lys-71, Arg-290 and Lys-308 residues (rP2X2 numbering) (Fig 1.14) (Hattori and Gouaux, 
2012; Chataigneau et al, 2013). 
The extensive number of interactions the γ-phosphate forms with surrounding residues gives 
partial insight into why P2XRs are responsive to ATP, but not to ADP or AMP (Coddou et al, 
2011). However the β- and γ- phosphate groups are not fully submerged in the binding pocket, 
raising a possible explanation for why rP2X receptors are activated by diadenosine 
polyphosphates (Wildman et al, 1999).  
The adenine base is buried deep within the binding pocket and forms a number of interactions 
with highly conserved residues. The side chain of Thr-184 forms 3 hydrogen bonds with the 
adenine base. The adenine base also undergoes interactions with the carbonyl oxygen groups 
in the main chain of Lys-71 and Thr-184. Furthermore, hydrophobic interactions are formed 
with Leu-186 and Ile-226 (rP2X2 numbering) (Fig 1.14) (Hattori and Gouaux, 2012). 
Many of the key residues identified in zfP2X4.1 involved in ATP binding are conserved across 
the mammalian P2X receptors studied, and molecular modelling implies that a similar agonist 
binding site is likely to exist in mammalian channels (see Fig 1.14B for example). Differences in 
the non-conserved residues lining the ATP binding cavity are likely to reflect differences in 
sensitivity to agonists and competitive antagonists. More detail on the key residues involved in 
ATP binding can be found in (Chataigneau et al, 2013). 
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1.3.8.4  Pore lining residues and the transmembrane domains 
Mutational analysis has been used extensively to study the transmembrane pore-lining 
residues of P2X receptors. P2X receptors show differential preference towards certain cations. 
For example, P2X2 has a much higher affinity for calcium over sodium (Virginio et al, 1998). 
Additionally, P2XRs demonstrate a specific selectivity sequence to alkali metal cations (K(+) > 
Rb(+) > Cs(+) > (Na(+) > Li(+)). This differs from the ions’ relative mobility in water, indicating 
that the receptors are able to distinguish between a selection of cations, regardless of size, 
Figure 1.14 - The ATP binding site of P2X receptors. (A) ATP-binding site of zfP2X4.1 (PDB ID - 
4DW1). (B) ATP binding site in a molecular model of rP2X2.  Black dashed lines designate 
hydrogen bonds. ATP is shown in orange and blue with nitrogen and oxygen atoms 
represented in dark blue and red respectively. Residues from chain A are shown in green. 
Residues from chain B are shown in grey. 
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and that cations are likely to undergo weak interactions with the interior of the channel pore 
(Ding and Sachs, 1999; Migita et al, 2001).  
The second transmembrane domain of rP2X2 contains a number of polar amino acids that are 
hypothesized to line the pore and form a hydrated surface for cation conductivity, regulating 
the current by solvating ions within the pore (Egan et al, 1998; Rassendren et al, 1997). Three 
of these polar residues in rP2X2, Thr-336, Thr-339 and Ser-340, are thought to be important 
for cation selectivity. Mutation of Thr-336, Thr-339 or Ser-340 to the hydrophobic amino acid 
tyrosine leads to a substantial change in calcium permeability and the alkali metal cation 
selectivity sequence (i.e. the receptor could no longer distinguish between the different ions). 
This data suggests the permeability sequence of P2X2 is partly composed of these 3 polar 
amino acids in TM2 interacting with permeating cations (Migita et al, 2001). 
In addition, mutation of Thr-339 in rP2X2 (T339S) gave rise to a channel with spontaneous 
opening activity. ATP was also ten times more potent at rP2X2 T339S compared to wild-type 
rP2X2, suggesting that the T339S mutation causes destabilisation of the closed channel. Lys-
308 and Lys-69 are conserved residues, likely to be involved in ATP binding, as previously 
described. A K69A/T339S double mutant channel gave the same phenotype as the T339S single 
mutant. However a K308A/T339S mutant channel underwent no spontaneous activity, 
implying that Lys-308 may be involved in channel gating as well as ATP binding (Cao et al, 
2007).  
The crystal structure of zfP2X4.1 revealed that interactions between Leu-332, Leu-338 and Ile-
347 are important for stabilizing the closed pore conformation. These interactions are broken 
upon activation of the channel as the transmembrane domains move apart. Additionally, new 
interactions are formed between Leu-338 and Ile-347. The ion permeation pathway pore of 
zfP2X4.1 is lined by Leu-332, Ala-336, Ala-339, Leu-343 and Ile-347 (rP2X2 numbering) (Hattori 
and Gouaux, 2012). It is noteworthy that the majority of the pore-lining residues possess 
hydrophobic side chains. This is in contrast to the key residues hypothesized to line the 
mammalian P2X2 pore, which predominantly consists of polar amino acids. For example, in 
rP2X2, the equivalent amino acid to the hydrophobic isoleucine residue at position 347 is the 
polar residue tyrosine. In the mammalian P2X2 receptor, the polar side chains lining the pore 
may interact directly with the hydrated cations. These significant differences in pore lining 
residues imply there may be dissimilarities in the way cations pass through the 
transmembrane domains in the zfP2X4.1 receptor and the mammalian receptors. Clearly this 
48 
 
 
observation has implications for interpretation of the pore function of mammalian P2X 
receptors based upon the zfP2X4.1 crystal structure. 
1.3.8.5  The N-terminus 
The roles of the N- and C-termini of P2X receptors in channel desensitization kinetics has been 
extensively studied in P2X1 and P2X2 receptors. The N-terminus of P2XRs contains a highly 
conserved protein kinase C (PKC) binding site, TX(K/R). Two conserved N-terminal residues – 
Thr-18 and Lys-20 in rP2X2 – are important for its slow rate of desensitisation compared to 
P2X1. Abolition of the PKC consensus site via T18A, T18N and K20T mutations in rP2X2 gave 
rise to a change in channel kinetics, with channels undergoing fast desensitization in response 
to ATP. A P19A mutation gave rise to channels with similar desensitisation kinetics to wild type 
P2X2 channels. These results implicate the TX(K/R) PKC consensus site as a critical determinant 
of P2X2 kinetics (Boué-Grabot et al, 2000). Similarly P2X1 Y16C, T18C and R20C mutants 
experienced a reduction in peak current amplitude and changes in desensitization kinetics, 
demonstrating an important role for these residues in specific channel kinetics (Wen and 
Evans, 2009).  
In 2013, Allsopp and colleagues used P2X1/2 N- and C- terminal chimeric proteins to 
investigate the effects of the intracellular termini on channel kinetics. They noted that 
mutating the N-terminus affects partial agonist efficacy without altering agonist potency. 
Additionally, the first 16 amino acids of the N-terminus predominantly control agonist efficacy, 
whereas the N-terminal region adjacent to TM1 is likely to fine-tune these effects (Allsopp et 
al, 2013). Specifically, residues 21-23 were suggested to affect desensitization in P2X1 and 
P2X2 receptors. (Allsopp et al, 2011).  
The zfP2X4.1 construct used for crystallization contained an N-terminal truncation (28 amino 
acids), therefore all the residues identified above with roles in channel kinetics of P2X1 and 
P2X2 were removed prior to protein expression, purification and structure determination. This 
N-terminal truncation may account for the large reduction in peak amplitude in response to 
ATP observed for the zfP2X4.1 crystal constructs. It may also play a role in delayed return of 
current to baseline after washout of agonist. 
1.3.8.6  The C-terminus 
The C-terminal domains are the most variable domains among the P2X receptors; P2X2 and 
P2X7 receptors have long intracellular C-termini for which no structural information is 
available. However these domains are thought to play important roles in channel kinetics, with 
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certain residues regulating recovery from desensitization. The partial agonist efficacy at a 
P2X1-2C chimeric channel was intermediary between efficacy at wild-type P2X1 and P2X2 
receptors. However unlike the N-terminus, the C-terminal domain was also associated with a 
decrease in agonist potency. Residues 360-364 are involved in regulation of channel recovery 
from desensitisation (Allsopp et al, 2013).  
Additional potential PKC sites are present in the C-terminus of rP2X2 at Thr-372 and Thr-464. 
Elimination of these sites from rP2X2 via a truncation of the receptor at His-375 and mutation 
of Thr-372 gave rise to channels that experience rapid desensitisation in response to ATP. 
Additionally, truncated channels in combination with N-terminal PKC site mutations (T18A, 
K20T) displayed peak currents with a significant smaller amplitude. This data indicates that in 
addition to the PKC site in the N-terminus, P2X2 receptors require specific intracellular 
interactions between the 2 cytoplasmic domains for complete cell surface expression of slowly 
desensitising channels (Boué-Grabot et al, 2000). 
The C-terminal domain of zfP2X4.1 was truncated at position 359 in zfP2X4.1-C so the YXXXK 
trafficking motif responsible for plasma membrane targeting was absent and this may have 
had a significant effect on receptor function (described in section 1.3.5). Additionally the 
mammalian P2X4 tyrosine based, endocytic motif (YEQGL) (described in section 1.3.5) is not 
present in zfP2X4.1; the equivalent residues following the tyrosine (GLLH) were truncated in 
the zfP2X4.1 construct used for crystallisation. Therefore if wild type zfP2X4.1 undergoes rapid 
internalisation and reinsertion into the membrane, disruption of these residues may have had 
an effect on channel trafficking and function. 
1.3.8.7  Apo, closed vs open state structures 
Publication of the crystal structures of the apo- and ATP-bound states of zfP2X4.1 receptors 
has provided valuable insight into the structure and mechanism of action of P2X receptors. The 
structures have enabled us to identify key residues involved in agonist binding and pore-lining 
residues with roles in cation selectivity (Kawate et al, 2009; Hattori and Gouaux, 2012).  
Kawate et al liken the receptor monomer to a leaping dolphin and the various domains have 
been named accordingly (Fig 1.15A). The transmembrane domains are referred to as the tail or 
fluke domain of the dolphin. The extracellular domain is made up of the upper body, lower 
body, dorsal fin, the left and right flippers and the head region. The body region of the dolphin 
is made up of β-sheets to form a β sandwich domain. The trimeric form of the closed-state 
receptor is represented as 3 dolphin monomers wrapped around one-another. The majority of 
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subunit-subunit interactions are found in the upper body domain, with fewer interactions 
found in the lower body domain, proximal to the TM domains, which is consistent with a 
structure that permits movement (transmission of a conformational change induced by agonist 
binding to the channel pore) (Hattori and Gouaux, 2012).  
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Mammalian P2X receptors contain 10 extracellular conserved cysteine residues that form 5 
disulphide bond pairs; 1-6 (Cys-119-Cys-168), 2-4 (Cys-129-Cys-152), 3-5 (Cys-135-Cys-162), 7-8 
(Cys-220-Cys-230), and 9-10 (Cys-264-Cys-273), (Corresponding to rP2X2 Cys-113, Cys-164, 
Cys-124, Cys-147, Cys-130, Cys-158, Cys-214, Cys-224, Cys-258 and Cys-267 respectively) 
confirmed by the zfP2X4.1 crystal structure (Fig 1.15B and 1.15C). Disulphide pairs 1-6, 2-4 and 
3-5 are located in the head region of the receptor, 7-8 is situated in the dorsal fin region and 9-
10 in the lower body region, proximal to the TM domains (Kawate et al, 2009). Disulphide 
bonds have important roles in the formation and maintenance of ion channel structure. 
Although in hP2X1, all single cysteine residue mutants gave rise to functional channels, some 
of the mutants (C264A, C273A, C135A, C162A corresponding to the 3-5 and 9-10 disulphide 
Figure 1.15 - Schematic of a zfP2X4.1 monomer and location of disulphide bonds. (A) 
Schematic structure of a zfP2X4.1 monomer, showing the analogy of the receptor monomer to 
a dolphin with labelled domains. (B) Close-up of the head domain showing the location of the 
disulphide bond pairs 1-6, 2-4 and 3-5. Disulphides are shown in yellow. (C) Close-up of the 
body and dorsal fin domains showing the location of the disulphide bond pairs 7-8 and 9-10. 
Disulphides are shown in yellow. 
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bond pairs (zfP2X4.1 numbering)) caused a reduction in current amplitudes. Additionally 
C264A and C273A channels are not efficiently trafficked to the cell surface. These results 
indicate that Cys-264 and Cys-273 are involved in the formation of a disulphide bond and 
disruption has implications on the tertiary structure of the protein, thereby preventing it from 
being trafficked to the cell membrane (Ennion and Evans, 2002). In addition, Dictyostelium 
discoideum P2XA (DdP2XA) does not contain any of the conserved disulphide bonds stated 
above, however it is still functional and low resolution structural studies indicate that it has a 
similar architecture to zfP2X4.1 (Valente et al, 2011). 
The extracellular domain of zfP2X4.1 appears to be shaped like an equilateral triangle, 
extending approximately 70 Å above the membrane. The transmembrane domain is 28 Å long 
and adopts a chalice-like shape through the membrane. The transmembrane helices show a 
left-handed twist orientation and are anti-parallel to one another, approximately 45° from the 
membrane plane (Kawate et al, 2009). The transmembrane pore is predominantly lined by the 
TM2 domains, with the TM1 helices positioned peripheral to the TM2 helices. The pore is open 
and continuous with the narrowest part of the pore marked by Ala-347 and Leu-351 (Thr-339 
and Val-343 in rP2X2) (Hattori and Gouaux, 2012). 
Superposition modelling of the two channel states shows that ATP binding does not greatly 
affect the conformation of the upper body domain, inferring that this part of the structure 
stays relatively rigid upon activation. Conversely, the lower body domain undergoes 
substantial conformational changes upon agonist binding, resulting in an outward ‘flexing’ of 
the lower body domain (Fig 1.13B). Movement of these domains results in an expansion of the 
transmembrane helices. The transmembrane domains undergo conformational changes in an 
iris-like movement when ATP binds to the extracellular domain. TM1 and TM2 rotate 
anticlockwise by 10° and 55° respectively proximal to an axis perpendicular to the membrane 
plane. Their tilt angle is also increased by 8° and 2° respectively about an axis parallel to the 
membrane. These movements result in the helices moving away from the central axis, allowing 
expansion of the ion conducting pore to a width that would permit the flow of ions through 
the channel, consistent with a transition from closed- to open-state (Hattori and Gouaux, 
2012). 
Inspection of the electron density of both the apo- and ATP-bound states reveals that it is of 
poorest quality in the transmembrane regions, which is not unusual for membrane proteins. 
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Several side chain positions within the TM domains cannot be assigned, and so care must be 
taken when interpreting data for the TM domains with these structures (Wang et al, 2012). 
Lateral fenestrations present in the extracellular vestibule of the receptor open wide upon ATP 
binding and provide a pathway for the influx of cations into the channel.  Once the ions have 
entered through the fenestrations, the highly acidic residues of the central vestibule attract 
only cations and repel anions, which is thought to contribute to the cation selectivity of the 
channel (Kawate et al, 2011; Samways et al, 2011; Hattori and Gouaux, 2012; Kracun et al, 
2010; Samways et al, 2012).  
The structure determination of zfP2X4.1 represents the first major breakthrough in high 
resolution imaging of a P2X receptor, providing great insight into the mechanism of action of 
the receptor and how the receptor is designed to open upon ATP binding. However, as noted 
above, zfP2X4.1 has some significantly different characteristics to most mammalian P2X 
receptors (relatively low ATP potency, hydrophobic residues lining the channel pore), and the 
function of the crystal constructs was significantly different to wild-type zfP2X4.1 and so it is 
still important to strive for high-resolution structures of mammalian P2X receptors, both for 
comparative structural biology and structure based drug design. 
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1.3.9  P2Y receptors  
P2Y receptors are metabotropic membrane proteins activated by ATP and ADP. Upon ATP 
binding to P2X and P2Y receptors, there is an increase in intracellular calcium either from the 
extracellular environment (P2X) or from intracellular stores (P2Y). Unlike P2X receptors, P2Y 
receptors, of which there are 8 subtypes (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and 
P2Y14), are G-protein coupled receptors. Their activation by ATP induces downstream 
signalling via intracellular second messengers that lead to calcium release from stores 
(Burnstock, 2007; Burnstock and Verkhratsky, 2010). P2Y activation induces activation of 
phospholipase C (PLC) by exchanging guanosine diphosphate (GDP) for guanosine triphosphate 
(GTP) on Gα subunits. PLC cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 
triphosphate (IP3) and diacylglycerol (DAG). IP3 binds to its cognate receptor in the 
endoplasmic reticulum and calcium is released from thapsigargin-sensitive stores (Fig 1.16) 
(Wu et al, 2007). 2-Aminoethoxydiphenyl borate (2-APB), a membrane-penetrable modulator, 
can block P2Y signaling by preventing IP3 induced calcium release (Maruyama et al, 1997). 
 
 
 
 
 
 
 
 
 
 Figure 1.16 – Calcium signalling pathway of P2Y receptors. ATP couples to the receptor 
inducing exchange of GDP for GTP. The release of Gα leads to activation of PLC. PLC cleaves 
PIP2 to form IP3 and DAG. IP3 binds to IP3 receptors in the endoplasmic reticulum leading to 
the release of calcium into the cell from intracellular stores (image adapted from Burnstock 
and Verkhratsky, 2010). 
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1.4  Pannexin channels 
1.4.1  Introduction to Pannexin channels 
Pannexin (Panx) channels are non-selective ion channels that allow the passage of small 
molecules up to 1kDa in size (Wicki-Stordeur and Swayne, 2014). The family of pannexin 
proteins was first identified due to their restricted sequence homology (25 – 33% identity) to 
the invertebrate family of Innexin gap junction proteins (Panchin et al, 2000). The pannexin 
family consists of 3 subtypes – Panx1, Panx2 and Panx3. Panx1 is expressed across a large 
range of cell and tissue types in mammals, whereas Panx2 and Panx3 have a more restricted 
pattern of expression (Baranova et al, 2004). Panx2 has a role in neuron differentiation 
(Swayne et al, 2010) and is found predominantly in brain tissues including the cerebellum and 
the cerebral cortex. Although low levels of Panx3 expression have also been detected in 
human hippocampus extracts (Baranova et al, 2004), it is predominantly expressed in bone 
and skin tissues (Penuela et al, 2012).  
Multiple factors can contribute to channel opening of Panx1, the most extensively studied of 
the pannexin family. Panx1 is activated by membrane depolarisation and increased 
extracellular potassium concentrations (Silverman et al, 2009). However it can also be 
modulated by mechanical stresses such as osmolarity and pressure changes (Bao et al, 2004). 
Panx1 is activated by Gαq coupled receptors via Rho and downstream kinase activity, however 
the exact mechanisms regulating this pathway are poorly understood (Sandilos and Bayliss, 
2012). Panx1 channel currents and ATP release are inhibited at multiple sites (Cys 40 and 
Cys346) by S-nitrosylation (Lohman et al, 2012).  
1.4.2  Pannexins - Expression and topology 
Pannexin channels are formed by multiple subunits; Panx1 is predicted to assemble into 
hexameric channels at the cell membrane, according to cross-linking and SDS-PAGE 
experiments performed by Boassa and colleagues (2007). Additionally, low resolution electron 
microscopy studies of protein purified from Madin-Darby canine kidney (MDCK) cells show 
that Panx1 and Panx2 form channel-like structures, similar in appearance to Connexin26 (Cx26) 
(Ambrosi et al, 2010). Panx1 and Panx2 were also expressed and purified from Sf9 insect cells 
and electron microscopy was used to determine the channel size of the proteins. Due to 
different orientations of the proteins, 2 diameter averages were obtained for each subtype – 
120 and 160 Å for Panx1, 183 and 190 Å for Panx2. These results agree with the hypothesis 
that Panx2 forms a higher oligomeric structure than Panx1. The predicted pore sizes of Panx1 
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are 17 and 21 Å, and for Panx2 29.5 and 30.5 Å. These pores are considerably larger than that 
noted for Cx26 which has a pore size of 12.5 Å. However these measurements were taken 
from averaged 2D projection images and pore size may vary across the axis of the pore 
(Ambrosi et aI, 2010).  
Despite the structural homology of Panx channels to connexin channels, multiple groups have 
shown that Panx receptors do not form gap junctions. For example, Ambrosi and colleagues 
(2010) used immunogold labelling experiments to show Panx1 expressing membranes were 
labelled on one side of the membrane, presumed to be the cytoplasmic side, whereas 
connexin expressing membranes were labelled on both sides of the membrane indicating the 
formation of gap junctions (Ambrosi et al, 2010).  
Due to the significant sequence similarity between Panx1 and Panx3, Panx3 is also predicted to 
form hexameric channels. On the other hand, cross linking experiments have predicted that 
Panx2 forms octameric channels (Ambrosi et al, 2010). Each monomeric subunit of all 
pannexin channels consists of 4 α-helical transmembrane domains, 2 extracellular loops, 1 
intracellular loop and intracellular N- and C- termini (Fig 1.16). Although the vertebrate gap 
junction family, connexins, share little sequence homology with pannexins, all three families of 
proteins (Pannexins, Connexins, Innexins) are predicted to have the same subunit topology 
(Yen et al, 2007; Baranova et al, 2004). 
1.4.3  Pannexins - Trafficking  
Trafficking of pannexin channels to the cell surface is vital for channel function and is regulated 
by cells in a number of ways. Both a fully intact C-terminal domain and appropriate N-linked 
glycosylation are required for Panx expression at the cell surface (Gehi et al, 2011). In addition, 
the number of channels expressed at the membrane is regulated by COP II (Coat-protein II), 
which has a role in the ER-to-Golgi trafficking transition. Pannexin channels can also be 
internalised independently of clathrin/calveolin/dynamin II mechanisms, regulating the level of 
protein expressed at the membrane (Gehi et al, 2011). 
Sequencing and site directed mutagenesis work by Penuela and colleagues in 2007 revealed 
that both Panx1 and Panx3 subunits contain one N-linked glycosylation site, Asn-254 in the 
second extracellular loop of Panx1 and Asn-71 in the first extracellular loop of Panx3. Panx2 
also contains a potential N-linked glycosylation site at Asn-86 in the first extracellular loop; 
however glycosylation at this site has not been ascertained (Fig 1.17) (Penuela et al, 2013).  
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Three glycosylation states of Panx1 have been identified, the non-glycosylated, core form of 
Panx1, the high mannose glycosylated form which is mostly located at the ER and the fully 
functional, complex glycosylated form of Panx1 (Penuela et al, 2009). Glycosylation of Asn254 
is important for trafficking of Panx1 to the plasma membrane. Upon mutagenesis of this 
residue (N254Q) there is a significant reduction in levels of Panx1 protein expressed at the cell 
surface, suggesting glycosylation plays an important role in protein trafficking (Boassa et al, 
2007). However glycosylation does not affect the function of the channels; the few receptors 
that are trafficked to the surface are fully functional (Penuela et al, 2009). The glycosylation of 
Panx1 at the extracellular domain (N254) is suggested to be responsible for interfering with 
the possible docking of 2 channels to form gap junctions, increasing the likelihood of the 
proteins forming singular membrane channels (Boassa et al, 2008).  
Co-expression of wild-type Panx1 channels with N254Q mutated channels in Madin-Darby 
canine kidney cells rescues the expression of Panx1 at the cell surface. This was one of the first 
pieces of evidence indicating the oligomerisation of Panx1 proteins (Boassa et al, 2008). 
Figure 1.17 – Membrane topology of Panx1, Panx2 and Panx3. Each subunit consists of 
intracellular N- and C- termini, 4 transmembrane domains and 2 extracellular loops. Panx2 is 
the largest of the pannexin subtypes, with an extensive C-terminus; Panx3 is the smallest. 
Panx1 contains a glycosylation site on its second extracellular loop (N254), Panx2 and Panx3 
each contain an N-glycosylation site on the first extracellular loop (N86 and N71 respectively) 
(Penuela et al, 2013).  
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1.4.4  Pannexin channels - Function 
The open Panx1 channel has been shown to be capable of ATP efflux, which may then go on to 
activate P2X and P2Y receptors (Romanov et al, 2012). This leads to downstream signalling and 
cell-cell communication, implicating Panx1 with roles in biological functions such as taste 
sensation, inflammatory conditions, immunity and tumorigenesis (Wicki-Stordeur and Swayne, 
2014; Penuela et al, 2013). The exact mechanism regarding the opening and functioning of 
pannexin channels is poorly understood. However there is evidence to suggest Panx1 is 
implicated in early stages of cell death to begin recruitment of immune cells via the release of 
ATP, a classic 'find-me' signal. Panx1 has been shown to be capable of activation by caspase 
3/7 cleavage at a specific DVVD site (residues 376-379) located in its C-terminal domain 
leading to efflux of ATP. Panx1 knockdown was shown to cause a decrease in recruitment of 
monocytes by apoptotic cells demonstrating that ATP release is important in early apoptotic 
signalling (Chekeni et al, 2010).  
P2X7 has been reported to interact with Panx1 during the immune response resulting in the 
formation of large pores that allow the passage of dye molecules (up to 900 Da) into the cell 
and release of the pro-inflammatory cytokine, IL-1β (Pelegrin and Surprenant, 2006). Upon 
activation of P2X7 by ATP, caspase-1 was activated inside the cell which in turn activated the 
NLRP inflammasome leading to production of active IL-1β. Activated IL-1β is released and 
secreted from the cell leading to activation of immune cells and destruction of the cell (Fig 
1.7). This shows that both P2X7 receptors and pannexin channels play important roles in the 
immune response (Pelegrin and Surprenant, 2006). 
As well as having a role in immunity, pannexins are implicated in taste perception. Pannexins 
are expressed in the receptor cells of the taste buds, alongside the presynaptic cells. Upon 
activation of pannexin, ATP is released and acts on the neighbouring presynaptic cells to 
induce the release of serotonin (Dando and Roper, 2009). 
Determining the structure of a pannexin channel would help to understand the underlying 
mechanism behind apoptotic induction by P2X7, and the role Panx1 may play in this process. It 
will also enable the design of new therapies targeting cancer and various other diseases. 
Additionally, if Panx1 is a hexamer, it will be a good candidate for low resolution structural 
studies using electron microscopy for which only a low yield of protein is required, as higher 
symmetry enables more accurate 3D-reconstructions. An expression system from which we 
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can successfully purify high quality protein, even at low yield, will be useful for low resolution 
studies.  
1.5  Drosophila as a model organism 
The fruit fly, Drosophila melanogaster, has served as a highly important model organism in 
biological research for many years. In addition to a short life cycle (10-18 days) and their ability 
to lay up to 100 eggs per day, they are easy and economical to culture, making them suitable 
for genetic and biomedical studies. Additionally, in 2000, the full genome of Drosophila 
melanogaster, with approximately 13,600 protein coding genes, was sequenced using whole 
genome shotgun sequencing (Adams et al, 2000).  More recently the genomes of many other 
Drosophila species have been sequenced (D. ananassae, D. erecta, D. Grimshawi, 
D.mojavensis, D. persimilis, D, sechellia, D. simulans, D. virilise, D. willistoni, D. yakuba (Clark et 
al, 2007), D. biarmipes, D bipectinata, D. elegans, D. eugracillis, D. ficusphila, D. kikkawai, D. 
rhopaloa, D. takahashii, (Flybase website) D. pseudoobscura (Richards et al, 2005). The well 
characterised Drosophila genome makes it suitable for a variety of genetic analyses. One of the 
most crucial biological discoveries of inheritance was solved by Thomas Hunt Morgan who won 
a Nobel Prize in 1933 for his work concerning the use of Drosophila to discover that genes 
were contained within chromosomes (Jennings, 2011). 
Although the fruit fly and humans are considerably different organisms, many key 
developmental processes and biological mechanisms are highly conserved between species. 
Furthermore, following analysis of the sequenced human and Drosophila genomes, it was 
discovered that 75% of known human disease genes have an equivalent orthologous gene in 
the fruit fly, further validating their role as a model organism (Reiter et al, 2001).  
1.5.1  The Life cycle of Drosophila melanogaster 
The fruit fly goes through a 4-stage life cycle that lasts approximately 10 – 18 days dependent 
upon temperature, allowing Drosophila geneticists a good control over fly generation times. 
Once a fertilised egg is laid by a female, it develops for approximately 1 day before hatching 
into a larva. The larva lives in the fly food for approximately 5 days (at 25°c) before pupation. 
Following pupation, much of the larval tissue undergoes histolysis and the adult tissues 
develop from the imaginal discs as the fly undergoes metamorphosis. Emergence or eclosion 
of the fly from the pupal case marks the end of metamorphosis (Jennings, 2011).  
 
60 
 
 
1.5.2  The use of insect cells for P2X and Pannexin expression 
Insect cells have been widely used for expression of P2X receptors. As mentioned previously, 
zP2X4.1 was expressed in Sf9 insect cells for purification and structural studies (Kawate et al, 
2009; Hattori and Gouaux, 2012). Sf9 cells were also used to express rP2X2, which was purified 
and used for negative-stain TEM. The receptor was presented as an inverted three sided 
pyramid, with the extracellular domain described as a crown shaped structure. However, their 
data estimated the volume of the receptor to be 1200 nm3 (Mio et al, 2005; Mio et al, 2009), 
which is significantly larger than what has been reported for the rP2X2 receptor using AFM 
(Barrera et al, 2005) or the zfP2X4.1 crystal structure (Kawate et al, 2009), indicating that it is 
likely that small protein aggregates were imaged as opposed to trimeric receptors (Fig 1.18).  
 
 
 
 
 
 
 
 
 
 
 
 
P2X2 and P2X3 receptors were also shown to be functional and respond to ATP in Sf9 cells 
using electrophysiological whole cell recordings (Radford et al, 1997). Additionally, hP2X4 and 
Dictyostelium discoideum P2XA (DdP2XA) were expressed in sf9 insect cells by Valente and 
colleagues, the latter of which was purified and used for low resolution electron microscopy 
structural studies. The DdP2XA structure was solved to a resolution of 21 Å. (Valente et al, 
2011). Therefore the capacity for insect cells to successfully express, fold and traffic P2X 
receptors is well documented. Similarly, Panx1 and Panx2 channels have been successfully 
Figure 1.18 – Low resolution structures of rP2X2. (A) A schematic drawing of the rP2X2 
receptor model. (B) A cartoon showing the estimated pyramid, crown like shape of the 
extracellular domain of rP2X2. Reprinted from Biochemical and Biophysical Research 
Communications, 337(3), Mio et al, Visualization of the trimeric P2X2 receptor with a crown-
capped extracellular domain, p998-1005., Copyright (2005), with permission from Elsevier. 
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expressed using a baculovirus sf9 expression system. The expressed protein was purified and 
used for low resolution electron microscopy (described in section 1.4.2) (Ambrosi et al, 2010). 
Furthermore, P2X receptors have been expressed in the fruit fly (Drosophila melanogaster) 
itself by various groups. Hu et al (2010) ectopically expressed rP2X2 receptors in the Kenyon 
cells of Drosophila mushroom bodies with the intention of studying functional feedback from 
mushroom bodies of the fly brain to antennal lobes. Due to the small size of Kenyon cells, it is 
difficult to specifically activate these cells using electrophysiological methods; expressing 
rP2X2 in specific neurons of the fly brain using the Gal4-UAS system (see section 4.1.2) 
enabled precise activation of individual neurons. The effective activation of these neurons in 
Drosophila provided evidence that rP2X2 could indeed by expressed, folded and is functional 
in parts of the Drosophila nervous system (Hu et al, 2010). 
Lima and Meisenbock expressed rP2X2 in parts of the giant fiber (GF) system of Drosophila, 
which is responsible for escape movements such as jumping (Koto et al, 1981), under control 
of the driver lines GAL4-C17 or shakB-GAL4. ATP was chemically modified with 
photoremovable groups rendering it inactive and was microinjected into the CNS of flies. A 
flash of 355 nm laser light which released the active agonist (ATP) from the caged precursor 
resulted in typical GF-mediated escape movements. In addition, laser pulses repeated at 2.5 s 
intervals caused repeated escape responses. As well as showing that P2X2 is functional when 
expressed in the Drosophila nervous system, this work implied that P2X2 did not noticeably 
desensitise and ATP was rapidly cleared from the extracellular space (Lima and Miesenbock, 
2005). 
In a third series of experiments, concatenated rP2X2 was introduced into Drosophila 
melanogaster as a novel method for measuring functional connectivity between separate, 
defined neuronal subsets in the fly brain. Yao and colleagues developed a system where they 
used stimulation of rP2X2 in a defined set of neurons via application of ATP and 
simultaneously imaged calcium and cAMP responses in potential target neurons in order to 
study neuronal interactions. Again, their data confirms the functional response of rP2X2 to ATP 
in this system (Yao et al, 2012). 
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1.6  Aims and Objectives 
The three main aims of this project are: 
1. To develop the eye of the fruit fly as a new expression system for mammalian ion 
channels, specifically P2X2 and Pannexin 1 receptors, in order to gain a high yield of 
homogenous, folded protein for structural studies. 
2. To further develop the system by expressing P2X2 in the taste system of Drosophila 
allowing us to test the function of the protein expressed in this system and determine 
whether or not the protein is folded and targeted correctly in Drosophila. 
3. To use the expression of P2X2 in the Drosophila taste system to screen compounds 
from both compound libraries and compounds designed using structure based drug 
design as potential new agonists and antagonists of P2X receptors. 
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Chapter 2 – Materials and Methods 
2.1  Cloning 
2.1.1  Site directed mutagenesis 
Mutagenesis was performed using the Quikchange Lightning site-directed mutagenesis kit 
according to manufacturer’s instructions [Agilent – Cat No. 210519]. Complementary primers 
that contained the chosen mutation flanked by unmodified sequence were designed and used 
to amplify the plasmid using the following conditions.  
Segment No. of Cycles Temperature (°c) Time (seconds) 
1 1 95 120 
2 18 95 20 
60 10 
68 30/kb plasmid length 
3 1 68 300 
 
Each polymerase chain reaction (PCR) reaction was made up according to the Quikchange 
manufacturer’s instructions in 50 µl reactions with 10 ng double stranded DNA template and 
125 ng of each primer. 
The PCR products were treated with 2 µl Dpn1 enzyme to digest any remaining parental DNA 
and incubated at 37°c for one hour. 45 µl XL-10 gold ultracompetent cells [Agilent] were 
transferred to a 14 ml BD polypropylene round-bottom tube. 2 µl β-mercaptoethanol was 
added to the cells and the mixture was incubated on ice for 2 min. 2 µl of DNA was transferred 
to an aliquot of ultracompetent cells, tubes were gently swirled and incubated on ice for 30 
min. Cells were heat pulsed at 42°c for 30s, placed on ice for 2 min and placed in a shaking 
incubator at 37°c for 1 hour. Cells were then plated onto ampicillin agar plates and incubated 
overnight at 37°c. 
Colonies from agar plates were inoculated in 5ml of liquid medium containing the appropriate 
antibiotic. Tubes were placed in a 37°c shaking incubator overnight. Minipreps were 
performed using the Qiagen Spin miniprep kit [Qiagen] according to manufacturer’s 
instructions (below). The presence of mutations was verified by DNA sequencing. 
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2.1.2  Minipreps 
Minipreps were performed using QIAprep spin miniprep kit (Qiagen – Cat No. 27104). Bacterial 
cultures were centrifuged at 6,800 g for 3 min at room temperature. The pellet was 
resuspended in 250 µl buffer P1 and transferred to a 1.5 ml tube. 250 µl buffer P2 was added 
and mixed thoroughly by inversion. 350 µl buffer N3 was added and immediately mixed by 
inversion. The tube was centrifuged at 13,000 rpm in a table top microcentrifuge.  
The supernatant was transferred to a QIAprep spin column and centrifuged at 13,000 rpm for 
1 min. The flowthrough was discarded, 500 µl buffer PB was added to the spin column and 
centrifuged for 1 min. 750 µl of buffer PE was added to the column, centrifuged at 13,000 rpm 
for 1 min and flowthrough discarded. The spin column was centrifuged for a further minute to 
discard any residual wash buffer and transferred to a new 1.5 ml tube; 30-50 µl Buffer EB was 
added to the centre of the column. After one min standing, the tube was centrifuged for 1 min 
at 13,000 rpm and DNA was collected in the microcentrifuge tube. 
2.1.3  Midipreps 
Midipreps were performed using Qiagen Plasmid Midi Kit (Qiagen - Cat no. 12143). 50 ml 
bacterial culture was centrifuged at 6000 g for 15 min at 4°c. The bacterial pellet was 
resuspended in 6 ml buffer P1. 6 ml buffer P2 was added and tubes were inverted 6 times and 
incubated at room temperature for 5 min.  Following the incubation, 6 ml buffer P3 was added 
and mixed thoroughly by inversion. The lysate was poured into the QIAfilter cartridge barrel 
and incubated at room temperature for 10 min.  
4 ml buffer QBT was added to a HiSpeed tip and filtered through the resin. The cell lysate was 
then filtered into the HiSpeed tip using a plunger and pushing it through the Qiafilter cartridge. 
The HiSpeed tip was washed with 20 ml buffer QC. DNA was eluted by adding 5 ml buffer QF to 
the HiSpeed tip. The eluted DNA was collected into a 15 ml falcon tube, 3.5 ml isopropanol was 
added and the tubes were incubated for 5 min.  
A QIAprecipitator module was added to the end of a 20 ml syringe. The isopropanol-eluate 
mixture was filtered through the precipitator using the plunger under constant pressure. The 
precipitator was washed with 2 ml 70% ethanol and then air dried by pushing air through the 
filter twice. The precipitator was attached to a 5 ml syringe and 1 ml buffer TE was added to 
elute the DNA which was collected in a 1.5 ml microcentrifuge tube. The eluate was 
transferred back to the 5 ml syringe and re-filtered through the precipitator and collected in 
the 1.5 ml microcentrifuge tube. 
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2.1.4  Ligation reactions 
Quick stick ligase [Bioline – Cat No. Bio27027] was used for ligations according to 
manufacturer’s instructions. Ligation mixtures were left for 5-10 minutes at room 
temperature. 
2.1.5  Bacteria transformation 
1. DNA was transformed into 10-beta competent E coli cells [NEB – Cat No. C3019H] 
according to the manufacturers’ high efficiency transformation protocol and as 
described above for XL-10 ultracompetent cells. 
2. Z competent cells were made using the Z competent E coli transformation buffer set 
[Zymo Research – Cat No. T3002]. 50 µl aliquots of cells were thawed on ice and 1 µl 
DNA was added and mixed. Cells were incubated on ice for 5 minutes. 30 µl of the 
mixture was then spread on an appropriate antibiotic agar plate. 
2.1.6  PCR 
All PCR reactions were carried out using Velocity polymerase [Bioline – Cat No. BIO-21098], 
Phusion High fidelity polymerase [NEB – Cat No. M0530] or Platinum taq polymerase 
[Invitrogen – Cat No. 10966034] according to standard conditions stated in manufacturer’s 
instructions. Details of specific melting temperatures and primers used can be found in Table 
2.1 (p80-83). 
2.1.7  Agarose Gel electrophoresis 
1% agarose [Bioline – Bio 41025] was added to 1 x Tris Acetate EDTA 
(Ethylenediaminetetraacetic acid) buffer (40 mM Tris, 20 mM acetic acid, 1mM EDTA) and 
heated in a microwave oven until fully dissolved. When the mixture had sufficiently cooled, 5 
µl SafeView [nbsbio] was added and the mixture was poured into gel holders until set. 
Following loading of DNA, gels were run at 60-70V for approximately 1 hour. Gels were 
visualised under UV light using the ChemiDoc MP Imaging system [Biorad] and Image lab 
software. 
2.2  Cell culture 
2.2.1  Culture of HEK-293 cells 
Human embryonic kidney (HEK) 293 cells were maintained at 37°c, 5% CO2 in Dulbecco’s 
modified Eagle’s medium containing 10% foetal calf serum (FCS), 1% penicillin/streptomycin 
and 1% L-glutamine. Trypsin-EDTA 0.05% [Life technologies – Cat No. 25300-054] was added to 
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cells when they reached approximately 80% confluency. Cells were diluted and transferred to 
new flasks every 4 – 7 days. 
2.2.2  Transfection of HEK-293 cells 
DNA was transfected into HEK-293 cells using Lipofectamine 2000 [Life technologies – Cat No. 
11668-027] according to manufacturers’ recommendations. Cells were grown in 6 well plates 
to 60 – 80 % confluency. 1 µg DNA was mixed with 100 µl Optimem [Life technologies – Cat 
No. 31985-070]. 3 µl Lipofectamine reagent was incubated with 100 µl Optimem and 
incubated at room temperature for 5 minutes. The DNA-Optimem mixture was then mixed 
with the Lipofectamine-Optimem mixture and incubated at room temperature for 20 minutes. 
The solution was added drop wise to the cells. 
Cells were incubated for 48 hours at 37°C following transfection and media was changed after 
16 – 24 hours. 
2.2.3  Confocal microscopy 
HEK-293 cells were transfected with Lipofectamine 2000 [see Section 2.2.2 for details] and 
incubated at 37°c for 48 hours. Cells were plated onto glass-bottomed 35 mm plates at 
approximately 20% confluency. These cells were left to grow overnight and visualised after 18 
hours using the Leica TCS SP2 AOBS spectral confocal microscope system with a Leica DMIRE2 
inverted microscope. GFP was excited at 495 nm and emission detected at 550 nm. Media was 
removed and 2 drops of DAPI-containing antifade reagent were added to visualise nuclei of the 
cells. DAPI was excited at 410 nm and emission detected at 480 nm.  
2.3  Drosophila techniques 
Fly stocks were stored at 18 °c in food vials, sealed with a cotton wool plug. The food vials 
were changed every 4 weeks. Flies were raised on a standard corn meal agar/yeast diet (yeast 
powder, corn flour, dextrose, plant agar, Nipagen (10% p-hydroxy benzoic acid methyl ester) 
and propanoic acid).  
Virgin female flies and male flies for crosses were anaesthetised using CO2 and were stored at 
room temperature or 25°c in food vials. The food vials were changed regularly (every 2 – 3 
days) until enough flies were obtained. Each cross contained approximately 4 – 8 virgin female 
flies and 2 – 3 male flies. 
To amplify stocks for large scale purification, approximately 100 – 200 flies were added to 
bottles and these were changed 3 times a week. Flies were collected from all bottles once a 
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week; flies were anaesthetised using CO2, stored in 1.5 ml microcentrifuge tubes and frozen in 
liquid nitrogen. Flies were stored at -80°C until required.  
2.3.1  Imaging flies 
Whole flies - Flies were anaesthetised using carbon dioxide gas and placed in a chamber 
containing FlyNap [Carolina – Cat No. 173010]. GFP was visualised with an Olympus BX50 
microscope and an ultraviolet light arc lamp. 
Fly heads - heads were removed using tweezers and mounted onto a microscope slide. GFP 
was visualised with an Olympus BX50 microscope and an ultraviolet light arc lamp. 
2.3.2  Injecting Drosophila embryos 
hP2X4-his and hP2X4-GFP DNA constructs were cloned into the multiple cloning site (MCS) of 
pUAST-attB (Bischoff et al, 2007).  rP2X2-GFP and rPanx1-GFP were cloned into the MCS of a 
modified version of pUAST-attB containing 19 UAS sites (kindly supplied by Sonia Lopez de 
Quinto, Cardiff University). See Table 2.1 (p80-83) for details. 
The Phi31C integrase system involves the use of a site specific integrase (PhiC31) to mediate 
recombination between attB and attP recognition sites (Thorpe et al, 1998; Groth et al, 2004). 
Constructs flanked by attB sites in specialised vectors (e.g. pUAST-attB) are injected into white 
eyed fly lines containing known intergenic attp landing sites and with endogenous sources of 
PhiC31 integrase for targeted and efficient integration. The vector also contains a mini-white 
gene that allows for efficient selection of transgenic progeny (Bateman et al, 2006; Bischof et 
al, 2007; Markstein et al, 2008). 
Approximately 60 flies from a Phi31C fly stock were placed in a laying cage at 18°c containing 
apple juice agar plates (Agar, sucrose, Nipagen, ethanol and apple juice) 4 days before 
microinjection. One day before microinjection these cages were moved to a 25°C incubator. 
The agar plates were changed every hour the morning prior to microinjection until the 
afternoon when microinjection was carried out. Method A was used for hP2X4-his construct, 
Method B was used for remaining constructs. All constructs were injected into flies with the 
attp40 on the second chromosome or attP2 landing site on the third chromosome (Markstein 
et al, 2008). 
a) A soft paintbrush was used to gently remove the embryos from the apple agar plates. 
Microscope slides were coated with a small layer of glue which was obtained by 
soaking brown packaging tape in N-heptane. The embryos were placed on the glue and 
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the membrane was peeled from the embryos using a needle. They were then aligned 
on the slide so all the embryos were in the same orientation.  
b) Embryos were washed in 50% bleach for 1 min to remove the outer, chorion 
membrane surrounding the embryo. Embryos were washed and placed on a fresh 
apple juice agar plate and aligned for injection. A glue coated coverslip was gently 
pressed over the embryos to transfer them onto the coverslip. Coverslips were placed 
over silica beads allowing embryos to dry for 14 minutes before being coated with 
Halocarbon oil 700 [Sigma]. 
 
DNA for injection was diluted to 100 ng/µl and briefly centrifuged to sediment particulates 
that could clog the injection pipette and the supernatant was transferred to a new tube. Using 
a microloader tip [Eppendorf] 2 µl DNA solution was loaded into microinjection needles, pulled 
on a Sutter Puller, whereupon the tip of the needle was broken to 1-2 µm diameter. DNA was 
injected into the posterior pole of fly embryos using a Narishige IM-30 micro injector and 
Nikon Eclipse T5100 microscope, until minor movement of the cytoplasm was observed in 
phase-contrast microscopy. 
Following injection the embryos were placed on apple juice agar plates and 1st instar larvae 
were transferred to food vials. When the flies emerged from pupal cases, they were crossed to 
W1118 flies that have a white eye colour. Transgenic flies were distinguished from siblings by 
selection for an orange eye colour marker (mini-white) present in the construct. Transgenic 
flies were balanced by crossing with If/CyO balancer fly stocks. 
2.3.3  Drosophila DNA extraction  
50 µl squishing buffer (10 mM Tris base, 1 mM EDTA, 25 mM NaCl, 0.5 µL proteinase K [Sigma 
– Cat No. P4850], adjusted to pH8) was used to homogenise fly tissue (single fly) using a 
pipette tip in a 1.5 ml tube. The tube was incubated at 25°c for 20 min and then heated at 95°c 
for 2 min. The tube was then centrifuged at 2000 g for 1 min to pellet fly debris and the 
supernatant was transferred to a new tube. The DNA was then ready for use or stored at -20°c. 
2.3.4  Drosophila RNA extraction 
1 ml Trizol was used to homogenise fly tissue (single fly) using a micro pestle in a 1.5 ml tube, 
all RNAse free. The tubes were incubated at room temperature for 5 min. 0.2 ml chloroform 
was added; tubes were incubated for a further 10 min at room temperature and centrifuged at 
12,000 g for 15 min, 4°c. Approximately 400 µl of the colourless, upper-phase was transferred 
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to a fresh RNAse free tube. An equal volume of 70% ethanol was added to give a final ethanol 
concentration of 35% and tubes were thoroughly mixed by vortexing and inversion. 
The RNA was prepared and purified using the GeneJET RNA purification kit according to 
manufacturer’s instructions [Thermoscientific]. RNA was stored at -80°c.  
cDNA synthesis was performed using the superscript III First Strand synthesis system [Life 
technologies]. 180 – 850 ng of RNA was added to a tube with 7.7 µM oligo (dT)18 [Fermentas] 
and 0.77 mM dNTPs [NEB N0447S], made to a final volume of 13 µl with H2O. The tubes were 
heated to 65°c for 5 min and on ice for 1 min. 50 mM Tris-HCl, 75mM KCl, 3 mM MgCl2 (1 x FS 
buffer), 5 mM DTT, 20 units RNasin and 200 units Superscript III RT [Life technologies] were 
added to each tube and tubes were centrifuged briefly before being incubated at 50°c for 30 – 
60 min. The enzyme was then inactivated by heating to 70°c for 15 min. To remove RNA, 5 
units RNase H [NEB – M0297S] was added and tubes were incubated at 37°c for 20 min. 
2.4  Protein extraction and analysis techniques 
2.4.1  Cell lysis and protein extraction (HEK-cells) 
Cells were washed twice in phosphate buffered saline (PBS), resuspended in PBS, transferred 
to a microcentrifuge tube and centrifuged at 4,000 g for 3 min.  The supernatant was removed 
and the pellet was resuspended in 50 µl of Radioimmunoprecipitation assay (RIPA) buffer (20 
mM Tris-HCl [pH7.4], 150 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, protease inhibitors mixture 
[complete-EDTA free, Roche]), 1% n- Dodecyl B maltoside (DDM) was also added. Cell lysis was 
completed for 30 min on ice with regular agitation.  The mixture was centrifuged at 13,000 
rpm in a table top centrifuge for 2 min to discard insoluble material and the supernatant was 
collected. 
2.4.2  Membrane protein extraction (Drosophila) 
2.4.2.1  50 – 100 flies 
50 – 100 whole flies were frozen in liquid nitrogen and transferred to -80°c. Upon removal 
from the freezer, flies were placed on ice. 500 µL of sucrose buffer [50mM Tris-HCl, 250mM 
sucrose, 180mM NaCl, 2mM MgCl2 plus protease inhibitors] was added to each tube and a 
micro-pestle was used to homogenise fly tissue thoroughly. Tubes were centrifuged at 5000 
rpm for 1 min in a table top centrifuge to collect fly debris. The supernatant was transferred to 
a collection tube and centrifuged at 60,000 g, 4°c for 30 min. The supernatant was discarded 
and the pellet was resuspended in sucrose buffer. Detergent was added to a final 
70 
 
 
concentration of 1% DDM (rP2X2-GFP) or 7.5mM FC-12 (rPanx-GFP). These tubes were placed 
on ice, regularly agitated for 30 min and centrifuged at 13,000 rpm in a table top centrifuge for 
2 min. The supernatant (solubilised protein) was collected and ready to use or stored at -20°c 
for up to a month. 
2.4.2.2  2000 – 5000 flies 
2000 - 5000 whole flies were frozen in liquid nitrogen and transferred to -80°c. Upon removal 
from the freezer, flies were placed on ice. Glass homogeniser, falcon tubes, glass beads and 
sucrose buffer were also cooled on ice prior to experiment. 
4 ml glass beads (5 mm) were added to a falcon tube. 600 – 1,200 flies were also added and 
placed in liquid nitrogen. Tubes were quickly inverted, briefly vortexed and placed back in 
liquid nitrogen. This was repeated 3 – 4 times until the heads became detached from the fly 
body.  
A 710 micron sieve was stacked above a 425 micron sieve to collect fly heads. Liquid nitrogen 
was briefly poured onto the sieves to keep them cool. The contents of the falcon tube were 
transferred straight from liquid nitrogen to the sieve stack and the sieves were shaken to help 
the heads pass through the 710 micron sieve. The wings remained attached to the outside of 
the falcon tube, the fly bodies were retained on the 710 micron sieve, the heads were retained 
on the 425 micron sieve and the legs fell through to be collected underneath.  
The heads collected by the smaller sieve were brushed into a 50 ml glass homogeniser using a 
funnel. 5 ml of sucrose buffer was added to the homogeniser and the heads were thoroughly 
homogenised using a drill attached to the homogeniser. The homogenised material was then 
transferred to a 15 ml falcon tube. Tubes were centrifuged at 2000 g for 10 min to collect fly 
debris. The debris was re-homogenised in 5 ml sucrose buffer and centrifuged at 2000 g. This 
was repeated 3 times. The supernatants were pooled, transferred to a Beckmann tube and 
centrifuged at 100,000 g, 4°c for 1 hour. The supernatant was discarded and the pellet was 
resuspended in 100 – 500 µl sucrose buffer. Detergent was added to a final concentration of 
1% DDM (rP2X2-GFP) or 7.5mM FC-12 (rPanx1-GFP). Tubes were placed on ice, regularly 
agitated for 30 min and centrifuged at 13,000 rpm in a table top centrifuge for 2 min. The 
supernatant (solubilised protein) was collected and ready to use or stored at -20°c for up to a 
month. 
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2.4.3  Protein quantification 
1. A series of bovine serum albumin (BSA) protein standards were made from 0 mg/ml to 
1 mg/ml. 900µl Bradford ultra [Expedeon – BFU1L] was added to 60 µl protein 
standard and the absorbance was measured using the Beckman DU530 Lifescience 
UV/vis spectrophotometer at 595nm. Absorbance was plotted to produce a protein 
standard curve. 54µl of PBS and 900 µl Bradford Ultra were added to 6µl of protein 
sample in a macro cuvette [VWR]. Samples were briefly vortexed to ensure thorough 
mixing. The absorbance of each sample was measured at wavelength 595nm. 
Concentrations were determined using the standard curve (See Appendix I) 
2. Biorad protein assay reagent [Biorad – Cat No. 500-0006] was diluted 1 in 5 with 
ddH2O. 1 ml diluted reagent was added to 10 µl protein sample in a macro-cuvette and 
the absorbance was measured using the Beckman DU530 Lifescience UV/vis 
spectrophotometer at 595nm (See Appendix I). 
2.4.4  Western Blotting 
1. 6 x Sample buffer (100mM Tris-HCl [pH7.6], 10mM EDTA, 10% glycerol, 12% sodium 
dodecyl sulphate (SDS), 0.04% Bromophenol blue, 50mM TCEP and NaOH to pH7.6) 
was added to protein at a 5:1 v:v ratio. Protein samples were heated at 100°c for 2 
min followed by centrifugation at 13,000 rpm, 2 min in a table top centrifuge. 
Samples were run on a 10% polyacrylamide gel (separating gel- 10% acrylamide 
[Sigma – Cat No. A3699], 0.26M Tris-HCl, 0.05% SDS, 0.05% APS and 0.08% TEMED, 
made up to 4 ml with H2O, pH8.8. Stacking gel – 8% acrylamide, 0.56M Tris HCl, 0.1% 
SDS, 0.1% APS and 0.1% TEMED, made up to 4 ml with H2O, pH 6.6) at 100-200V for 1 
hour (Running buffer – TGS [25 mM Tris, 192 mM glycine, 0.1% SDS]) and transferred 
to a nitrocellulose membrane at 40 V for 1 hour (transfer buffer – 1 x NuPAGE 
transfer buffer [Invitrogen], 20% methanol).   
2. 6 x Sample buffer (100mM Tris-HCl, 10mM EDTA, 10% glycerol, 12% SDS, 0.04% 
Bromophenol blue, 50mM TCEP and NaOH to pH7.6) was added to protein sample at 
a 5:1 v:v ratio. Protein samples were heated at 100°c for 2 min followed by 
centrifugation at 13,000 rpm for 2 min in a table top centrifuge. Samples were run on 
4-15% mini-PROTEAN TGX stain free gels [BioRad – Cat No. 456-8085] at 250 - 300V 
for 20 minutes. The gel was UV illuminated for 5 minutes before being imaged on the 
Chemidoc MP imaging system [Biorad] to test for equal loading. Gels were blotted 
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onto Trans-blot turbo mini PVDF transfer packs [Biorad – Cat No. 170-4156] at 25V for 
3 minutes using BioRad Trans-blot turbo transfer system. 
Membranes were blocked in 3% Bovine Serum Albumin [PAA] in TBS (Tris Buffered Saline – 20 
mM Tris, pH7.5, 150 mM NaCl) or 5% dried milk [Marvel] in TBST (Tris Buffered Saline with 
Tween – 50 mM Tris, 150 mM NaCl, 0.05% Tween 20) depending on the antibody used [See 
section 2.4.4.1]. Primary antibodies were applied in 3% BSA or 5% milk and tubes rotated 
overnight at 4°c.  Membranes were washed in TBST 3 x 5 min and incubated with the 
secondary antibody in 3% BSA or 5% milk for 45min-1hour. Membranes were washed 4 x 5 min 
in TBST and developed with ECL prime kit [Amersham Biosciences] and viewed using ChemiDoc 
MP Imaging system [Biorad] and Image lab software. 
2.4.4.1  Antibodies 
Mouse monoclonal primary antibodies: Tetra-his antibody was used at 1:2000 [Qiagen – Cat 
No. 34670] in 3% BSA. β-actin antibody was used at 1:1000 [Abcam – Cat No. ab8224] in 3% 
BSA. Drosophila Rhodopsin antibody was used at 1:300 in 3% BSA [DSHB – Cat No. 4C5].  
Rabbit polyclonal primary antibodies: P2X2 antibody was used at 1:2000 in 5% milk [Alomone 
labs – Cat No. APR-003]. GFP antibody was used at 1:1000 in 5% milk [Invitrogen – Cat No. 
A11122]. 
Secondary antibodies: Polyclonal goat anti rabbit IGg / HRP [Dako – Cat No. P0448] was used 
at 1:2000 in 5% milk. Mouse IgG HRP-linked antibody [Cell signalling – Cat No. 70765] was used 
at 1:5000 in 3% BSA. 
2.4.5  Perfluorooctanoate-polyacrylamide gel electrophoresis 
For perfluorooctanoate-polyacrylamide gel electrophoresis (PFO-PAGE), 2 x sample buffer (100 
mM Tris base, 1% (w/v) NaPFO, 20% (v/v) glycerol, 0.005% Bromophenol Blue, adjusted to pH 
8 with NaOH) was added to protein in a 1:1 v:v ratio. SDS free 6 % polyacrylamide gels were 
run at 140 V at room temperature in PFO-containing buffer (25 mM Tris, 192 mM glycine, 0.5% 
PFO (w/v), adjusted to pH 8.5 With NaOH). Membranes were blocked and antibodies added as 
described in section 2.4.4 Membranes were developed with ECL prime kit [Amersham 
Biosciences] and viewed using ChemiDoc MP Imaging system [Biorad] and Image lab software. 
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2.4.6  Coomassie gels 
6 x Sample buffer (100mM Tris-HCl, 10mM EDTA, 10% glycerol, 12% SDS 0.04% Bromophenol 
blue, 50mM TCEP and NaOH to pH7.6) was added to protein sample at a 5:1 v:v ratio. Protein 
samples were heated at 100°c for 2 minutes followed by centrifugation at 13,000 rpm for 2 
min in a table top centrifuge. Samples were run on 4-15% mini-PROTEAN TGX stain free gels 
[BioRad – Cat No. 456-8085] at 250 - 300V for 20 min. Gel was then covered in Quick 
Coomassie Stain [Generon – Cat No. Gen-QC-Stain] for 1h – 16h at room temperature. Gels 
were washed 4 x 5 min with water prior to visualisation. 
2.4.7  Deglycosylation assays 
Endoglycosidase H (Endo H) [NEB – Cat No. P0702] – Approximately 35 – 45 µg (12.5 µl) of 
total extracted protein from HEK-293 cells or membrane protein extracted from approximately 
18 -20 flies (18 µl) was incubated with 2 µl denaturing buffer and H2O to make a final volume 
of 20 µl at 100°c for 10 min. Following the incubation 4 µl G5 buffer, 2 µl Endo H and 14 µl H2O 
were added and the protein was incubated for 1 hour at 37°c. 
Peptidyl -N-Glycosidase F (PNGase F) [NEB – cat# P0704] - Approximately 35 – 45 µg (12.5 µl) 
of total extracted protein from HEK-293 cells or membrane protein extracted from 
approximately 18 -20 flies (18 µl) was incubated  with 2 µl denaturing buffer and H2O to make 
a final volume of 20 µl at 100°c for 10 min. Following the incubation 4 µl G7 buffer, 2 µl 10% 
nonyl phenoxypolyethoxyethanol (NP40), 2 µl PNGase F and 12 µl H2O were added and the 
protein was incubated for 1 hour at 37°c. 
2.5  Protein purification techniques 
2.5.1  Nickel affinity purification (HEK) 
Protein was extracted from 4 x transfected T75 flasks (section 2.4.1). 0.5 ml Tris binding wash 
buffer (20 mM Tris HCl, 150 mM NaCl, 25 mM Imidazole, 0.2% DDM, protease inhibitors, 
pH7.4) and 25 µl nickel sepharose beads [GE Life Science – Cat No. 17-5268-01] were added to 
the protein sample. Samples were rotated for 1 hour at room temperature and centrifuged at 
5000 rpm for 1 min. The supernatant was removed and 0.5 ml wash buffer was added to the 
beads. Tubes were centrifuged at 5000 rpm for 1 min in a table top centrifuge and supernatant 
removed. This wash step was repeated 4 times. 50 µl elution buffer (20mM Tris-HCl, 150 mM 
NaCl, 1 mM TCEP, 500 mM Imidazole, 0.1% DDM, 1 x protease inhibitors, adjusted to pH7.9) 
was added to the pellet and mixed for 1-2 min. Tubes were centrifuged for 1 min at 5000 rpm 
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in a table top centrifuge for protein elution. The supernatant (elution) was transferred to a 
new tube. 
2.5.2  Nickel affinity purification (Drosophila) 
Protein samples were rotated with 0.5 – 1 ml sepharose beads [Nickel beads stripped with 
EDTA] for 2 to 3 hours at room temperature. Samples were then centrifuged at 5000 rpm in a 
microcentrifuge for 1 min. The supernatant was transferred to a fresh tube and the beads 
were discarded or kept for a western blot control. 25 µl nickel sepharose beads [GE Life 
Sciences] were added to the supernatant. Tubes were rotated overnight at 4°. 
The tubes were centrifuged at 5,000 rpm for 1 min. The supernatant was collected and stored 
(flowthrough). 500 µl wash buffer was used to resuspend the nickel beads. Tubes were 
centrifuged for 1 min at 5000 rpm, the supernatant was discarded. This wash step was 
repeated 5 times (retaining the wash 1 and wash 5 samples for western blotting purposes). 50 
– 100 µl elution buffer was added to the beads and mixed thoroughly for 1 – 2 min. Tubes 
were then centrifuged for 1 min at 5000 rpm. The supernatant (elution) was collected and 
transferred to a new tube. The beads were resuspended in sample buffer for western blotting.   
2.5.3  GFP TRAP 
The GFP-TRAP system [Chromotek] was developed to enable efficient one-step isolation of 
fluorescent fusion proteins. GFP TRAP involves the use of small recombinant alpaca antibody 
fragments covalently coupled to the surface of agarose beads which bind to fluorescent labels 
(e.g. GFP, YFP, CFP) and allow purification by immunoprecipitation. 
The GFP TRAP purification was performed using the GFP TRAP-A kit [Chromotek]. Total 
membrane protein was extracted from 1,500 fly heads and solubilised in 300 µl of sucrose 
buffer plus detergent (concn. 3 mg/ml) (see section 2.4.2 for details). The protein sample was 
further diluted to a total volume of 600 µl with ice-cold dilution buffer (10 mM Tris-HCl, pH 
7.5, 150 mM NaCl, 0.5 mM EDTA). 
20 µl bead slurry was resuspended in 500 µl ice-cold dilution buffer and centrifuged at 2500 g 
for 2 min at 4°c. The supernatant was discarded. This wash step was repeated twice. The 
diluted protein sample was added to the washed GFP-TRAP beads, mixed for 1 hour at 4°c 
under constant mixing and centrifuged at 2500 g for 2 min at 4°c. The supernatant was 
discarded 500 µl ice-cold dilution buffer was used to resuspend the beads. The beads were 
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centrifuged at 2500 g for 2 min at 4°c and supernatant discarded. This wash step was repeated 
twice.  
The beads were resuspended in 50 µl 0.2 M glycine, mixed for 30 sec and centrifuged at 2,500 
g for 2 min. Following centrifugation, the supernatant was transferred to a new 
microcentrifuge tube and immediately neutralised with 5 µl 1 M Tris base. This elution step 
was repeated and the supernatants pooled.  
2.5.4  Immunoprecipitation 
Total membrane protein was extracted from 1,800 fly heads and solubilised in 200 µl PBS + 
detergent (see section 2.4.2 for details). Immunoprecipitation was performed using Pierce 
classic IP kit [Pierce – Cat No. 26146] and the Invitrogen GFP antibody [Invitrogen – Cat No. 
A11122]. 10 µg anti-GFP was added to the protein sample. IP lysis/wash buffer was added to 
make a total volume of 500 µl and incubated overnight at 4°c.  
20 µl protein A/G agarose resin was added to a spin column placed in a collection tube and 
centrifuged at 1000 g for 1 minute. The flowthrough was discarded and the column was 
washed twice with 100 µl IP lysis/wash buffer. The bottom plug was inserted into the spin 
column and the antibody/protein sample mix was added to the tube and sealed with a screw 
cap. This was incubated under constant mixing for 1 hour at 4°c. The plug was removed and 
the spin column was placed in a fresh collection tube. The tube was centrifuged at 2000 g for 1 
minute and washed 4 times with 200 µl IP lysis/wash buffer followed by centrifugation. The 
tube was then further washed with 100 µl conditioning buffer.  
To elute the protein, the spin column was placed in a new collection tube. 50 µl elution buffer 
was added to the tube and incubated at room temperature for 10 min. The tube was then 
centrifuged at 2000 g for 1 min and the supernatant was collected [elution]. 
2.5.5  Ion exchange chromatography 
Membrane protein pellets prepared from 2000 – 5000 flies were solubilised in 1 – 1.5 ml low 
salt sucrose buffer (50 mM Tris-HCl, 250 mM sucrose, 20 mM NaCl, pH 7.4). Detergent was 
added to a final concentration of 1% DDM (rP2X2-GFP) or 7.5 mM FC-12 (rPanx1-GFP) (see 
section 2.4.2). After solubilisation, samples were made up to a total volume of 2 ml with start 
buffer (20 mM Tris-HCl, 20 mM NaCl and detergent [3 mM FC-12 for rPanx1-GFP and 0.2% 
DDM for rP2X2-GFP]). Protein was loaded onto a 5 ml HiTrap Q column [GE healthcare] using a 
2 ml sample loop and 5 ml syringe. A salt gradient was set up from 20 mM to 500 mM NaCl 
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using the standard ion exchange protocol for the Akta Prime. The gradient was set up over a 
20-minute period between start buffer and elution buffer (20 mM Tris-HCl, 500 mM NaCl, 3 
mM FC-12 (rPanx1-GFP) or 0.2% DDM (rP2X2-GFP) pH 7.4) at a flow rate of 1 ml per minute 
and 1 ml fractions were collected.  
2.5.6  Chitin bead protein purification 
HEK-293 cells were transfected with P2X4-int-CBD in 6 x 35 mm dishes (see section 2.2.2 for 
details). The protein pellets solubilised in 400 µl RIPA buffer plus detergent (see section 2.4.1) 
and were diluted to a total volume of 800 µl with column buffer (20 mM Tris-HCl, 500 mM 
NaCl, 1 mM EDTA, 0.1% DDM, pH 8.5). 
500 µl column buffer was added to 100 µl chitin bead slurry and centrifuged at 5000 rpm in a 
microcentrifuge for 1 min. The supernatant was removed and this wash step repeated.  The 
diluted protein sample was added to the washed beads and incubated under constant mixing 
for 1 hour at 4°c.  Following the incubation, samples were centrifuged at 5000 rpm for 1 min 
and the supernatant [flowthrough] was collected. The beads were washed 5 times with 1 ml 
column buffer. 100 µl cleavage buffer (20 mM Tris-HCl, 500 mM NaCl, 1 mM EDTA, 50 mM 
DTT, 0.2% DDM, pH8.5) was added to the beads and incubated overnight at 4°c. 
Tubes were then centrifuged at 5000 rpm for 2 min and supernatant [elution] was collected.                                                                                                                                                                                                                                                                                                                                                                  
2.5.7  Gel filtration chromatography 
300 - 450 µl of wash buffer (20 mM Tris-HCl, 150 mM NaCl, 25 mM Imidazole, 0.2% DDM or 3 
mM FC-12, pH 7.9) was added to 50 µl partially purified protein (HEK) or 200 µl purified 
protein (Drosophila) and centrifuged at 13,000 rpm, 2 min in a table top centrifuge to pellet 
protein aggregates. The column was washed with filtered, degassed ultrapure water and 
titration buffer (20mM Tris-HCl, 50mM NaCl, 0.05% DDM or 3mM FC-12, pH 7.9). The 
supernatant was injected into a Superdex 200 column [GE healthcare] using a 1ml syringe. The 
column was run at 0.5ml/minute and separated into 1 ml fractions according to size. A gel 
filtration standard [BioRad – Cat No. 151-1901] was used to calibrate the column (see 
appendix I). 
2.5.7.1  Fluorescence measurements 
200 µl of each fraction collected during gel filtration was transferred to a black 96 well plate 
and the fluorescence of each well was measured using the Fluoroskan Ascent FL [Thermo 
labsystems], excitation: 485 nm, Emission: 538 nm, integration time: 100 ms. 
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2.6  Electron microscopy 
Purified protein samples obtained after gel filtration were concentrated using a 50 kDa MWCO 
viva-spin-column to a volume of 200 µl. Protein samples were adsorbed onto a glow-
discharged carbon-coated grid and negatively stained with 2% uranyl acetate. Transmission 
electron microscopy images were recorded at a specimen level increment of 2.43 Å/pixel using 
a Jeol JEM-2100 LaB6 electron microscope at 200 kV. Samples were prepared for electron 
microscopy by Dr Mark T Young at the School of Biosciences, Cardiff University and images 
were taken by Dr Georgi Lalev at the School of Chemistry, Cardiff University. EMAN software 
was used to manually select, process and measure particles. 
2.7  Electrophysiology of the Drosophila taste system 
Taste recordings were performed on flies 5 – 15 days old following the protocol published by 
Benton and Dahanukar (2011). A high input-impedance (>1015 ) amplifier was used to record 
action potentials, and signals were digitised at 10000 sample/s in a Syntech A/D converter, and 
band-pass filtered between 50 and 5000 Hz. The rig was placed in a Faraday cage on a 
stabilized base plate. The fly was observed under 240x magnification using an Olympus SZ-70 
binocular. Electrodes were fashioned using chloride silver wire sheathed with 1 mm 
borosilicate glass micropipettes, which had been pulled to a fine tip. The tip of the recording 
electrode was broken to an approximately 5-10 m opening. 
The reference electrode was filled with Beadle-Ephrussi Ringer solution using a syringe and 
tapped to dislodge any air bubbles. The electrode was placed in the reference electrode 
holder. 
 A single fly and the microscope base plate were placed on ice for a minimum of 5 minutes. 
The fly was then placed on the base plate under the microscope and the forelegs of the fly 
were removed using forceps. The tip of the reference electrode was inserted into the dorsal 
side of the thorax. The electrode was pushed through the neck of the fly and into the 
proboscis until movement of the proboscis was minimal. 
The recording electrode was filled with the test solution using a syringe and was placed onto 
the recording electrode holder.  All test compounds were dissolved in water and tricholine 
citrate (TCC) was added as an electrolyte to a final concentration of 0.03M. Using the 
microscope and micro-manipulator the recording electrode was carefully placed over the tip of 
the sensillum, with the tip just breaking the meniscus of the solution. Action potentials were 
recorded using Autospike 32 software. 
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Consecutive stimuli applied to the same sensillum were applied at a minimum of one minute 
intervals. For changing solutions, the recording electrode was washed 15 times with water 
following by 6 washes with the new solution before filling the electrode. 
2.7.1  Testing the function of rP2X2-GFP in Drosophila 
100 mM sucrose was applied to each sensillum used to ensure the sensillum was still 
responsive. The solvent control (TCC), 100 µM ADP and 100 µM ATP were then applied to each 
sensillum in turn for 30 seconds and action potentials recorded. This was repeated on 10 – 12 
sensilla from a minimum of 3 different flies for each genotype tested (control: w; UAS-rP2X2-
GFP;+, panneural expression: C155-Gal4; UAS-rP2X2-GFP, and sugar neuron expression: w; 
UAS-rP2X2-GFP; Gr5a-Gal4). The number of action potentials was counted between 10 and 15 
s after compound application. 
2.7.2  Dose response curves 
100 mM sucrose was applied to each sensillum used to ensure the sensillum was still 
responsive. The solvent control TCC was then applied to each sensillum for 30 seconds and 
action potentials recorded. 1 µM, 3 µM, 10 µM, 30 µM, 100 µM and 300 µM ATP solutions 
were then applied to each sensillum in turn for 30 seconds. An additional concentration of 1 
mM was tested on w; rP2X2-GFP; Gr5a-Gal4 flies. The number of action potentials was 
counted between 10 and 15 s after compound application. This was repeated on 6 – 9 sensilla 
from a minimum of 3 different flies for each genotype tested (C155-Gal4; rP2X2-GFP, w; 
rP2X2-GFP; Gr5a-Gal4). 
2.7.3  Testing the adenosine nucleotide compound library 
100 mM sucrose was applied to each sensillum (C155-Gal4; UAS-rP2X2-GFP flies) to ensure it 
was still responsive after mounting. TCC and 100 µM ATP were then applied to each sensillum 
in turn for 20 seconds and action potentials were recorded. The sensillum was only used if the 
ATP response was more than 3 times greater than the TCC response. Each nucleotide from the 
adenosine nucleotide library [Jena Biosciences] was diluted in TCC to make a 100 µM stock in a 
final concentration of 0.03M TCC. Each nucleotide was then applied to one sensillum per fly for 
20 seconds on a total of 3 different flies (n=3) and action potentials recorded. One compound 
was tested per sensillum, up to 4 compounds were tested per fly. Action potentials were 
counted between 10 and 15 s after compound application. The compound responses and the 
TCC responses were normalised to the ATP response (100%). The four most effective 
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compounds were tested on an additional 3 flies to give an n of 6. These compounds were also 
tested on 3 control flies. 
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Construct Cloned from: Cloned into: Restriction 
enzymes: 
Primers: Tm Details 
pE-GFP-C1_int_CBD 
(with SapI site) 
 
PTXB1 (Contains 
intein-chitin binding 
domain region) 
pE-GFP-C1 Nhe1, BamHI 1, 2 66°c GFP removed from pE-GFP-C1 by 
restriction digest and replaced with int-
CBD obtained from PTXB1 using PCR 
(Phusion), restriction digest and 
ligation. 
pE-GFP-C1_int_CBD - - - 3, 4 60°C SapI sites removed from pE-GFP-C1-int-
CBD using Quikchange lightning SDM 
kit. 
hP2X4-int-CBD pL118 (hP2X4 full 
coding sequence in 
pcDNA3.1) Gift from 
Mark Young. 
pE-GFP-
C1_int_CBD 
NheI, SapI 5, 6 54°C hP2X4 amplified from pL118 by PCR 
(Phusion). PCR product and pE-GFP-C1-
int-CBD digested with NheI and SapI 
and ligated. 
hP2X4-GFP pL118 pE-GFP-C1 
(zfP2X4.1-
thr-GFP-his) 
XhoI, EcoRI 7, 8 54°C zfP2X4.1 removed from vector using 
XhoI and EcoRI. hP2X4 amplified from 
pL118 using PCR (Phusion DNA pol), 
restriction digest and ligation. 
 
Table 2.1 – Cloning of DNA constructs. Primers are located below table and maps of vectors/constructs in Appendix II. 
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rPanx1-GFP rPanx1 full coding 
sequence in 
pcDNA3.1. Gift from 
Pablo Pelegrin. 
pE-GFP-C1 
(zfP2X4.1-
thr-GFP-his) 
XhoI, EcoRI 9, 10 54°C zfP2X4.1 removed from vector using 
XhoI and EcoRI. rPanx1 amplified from 
Panx1 vector using PCR (Phusion DNA 
pol), restriction digest and ligation. 
rP2X2-GFP P698 (rP2X2 full 
coding sequence in 
pcDNA3.1) Gift from 
Alan North. 
pE-GFP-C1 
(zfP2X4.1-
thr-GFP-his) 
NheI, EcoRI 11, 12 48°C zfP2X4.1 removed from vector using 
NheI and EcoRI. rP2X2 amplified from 
p698 using PCR (Phusion DNA pol), 
restriction digest and ligation. 
rP2X7-GFP P927 (rP2X7 full 
coding sequence in 
pcDNA3.1)  
pE-GFP-C1 
(zfP2X4.1-
thr-GFP-his) 
XhoI, EcoRI 13, 14 54°C zfP2X4.1 removed from vector using 
XhoI and EcoRI. rP2X7 amplified from 
p927 using PCR (Phusion DNA pol), 
restriction digest and ligation. 
UAS-hP2X4-his pL118 pUAST-attB 
(from Basler 
lab in Zurich, 
Switzerland) 
XhoI, XbaI 15, 16 60°C PCR was used to amplify hP2X4-his 
from pL118. PCR product was cleaved 
with XhoI and XbaI and ligated into 
pUAST-attB cut with XhoI and XbaI. 
UAS-hP2X4-GFP hP2X4-GFP pUAST-attB XhoI, XbaI n/a  hP2X4-GFP cut out of vector with XhoI 
and XbaI and ligated into pUAST-attB 
cut with XhoI and XbaI. 
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UAS-rP2X2-GFP rP2X2-GFP pUAST-attB XbaI 17, 18 60°C PCR used to insert XbaI sites to each 
end of P2X2-GFP. Both PCR product 
and pUAST-attB cut with XbaI and 
ligated. Orientation checked with NotI 
digestion.  
UAS-rPanx1-GFP rPanx1-GFP pUAST-attB XhoI, XbaI n/a  rPanx1-GFP cut out of vector with XhoI 
and XbaI and ligated into pUAST-attB 
cut with XhoI and XbaI. 
UAS19-rP2X2-GFP UAS-rP2X2-GFP pUAST19-
attB (pUAST-
attB with 19 
UAS sites) 
Gift from 
Sonia Lopez 
de Quinto. 
XbaI n/a  rP2X2-GFP removed from UAS-rP2X2-
GFP using XbaI and purified by gel 
extraction. pUAST19-attB cut with XbaI 
and ligated to rP2X2-GFP.  Orientation 
checked with NotI digestion. 
UAS19-rPanx1-GFP UAS-rPanx1-GFP pUAST19-
attB 
XhoI, XbaI n/a  rPanx1-GFP removed from UAS-
rPanx1-GFP using XhoI and XbaI and 
purified by gel extraction. pUAST-
attB19 cut with XhoI and XbaI and 
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ligated to rPanx1-GFP. 
UAS19-rP2X2-LTS-1 UAS19-P2X2-GFP UAS19-P2X2-
GFP 
a) EcoRI 
b) NotI and 
BglII 
19,20 60°c LTS sequence from Gr64a was 
amplified by PCR from w1118 flies 
using primers 19 and 20. P2X2-GFP was 
removed from UAS19-P2X2-GFP by 
cutting with EcoRI and religating the 
vector. GFP was removed by cutting 
with NotI and BglII. The LTS-1 PCR 
product was ligated into the vector 
using Not I and BglII. Vector was cut 
with EcoRI and P2X2-GFP was re-
ligated into the vector. 
UAS19-rP2X2-STS-10 UAS19-P2X2-GFP UAS19-P2X2-
GFP 
a) EcoRI 
b) NotI and 
BglII 
21,20 60°c STS sequence from Gr64a was 
amplified by PCR from w1118 flies. 
Vector was prepared as above for 
rP2X2-LTS-1. (STS cloned in instead of 
LTS) 
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Primers: 
1. AGCGCTAGCTCGCGAGTCGACGGC 
2. AAGGGATCCCCTTCCTGCAGTCATTG 
3. CAGGATGATCTGGACGAGGAGCATCAGGGGCTC 
4. GAGCCCCTGATGCTCCTCGTCCAGATCATCCTG 
5. TATGCTAGCCCACCATGGCGGGCTGCTGC 
6. GGTGGTTGCTCTTCCGCACTGGTCCAGCTCACTAG 
7. TATCTCGAGCCACCATGGCGGGCTGCTGC 
8. ATAAGAATTCGCCTGGTCCAGCTCACTAG 
9. TATCTCGAGCCACCATGGCCATCGCCCAC 
10. ATAAGAATTCGCGCAGGATGAATTCAGAAG 
11. TATGCTAGCGCCACCATGGGCCGGCGCTTG 
12. ATAAGAATTCGCCAGTTGGGCCAAACC 
13. TATCTCGAGCCACCATGCCGGCTTGCTGCA 
14. ATAAGAATTCGCGTAGGGATACTTGAAGC 
15. TATCTCGAGAAGCTTATGGCGGGCTGCT 
16. ATATCTAGACTATCAGTGATGGTGGTG 
17. CTATTCTAGACAAAATGGGCCGGCGCTTGGC 
18. TATATCTAGACTATCAGTGATGGTGGTGATG 
19. AAAGCGGCCGCAGAGGAGCAGAAGCTGATCTCGGAGGAGGATCTGCTGAAGATGTGCGAGCTACTGGA 
20. TTTAGATCTTCAGGAGCACAGTGGCTG 
21. AAAGCGGCCGCAGAGGAGCAGAAGCTGATCTCGGAGGAGGATCTGCTGTTCCAGATGACCACACAGAC 
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Mutation Sense primer Antisense primer vector Tm of PCR 
reaction 
Reagent 
F81E ACCAACACTTCTAAACTTGGAGAGC
GGATCTGGGATGTGGCGGAT 
ATCCGCCACATCCCAGATCCGCTCT
CCAAGTTTAGAAGTGTTGGT 
pL118 60 °c Phusion DNA Polymerase (NEB) 
A93P GCGGATTATGTGATACCACCTCAG
GAGGAAAACTCCCTC 
GAGGGAGTTTTCCTCCTGAGGTGG
TATCACATAATCCGC 
pL118 60 °c Quikchange lightning SDM kit (Agilent) 
N97G ATACCAGCTCAGGAGGAAGGCTCC
CTCTTCGTCATGACC 
GGTCATGACGAAGAGGGAGCCTTC
CTCCTGAGCTGGTAT 
pL118 60 °c Quikchange lightning SDM kit (Agilent) 
A162L AAGACGTGTGAGGTGCTGGCCTGG
TGCCCGGTG 
CACCGGGCACCAGGCCAGCACCTC
ACACGTCTT 
pL118 60 °c Quikchange lightning SDM kit (Agilent) 
W194R CTTTTGGTTAAGAACAACATCCGGT
ATCCCAAATTTAATTTCAGC 
GCTGAATTAAATTTGGGATACCGG
ATGTTGTTCTTAACCAAAAG 
pL118 60 °c Quikchange lightning SDM kit (Agilent) 
H286N GATACACGGGACGTTGAGAACAAC
GTATCTCCTGGCTAC 
GTAGCCAGGAGATACGTTGTTCTCA
GTCCGTGTATC 
pL118 60 °c Quikchange lightning SDM kit (Agilent) 
 
 
  
Table 2.2 – Primers used during site directed mutagenesis of hP2X4. Altered amino acids are underlined. 
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Stock name Source Reference Genotype 
BL8121 – GMR-Gal4 Bloomington Drosophila stock 
center 
Freeman, M, MRC lab of 
molecular biology  
y1 w*; wgSp-1/CyO; P{longGMR-GAL4}3/TM2 
BL458 – Elav-Gal4 Bloomington Drosophila stock 
center 
Lin and Goodman, 1994 P{GawB}elavC155 
BL8691 – Rh1-Gal4 Bloomington Drosophila stock 
center 
Treisman, J, NYU Langone 
medical centre 
P{rh1-GAL4}3, ry506 
Gr5a-Gal4 Gift from Anupama Dahanukar 
(UCR) 
Ueno et al, 2006 w ; Gr5a-GAL4 ; Gr5a-GAL4 
nanos-phic31 ; attP40 (Stock 
13 – 18) 
Cambridge Stock Collection Markstein et al. 2008 y w M(eGFP, vas-int, dmRFP)ZH-2A; P{CaryP}attp40 
nanos-phiC31 ;; attP2 (Stock 
13 -20) 
Cambridge Stock Collection Markstein et al. 2008 y w P{y[+t7.7]=nos-phiC31\int.NLS}X #12;; 
P{y[+t7.7]=CaryP}attP2 
Double balancer stock Gift from Helen White Cooper 
(Cardiff University) 
n/a w ; If / CyO ; TM3 / TM6 
X-chromosome balancer 
stock 
Gift from Helen White Cooper 
(Cardiff University) 
n/a w-Lethal/FM7b; Sco/CyO 
UAS-eGFP Lab stock Spana, E, Harvard Universityf w; UAS-eGFP; UAS-eGFP 
W1118 Gift from Helen White Cooper 
(Cardiff University) 
n/a w-;+;+ 
Table 2.3 – Fly stocks and genotypes. 
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Chapter 3 - Expression of membrane 
protein constructs in mammalian cells 
3.1  Chapter 3 - Introduction 
3.1.1  Translation of membrane proteins 
P2X receptors and pannexin channels (Panx) are eukaryotic membrane proteins which play 
roles in many physiological processes, and are implicated in a number of diseases including 
cancer, arthritis, male fertility and mood disorders (Labasi et al, 2002; Xu and Huang, 2002; Li 
et al, 2014; White and Burnstock, 2006; Ralevic and Burnstock, 1998; Pelegrin and Surprenant, 
2007; White et al, 2005; Greig et al, 2003; Barden et al, 2006; Lucae et al, 2006; Hejjas et al, 
2009; Erhardt et al, 2007; Roger et al, 2010; White et al, 2013; Mulryan et al, 2000).  
Eukaryotic membrane protein biosynthesis occurs on the membrane of the ER. As the protein 
chain emerges from the ribosome, it is recognised by a signal recognition particle (SRP) that 
transfers the ribosome-chain complex to the translocon machinery; the extracellular portions 
of the membrane proteins are extruded into the lumen of the ER and the transmembrane 
domains (TMs) exit laterally through the translocon into the ER lipid bilayer (Geest and 
Lolkema, 2000; Ott and Lingappa, 2003). Evidence from co-expression studies with 
complementary fragments of rP2X2 indicates that the first transmembrane domain (TM1) 
‘waits’ in the translocon pore for the second transmembrane domain (TM2), and will not exit 
without it (Cross and High, 2009).  Several chaperone proteins are present in the ER lumen, 
including protein disulfide isomerase A3, calreticulin and calnexin to aid the correct folding and 
oligomerisation of the newly synthesised protein (Moremen et al, 2012). It is thought that, for 
P2X receptors, oligomerisation occurs in the ER, because the P2X6 subunit (which is incapable 
of forming homotrimers, but can form heteromeric receptors with P2X2 or P2X4 receptors) 
does not exit the ER, but when co-expressed with either P2X2 or P2X4, is found at the cell 
surface in heteromeric receptors (Ormond et al, 2006).  
 
3.1.2  Post-translational modification; N-linked glycosylation 
P2X receptors and Panx channels contain consensus N-glycosylation sequences (N-X-S/T, 
where X represents any amino acid except proline (Burda and Aebi, 1999), and several 
members of both protein families have been shown to be post-translationally modified by N-
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glycosylation (Rettinger et al, 2000b; Newbolt et al, 1998; Young et al, 2008; Vacca et al, 2011; 
Qureshi et al, 2007; Jones et al, 2004; Lenertz et al, 2010; Boassa et al, 2007; Penuela et al, 
2009). N-glycosylation is a post-translational modification that is added to a protein in the ER 
(core, high-mannose) by oligosaccharyl transferase (OST) which is embedded in the ER 
membrane with its catalytic site facing the lumen  (Geest and Lolkema, 2000). The saccharide 
chain is then subsequently modified (complex) as the protein traffics to the cell surface via the 
Golgi apparatus (see Section 1.2.4). Protein glycosylation has been demonstrated to be 
important for correct eukaryotic membrane protein trafficking to the cell surface, and P2X 
receptors and Panx channels are no exception; abolition of the N-glycan acceptor sequences 
by mutagenesis in P2X receptors leads to a loss of trafficking to the cell surface and thus a loss 
of protein function (Rettinger et al, 2000b; Newbolt et al, 1998; Vacca et al, 2011; Lenertz et al, 
2010). Furthermore, in P2X4 receptors, N-glycosylation has been shown to protect the protein 
from degradation in the lysosome which is essential for regulation of P2X4 expression at the 
cell surface (Qureshi et al, 2007). Conversely, although there is a preference for complex 
glycosylated species of Panx1 and Panx3 to be trafficked to the cell surface, non-glycosylated 
forms of both mouse channels were also shown to be able to reach the membrane (Penuela et 
al, 2009). Similarly, mutated rPanx1, which lacks a glycosylation site, showed a reduction but 
not abolition of cell surface expression (Boassa et al, 2008). Analysis of the N-glycosylation 
state of a eukaryotic membrane protein can provide information about protein quality in a 
heterologous expression system. N-glycosylation is also a potential problem for structural 
studies of membrane proteins because it adds unstructured regions to the protein and can 
increase heterogeneity, both of which inhibit crystallisation and reduce the obtainable 
resolution in particle averaging techniques (Chang et al, 1993). For these reasons it is often 
desirable to remove N-glycosylation by either mutagenesis (problematic for P2X receptors and 
Panx channels (see above)) or enzymatic treatment post-purification. 
Endoglycosidase H (Endo H) and Peptidyl-N-Glycosidase F (PNGase F) are glycosidase enzymes 
commonly used to study the N-glycosylation state of proteins. Endo H, isolated from 
Streptomyces plicatus, specifically cleaves asparagine-linked mannose-rich oligosaccharides 
from glycoproteins, cleaving between the 2 GlcNAc subunits adjacent to the asparagine 
residue (Maley et al, 1989) (see Fig 1.4). Hence following digestion with Endo H, a reduction in 
molecular weight of a glycoprotein indicates the protein undergoes high mannose 
glycosylation. PNGase F, isolated from Flavobacterium meningosepticum, cleaves between the 
innermost GlcNAc subunit and the asparagine residue of all high mannose, hybrid and complex 
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glycoproteins (Maley et al, 1989). If a further reduction in molecular weight of a glycoprotein is 
observed upon digestion with PNGase F, this signifies that the protein undergoes complex 
glycosylation. A reduction in molecular weight of approximately 2.5 kDa would be expected 
when an oligosaccharide chain is cleaved from a single glycosylation site (Geest and Lolkema, 
2000). For the removal of N-glycosylation for structural work, Endo H is the preferred 
treatment, because it cleaves efficiently under native conditions, as opposed to PNGase F, 
which works best on denatured protein. If any remaining complex glycosylation following 
deglycosylation with Endo H is still problematic for structure determination, the expression 
system can be changed (insect expression systems are not capable of complex glycosylation 
(see Introduction and Chapter 4)), or specialised mammalian cell lines deficient in complex 
glycosylation (GnTI- HEK-293 cell lines) (Reeves et al, 2002; Chaudhary et al, 2012) can be used.  
3.1.3  Mammalian protein expression: purification tags 
It is often the case with mammalian protein over-expression systems that the relative yield of 
protein (protein of interest as a percentage of total protein) is much lower than with other 
over-expression systems (approximately 0.1% in mammalian cells versus 20-30% in E. coli 
(Bernaudat et al, 2011; Gan et al, 2006)). For this reason it is important to use affinity 
purification tags which have high binding capacity and low non-specific binding. There are a 
large variety of purification tags available. Some of the techniques that can be employed for 
protein purification include ion-exchange chromatography, size-exclusion chromatography, 
affinity chromatography and immunoprecipitation. More than one of these methods is often 
required for efficient protein purification (Hagel, 2001). 
Immobilised metal affinity chromatography (IMAC) is very commonly used to purify proteins 
which contain an N- or C- terminal small poly-histidine (approximately 6-10 residues) affinity 
tag (His-tag), because of its low cost and ease of use. Transition metal ions (commonly Co2+, 
Ni2+) are immobilised to a solid matrix; these ions interact with the side chains of histidine 
residues upon contact with the protein of interest. Electron-donor groups of the histidine 
imidazole ring form bonds with the metal ion (Fig 3.1). Other proteins should not bind to the 
solid matrix and can be eluted (Bornhorst and Falke, 2000). Following immobilisation of the 
protein to the matrix, a change in pH or the addition of imidazole can be used to elute the 
protein. However, a drastic change in pH can cause protein denaturation and so low pH elution 
is unsuitable for purification if protein structure is to be retained.  
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This method has been successfully used to purify proteins expressed in a number of systems 
including E. coli, S. cerevisae, mammalian cells and baculovirus-infected insect cells (Van-Dyke 
et al, 1992; Kaslow and Shiloach, 1994; Janknecht and Nordheim, 1992; Kuusinen et al, 1995), 
with up to 95% purity (Janknecht et al, 1991). Although it is possible that the His-tag can 
impede protein activity, this is unlikely due to the small size and charge of the tag. Additionally 
the folded protein may cause occlusion of the tag and nickel affinity purification would not be 
useful when trying to maintain protein structure. 
 
 
 
 
 
 
 
An additional system which allows purification in a single chromatographic step is the IMPACT 
(Intein mediated purification with an affinity chitin-binding tag) system. This system is a 
tandem-tag consisting of a self-cleaving protein (intein) and a chitin binding domain (CBD) 
affinity tag, which can be cloned onto the N- or C- terminus of a protein construct, and which 
enables purification of the protein by affinity purification on a chitin resin. The addition of thiol 
reagents such as DTT (dithiothreitol) activates the intein and enables release of the target 
protein from the intein-CBD tag (Watanabe et al, 1994; Chong et al 1998). 
Similarly the addition of other tags such as a strep-tag, which is an 8 residue peptide sequence 
(Trp-Ser-His-Pro-Gln-Phe-Glu-Lys) or a myc-tag which is a 10 residue peptide sequence (Fly-
Gln-Lys-Leu-Ile-Ser-Glu-Glu-AsP-Leu), to the N- or C-terminus of a protein will allow protein 
purification using immobilised streptavidin or a high affinity anti-myc antibody respectively 
(Schmidt and Skerra, 1994; Zhao et al, 2013).  
Removal of the purification tag before structural studies is often desirable, and one way to 
achieve this is to introduce a thrombin cleavage site (TCS) (Leu-Val-Pro-Arg-Gly-Ser) between a 
protein and its tag. Upon the addition of thrombin under native conditions, the tag is cleaved 
between the Arg and Gly residues. In addition, appropriately tagged thrombin can be used as 
Figure 3.1 – Nickel affinity chromatography. (A) Schematic of sepharose bead (grey sphere) 
bound to nickel (blue sphere). (B) Nickel sepharose bead bound to hexa-histidine tag. 
A B 
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the final purification step (i.e. instead of imidazole during metal affinity chromatography) to 
remove the protein from the resin (Hefti et al, 2001). 
Immunoprecipitation is another method which can be used for the purification of an individual 
protein from a protein mixture or cell lysate, providing a relevant antibody which binds to the 
protein of interest is available.  The antibody is often coupled to a solid substrate such as 
protein A- or protein G- (immunoglobulin binding proteins)-agarose. Upon contact with the 
protein antigen, the antibody-substrate complex will bind to the protein enabling physical 
separation from the rest of the protein mixture using centrifugation (Fig 3.2) (Bonifacino et al, 
2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 – Immunoprecipitation. Cell lysates or protein extractions can be purified using a 
specific antibody in Immunoprecipitation. The antibody is bound to a protein A/G-agarose 
substrate and incubated with a cell lysate or protein preparation. The protein with the antigen 
specific to the antibody will bind to the beads and can be separated from the remaining, 
unbound proteins. The protein of interest can then be eluted by low pH elution or antigen 
competition. 
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Gel filtration chromatography is a technique used to separate proteins according to their 
molecular size by passing the protein mixture through a porous column. Large molecules elute 
first due to exclusion from the matrix and small molecules elute later due their penetration 
into a larger number of pores within the matrix. Gel filtration is often used as an additional 
purification step following IMAC or immunoprecipitation. Additionally gel filtration can be used 
to assess the oligomeric state of a protein and separate monomers from protein oligomers 
(Hagel, 2001). 
3.1.4  Aims of this chapter 
The aims of this chapter were to construct and express a series of membrane protein 
constructs, which were fused to purification tags, in HEK-293 cells. It also aimed to study the 
glycosylation, localisation and purification of the constructs. The membrane protein constructs 
generated were rP2X2-GFP, rPanx1-GFP, rP2X7-GFP, hP2X4-GFP and hP2X4-int-CBD. These 
constructs were transfected into HEK-293 cells to determine whether or not they could be 
expressed. In addition, their glycosylation state, oligomeric state and expression pattern within 
the cell was studied to help assess protein quality. Two purification strategies were tested; 
metal affinity chromatography and the IMPACT system.  
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3.2  Chapter 3 – Results 
3.2.1  Mutagenesis of hP2X4 receptors 
zfP2X4.1 was chosen for structural studies by Kawate and colleagues due to its stability and 
ability to form trimers in detergent solution (Kawate et al, 2009). Previous work (Valente et al, 
2011) used non-denaturing PFO-PAGE to analyse the degree of trimer formation of both hP2X4 
and Dictyostelium discoideum P2XA (DdP2XA), finding that wild-type hP2X4 did not form stable 
trimers when assessed using this technique, whereas DdP2XA did. The authors concluded that 
improving the trimer stability of hP2X4 was a prerequisite for successful structure 
determination.  
For this reason, I introduced a number of mutations into hP2X4 based upon amino-acid 
sequence differences between hP2X4 and zfP2X4.1 to try and increase the strength of the 
subunit-subunit interactions and hence the stability of hP2X4 trimers in detergent solution. 
Amino-acid residues positioned at the subunit interface of zfP2X4.1 were compared with the 
equivalent residues in a molecular model of hP2X4 based upon the zfP2X4.1 crystal structure. I 
identified six differences which gave rise to significant changes in the amino-acid properties 
and used site-directed mutagenesis to mutate these residues to their corresponding residue in 
zfP2X4.1 (Phe81Glu, Ala93Pro, Asn97Gly, Ala162Leu, Trp194Leu and His296Asn) (shown in 
magenta in Fig 3.3A). 
Mutant constructs were expressed in HEK-293 cells by transient transfection and their 
expression was confirmed by western blotting (Fig 3.3A). Notably, the expression level of 
zfP2X4.1-GFP was considerably lower than that of hP2X4 and the mutant constructs. 
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PFO-PAGE was used to assay the oligomeric state of hP2X4 and the 6 hP2X4 mutants to see if 
any of the mutations had a significant effect on trimer stability in detergent. However the 
protein for all P2X4 constructs formed a mixture of monomers, dimers and trimers but the 
B 
A 
Figure 3.3 – Site directed mutagenesis of hP2X4. (A) Homology model of hP2X4, based on 
zfP2X4.1. Green, blue and grey cartoons represent the different subunits. Amino acid residues 
modified using site directed mutagenesis (SDM) are shown by fuchsia spheres. Inset – close up 
of the location of 2 modified amino acids acting at the subunit interface. Black shows the 
surrounding location in the adjacent subunit. (B) [top] Western blot of zfP2X4-GFP, hP2X4-his 
and the 6 mutant hP2X4-his constructs in HEK-293 cells. Proteins were detected using a tetra-
his primary antibody [Qiagen]. hP2X4 and the 6 mutants show a high level of expression. 
zfP2X4-GFP is expressed at a much lower level in HEK-293 cells. [Bottom] Western blot of the 
same protein set probed with anti-β-actin [Abcam] to ensure equal loading. All cells were 
transfected for 48 hours using Lipofectamine 2000 [Invitrogen]. 
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majority was monomeric (Fig 3.4A). zfP2X4-GFP was shown to form strong trimers in detergent 
using fluorescence size exclusion chromatography (FSEC) (Kawate et al, 2009). DdP2XA, a P2X 
receptor expressed in the slime mould, Dictyostelium discoideum, was also shown to form 
stable trimers, by PFO PAGE (Valente et al, 2011). Consequently the oligomeric state of zfP2X4-
GFP and DdP2XA were investigated to use as controls in PFO PAGE. DdP2XA formed stable 
trimers (MW approximately 125kDa). However zfP2X4-GFP did not form stable trimers in PFO 
detergent (MW approximately 80kDa); the majority of the protein was monomeric (Fig 3.4B).  
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P2X-GFP monomer
DdP2XA trimer
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Figure 3.4 – PFO PAGE of constructs in HEK-293 cells. (A)  Western blot analysis of hP2X4-his 
and the 6 mutant proteins following PFO-PAGE [anti-His, Qiagen]. HEK-293 cells were 
transfected with P2X4 receptor constructs carrying a C-terminal his-tag. All constructs formed 
a mixture of monomers, dimers and trimers. The result shown is representative of 3 assays. 
(B) Western blot analysis of hP2X4-his, DdP2XA and zfP2X4.1-GFP following PFO-PAGE [anti-
His, Qiagen]. The majority of DdP2XA formed stable trimers, whereas hP2X4-his and zfP2X4-
GFP were mostly monomeric (Note: the size of zfP2X4 is slightly larger than hP2X4-his due to 
the addition of GFP). The result shown is representative of 2 assays. 
96 
 
 
As zfP2X4-GFP did not form stable trimers using the PFO-PAGE assay as expected, FSEC was 
used to further investigate its oligomeric state to distinguish between the two possibilities 
that; (1) the protein is being denatured or the oligomer is not stable in PFO detergent or (2) 
the protein was not forming trimers in HEK-293 cells. The hP2X4 construct was cloned into the 
zfP2X4.1-GFP vector which allowed the his-tag to be replaced with a thrombin-cleavable GFP 
his-tag for visualisation and comparative purposes (Fig 3.6). The proteins were purified via 
their C-terminal his-tag using nickel affinity chromatography. The partially purified protein was 
applied to a Superdex 200 size exclusion column and the protein was separated into fractions 
according to size. The GFP fluorescence of a sample from each fraction was subsequently 
measured in a fluorescence plate reader.  
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Figure 3.5 – Fluorescence size exclusion chromatography elution profiles. FSEC profiles of 
zfP2X4-GFP (top) and hP2X4-GFP (bottom) protein extracted and purified from HEK-293 cells. 
Yellow arrow indicates the void volume. Numbers adjacent to peaks show the estimated 
molecular weight of the protein elution (kDa). Expected size of hP2X4-GFP and zfP2X4-GFP 
monomer approximately 80 kDa + 60 kDa detergent micelle. 
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The FSEC results show that purified zfP2X4-GFP protein forms an oligomeric structure in DDM 
detergent with a molecular weight of approximately 466 kDa; the purified protein is made up 
of a mixture of a large oligomer (possibly a trimer) and a smaller band of approximately 23 kDa 
which may represent free GFP (Fig 3.5). Purified hP2X4-GFP also formed an oligomer of the 
same molecular weight (466 kDa) in DDM detergent and free GFP (17 kDa) (Fig 3.5). The data 
for the column calibration standards can be found in Appendix I. Taking these results into 
account it was decided to continue working with wild type hP2X4 as both proteins (hP2X4-GFP 
and zfP2X4-GFP) gave similar FSEC profiles but hP2X4 was expressed at a higher level with less 
GFP degradation. 
3.2.2  Construction of membrane protein constructs 
Three other membrane protein DNA constructs were cloned into the zfP2X4-GFP vector – 
rP2X2, rP2X7 and rPanx1 giving rise to rP2X2-GFP, rP2X7-GFP and rPanx1-GFP protein 
constructs, each of which has a thrombin cleavable GFP his-tag (Fig 3.6).  
 
 
 
 
 
 
 
Additionally, a hP2X4 construct with an intein chitin-binding-domain tag to enable protein 
purification using a chitin column was cloned. The intein allowed for straightforward tag 
removal using thiol reagents such as DTT. 
3.2.3  Expression and purification of protein constructs in HEK cells 
The constructs were expressed in HEK-293 cells and their expression was analysed using 
western blotting. hP2X4-GFP, rP2X2-GFP, rPanx1-GFP and hP2X4-int-CBD constructs were 
successfully expressed  in HEK cells and detected by western blotting with anti-GFP and anti-
P2X4 antibodies appropriately. However, rP2X7-GFP was not expressed in HEK-293 cells (Fig 
Figure 3.6 – Protein construct schematic – Each protein (rP2X2, hP2X4, rP2X7 and rPanx1) was 
cloned into the zfP2X4.1-GFP vector. Each protein was fused to a GFP tag (for visualisation 
purposes), C-terminal his-tag (for purification) and a thrombin cleavage site (to enable removal 
of the tag). 
99 
 
 
Figure 3.7 – Expression of protein constructs in HEK-293 cells. (A) Western blot of rP2X2-GFP, 
rPanx1-GFP, hP2X4-GFP and rP2X7-GFP protein constructs expressed and extracted from HEK-
293 cells (anti-GFP, Invitrogen). 10 µg protein loaded/lane. (B) Stain-free gel (blotted in A) 
visualised under UV light following SDS PAGE to ensure equal loading. (C) Western blot of 
hP2X4-GFP and hP2X4-int-CBD protein constructs expressed and extracted from HEK-293 cells 
(anti P2X4, Alomone). 10 µg loaded per lane. (D) Stain-free gel (blotted in C) visualised under 
UV light following SDS PAGE to ensure equal loading. 
3.7). Due to the lack of expression of rP2X7-GFP in HEK-293 cells, no more work was 
performed with this construct. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
rP2X2-GFP and rPanx1-GFP were purified from HEK-293 cells using nickel affinity 
chromatography. Fractions were taken at each stage of the purification process to assess 
binding and elution of protein to nickel beads (see Fig 3.8). The majority of the protein bound 
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successfully to the nickel beads with a small amount observed in the nickel flowthrough 
fraction. Most of the protein was eluted upon the addition of 1M imidazole. However some 
remained bound to the nickel beads (Fig 3.8 B/C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
hP2X4-int-CBD was purified by binding to a chitin resin and eluting with DTT. Most of the 
protein did not bind to the chitin beads and washed out in the flowthrough. Additionally more 
Figure 3.8 – Purification of rPanx1-GFP and rP2X2-GFP from HEK-293 cells. (A) Schematic 
showing steps undertaken during rPanx1-GFP purification. (B/C) Western blots showing 
purification of rPanx1-GFP (B) and rP2X2-GFP (C) from HEK cell extracts using nickel affinity 
chromatography (anti GFP, Invitrogen). Each blot shows the ‘Total’ starting fraction, the nickel 
flowthrough (Ni FT), wash 1 and wash 5, the elution and what remains on the nickel beads 
after elution (as shown in purple in A). The majority of the protein successfully bound to nickel 
beads and was eluted with 1M imidazole. rPanx1-GFP is shown as an example in (A).  
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protein became displaced during washing steps. Cleaved protein can be observed in both the 
elution and remaining on the chitin beads (Fig 3.9). 
 
 
 
 
 
 
 
 
 
 
 
The oligomeric state of purified rP2X2-GFP and rPanx1-GFP was investigated using FSEC. 
rPanx1, suggested to form hexamers based on results from cross-linking experiments and SDS-
PAGE, where a protein band of approximately 290 kDa was observed (Boassa et al, 2007), did 
not appear to form hexamers under these conditions (expected molecular weight of Panx1-
GFP hexamer with a DDM detergent micelle – 450 – 490 kDa). The majority of the protein, 
separated by FSEC gave peaks corresponding to molecular weights of 156 kDa and 17 kDa, 
which are likely to represent dimeric protein and free GFP respectively. Unlike hP2X4, rP2X2 
did not form a stable oligomer in detergent; the majority of the protein corresponded to a 
molecular weight of 30 kDa, indicating that the GFP is largely cleaved from the protein during 
FSEC. There is also a peak in the void volume which is aggregated protein (Fig 3.10).  
  
Figure 3.9 – Purification of hP2X4-int-CBD – Western blot showing purification of hP2X4-int-
CBD extracted from transfected HEK cells using chitin beads [anti P2X4, Alomone]. Little 
protein bound to the chitin beads and some was also displaced during the washing steps. A 
small amount of protein was successfully eluted following cleavage and some remained bound 
to the beads after cleavage of the tag. 
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3.2.4  Localisation of constructs in HEK-293 cells 
The localisation of membrane proteins is very important for correct protein function. The 
distribution of hP2X4-GFP, rP2X2-GFP and rPanx1-GFP was investigated in HEK-293 cells using 
confocal microscopy. hP2X4-GFP displayed a punctate distribution throughout the cell with the 
majority expressed inside the cell (Fig 3.11). rPanx1-GFP expression was more defined to the 
cell surface with a lower level of intracellular expression than hP2X4-GFP (Fig 3.11). rP2X2-GFP 
displayed a similar expression distribution in HEK-293 cells to hP2X4-GFP. However the 
Figure 3.10 – Fluorescence size exclusion chromatography elution profiles. FSEC profiles of 
rP2X2-GFP (top) and rPanx1-GFP (bottom) protein extracted and purified from HEK-293 cells. 
Yellow arrow indicates the void volume. Numbers adjacent to peaks show the estimated 
molecular weight of the protein elution (kDa). Expected size of rP2X2-GFP monomer – 
approximately 85 kDa + 60 kDa detergent micelle. Expected size of rPanx1-GFP monomer – 
approximately 70 kDa + 60 kDa detergent micelle. 
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localisation of rP2X2-GFP is less punctate but still predominantly intracellular, possibly being 
retained at the ER or Golgi (further experiments would be required to confirm the exact 
localisation).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 – Confocal Images of protein constructs expressed in HEK-293 cells. Images 
taken using a Leica confocal microscope. Protein-GFP constructs are shown in green – hP2X4-
GFP (left), rPanx1-GFP (middle) and rP2X2-GFP (right). The nuclei were stained using dapi and 
are shown in blue in the bottom images for hP2X4-GFP and rPanx1-GFP. Scale bar = 10µm. 
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3.2.5  Glycosylation of hP2X4-GFP, rP2X2-GFP and rPanx1-GFP in 
HEK-293 cells 
As explained in the introduction, correct glycosylation of membrane proteins is important for 
protein targeting and/or function. To investigate the glycosylation state of rP2X2-GFP and 
rPanx1-GFP protein constructs in HEK-293 cells 2 deglycosylation enzymes were used; PNGase 
F which is capable of deglycosylating all glycoproteins including complex and hybrid 
glycoproteins and Endo H which only deglycosylates high-mannose glycoproteins. 
rP2X2-GFP underwent high mannose glycosylation in HEK cells as shown by the reduction in 
molecular weight by western blotting following incubation with Endo H. However following 
digestion with PNGase F, the protein did not undergo a further reduction in molecular weight 
(Fig 3.12B). This data suggests that rP2X2-GFP does not undergo complex glycosylation in this 
system. rPanx1-GFP protein underwent high mannose glycosylation in HEK cells; the lower 
molecular weight band is reduced upon digestion with Endo H. Additionally rPanx1-GFP 
underwent hybrid/complex glycosylation in HEK cells; the band of higher molecular weight was 
reduced to a basal size upon digestion with PNGase F (Fig 3.12A). Like rP2X2-GFP, hP2X4-GFP 
underwent high mannose but no complex glycosylation in HEK cells (Fig 3.12C). 
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Figure 3.12 – Glycosylation of protein constructs in HEK-293 cells. – (A) Western blot showing 
deglycosylation of rPanx1-GFP extracted from HEK cells with Endo H and PNGase F. (B) 
Western blot showing deglycosylation of rP2X2-GFP extracted from HEK cells with Endo H and 
PNGase F. (C) Western blot showing deglycosylation of hP2X4-GFP extracted from HEK cells 
with Endo H and PNGase F. (All blots detected with anti-GFP, Invitrogen). G0 = non-
glycosylated protein, G1 = high mannose glycosylated protein, G2 = complex glycosylated 
protein. All blots representative of 2 assays. 
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3.3  Chapter 3 – Discussion 
3.3.1  PFO-PAGE and FSEC of zfP2X4-GFP and hP2X4-GFP 
zfP2X4-GFP formed stable trimers following FSEC according to Kawate et al, 2009, when the 
closed state crystal structure was solved to a resolution of 2.9 Å. Although the data was not 
shown, they also assessed the oligomeric state of 34 other P2X receptors following 
solubilisation in detergent and stated that zfP2X4.1 was chosen as a candidate for 
crystallisation due to its sharp and symmetrical elution profile. They also showed that rP2X4 
largely dissociates following solubilisation in detergent without the use of high concentrations 
of cross-linkers (Kawate et al, 2009). Using this knowledge, I sought to improve the 
solubilisation behaviour of hP2X4 based on the zfP2X4 structural data. As previously stated, 
residues acting at the subunit interfaces were analysed and 6 residues with significantly 
different properties in zfP2X4 and hP2X4 were identified (F81, A93, N97, A162, W194 and 
H286). These residues were mutated to the equivalent residues present in zfP2X4.1. The 
oligomerisation state of the mutated proteins was then analysed using PFO PAGE to allow the 
assessment of the native quarternary structure of membrane proteins in the presence of the 
mild detergent, PFO (Fig 3.4) (Ramjeesingh et al, 1999). Wild type hP2X4 dissociated in the 
presence of PFO and the majority of the protein was monomeric. In addition, none of the 6 
mutations had a significant effect on trimer formation (Fig 3.4). Two control proteins were also 
assessed using this method; DdP2XA, which was previously shown to form stable trimers in 
PFO detergent (Valente et al, 2011) and zfP2X4.1 (Fig 3.4B). Although DdP2XA formed trimers 
(with an approximate molecular weight of 120 kDa) following PFO PAGE, the majority of 
zfP2X4-GFP protein formed monomers (with an approximate molecular weight of 80 kDa). As 
the control protein, zfP2X4-GFP, did not form trimers with PFO solubilisation, the 
oligomerisation state was further investigated using FSEC. 
hP2X4-GFP and zfP2X4-GFP constructs were purified using nickel affinity purification and the 
purified protein was analysed using FSEC. Contrary to PFO results, both protein constructs 
formed an oligomer of approximately 466 kDa in the presence of the detergent, DDM. DDM 
was chosen for protein solubilisation due to its previous successful use with P2X receptors (Sim 
et al, 2004; Mio et al, 2005; Kawate et al, 2009; Valente et al, 2011). DDM is a mild, non-ionic 
detergent commonly used for membrane protein solubilisation due to its ability to readily 
solubilise many membrane proteins in a functional state (Seddon et al, 2004). The calculated 
molecular weights of both hP2X4-GFP and zfP2X4-GFP are higher (466 kDa) than the expected 
molecular weight of a hP2X4-GFP trimer with a DDM micelle (300 kDa), and the peak is more 
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comparable to that of a P2X4 tetramer than a trimer. The peaks are not likely to represent 
aggregated protein as aggregates would be observed in the void volume of the column. 
Although it cannot be ascertained, column calibration may have been inaccurate as the 
molecular weight markers were run in the presence of detergent and so could have affected 
the molecular mass of the individual protein standards; if this was the case, it is possible that 
both proteins were forming stable trimers in DDM. The gel filtration results showed that a 
larger proportion of hP2X4-GFP formed stable oligomers compared to zfP2X4-GFP (Fig 3.5). In 
light of this result I decided to discontinue working with the 6 hP2X4 mutant constructs. 
The PFO-PAGE and gel filtration results differed from one-another significantly for both the 
hP2X4 and zfP2X4 protein constructs; PFO-PAGE indicated that the proteins all formed a 
mixture of monomers, dimers and trimers and gel filtration indicated formation of an oligomer 
with a molecular weight higher than would be expected for a trimer. As zfP2X4-GFP was 
previously shown to form strong trimers in the presence of DDM, it was expected to form a 
trimer in both assays. It may be that although PFO-PAGE appeared to be a valid technique for 
assessing the oligomerisation state of DdP2XA, it is not valid for studying other P2X receptors. 
One possible reason for this is that while PFO preserves some oligomeric protein structures, it 
may destabilise and cause dissociation of others. In this case, PFO appears to destabilise the 
P2X4 oligomer and so is not sufficient for the solubilisation of hP2X4 or zfP2X4.1. However, 
Compan and colleagues have shown that in contrast, the oligomeric states of P2X2 and P2X5 
are efficiently preserved by PFO detergent with dimers and trimers observed with PFO-PAGE 
(Compan et al, 2012). This suggests that small differences between the different P2X receptors 
can affect the stabilising effect of PFO on oligomer structure preservation.   
3.3.2  rP2X7-GFP was not expressed in mammalian cells 
As well as hP2X4-GFP, the rP2X2-GFP, rPanx1-GFP and rP2X7-GFP constructs were transfected 
into HEK-293 cells and their expression was assessed using western blotting. The western blots 
showed that of these constructs, rP2X2-GFP, rPanx1-GFP and hP2X4-GFP were expressed 
successfully at varying levels in HEK cells. However the rP2X7-GFP construct was not expressed 
(Fig 3.7). The reasons underlying the inability of HEK cells to express the rP2X7-GFP construct 
are unclear. The addition of a tag to a protein can have significant effects on protein 
expression. However, the fusion of a His-tag to a protein is unlikely to have an effect on 
protein expression or activity due to its small size and charge (Terpe et al, 2003). In addition, 
Mohanty and Weiner looked into the effects of the size and position of the His-tag on many 
aspects of protein expression; they concluded that all combinations that were tested yielded 
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similar expression levels indicating that the His-tag is unlikely to be the underlying cause of 
P2X7 not being expressed (Mohanty and Weiner, 2004). 
The GFP tag is a much larger tag that was added to each of the protein constructs. Although it 
is possible that the GFP tag is responsible for interfering with protein expression, previous 
work has demonstrated the expression of rP2X7 with a C-terminal GFP tag in HEK-293 cells 
(Ferrari et al, 2007). However the linker sequences which were cloned between the protein of 
interest and the GFP sequence could have a significant effect on protein expression (Zhang, 
2009; Minskaia and Ryan, 2013). The number of linker amino acids can be critical for correct 
protein expression and membrane targeting (Tavoularis et al, 2001). Therefore it is possible 
that the linker sequences used in the rP2X7-GFP construct may have affected expression of the 
protein. This would have to be further investigated by testing a range of linker sequences to 
determine if the linker sequences are problematic. In addition, the linker sequence used in 
previous work where P2X7-GFP expression was successful could be cloned into the rP2X7-TCS-
GFP-His construct and expressed in HEK cells to see if there is an improvement in expression 
levels. 
Another difference between other expressed P2X7 constructs and the rP2X7-TCS-GFP-His 
construct is the addition of the TCS and the His-tag to the C-terminus of the protein resulting in 
a very lengthy C-terminus. Thus one possibility is that the extensive C-terminus of rP2X7, 244 
amino acids in length, and is extended by the addition of the TCS, GFP tag and His-tag, caused 
the protein to become unstable and degraded by the cell. The C-terminus of the rP2X2-GFP 
and hP2X4-GFP protein constructs are considerably smaller consisting of 124 and 35 amino 
acids respectively, before the addition of the tag. In addition, the larger of the two (rP2X2-GFP) 
is expressed at significantly lower levels than hP2X4-GFP. It is possible that a lengthy C-
terminus has a negative effect on protein expression levels. 
3.3.3  Expression, glycosylation and localisation of hP2X4-GFP, 
rP2X2-GFP and rPanx1-GFP in HEK cells 
The confocal images of HEK-293 cells transiently transfected with hP2X4-GFP showed that the 
protein had a punctate distribution throughout the cytoplasm with low levels at the plasma 
membrane (Fig 3.11). The intracellular localisation of hP2X4 was previously shown to 
correspond to localisation at endosomes and lysosomes where it is thought to be continuously 
recycled to and from the plasma membrane due to its roles in synaptic transmission 
(Bobanovik et al, 2002). hP2X4-GFP underwent high mannose glycosylation in HEK-293 cells 
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(Fig 3.12) with a reduction in molecular weight observed upon incubation with Endo H. 
However it did not display complex glycosylation. These results are in contrast to a previous 
report where P2X4 was shown to possess both high mannose and complex glycosylation in 
NRK (normal rat kidney epithelial) cells (Qureshi et al, 2007). Glycosylation of P2X4 is known to 
be important to protect the receptor from degradation when localised to endosomes and 
lysosomes (Qureshi et al, 2007). However whether or not high mannose glycosylation is 
sufficient to prevent degradation in lysosomes has not been determined. 
In contrast, FSEC showed that the majority of the purified rP2X2-GFP protein formed protein 
aggregates and a smaller peak at 30 kDa that may represent free GFP following purification 
from HEK-293 cells suggesting that the protein is not forming trimers and functioning correctly 
in these cells. If the gel filtration protein standards are correct, one possible explanation for 
these results is that the GFP was degraded/cleaved from the P2X2 receptor during gel 
filtration, this may explain why a larger oligomer cannot be observed. Unfortunately, the yield 
was too low for peaks to be observed on the UV trace and thus we cannot determine the 
oligomeric state of P2X2 from these experiments. Imaging of HEK-293 cells transiently 
transfected with rP2X2-GFP showed that the protein was localised mostly within the cell with 
some expression at the cell membrane. This is not typical of rP2X2 localisation in HEK-293 cells 
according to previous experiments. For example, wild type P2X2 and P2X2-GFP constructs 
were expressed in HEK-293 cells and olfactory bulb neurons by Bobanovik and colleagues; both 
constructs were localised predominantly to the cell surface in both cell types (Bobanovik et al, 
2002). In addition, an experiment by Vulchanova et al, 1996 showed that P2X2 was expressed 
at the cell periphery in HEK cells. The deglycosylation assays show that rP2X2-GFP underwent 
high mannose glycosylation but not complex glycosylation in HEK-293 cells. This is in contrast 
to previous work that showed that rP2X2 underwent complex glycosylation in HEK cells (Young 
et al, 2008). Removal of 2 out of the 3 glycosylation sites located on the extracellular domain 
of P2X2 led to a large reduction in channel function and trafficking to the cell surface (Newbolt 
et al, 1998). Additionally, P2X receptors are synthesised and undergo core glycosylation in the 
endoplasmic reticulum before being transported to the Golgi apparatus for further 
glycosylation to allow transportation to the cell surface. The differences observed in P2X2 
distribution in this study and others may have been as a result of the incomplete glycosylation 
of this rP2X2-GFP protein construct, and this may have, in turn, had an effect on the oligomeric 
state of the protein. However, the gel filtration results are particularly difficult to interpret 
because western blotting showed that GFP remained bound to the P2X2 protein following 
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extraction from cells and solubilisation in detergent throughout the purification process with 
no free GFP observed with a GFP antibody (Fig 3.7, 3.8). This would indicate that the 30 kDa 
peak could not represent free GFP and as it smaller than a P2X2-GFP monomer, it could be 
assumed that the column has not been calibrated correctly. In addition, this peak is larger than 
the peaks observed for rPanx1-GFP, hP2X4-GFP and zfP2X4-GFP samples that were assumed to 
represent free GFP.  
The localisation and glycosylation state of rPanx1-GFP corresponded closely to what has been 
observed previously. The majority of the protein is localised to the plasma membrane as other 
groups noted for mPanx1 (Penuela et al, 2009) and hPanx1 (Ma et al, 2009). rPanx1-GFP was 
sensitive to cleavage by Endo H, indicating that it endured high mannose glycosylation. In 
addition, further cleavage was observed following incubation with PNGase F suggesting the 
protein also underwent complex glycosylation in HEK cells, in agreement with work by Boassa 
et al where it was shown that complex glycosylation is important for membrane targeting 
(Boassa et al, 2007). Crosslinking experiments were also used to demonstrate that rPanx1 
channels were capable of forming hexameric assemblies (Boassa et al, 2007). However when 
the rPanx1-GFP construct was purified from HEK-293 cells and analysed by gel filtration 
chromatography there was no evidence to suggest the formation of hexamers; the majority of 
the protein was present in two distinct peaks corresponding to molecular weights of 17 kDa 
and 156 kDa. These peaks are likely to account for free GFP and dimeric protein respectively. 
An additional ‘shoulder’ to the in-gel fluorescence trace was observed in the void volume that 
was likely to be aggregated protein. Therefore although the protein appeared to be 
glycosylated and localised correctly, it may not have formed hexameric channels in HEK-293 
cells and consequently may not be functional. To determine whether or not the protein is 
functional, electrophysiology and biochemical experiments would have to be performed. 
However, these experiments were not undertaken due to time constraints.  
The results from this chapter suggest that the rPanx1-GFP construct can be expressed and fully 
glycosylated in HEK-293 cells. In addition, confocal microscopy experiments showed that it was 
localised to the plasma membrane. However, when it was removed from the membrane and 
solubilised in detergent, it appeared to form predominantly dimers and free GFP indicating 
that either (i) the protein was not sufficiently solubilised by DDM, (ii) the protein was not 
forming hexamers in HEK cells or (iii) column calibration was incorrect and the observed peaks 
corresponded to different molecular weights. However, as the observed peak (156 kDa) was 
smaller than the peaks for zfP2X4-GFP and hP2X4-GFP (466 kDa), if zfP2X4-GFP and hP2X4-GFP 
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were forming trimers as expected, the rPanx1-GFP could not be forming hexamers. If, 
however, the P2X4 constructs were aggregating, it is possible that rPanx1-GFP was forming 
hexamers and rP2X2-GFP forming trimers. A much more detailed analysis of these protein 
constructs would be required to determine the correct molecular weight of these constructs.  
rP2X2-GFP and hP2X4-GFP underwent core glycosylation but not complex glycosylation in HEK 
cells; this was in contrast to published data regarding P2X2 and P2X4 in the past whereby both 
undergo complex glycosylation in HEK cells. One explanation is that the lack of complex 
glycosylation was preventing the protein from reaching the cell surface efficiently and this may 
have resulted in the majority of the protein being expressed within the cell rather than at the 
surface. Additionally, incomplete glycosylation may have had an effect on the formation of 
functional oligomers. Alternatively, GFP tagging of the protein may have caused incorrect 
trafficking and glycosylation of P2X2 and P2X4. However there is little evidence to suggest that 
C-terminal GFP tagging of proteins has a negative effect on protein localisation (Palmer and 
Freeman, 2004; Lamping et al, 2007; Skube et al, 2010). 
3.3.4  Conclusions 
zfP2X4-GFP, rP2X2-GFP, rPanx1-GFP, hP2X4-GFP and hP2X4-int-CBD constructs were 
successfully expressed in HEK cells. hP2X4-GFP appeared to form a higher level of stable 
oligomers in detergent than zfP2X4-GFP but the exact oligomeric state of these proteins 
remains to be determined. In addition, the expression levels of hP2X4-GFP were significantly 
higher. However, rP2X2-GFP and rPanx1-GFP did not form stable trimers and hexamers 
respectively in detergent when purified from HEK cells. Although rPanx1-GFP expression was 
observed at the cell surface, both rP2X2-GFP and hP2X4-GFP were expressed predominantly 
intracellularly as expected for hP2X4-GFP due to localisation to lysosomes and endosomes. 
However rP2X2-GFP is usually localised mostly to the cell surface in HEK cells; one possible 
reason for this was that the GFP interfered with the correct glycosylation and trafficking of 
rP2X2-GFP.  
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Chapter 4 - Expression of rP2X2 and 
rPanx1 in the Drosophila eye 
4.1  Chapter 4 introduction 
4.1.1  The fruit fly, Drosophila melanogaster 
The fruit fly, Drosophila melanogaster, has been used as a model organism for a great variety 
of biological and genetic research applications for many years due to their cheap maintenance 
costs, short life cycle and fully sequenced genome, allowing manipulation and analysis of many 
aspects of their genome and proteome (Adams et al, 2000). In addition, a system has been set 
up allowing a transgene to be expressed in any tissue of the fly under control of the Gal4-UAS 
system. 
 
4.1.2  The Gal4-UAS system 
The Gal4-UAS system, present in yeast, is used for specific and targeted gene expression 
(Laughon and Gesteland, 1984). Gal4 encodes a large regulatory protein (881 amino acids) of 
two galactose induced genes, Gal1 and Gal10 in yeast (Saccharomyces cerevisae). It was 
discovered by Guarente and colleagues that Gal4 binds to four specific 17 base pair sequences 
within DNA sequences, these sites are known as Upstream Activating Sequences (UAS) 
(Guarente et al, 1982). Using this knowledge, Fischer and colleagues went on to demonstrate 
that Gal4 could be used in D. melanogaster to direct expression of a reporter gene under the 
control of a UAS promoter (Fischer et al, 1988; Duffy, 2002; Brand and Perrimon, 1993). Vitally, 
the Gal4 protein itself appears to have no significant deleterious effects on the Drosophila 
phenotype (Duffy, 2002).  
Applying this system to Drosophila, it is now possible to express a target gene in any specific 
tissue of the fly using a designated promoter cloned upstream of the Gal4 protein. A library of 
such fly stocks is readily available from Bloomingtons stock centre. Cloning a target gene 
downstream of a series of UAS sites (minimum of 3) will allow specific activation of that gene 
under the control of the Gal4 driver (Pfeiffer et al, 2010).  
Initially a transgenic fly containing the target gene under the control of the UAS promoter is 
generated (see section 4.1.3). These flies are then crossed with flies carrying a Gal4 driver for 
controlled gene expression, this process is illustrated in Fig 4.1. In the absence of a Gal4 driver, 
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the target gene will remain silent, although a very low basal level of transcription can occur in 
some cases.  
 
 
 
 
 
 
 
 
 
 
For example, the glass multimer reporter (GMR)-Gal4 driver will promote expression of a 
protein under the control of the UAS promoter in the photoreceptor cells of the Drosophila 
eye, in all cells posterior to the morphogenetic furrow (Kramer and Staveley, 2003). This driver 
represents a pentameric repeat of the glass binding site, an enhancer region of the Rhodopsin 
1 (Rh1) promoter. However it has been shown to drive a higher level of target protein 
expression when compared to the natural Rhodopsin-1 promoter, known as ninaE (Panneels et 
al, 2011). 
 
4.1.3  Generating transgenic flies 
To incorporate transgenes into the Drosophila genome, recombination at specific sites can be 
used. The site specific integrase from Phage φC31 mediates recombination between attB and 
attP recognition sites and can be used for the generation of transgenic flies (Thorpe et al, 
1998; Groth et al, 2004). Two such transgenic Drosophila fly lines, attP40 and attP2, contain an 
intergenic attP site on the third and second chromosome respectively. Endogenous sources of 
φC31 integrase were generated in the flies to circumvent the problems associated with co-
injecting integrases, and thus raising the transformation efficiency (Bateman et al, 2006, 
Markstein et al, 2008). pUAST-attB is a vector containing an attB recognition site that allows it 
Figure 4.1– Schematic of the Gal4-UAS system, naturally present in yeast and transferred for 
use in fruit flies following evidence that GAL4 is able to induce transcription in D. 
melanogaster (Fischer et al, 1988). Upon production of GAL4 in a tissue of choice designated 
by the promoter, GAL4 binds to the UAS sites of a target gene, resulting in specific, targeted 
expression of a protein of interest.  
Driver Gal4 Gene X 
UAS sites 
FLY 1 FLY 2 X 
Driver Gal4 Gene X 
Gal4 
protein 
Protein X 
Tissue-specific expression of Gal4 Gal4 drives expression of Gene X in specific tissue 
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to be recombined into the specific attP site in the fly genome, integrating the cloned transgene 
into Drosophila under control of 5 UAS sites. In addition, the vector contains a white gene 
which enables visual selection of flies with the specific, targeted transgene. This gene is 
responsible for restoring the orange eye colour in the white eyed attP2 and attP40 fly lines 
(Bischof et al, 2007) thus transgenic flies can be selected based on eye colour. 
 
4.1.4  Expression of proteins in the Drosophila eye 
The visual system of Drosophila melanogaster is incredibly complex; each photoreceptor cell 
contains a specialised membrane system that has evolved to hold millions of molecules of 
rhodopsin, the light-absorbing visual protein of the eye (Zuker et al, 1996). The compound eye 
is made up of approximately 800 unit eyes, termed ommatidia (Pichaud and Desplan, 2001), 
each of which holds 8 photoreceptor cells (R1-R8) (Fig 4.2 A). 
Photoreceptor cells consist of a main cell body and a membranous structure, the rhabdomere, 
that is approximately 100 μM in length and is made up of a brush of roughly 60,000 tightly 
folded microvilli (Fig 4.2 B/C) (Kumar and Ready, 1995). Each microvillus is around 60 nm wide 
and 1-2 μM in length generating a huge surface area of approximately 3.6 – 7.2 m2 membrane 
per cell (Hardie and Raghu, 2001).  
 
 
 
 
 
Figure 4.2 – The Drosophila visual system. (A) Section through adult eye. Individual 
photoreceptor cells (7 visible) within ommatidia in the eye can be distinguished from their 
dark circular rhabdomeres [Freeman, 2002– reprinted with permission from Wiley]. (B) 
Diagram of an individual photoreceptor cell showing the position of the rhabdomere. SMC = 
submicrovillar cistaernae [Hardie and Raghu, 2001]. (C) Scanning electron micrograph of a 
single rhabdomere organised into tightly packed tubular microvilli. Each microvillus is 
approximately 60 nm in diameter and 1-2 µm long. Fig 4.2B/C reprinted by permission from 
Macmillan Publishers Ltd: [Nature] (Hardie and Raghu), copyright (2001). 
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The photoreceptor cell subtypes (R1-R8) in Drosophila express different isoforms of rhodopsin. 
R1-R6 express only Rhodopsin 1 (Rh1), encoded by ninaE, the dominant form of rhodopsin that 
absorbs blue light. R7 cells express either Rh3 or Rh4 which are UV light absorbing molecules. 
R8 cells express either Rh5 or Rh6 which absorb blue and green light respectively (Earl and 
Britt, 2006). All rhodopsin isoforms are first expressed during pupal development relatively 
close together in time, with the onset of rhodopsin 1 expression occurring first, shortly 
followed by that of rhodopsin 3, 4 and 5 concurrently. Rhodopsin 6 is the last to be expressed, 
shortly after Rh3, Rh4 and Rh5 (Earl and Britt, 2006). 
In Drosophila melanogaster, phototransduction involves a G-protein-coupled phosphoinositide 
pathway. Rhodopsin is converted to metarhodopsin upon photoisomerisation, activating 
heteromeric Gq protein and releasing the Gqα subunit by GTP-GDP exchange. The Gqα subunit 
subsequently activates phospholipase C resulting in the hydrolysis of PIP2 to IP3 and DAG. The 
increase in DAG or the reduction in PIP2 levels has been hypothesised to lead to activation of 
the light sensitive channels, TRP and TRPL (Hardie, 2001). 
The membranous structure of the fly compound eye, the rhabdomere, has been exploited to 
exogenously express a number of different membrane proteins, with the aim of overcoming 
some of the problems faced with low membrane protein yields using conventional expression 
systems. Panneels and colleagues trialled expression of ten different membrane proteins 
representing 3 important classes of membrane proteins (GPCRs, transporters and channels) in 
the compound eyes of Drosophila (see Table 4.1). Their results revealed the large capacity of 
the photoreceptor cells to express high levels of membrane protein, with expression levels of 
some targets nearing the natural levels of rhodopsin. The level of rhodopsin expressed in the 
membrane stacks was unaffected by the expression of other proteins. The resulting yield 
varied from 0.2 – 0.4 mg of purified membrane protein per 10,000 flies. Furthermore this 
system provided a more homogeneous population of protein when compared to insect cell 
expression, ideal for crystallisation and structural studies (Panneels et al, 2010; Panneels et al, 
2011). 
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Membrane protein Protein family Expression level [pmol/mg 
total MP] 
Rhodopsin-1 (Endogenous) GPCR 272-544 
Rhodopsin-1 (Drosophila) GPCR 502 
V2R (Human vasopressin receptor) GPCR >1000 
CCR5 (Human chemokine receptor) GPCR 555 
DmGluRA (Drosophila glutamate 
receptor) 
GPCR 226 
mGluR5 (rat glutamate receptor) GPCR 192 
ChR2 (Clamydomonas 
channelrhodopsin) 
Channel 206 
SERT (Drosophila serotonin 
receptor) 
Transporter 493 
SERT (Human serotonin receptor) Transporter 220 
EAAT2 (Human glutamate 
transporter) 
Transporter 173 
EAAT1 (Drosophila  glutamate 
receptor) 
Transporter 716 
 
4.1.5  Protein glycosylation in insects 
Glycosylation of proteins in insects differs significantly from that in vertebrates. In vertebrates, 
there are three species of N-glycosylated proteins; (1) non-glycosylated proteins, (2) core, high 
mannose glycosylated proteins and (3) complex glycosylated proteins that have undergone 
further modifications in the Golgi (Freeman, 2000) (see introduction section 1.2.2 for more 
details). Correct glycosylation of membrane proteins is often essential for membrane targeting 
and function. However, in insects, complex glycosylation is a very rare event with the majority 
of N-glycosylated proteins existing as core glycosylated forms (Rendic et al, 2008). This may 
Table 4.1 – Expression levels of membrane proteins in the Drosophila eye. The specific 
protein and species are shown in column 1; the protein family each protein belongs to is 
shown in column 2. The expression level of each protein is shown in column 3. Rhodopsin 1 
(endogenous) represents naturally expressed rhodopsin in the eye. Rhodopsin 1 (Drosophila) 
represent exogenously expressed recombinant GFP-fused rhodopsin-1. MP = membrane 
protein (Panneels and Sinning, 2010). 
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affect the expression profile of membrane proteins expressed in Drosophila melanogaster.  
However, complex glycosylation of proteins can cause problems for crystallisation of proteins 
and structure determination due to the heterogeneity of the protein sample. Consequently if 
the protein is functional and targeted to the membrane in Drosophila, the lack of glycosylation 
may be advantageous for purification and structure determination (see section 1.2.2.4 ). 
 
4.1.6  Aims of this chapter 
In this chapter I aimed to express a number of membrane protein constructs in the Drosophila 
eye, to achieve a high yield of homogeneous, functional protein for purification and structural 
studies. rP2X2-GFP, hP2X4-GFP and rPanx1-GFP constructs were expressed in the Drosophila 
eye, which does not naturally express any P2X receptors or Panx channels, and proteins were 
purified using a number of different techniques including ion exchange chromatography, nickel 
affinity chromatography and immunoprecipitation. In addition the glycosylation and 
oligomeric state of these proteins was investigated using deglycosylation assays and size 
exclusion chromatography.  
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4.2  Chapter 4 results 
4.2.1  Expression of membrane protein constructs in the fly eye 
A fly line expressing UAS-eGFP (obtained from Bloomingtons stock centre) was crossed with a 
GMR-Gal4 driver fly line and a Rh1-Gal4 driver fly line to compare the ability of each driver to 
express high levels of GFP in the Drosophila eye. Visualisation of the fly eye under fluorescent 
conditions (using U-M401001 filter) showed that the GMR-Gal4 driver promoted a higher level 
of expression of eGFP in the eye compared with the Rh1-Gal4 driver (Fig 4.3) and hence GMR-
Gal4 was used for expression of all membrane protein constructs in the following experiments.  
 
 
 
To ensure that all the membrane protein was efficiently separated from the cytoplasmic 
protein during membrane protein extraction from flies, membrane and cytoplasmic protein 
fractions were blotted for rhodopsin (membrane protein) and β-actin (cytoplasmic protein). 
Membrane protein fractions were shown to contain rhodopsin but not β-actin. Additionally 
cytoplasmic fractions were shown to contain β-actin and not rhodopsin, indicating that the 
membrane protein extraction method is working correctly (Fig 4.4). 
Figure 4.3 – GMR-Gal4  drives a higher level of eGFP expression in the eye than Rh1-Gal4. 
(A) UAS-eGFP expressed under control of the Rh1-Gal4 driver. (B) UAS-eGFP expressed under 
control of the GMR-Gal4 driver. Fly heads visualised under fluorescent conditions. 
A B 
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Initially, transgenic flies expressing UAS-hP2X4::His (hP2X4-His) on the second chromosome 
(attP40 landing site) were generated and crossed with GMR-Gal4 (BL8121) flies. However, very 
little or no protein expression was observed using either anti-His or anti-P2X4 antibodies 
(results not shown). It was then decided to couple constructs to eGFP for ease of detection, 
and to extend the study to other ion channels – flies expressing UAS-hP2X4::GFP (hP2X4-GFP), 
UAS-rP2X2::GFP  (rP2X2-GFP) and UAS-rPanx1::GFP (rPanx1-GFP) transgenes on the second 
chromosome (attP40 landing site) were subsequently generated and crossed with GMR-Gal4 
(BL8121) flies. Membrane protein was extracted from approximately 200 progeny fly heads 
and western blotting was used to detect expression of the protein constructs in the fly. rP2X2-
GFP (approx. 80 – 85 kDa) and rPanx1-GFP (approx. 65 – 70 kDa) were successfully expressed 
(Fig 4.5E). These GFP fusion proteins were also visualised in the eye using fluorescence 
microscopy (Fig 4.5 B/D). However, in confirmation of the previous negative result with hP2X4-
His, hP2X4-GFP did not appear to be expressed in the fly under the control of GMR-Gal4 (Fig 
4.5E). The effect of fly maintenance temperature and the number of copies of each transgene 
was also investigated. The data showed that a higher protein expression level was obtained 
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Figure 4.4 – Membrane and cytoplasmic protein fractions were efficiently separated after 
protein extraction from fly heads. Protein preps were made from 200 control fly heads and 
membranes were separated from cytoplasmic proteins by high-speed centrifugation. Western 
blots were performed using the cytoplasmic and membrane protein fractions with (A) anti-
rhodopsin [DSHB] and (B) anti-β-actin [abcam]. 
A B 
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from rP2X2-GFP flies with 2 copies of both the rP2X2-GFP transgene and the GMR-Gal4 driver. 
In addition, the temperature at which the flies were maintained did not appear to have a large 
effect on protein expression levels (Fig 4.5F).  
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Figure 4.5 – rP2X2-GFP and rPanx1-GFP were successfully expressed in the Drosophila eye. 
rPanx1-GFP expressed in the fly eye under the control of the GMR-Gal4 driver visualised 
under bright field conditions (A) and fluorescent conditions (B). rP2X2-GFP expressed in the 
fly eye under the control of the GMR-Gal4 driver visualised under bright field conditions (C) 
and fluorescent conditions (D). Scale bars = 200 µm. (E) Western blot of protein extracted 
from control flies and flies expressing hP2X4-GFP, rP2X2-GFP and rPanx1-GFP under control 
of the GMR-Gal4 driver (lanes 1 – 4) and transfected HEK cells appropriately (lanes 6 – 9) [anti 
GFP, Invitrogen]. 10 µg membrane protein loaded per lane.  (F) Western blot of protein 
extracted from flies of various genotypes [anti P2X2, Alomone]; ‘rP2X2-GFP parent’ has copy 
of the rP2X2-GFP transgene but no driver to induce expression. ‘rP2X2-GFP het.’ has one copy 
of the rP2X2-GFP transgene and the driver. ‘rP2X2-GFP; GMR-G4/TM3’ flies are homozygous 
for the rP2X2-GFP transgene but only possess one copy of the Gal4 driver. ‘rP2X2-GFP hom’ 
flies are homozygous for both the rP2X2-GFP transgene and the Gal4 driver. RT (room 
temperature) or 25°c indicates the temperature at which the flies were raised. Lower 
molecular weight bands are assumed to be non-specific bands. 10 µg membrane protein 
loaded per lane. 
E 
E 
A – Bright field 
B – Fluorescent conditions 
C – Bright field 
D – Fluorescent conditions 
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To confirm the presence of the transcript and message for hP2X4-His and hP2X4-GFP in flies 
that did not appear to express protein, total DNA and RNA were extracted from hP2X4 parent 
flies, w; hP2X4; GMR-Gal4 flies, hP2X4-GFP parent flies and w; hP2X4-GFP; GMR-Gal4 flies. 
Specific primers were used to amplify the hP2X4 and hP2X4-GFP constructs from the DNA 
using PCR. In addition these primers were used on a cDNA prep made from the RNA extracts. 
The results showed that the hP2X4 DNA was present in both parent flies and flies also carrying 
a GMR-Gal4 driver (although bands are faint in DNA preps made from hP2X4-GFP parent flies 
and hP2X4-GFP; GMR-Gal4 flies due to poor quality DNA). In addition the hP2X4 RNA was 
present in w;hP2X4-his; GMR-Gal4 and w;hP2X4-GFP; GMR-Gal4 flies. LUSH primers 
(responsible for amplifying a housekeeping gene, LUSH) were used as a control to ensure 
sufficient RNA extraction and cDNA preparation. hP2X4 and hP2X4-GFP vector controls were 
also included to confirm that the PCR reaction took place and the primers were able to amplify 
the DNA (Fig 4.6). These results show that the DNA and mRNA are successfully made in the fly 
lines containing a Gal4 driver, therefore the problems underlying the low expression levels are 
downstream i.e. during or after protein synthesis. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 – P2X4 RNA is made in hP2X4-his; GMR-Gal4 and hP2X4-GFP; GMR-Gal4 flies. 
PCR of hP2X4-his and hP2X4-GFP from cDNA preps made from parent flies (w; hP2X4; + and 
w; hP2X4-GFP; + respectively) which possess the hP2X4 transgene but no driver to induce 
expression and flies expressing hP2X4 and hP2X4-GFP under control of the GMR-Gal4 driver 
(w; hP2X4/+; GMR-G4/+ and w; hP2X4-GFP/+; GMR-Gal4/+ respectively) (underlined in blue). 
PCR of housekeeping LUSH gene from cDNA prep of the same fly lines (underlined in red). 
PCR of hP2X4-his and hP2X4-GFP from the same fly line (underlined in green). Vector controls 
were also included to confirm working PCR conditions (Lane 13 and 14). 
1000
Fly RNA – P2X4 primers Fly RNA – LUSH primers
1000
Fly DNA – P2X4 primers
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DDM has been shown to work well for the solubilisation of several P2X receptors (Sim et al, 
2004; Mio et al, 2005; Mio et al, 2009; Kawate et al, 2009; Valente et al, 2011), thus this 
detergent was chosen for the solubilisation of rP2X2-GFP. To determine which was the most 
efficient detergent to use for solubilisation of rPanx1-GFP, a detergent screen was used to 
compare a number of different detergents; DDM, FC-12, NP40 (nonyl 
phenoxypolyethoxylethanol), N-OG (N-octyl glucosmine) and Triton (Triton-X-100), for protein 
extracted from both HEK-293 cells and flies. The screen showed that FC-12 and Triton were 
efficient at solubilising protein from both HEK-293 cells and Drosophila, whereas DDM and N-
OG were less efficient at solubilising protein extracted from flies compared with HEK-293 cells. 
NP40 was inefficient at solubilising proteins from both flies and HEK-293 cells (Fig 4.7). FC-12 
was used in all experiments for the solubilisation of rPanx1-GFP. Triton was not chosen for 
solubilisation due to its heterogeneous nature. 
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Figure 4.7 – Detergent screen for rPanx1-GFP. (A) Western blot of rPanx1-GFP extracted from 
HEK-293 cells and solubilised in various detergents [anti-GFP, Invitrogen]. For each detergent, 
protein was extracted from a 35 mm dish of cells and solubilised in RIPA buffer plus 
appropriate detergent. The insoluble pellet was resuspended RIPA buffer and the soluble 
supernatant fraction was collected. 10 µg protein was loaded in each lane. (B) Western blot of 
rPanx1-GFP extracted from Drosophila and solubilised in various detergents [anti GFP, 
Invitrogen]. For each detergent, membrane protein was extracted from 200 flies and 
solubilised in sucrose buffer. The insoluble pellet was resuspended in sucrose buffer and the 
soluble supernatant fraction was collected. Protein from the equivalent of ten flies was loaded 
in each lane. Detergent concentrations used – 1% DDM, 7.5mM FC12, 1% NP40, 1% N-OG, 1% 
Triton. 
A 
B 
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4.2.2  Glycosylation of rP2X2-GFP and rPanx1-GFP in Drosophila 
The N-glycosylation state of rP2X2-GFP and rPanx1-GFP was investigated by incubating the 
proteins with Endo-H and PNGase F and investigating any changes in molecular weight. 
rPanx1-GFP did not undergo cleavage by either Endo-H or PNGase F suggesting it was not N-
glycosylated in the fly. However, a reduction in the molecular weight of rP2X2-GFP following 
incubation with Endo H was observed suggesting it underwent high mannose glycosylation in 
the fly. However, as expected, neither protein underwent complex glycosylation in this system 
(Fig 4.8).  
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Figure 4.8 – N-linked glycosylation of rPanx1-GFP and rP2X2-GFP in Drosophila. (A) Western 
blot showing rPanx1-GFP extracted from Drosophila before (control) and after incubation with 
Endo H or PNGase F [anti-GFP, Invitrogen]. No decrease in molecular weight was observed 
indicating the protein is not glycosylated. Blot representative of 2 assays. (B) Western blot 
showing rP2X2-GFP extracted from Drosophila before (control) and after incubation with Endo 
H or PNGase F [anti-GFP, Invitrogen]. A reduction in the molecular weight of rP2X2-GFP 
following cleavage by Endo H is observed indicating high mannose glycosylation in Drosophila. 
Blot representative of 3 assays. G0 relates to the non-glycosylated protein, G1 relates to high-
mannose glycosylated protein. 
A B 
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4.2.3  Purification of membrane proteins expressed in fly eyes 
For small scale purification trials, membrane protein was extracted and purified from 
approximately 150 - 200 w; rP2X2-GFP; GMR-Gal4 and w; rPanx1-GFP; GMR-Gal4 flies using 
nickel affinity purification. Western blotting with an anti-GFP antibody demonstrated that both 
proteins successfully bound to nickel beads with no/very little protein remaining in the 
flowthrough/unbound fraction. Some of the rP2X2-GFP protein was successfully eluted with 
500mM Imidazole; however a large proportion remained bound to the nickel beads (Fig 4.9A). 
The majority of rPanx1-GFP protein was successfully eluted with 500 mM Imidazole (Fig 4.9B).  
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.9 – Nickel affinity purification of rP2X2-GFP and rPanx1-GFP (200 flies). (A) Western 
blot showing nickel affinity purification of rP2X2-GFP from approx. 200 fly heads [anti-GFP, 
Invitrogen]. (B) Western blot showing nickel affinity purification of rPanx1-GFP from approx. 
150 fly heads [anti-GFP, Invitrogen]. The equivalent of membrane protein from ten flies is 
loaded per lane. Total = Total protein from initial membrane protein extraction, Flowthrough = 
protein which didn’t bind to nickel beads, Wash 1/6 = flowthrough after beads were washed 
with wash buffer, elution = protein eluted with 500 mM Imidazole, Beads = protein remaining 
stuck to beads after elution. 
A 
B 
250 
150 
100 
75 
50 
37 
25 
rP2X2-GFP 
monomer 
rP2X2-GFP 
trimer 
150 
100 
37 
75 
50 
25 
250 
rPanx1-GFP 
monomer 
rPanx1-GFP 
trimer 
126 
 
 
Purification of rPanx1-GFP was then performed on a larger scale; membrane protein was 
extracted from approximately 2,000 w; rPanx1-GFP; GMR-Gal4 fly heads and purified using 
nickel affinity chromatography. As shown in Figure 4.10A, the majority of the protein 
successfully bound to nickel beads but a large amount was not eluted with 1M imidazole and 
remained bound to the nickel beads. In addition, a Coomassie-stained gel showed that large 
numbers of other proteins were also present in the elution, indicating that the purified protein 
fraction contained many contaminating proteins. In addition a band was not observed at 65 – 
70 kDa, the molecular weight of pure rPanx1-GFP (Fig 4.10B). 
 
 
 
 
 
 
 
 
 
 
To try and improve the purity of the protein extracted from flies, alternative purification 
strategies were attempted. The next approach, in this case in an attempt to purify rP2X2-GFP 
from flies, was immunoprecipitation using a GFP antibody. Membrane protein was extracted 
from 1,800 w; rP2X2-GFP; GMR-Gal4 fly heads and incubated with the GFP antibody 
[Invitrogen]. The protein-antibody complexes were then captured using protein A/G agarose 
resin. The purified protein was denatured and separated by SDS-PAGE, blotted with an anti-
GFP antibody (Fig 4.11A) and stained with Coomassie (Fig 4.11B). A faint band was observed at 
approximately 80 kDa that was assumed to be purified rP2X2-GFP. Additional bands were 
observed at 25kDa and 50kDa representing the light and heavy chains of the immunoglobulin 
respectively (Fig 4.11). Although the protein elution following immunoprecipitation appeared 
relatively pure, the yield was low (1 µg BSA can be used for reference). The detection limit of 
the Coomassie stain used was approximately 100 ng and since the band was very faint, the 
A B 
Figure 4.10 – Nickel affinity purification of rPanx1-GFP (2,000 flies) (A) Western blot showing 
nickel affinity purification of rPanx1-GFP extracted from approx. 2,000 fly heads [anti GFP, 
Invitrogen]. Protein from equivalent 10 heads loaded per lane. (B) Coomassie-stained gel of 
elution fraction following nickel affinity purification of rPanx1-GFP (approx. 500 fly heads 
loaded). 1 µg BSA control is shown for reference. 
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band appeared to be close to this limit, we estimated that 500 fly heads equated to 
approximately 100 ng pure protein (Fig 4.11). Immunoprecipitation experiments were 
performed by Hannah Garrard.  
 
 
 
 
 
 
 
 
 
 
 
To distinguish between the possibilities that (1) the yield of protein expressed in the fly was 
low or (2) a large amount of the protein was lost during the immunoprecipitation procedure, 
further purification procedures were investigated. Membrane protein was extracted from 
1,800 fly heads and purified using the GFP-TRAP system [Chromotek] for both rP2X2-GFP and 
rPanx1-GFP (Fig 4.12). However, the protein constructs did not bind to the GFP-TRAP beads (all 
protein was found in the flow-through fraction) and the purification was unsuccessful.  
 
 
 
 
 
 
Figure 4.11 – Immunoprecipitation of rP2X2-GFP. Membrane protein was extracted from 
1,800 rP2X2- GFP; GMR-Gal4 fly heads and purified using immunoprecipitation with a P2X2 
antibody [Alomone, 1:2000]. (A) Western blot of IP fractions [anti-GFP, Invitrogen]. Equivalent 
10 fly heads loaded per lane, 50 fly heads loaded in elution (accounts for higher expression 
levels). (B) Coomassie-stained gel – purified protein from approximately 500 fly heads 
[Elution], 1 µg BSA is shown for reference (data - Hannah Garrard). 
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Reverting to the use of nickel affinity chromatography, membrane proteins were first bound to 
sepharose beads to eliminate any proteins binding non-specifically to the agarose bead itself 
(pre-clearance). Membrane protein was extracted from 500 w; rP2X2-GFP; GMR-Gal4 fly heads 
and incubated with sepharose beads for 3 hours. The flowthrough from sepharose beads was 
used for nickel affinity chromatography. The majority of the protein successfully bound to 
nickel beads and was eluted upon addition of 1M imidazole (Fig 4.13A). However the purified 
fraction still contained high numbers of non-specific proteins (Fig 4.13B). 
 
 
A 
B 
Figure 4.12 – GFP TRAP of rPanx1-GFP and rP2X2-GFP. Western blots of rPanx1-GFP (A) and 
rP2X2-GFP (B) protein fractions from Drosophila after GFP TRAP purification [Chromotek] [anti 
GFP, Invitrogen]. Membrane protein from w; rPanx1-GFP; GMR-Gal4 flies (A) and w; rP2X2-
GFP; GMR-Gal4 flies (B) was extracted from 1,800 fly heads and incubated with GFP-TRAP 
beads. Agarose FT = protein which didn’t bind to control agarose beads. Agarose beads = 
protein bound to agarose beads. GFP beads FT = protein which didn’t bind to GFP beads. 
Elution = protein eluted from GFP-TRAP beads GFP beads = protein remaining on beads after 
elution.  
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To further purify the protein, ion exchange chromatography was used as a pre-purification 
step before proceeding with sepharose bead and nickel bead purification. Membrane proteins 
were extracted from 5,000 w; rPanx1-GFP; GMR-Gal4 fly heads and were separated using 
anion exchange chromatography. rPanx1-GFP was eluted from fraction 12 onwards and the 
majority was eluted in fractions 12 – 16. These fractions were collected and pooled (Fig 4.14A). 
The pooled protein was incubated with sepharose beads and the flowthrough was purified 
using nickel affinity chromatography. The protein successfully bound to the nickel beads and 
was eluted with 1M imidazole (Fig 4.14B). Protein from the equivalent of 500 fly heads and 
1000 fly heads was run on a gel and stained with Coomassie. The protein was relatively pure 
with 2 bands at approximately 70 kDa and 160 – 200 kDa (Fig 4.14D). The purified protein was 
separated using fluorescence size exclusion chromatography to assess the oligomeric state of 
the protein. Two peaks were observed at approximately 17 kDa and 156 kDa (Fig 4.14E) 
 
 
 
 
 
 
 
Figure 4.13 – Sepharose bead and nickel bead purification of rP2X2-GFP. (A) Western blot 
showing sepharose and nickel bead purification fractions from 500 w; rP2X2-GFP; GMR-Gal4 
flies (anti GFP, Invitrogen). 10 fly heads loaded per lane. (B) Coomassie-stained gel – 200 fly 
heads of purified protein loaded [elution], 1 µg BSA is shown for reference. 
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Figure 4.14 – Ion exchange chromatography, sepharose bead and nickel bead purification of 
rPanx1-GFP. (A) Western blot of rPanx1-GFP fractions which were separated using anion 
exchange chromatography [anti GFP, Invitrogen]. FT = flowthrough, F = fraction. 20 fly heads 
of protein loaded per lane. (B) Western blot showing sepharose bead and nickel affinity 
purification of fractions 12 – 16 [anti-GFP, Invitrogen]. 10 fly heads of protein loaded per lane. 
(C) Coomassie gel of purified rPanx1-GFP protein (Elution). The number of fly heads of protein 
loaded is shown above the lane. A 1 µg BSA sample is shown for reference. (D) FSEC elution 
profile of purified rPanx1-GFP from 5,000 flies (red). Two peaks are observed at fraction 11 
and fraction 15 which correspond to molecular weights of approximately 156 kDa and 17 kDa 
respectively. The FSEC trace previously shown for purification of rPanx1-GFP from HEK-293 
cells is shown in blue. 
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The expression levels of rP2X2-GFP were compared in protein extracts from w; rP2X2-GFP; 
GMR-Gal4, and C155-Gal4; rP2X2-GFP whole flies that express rP2X2 in the nervous system 
under control of C155, an enhancer trap line that expresses Gal4 under control of the elav 
promoter via the P{w+=GawB}elavC155 transgene (Lin and Goodman, 1994). The elav 
(embryonic lethal abnormal visual system) functions in nervous system development and 
maintenance. (Campos et al ,1985, 1987). The western blot shows that per fly, the amount of 
rP2X2-GFP protein is higher in flies when expressed under control of the pan-neural driver (Fig 
4.15). Therefore for the final purification experiment of rP2X2-GFP, C155; rP2X2-GFP flies were 
used.   
 
 
 
 
 
 
 
 
 
Membrane protein was extracted from 2,400 C155; rP2X2-GFP whole flies and purified using 
anion exchange chromatography, sepharose and nickel affinity purification as previously 
described for rPanx1-GFP. During ion exchange chromatography, the protein was eluted in 
fractions 12 to 21 with the majority in fractions 13 to 17 (Fig 4.16A). Thus fractions 13 – 17 
were pooled and further purified. Although the protein successfully bound to nickel beads and 
was efficiently eluted with 1M imidazole, the Coomassie-stained gel (not shown) contained a 
very high number of impurities suggesting the purification was unsuccessful. As a result, 
purification experiments with C155; rP2X2-GFP flies were not continued. 
 
 
 
Figure 4.15 – C155-Gal4 drives a higher level of rP2X2-GFP expression than GMR-Gal4. 
Western blot comparing expression of rP2X2-GFP under the control of the pan neural (C155-
Gal4) driver and eye (GMR-Gal4) driver [anti GFP, Invitrogen]. 10 flies loaded per lane. Blot 
representative of 3 assays.  
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4.2.4  Electron microscopy of rPanx1-GFP 
The purified rPanx1-GFP was visualised using transmission electron microscopy. The yield of 
protein was low but the protein particles on the grid appeared to be relatively homogeneous 
(Fig 4.17). Due to time constraints, it was not possible to do extensive analysis of the particles 
and thus symmetry of the particles was not investigated. However by measuring the cross-
sections of 100 particles and making a number of assumptions, the estimated mass of the 
particles was determined.  
A 
Figure 4.16 – Ion exchange chromatography, sepharose bead and nickel bead purification of 
rP2X2-GFP. (A) Western blot of rP2X2-GFP fractions which were separated using anion 
exchange chromatography [anti GFP, Invitrogen]. FT = flowthrough, F = fraction. Protein from 
equivalent of 20 flies loaded per lane. (B) Western blot showing further purification of rP2X2-
GFP by sepharose bead and nickel affinity purification of fractions 13 – 17 [anti-GFP, 
Invitrogen]. 10 fly heads of protein loaded per lane.  
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The first assumption made was that the channel is a cylindrical shape. The shortest (L1) and 
longest (L2) cross section of each of 100 particles was measured. The average L1 was 7.67 ± 
1.82 nm and the average L2 was 11.15 ± 2.3 nm. L1 was assumed to be the diameter of the 
channel, L2 was assumed to be the length of the channel. 
Using the equation: Volume of cylinder (𝑉) =  𝜋(𝐿12 ÷ 4)𝐿2, the volume of the cylinder was 
estimated to be 515.18 nm3. Assuming the average density of a protein is 1.35 g/cm3 (Fischer 
et al, 2004) and the protein particles are solid blocks of protein with no water-filled cavities, 
the mass of each particle was calculated as 6.95 x 10-19 g.  Each rPanx1-GFP monomer was 
estimated to have a mass of about 1.17 x 10-19 g based on a molecular weight of 70 kDa. Thus 
the mass of each particle equated to approximately 5.94 rPanx1 monomers. These results 
argue that, in contrast to the gel filtration results, rPanx1-GFP does form hexamers in 
Figure 4.17 – Transmission electron microscope image of purified rPanx1-GFP. rPanx1-GFP 
was purified by IEC, IMAC and FSEC. The purified protein was concentrated and imaged in 
negative stained (2% uranyl acetate). TEM images were taken using a JEOL JEM 2100 LaB6 
microscope. Images were processed using EMAN Boxer software. 
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Drosophila. However, due to the number of assumptions made during these calculations, and 
the low number of particles measured, a much more detailed analysis on a larger scale is 
necessary to come to any definitive conclusions.  
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4.3  Chapter 4 – Discussion 
4.3.1  Low-resolution structural studies of rP2X2 and rPanx1 
Low resolution structures of both rP2X2 and rPanx1 have been published using EM (Mio et al, 
2005; Mio et al, 2009; Ambrosi et al, 2010). For more details on these structures please see 
sections 1.5.2 and 1.4.2 respectively. 
4.3.2  Expression of protein constructs in Drosophila 
rP2X2-GFP and rPanx1-GFP protein constructs were successfully expressed in the Drosophila 
eye (Fig 4.5). However, hP2X4-GFP and hP2X4-his constructs did not appear to be expressed in 
this system. The underlying cause behind hP2X4 not being expressed is unclear. However the 
DNA and mRNA are present in the flies also carrying the GMR-Gal4 driver (Fig 4.6). This 
suggests that the DNA constructs were successfully integrated into the genome and were 
being transcribed in the presence of a Gal4 driver. One possibility is that the protein was being 
translated but immediately degraded by the cells, possibly due to misfolding, and thus the 
expression levels were very low and could not be observed by western blotting or fluorescence 
microscopy. Alternatively the mRNA may not have been translated efficiently, possibly due to 
the presence of rare Drosophila codons in the hP2X4 sequence.  
Differences in codon usage between the construct to be expressed and the expression system 
can have a significant effect on protein expression as was demonstrated for the chemokine 
receptor, CCR5 in mammalian cells (Mirzabekov et al, 1999). The Graphical Codon Usage 
Analyser (GCAU) tool (accessed at http://gcua.schoedl.de/) was used to investigate codon 
usage of rP2X2-GFP, rPanx1-GFP and hP2X4-GFP to see if there were any significant differences 
between codon usage in the constructs and codon usage in Drosophila that might have 
affected protein expression. However the mean difference between the rPanx1-GFP sequence 
and Drosophila melanogaster codon usage was higher (21.27%) than for the hP2X4-GFP 
sequence (20.7%) and the hP2X4-his sequence (18.75%) (See appendix III). In addition there 
was little use of the codons that are rarely used in Drosophila such as TTA (Leu) and GGG (Gly) 
with relative adaptiveness values of 3% and 22% respectively (the relative adaptiveness values 
are based on the frequency of the codons used for each amino acid; the codon with the 
highest frequency is set at 100% relative adaptiveness and are all codons for that amino acid 
are scaled accordingly). This suggests that it is unlikely that any differences in codon usage 
were responsible for interfering with hP2X4 expression. 
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4.3.3  Purification of rP2X2-GFP and rPanx1-GFP 
rP2X2-GFP and rPanx1-GFP were successfully expressed in Drosophila as shown by western 
blot analysis and fluorescence imaging (Fig 4.5). Purification of protein constructs from 
Drosophila eyes using nickel affinity purification alone was not successful as a large number of 
other proteins bound to the nickel beads and eluted upon the addition of imidazole (Fig 4.10). 
Work performed by Lichty et al compared the use of a number of affinity tags (including his-
tag, Strep-tag, calmodulin-binding-peptide and FLAG-tag) to purify E.coli dihydrofolate 
reductase from E. coli, Drosophila, yeast and HeLa extracts. Whilst purification via the his-tag 
provided moderate purity from E. coli extracts, the purity was poor from Drosophila, yeast and 
HeLa extracts. Conversely, purification from Drosophila extracts using a strep-tag and 
streptactin resin or a FLAG tag and FLAG monoclonal antibody provided a much higher purity 
of eluted protein (Fig 4.18) (Lichty et al, 2005). Consequently, to improve protein purification 
using the Drosophila system, the His-tag should be replaced with either a strep-tag or a FLAG-
tag for purification purposes.  
 
 
 
 
 
 
The approximate yield of pure protein obtained from the Drosophila eye using ion exchange 
chromatography (IEC), sepharose and nickel affinity chromatography was 1 µg rPanx1-GFP per 
Figure 4.18 – Comparison of multiple resins for purification of tagged DHFR (E. coli 
dihydrofolate reductase) protein from Drosophila extracts. CBP = Calmodulin binding 
peptide. CAM = calmodulin. STR – Strep II tag. Lane 1 shows protein input. Lane 2 (Talon CBP) 
shows purification of DHFR via its His-tag using a Talon resin. Lane 3 (CAM CBP) shows 
purification via a CBP tag on a calmodulin resin. Lane 4 (Strep-tactin STR) shows purification 
via a Strep II tag on a Strep-tactin resin. Lane 5 (M2 mAb FLAG) shows purification via a FLAG 
tag using a FLAG monoclonal antibody. Reprinted from Protein Expression and Purification, 
41(1), Lichty et al, Comparison of affinity tags for protein purification, p98-105., Copyright 
(2005), with permission from Elsevier. 
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500 fly heads (Fig 4.14). However previously published data showed purified proteins with 
yields of up to 0.2 – 0.4 mg protein per 1g of fly heads, this roughly equates to 10-20 µg 
protein per 500 flies (Panneels et al, 2011). Therefore the rPanx1-GFP yield is 10 – 20- fold 
lower than what has previously been obtained for other membrane proteins in this system 
which included 10 proteins from three major classes – GPCRs, transporters and channels 
(Table 4.1). It is unclear whether the starting yield of protein expressed in the Drosophila eye is 
much lower or if the lengthy purification process resulted in a large loss of protein. To help 
distinguish between these two possibilities, a non-denaturing gel and GFP antibody could be 
used to compare the yield from a whole protein extract to a known concentration of eGFP to 
see if this differs significantly from the yield of pure protein that was obtained. 
However, when the protein (rP2X2-GFP) was purified using immunoprecipitation, a very low 
yield of protein was also obtained with an estimated concentration of 100 ng per 500 fly heads 
(Fig 4.11). This suggests that the protein expression levels are low in Drosophila as both 
purification methods give a low yield of purified protein. However the yield of rP2X2-GFP 
protein purified by immunoprecipitation was approximately 10-fold lower than the yield of 
rPanx1-GFP purified by IEC and nickel affinity chromatography. This difference could be as a 
result of the differing expression levels of rP2X2-GFP and rPanx1-GFP in the fly. 
The use of the GFP-TRAP system was unsuccessful for the purification of both rP2X2-GFP and 
rPanx1-GFP from Drosophila as the proteins did not bind to the GFP-binding matrix (Fig 4.12). 
It is unclear why the proteins were unable to bind to the matrix; it is clear both proteins 
express the GFP fusion product in Drosophila from microscopy and western blotting with a GFP 
antibody (Fig 4.5). As the proteins are solubilised in detergent prior to purification, it is 
possible that the detergent molecules are blocking parts of the GFP and preventing it from 
binding to the GFP TRAP matrix.  
4.3.4  Glycosylation of protein constructs in Drosophila 
rPanx1-GFP does not appear to undergo high mannose or complex glycosylation in the 
Drosophila system, contrary to the complex glycosylation that occurs in HEK-293 cells (Fig 4.8). 
The high mannose form of rPanx1 is predominantly located at the endoplasmic reticulum 
whereas the complex glycosylated form is trafficked to the cell surface; thus glycosylation of 
pannexin 1 channels is important for membrane targeting. However glycosylation has no 
known effect on channel function or structure; the channels that reach the cell surface are 
fully functional (Penuela et al, 2009). This indicates that in this system, the channels may still 
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be successfully translated and folded but the majority may be unable to reach the cell surface 
and retained in the ER membranes. High resolution imaging techniques would be required to 
determine whether or not the protein is targeted to the cell surface in Drosophila. 
FSEC of rPanx1-GFP showed that the protein does not form stable hexamers following 
purification from the fly eye. Two distinct peaks are observed at molecular weights equating to 
approximately 17 kDa and 156 kDa suggestive of the formation of free GFP and dimeric protein 
respectively (Fig 4.14). However the purified protein showed a very similar elution pattern 
when purified from HEK-293 cells, with peaks at the same molecular weights (Fig 3.8). This 
work suggested that rPanx1 does not form hexamers, contrary to evidence from previous cross 
linking experiments and the influence derived from their similarity to connexins (Boassa et al, 
2007). In contrast, calculations performed using low resolution TEM images indicated that the 
protein was indeed hexameric (Section 4.2.44.2.4 ). However, to perform these calculations a 
number of assumptions were made. Firstly, it was assumed that the protein was the shape of a 
cylinder and secondly, it was assumed that the protein was a solid block of protein, with no 
water filled cavities. By making these assumptions, the size estimations made could be very 
inaccurate. In the future, a much larger number of particles will be used for the estimation of 
size and symmetry of the particles in order to build a model of structure. This will give much 
more insight into the state of the protein. The average cross sections of the particles were 7.67 
nm and 11.18 nm for the short and long cross sections respectively. The estimated oligomer 
diameter for Panx1 calculated by Ambrosi and colleagues was 12 and 16 nm for two differing 
image averages. These averages are significantly higher than our estimated diameter of 7.67 
nm. However, they did not provide an estimate of the length of the channel and thus this it is 
not possible to directly compare the results. To make any significant conclusions regarding the 
size and oligomeric state of the purified rPanx1-GFP, further analysis will need to be performed 
on the TEM images. 
The deglycosylation assays demonstrated that rP2X2-GFP undergoes high mannose 
glycosylation but not complex glycosylation in the Drosophila system with a reduction in 
molecular weight observed following cleavage by Endo H (Fig 4.8) This result is in accordance 
with work that suggested insects including Drosophila only have the ability to perform high 
mannose glycosylation (Rendic et al, 2008), with very few examples of insect proteins that 
undergo complex glycosylation. In other systems such as HEK-293 cells, rP2X2 is shown to 
undergo complex glycosylation (Young et al, 2008). Glycosylation of P2X2 has been shown to 
be important for targeting to the cell membrane as well as protein function (Torres et al, 1998; 
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Newbolt et al, 1998). However distinguishing between the effects of high mannose 
glycosylation and complex glycosylation on protein targeting and function has not been 
determined. The oligomeric state of rP2X2-GFP was not determined because purification from 
whole flies (C155; rP2X2-GFP) was unsuccessful due to the larger number of contaminating 
proteins present in whole fly samples (Fig 4.16). This would need to be further investigated by 
either (i) using a purification procedure that further eliminates contaminating proteins or (ii) 
reverting back to the use of the GMR-Gal4 driver and purifying using IEC and nickel affinity 
chromatography. However generating flies expressing a new construct with a FLAG or Strep 
tag fused to rP2X2 may result in a more reliable and easier purification procedure.  
4.3.5  Structure determination of membrane proteins 
In order to crystallise a membrane protein, approximately 1 mg of pure protein is required for 
structure determination. Due to the low yield of both rPanx1-GFP and rP2X2-GFP obtained 
from Drosophila, crystallisation would require protein to be purified from 500,000 flies. 
However as recently published by Liao et al, high resolution protein structures can be obtained 
without crystallisation. Liao and colleagues solved the structure of TRPV1 to a resolution of 3.4 
Å using electron cryo-microscopy in the native and ligand-bound state (the modified ‘minimal 
functional construct’ used was a tetramer of approximately 270 kDa in mass) (Liao et al, 2013; 
Liao et al, 2014). This required the use of a newly developed direct electron detector and new 
image processing algorithims in order to improve signal and contrast of cryo-EM images. 
Although the construct required significant mutagenesis to achieve a homogenous population 
for structure determination, the final protein concentration that was required was only 0.7 
mg/ml. This significant advance in membrane protein structure determination may be able to 
be extended in the future for even smaller molecules such as P2X receptors. Despite the low 
yield of protein obtained from the Drosophila system, if the protein is of sufficient quality and 
homogeneity, it may be possible to solve the structure of a P2X receptor or Panx channel using 
this technique. 
4.3.6  Conclusions 
rP2X2-GFP and rPanx1-GFP were successfully expressed in the eye of the fruit fly, Drosophila 
melanogaster. However, purification of these proteins proved difficult and lengthy, partially 
due to the choice of purification tag (His-tag) which was previously shown to be inefficient for 
purification from Drosophila (Lichty et al, 2005). The yield of rPanx1-GFP purified by IEC and 
IMAC was low equating to approximately 1 µg of protein per 500 flies. The yield of rP2X2-GFP 
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purified by immunoprecipitation with a GFP antibody was even lower, equating to 
approximately 100 ng of protein per 500 flies. These results indicate that either there is a large 
loss of protein during extraction and purification or the starting yield of both proteins is very 
low. The answer to this question will hold relevance to the future of using this system for 
expression of P2X receptors and pannexin channels for structural studies.  
In Drosophila, rP2X2-GFP was demonstrated to undergo high mannose, core glycosylation, 
which is important for protein trafficking and function. We also prove that rP2X2-GFP is 
functional in Drosophila (see chapter 5) indicating that at least a proportion of the protein is 
indeed correctly targeted to the cell surface and folded. The rPanx1-GFP results are more 
inconclusive as the protein did not appear to undergo N-glycosylation, which is important for 
Panx trafficking. In addition, following purification and FSEC, the majority of the protein 
appeared to form dimers in contrast to analysis of TEM images that indicated the formation of 
hexamers. 
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Chapter 5 - Expression of rP2X2-GFP in 
the Drosophila taste system 
5.1  Chapter 5 – Introduction 
5.1.1  The Drosophila taste system 
Taste reception in Drosophila melanogaster is mediated by sensory neurons that are contained 
in hair-like cuticular structures called sensilla. These sensilla are distributed widely over the 
body surface but are particularly concentrated in the mouthparts, legs, anterior wing margins, 
and in the ovipositor in females (Montell, 2009) (Fig 5.1). The distal part of the proboscis is 
formed by two labella, each of which holds approximately 31 external taste sensilla (Wang et 
al, 2004), in addition to the smaller taste pegs that are present in the pseudotrachea (the 
ridges on the labellum) and internal proboscis, leading to the oesophagous. The taste sensilla 
function in the decision to accept or reject food, but may also participate in pre-copulatory 
behaviour by the male (Greenspan and Ferveur, 2000; Thorne et al, 2004). Like the sensilla on 
the mouthparts, the leg sensilla are also involved in the detection of attractive and aversive 
compounds in food, whereby contact can induce proboscis extension and retraction 
respectively (Wang, 2004). In addition, they are involved in the detection of pheromones 
during courtship in males (Bray and Amrein, 2003; Montell, 2009). The sensilla located around 
the ovipositor of female flies possibly play a different role allowing the assessment of food 
quality for larvae before laying eggs (Yang et al, 2008). 
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The labellar taste sensilla can be divided into three morphological types –the small ‘S’, 
intermediate ‘I’ and long ‘L’ type sensilla. The location of each sensillum on the labellum is 
similar between different labella, and all have been named according to their morphological 
type and position (see Fig 5.2). ‘S’ and ‘L’-type sensilla contain one mechanosensory neuron 
and 4 gustatory receptor neurons (GRNs). The GRNs are the “water” cell (W), the “sugar” cell 
(S), the “salt” cell (L1) and the “bitter” cell (L2). The GRNs are bipolar neurons with a cell body 
located beneath the cuticle in the sensillum, a dendrite that extends to the tip of the taste 
sensillum and an axon that projects to taste centres in the CNS. The major taste centre for the 
labellum is in the suboesophageal ganglion (SOG) whereas the leg GRNs project to the 
thoracic-abdominal ganglion or the SOG (Dunipace et al, 2001; Stocker, 2004). The four GRNs 
are sensitive to aqueous solutions of low osmolarity (i.e. water), various sugars, salts (such as 
monovalent alkali halides) and compounds that humans perceive as bitter, respectively 
(Dunipace et al, 2001; Stocker, 2004; Weiss et al, 2011). ‘I’ sensilla contain only 2 GRNs, one 
responds to both sugar compounds and low salt concentrations (10 - 50mM NaCl), the other 
responds to bitter compounds and high salt concentrations (over 400mM NaCl) (Hiroi et al, 
2004; Montell 2009). Among and within the morphological types of sensilla there is functional 
heterogeneity. For example, the bitter neurons within ‘S’ and within ‘I’ type sensilla can be 
divided into several classes with different but overlapping ligand specificities. Denatonium 
Figure 5.1 – The taste system of Drosophila melanogaster. (A) Cartoon showing the position 
of taste sensilla on Drosophila melanogaster (highlighted in purple). (Anterior wing margins, 
Ovipositor [females], legs and labellum). (B) Cartoon showing the structure of a typical taste 
sensillum. Each sensillum contains 4 GRNs (S, W, L1 and L2) and a mechanosensory neuron (M) 
with dendrites extending to the tip of the sensillum and cell bodies located beneath the 
cuticle. The apical pore is also shown at the tip of the sensillum. The auxillary cells are the 
trichogen, tormogen and thecogen cells. The sinus is produced from the trichogen and 
tormogen cells (Schweisguth and Posakony, 1994). The thecogen cell is responsible for 
envleloping the neurons (Isono and Morita, 2010). Cartoons drawn by Dr Wynand Van der 
Goes van Naters, Cardiff University  
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benzoate, berberine chloride and sparteine sulphate were best ligands for class Ia neurons 
while caffeine, umbelliferone and theophylline elicited strongest responses from class Ib 
neurons among the chemicals tested. Bitter compounds that activate GRNs in ‘L’ type sensilla 
have not yet been identified (Weiss et al, 2011).  
 
 
 
 
 
 
 
 
 
 
Sensilla have an apical pore through which chemicals from the substrate diffuse upon contact 
(Mitchell et al, 1999). Tastants then interact with receptors in the dendrites of the taste 
neurons. The Gr gene family (Clyne et al, 2000; Dunipace et al, 2001; Scott et al, 2001) 
underlies sugar and bitter taste. As is the case for signalling in olfactory receptors encoded by 
the Or gene family (Sato et al 2008; Wicher et al 2008), it is not yet clear whether Gr receptors 
function as ionotropic or metabotropic receptors, or both. In heterologous expression systems 
(HEK cells and Xenopus oocytes) a Gr from the silkworm, Bombyx mori, was able to respond 
selectively to D-fructose in a G-protein independent manner (Sato et al 2011), while several 
other studies have shown that sugar reception in Drosophila is reduced in mutants of G-
proteins (Ishimoto et al, 2005; Ueno et al, 2006; Kain et al, 2010). There are 60 Gr genes in 
Drosophila, some of which undergo alternative splicing so that the family encodes a total of 68 
gustatory receptors. Each sugar GRN in adults expresses a defined set of at least 3-5 Gr genes, 
whereas bitter GRNs co-express 6-29 gustatory receptors (Weiss et al, 2011). The expression of 
some Gr genes is restricted to a small number of neurons, and others are widely expressed 
(Stocker, 2004). The Gr5a receptor mediates responses to trehalose, m--glucoside, glucose 
Figure 5.2 – The location of each taste sensillum on the fly labellum. Schematic of a typical 
Drosophila labellum showing the position of each of the 31 taste sensilla. Each sensillum is 
labelled according to its morphology and position on the labellum, although there is some 
variation between different labella. A – anterior, P – posterior, M – medial, L – lateral. Image 
– Weiss et al, 2011. Reprinted from Neuron, 69(2), Weiss et al, The Molecular and Cellular 
Basis of Bitter Taste in Drosophila, 258-272., Copyright (2011), with permission from Elsevier. 
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and melezitose (Dahanukar et al, 2001, 2007) and is expressed in the sugar neuron in all 
labellar sensilla (Thorne et al, 2004; Weiss et al. 2011). Different subsets of the Gr64 gene 
cluster (Gr64a-f) are co-expressed with Gr5a and mediate responses to a complementary set 
of attractive compounds including sucrose, maltose, several other sugars and glycerol 
(Dahanukar et al, 2007; Jiao et al, 2007; Wisotsky et al, 2011) 
5.1.2  Taste recordings in Drosophila 
 A taste sensillum has an apical pore that allows entry of tastants into the hair where they 
interact with receptors in the dendrites of the GRNs (Sellier, 2010). Extracellular recordings of 
the action potentials generated by GRNs can be attained by placing the tip of an electrode over 
the tip of a taste sensillum and thus into contact with the pore. In the technique described by 
Hodgson et al (1955), the recording electrode is also used to deliver the stimulus: a chemical is 
dissolved with an electrolyte in a solution that is taken up in a glass pipette placed over an 
Ag/AgCl wire electrode. To record responses to stimuli, the glass pipette is positioned over the 
tip of the hair (Fig 5.3).   
The taste system can be manipulated by expressing a protein of interest in the GRNs using the 
Gal4-UAS system (see section 4.1.2). This can be achieved using a pan-neural driver such as 
C155-Gal4, an enhancer trap line that expresses Gal4 under control of the elav promoter.  
C155-Gal4 drives expression of the protein in all of the GRNs (Lin and Goodman, 1994). 
Alternatively a more specific driver such as Gr5a-Gal4 can be used to induce expression 
specifically in sugar neurons (Stocker, 2004). 
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5.2  Aims and objectives 
In this chapter, I aimed to investigate the function of the rP2X2-GFP channel expressed in GRNs 
of Drosophila melanogaster. In addition I sought to use the Drosophila taste system as a novel, 
medium throughput drug screening system for rP2X2 receptors using an adenosine nucleotide 
library consisting of 80 compounds.  
Figure 5.3 – Taste recordings in Drosophila. Image showing how the reference electrode 
containing salt solution is inserted into the back of the fly and extended through the neck and 
proboscis until movement of the proboscis is ceased. A second electrode containing the 
stimulus dissolved in water with 30 mM tricholine citrate (TCC) added as electrolyte is placed 
over the tip of the taste sensillum to record action potential responses to the stimulus. 
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5.3  Chapter 5 – Results 
5.3.1  Expression of rP2X2-GFP in the nervous system 
To determine whether rP2X2 is produced as a functional protein in Drosophila, taste neurons 
expressing rP2X2 were tested for sensitivity to ATP. Using the pan-neural driver C155, rP2X2-
GFP was expressed in the taste hairs of the fly. In flies expressing P2X2-GFP under control of 
the pan-neural driver, fluorescence microscopy shows expression in both taste cell bodies and 
their processes (Fig 5.4). Under low magnification in these flies, the body is fluorescent where 
large densities of neurons are present, such as the brain and other parts of the CNS.  
Electrophysiological recordings of action potentials from taste neurons were performed 
according to the technique of Hodgson et al (1955). In this technique, a pipette containing the 
stimulus solution is placed over the hair tip; the pipette also acts as the recording electrode 
(see section 5.1.2). A solvent control (30 mM tricholine citrate, TCC), 100 µM ADP and 100 µM 
ATP were tested on up to three taste sensilla per fly. Each stimulus was also tested on control 
flies that carry the UAS-rP2X2::GFP::his  transgene but not a driver to induce expression.  
In these control flies the stimuli elicited a low level of action potential activity (3.9±0.8 
impulses in 5s; mean±SEM) and no significant difference between the responses to the solvent 
control and ATP were observed (Mann Whitney, p=0.8817).  
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Fluorescence image Bright field 
G P2X2-GFP whole fly H 
A Control fly - labellum B 
C P2X2-GFP fly - labella 
E P2X2-GFP fly - labella 
D  
F  
Labellum 
Taste 
hairs 
Figure 5.4 – Expression of P2X2-GFP in the Drosophila nervous system. (A) Bright field image 
of a labellum in a fly not expressing P2X2-GFP. (B) Fluorescence image of the same labellum. 
In C-H, P2X2-GFP was expressed under control of the C155-Gal4 pan-neural driver and flies 
were imaged in bright field illumination (C,E,G) and in fluorescent conditions (D,F,H). A- F 
scale bars = 50 μm. G-H scale bars = 200 μm. 
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In flies with the C155 transgene driving expression of rP2X2-GFP, the non-stimulated impulse 
activity, measured by applying a solvent control, was significantly higher than in flies not 
expressing rP2X2-GFP (Mann Whitney, p=0.0002). Again the response to ADP did not differ 
from the response elicited by the solvent control. However, ATP did elicit a strong response 
(Fig 5.6; 189±43 impulses per 5 s, mean±SEM). This shows that expression of rP2X2-GFP 
provides the Drosophila taste neurons with sensitivity to ATP, but not to ADP, as expected 
from a functional P2X receptor.  
However, the onset-kinetics of P2X mediated responses in Drosophila taste neurons were 
much slower than those mediated by endogenous gustatory receptors. When sucrose, a 
tastant to which Drosophila responds behaviourally, was applied to the tip of a taste sensillum, 
a phasic tonic train of action potentials was elicited (Fig 5.5). The peak impulse rate, as defined 
by the shortest two consecutive interspike intervals in the spike train between three spikes of 
similar amplitude, in response to sucrose was attained within 40 ms of application (30±2 ms, 
mean±SEM, N=10). However, when ATP was applied to the tip of a taste sensillum in a rP2X2-
GFP expressing fly, on-kinetics were much slower; the impulse rate increasing gradually over 
20 s of recording (Fig 5.5). For this reason, response magnitude was determined by counting 
the number of action potentials between 10 and 15 s following compound application in all 
experiments with nucleotides in sections 5.2.1 and 5.2.2. It was not possible to reliably 
distinguish the activities of the four chemosensory neurons in a sensillum during responses to 
ATP, and so the total number of action potentials generated by the neurons have been 
summed.  
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To obtain responses to ATP from only one of the neurons in the sensilla, expression of rP2X2-
GFP under control of a driver specific to the neuron that responds to sucrose and other sugars, 
referred to as the “sugar” neuron, was investigated. The labellar sugar neuron expresses 
receptors from an 8 member subfamily of the 60 member Gr gene family. One of these is Gr5a, 
which is required for the reception of trehalose, melezitose, glucose and m-α-glucoside 
(Dahanukar et al., 2001, 2007). The promoter of Gr5a fused to GAL4 was tested as a driver for 
the expression of rP2X2-GFP. In these flies (genotype w; UAS-rP2X2::GFP::His; Gr5a-GAL4), 
rP2X2-GFP should only be expressed in the sugar neuron in each sensillum. As was the case 
with the pan-neural driver, non-stimulated activity was higher in flies expressing rP2X2-GFP 
under control of the Gr5a promoter than in control flies (9.8±2.6, mean±SEM, N=10, Mann 
Whitney, p=0.0134). ATP elicited a higher level of excitatory responses (Fig 5.6). However, 
contrary to expectation, responses were elicited by ATP in more than one neuron in each 
sensillum suggesting that Gr5a-GAL4 drove expression in multiple neurons.    
Figure 5.5 – The on-kinetics of the response to ATP is much slower than to sucrose. Top 
trace: 2 s response to sucrose applied to a taste sensillum. Middle trace:  2 s response to ATP 
applied to a taste sensillum of a P2X2-GFP fly.  Bottom trace: 20 s response to ATP applied to 
a taste sensillum of a P2X2-GFP fly. Arrowheads indicate onset of stimulus application. 
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 Figure 5.6 – ATP elicits responses in flies expressing rP2X2-GFP. (Top) Representative 
traces of responses elicited by ADP and ATP in control, P2X2-GFP; Gr5a and C155; P2X2-
GFP flies. Traces show responses elicited between 10 and 15 s after compound application. 
(Bottom) Graph showing mean response to solvent control (30mM TCC), 100 µM ADP and 
100 µM ATP from taste neurons in control flies (a) and in flies expressing P2X2-GFP using a 
pan-neural driver (b) or Gr5a-Gal4 (c). N = 10 – 12. Error bars represent SEM. (*** 
p<0.0001; ** p= 0.0002, pKruskal-Wallis one-way ANOVA; Dunn’s post test). No significant 
difference between responses was observed for control flies (p=0.978).  
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A range of ATP concentrations were tested on C155; rP2X2-GFP and w; rP2X2-GFP; Gr5a flies 
to construct a dose response curve. The concentrations tested ranged from 1 µM to 1000 µM 
both sets of flies (Fig 5.7). The ATP responses in both sets of flies were dose dependent with a 
threshold of approximately 10-5 M, the calculated EC50 for ATP in C155; P2X2-GFP flies was 147 
µM and the hill slope was 1.938. The EC50 of ATP in P2X2-GFP; Gr5a flies was 206 µM with a hill 
slope of 2.049 (Fig 5.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5.7 – The ATP response is dose-dependent in P2X2-GFP flies. ATP dose response 
curve for P2X2-GFP; Gr5a flies (grey) and C155; P2X2-GFP flies (black). N = 6-12 sensilla per 
concentration. Error bars represent SEM. Each ATP concentration was tested on a minimum 
of 2 different flies. 
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5.3.2  Testing an adenosine nucleotide library as rP2X2-GFP 
agonists 
Having determined that rP2X2 acts as a functional ligand-gated ion channel in Drosophila taste 
neurons, we considered whether the taste system of Drosophila could be developed as an 
assay system to screen for agonists of P2X receptors. Although the pharmacology of P2X2 has 
been studied more thoroughly than that of any other P2X receptor, a limited number of 
chemicals have been tested as agonists of P2X2. We obtained an 80 compound adenosine 
nucleotide library (Jena Biosciences), which comprises ATP and a great variety of modifications 
both in the adenine and ribose moieties as well as in the number and bonding of the 
phosphate groups (see Appendix IV for a full list of structures).  All 80 compounds from the 
adenosine nucleotide library were tested as potential agonists of rP2X2-GFP using the 
Drosophila taste system. 2MeSATP has been reported to be a P2X2 agonist (Evans et al, 1999) 
and was also tested. To verify that the neurons in a sensillum were still functional after 
preparing the fly for recordings, sucrose, a solvent control and 100 µM ATP were applied 
before testing each adenosine nucleotide. Only sensilla with a robust response to sucrose and 
an ATP response more than three times that of the solvent control were used for experiments. 
ATP responses among different sensilla were variable and ranged from 13 to 712 impulses. The 
nucleotide responses have therefore been normalised to ATP. The average TCC control 
response corresponded to approximately 10% of the ATP response.  Some of the nucleotides 
elicited a similar or higher response than ATP which was significantly different from the TCC 
response; these were ATPγS, ATPαS, and 2F-ATP with responses corresponding to 102%, 114% 
and 142% of the average ATP response, respectively (Fig 5.8). These highly effective agonists 
were retested on an additional three sensilla (Fig 5.9). Most nucleotides elicited responses 
intermediate between the solvent control TCC and ATP; the four strongest partial agonists 
were mant-n6-methyl-ATP, AP4, dATP, and araATP with responses corresponding to 33%, 31%, 
44% and 43% of the average ATP response respectively (Fig 5.8). However statistical analysis 
suggested that the responses did not differ significantly to that of TCC. However due to the low 
number of repeats for each compound and thus the large error, it would be useful to repeat 
each compound an additional 3 times to get more reliable results and statistical analysis.  
Other nucleotides elicited a response that was lower than the average solvent control 
response (10%). These included 8-[(4-Amino)butyl]-amino-ATP, N6-(6-Amino)hexyl-dATP, N6-
(6-Amino)hexyl-ATP and AP5A with normalised responses corresponding to 2.7%, 4.0%, 4.5% 
and 5% respectively (Fig 5.8). Expression of rP2X2-GFP in neurons appears to endow the 
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neurons with a non-stimulated action potential activity, as measured by responses to the 
solvent control, which may result from spontaneous channel openings. One interpretation of a 
suppression of the solvent control response by these four compounds is that they interact with 
the P2X2 receptor to stabilise a closed conformation of the channel. However statistical 
analysis suggested that the responses did not differ significantly from TCC and thus this would 
need to be investigated further to see if these compounds have an effect on the receptor. 
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Figure 5.8 – Mean responses of P2X2-GFP to 80 adenosine nucleotides. 80 adenosine 
nucleotides were applied to the tip of taste sensilla of flies expressing P2X2-GFP under the 
control of the pan-neural driver C155-Gal4. Bars show the mean compound response 10 – 15 
s after application to the taste sensillum, normalised to the number of action potentials 
elicited by ATP. Error bars are SEM, N=3. ATP is shown in brown and the solvent control (TCC) 
is shown in purple. Blue bars represent AMP/ADP/ATP derivatives with altered adenine 
moieties, orange represents altered phosphate groups and cyan represents altered ribose 
moieties. See Appendix IV for structures. One way ANOVA was used to determine if the ten 
compounds with the highest and lowest responses were significantly different from the 
control TCC response and thus represent agonists and antagonists respectively. Significant 
responses are represented by ** (P<0.01) and * (P<0.05). ns = not significant. 
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To ensure that the effects of the nucleotides that gave a higher response than TCC were as a 
result of rP2X2 activation and not activation of endogenous Drosophila receptors, they were 
also tested on control flies. None of the compounds induced a higher response than TCC in 
control flies demonstrating that they act on rP2X2 (Fig 5.10).  
 
 
 
 
 
 
 
 
 
Figure 5.9 – 2F-ATP, ATPαS and ATPγS elicit responses significantly different from TCC. Each 
compound was tested on 6 sensilla, each on a different fly. Graph shows the mean response 
for each compound normalised to ATP. Statistical analysis: (*** p<0.0001; Kruskal-Wallis one-
way ANOVA; Dunn’s post test, N=6). 2F-ATP (P=0.1233), ATPαS (p=0.2422) and ATPγS 
(p=0.2425) responses do not differ significantly from that of ATP (one sample t-test, N=6). 
TC
C
A
TP
2F
-A
TP S
A
TP
S
A
TP
0
50
100
150
200
250
N
o
rm
a
li
s
e
d
 r
e
s
p
o
n
s
e
 (
%
)
*** 
157 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
                  
Separating out the compound library into ATP, ADP and AMP derivatives allows comparison 
among agonists within these groups. As noted before 2-fluoro-ATP, which has a substitution in 
the purine base, is the best ligand among the ATP derivatives (Fig 5.11A). While some 
modifications in the phosphate groups are tolerated, modifications of the ribose sugar all 
cause loss of effectiveness. Among the ADP derivatives, ADP itself elicited the lowest response; 
any derivative tested appears to give a higher response (Fig. 5.11B). Likewise, among the AMP 
derivatives AMP itself was least effective (Fig. 5.11C). As the modifications available in the 
library for ADP and AMP corresponded only partly, it is not possible to compare the profiles 
between agonists in these two groups.   
Figure 5.10 – None of the P2X2 agonists elicit responses in control flies. The compounds 
which initiated a response of more than 50% of the ATP response in rP2X2-GFP flies were 
tested on control flies (rP2X2-GFP parent flies) and action potentials were recorded. None of 
the compounds tested (ATPαS, ATPγS or 2F-ATP) induced a response largely different from the 
TCC response in control flies demonstrating that they act specifically on rP2X2-GFP.  
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5.3.3  Localising rP2X2-GFP to the tip of the taste sensillum 
Work by Dr Wynand van Der Goes van Naters showed that removing the tip of the Drosophila 
taste sensillum caused a loss of response to sucrose. This suggests that the gustatory receptors 
are localised to the tip of the taste sensillum. However, the sensilla in rP2X2-GFP flies were still 
responsive to ATP following tip removal suggesting the rP2X2 receptors are not being targeted 
Figure 5.11 – Comparison of responses to ATP, ADP and AMP derivatives. Compounds were 
grouped according to the number of phosphate groups they have. (A) ATP derivatives with 
ATP shown in brown, compounds with ribose modifications are shown in cyan, phosphate 
modifications are shown in orange and adenine modifications are shown in blue. (B) ADP 
derivatives and (C) AMP derivatives. The bars shown represent the average response relative 
to ATP (%). The line at approx. 10% shows the average solvent control TCC response. The line 
at 100% represents the ATP response. 
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to the tip of the hair (data not shown). This may explain why sucrose responses are observed 
immediately after agonist application whereas the ATP response has much slower on-kinetics. 
The gustatory receptor protein is likely to contain a subcellular targeting motif because a 
transgene carrying only the coding region of a gustatory receptor gene can fully rescue 
responses in a deletion mutant for the receptor (Dahanukar et al, 2007). We surmised a 
targeting motif may be conserved among Gr proteins.  Amino acid sequences of five gustatory 
receptors were aligned (Gr64a, Gr64e, Gr5a, Gr32a and Gr43a) to identify conserved candidate 
regions that could be involved in localisation of the receptors to the apical tip of the GRN 
dendrite (Fig 5.12). The C-terminal domain of the receptors appeared to be the most highly 
conserved. A putative Short Targeting Sequence (STS, from residue 430 onwards) and a Long 
Targeting Sequence (LTS, from residue 332 onwards) were selected. Regions encoding the STS 
and LTS of Gr64a were amplified by PCR from cDNA from w1118 flies, using forward primers 
that also encode a Thrombin cleavage site and a Myc-tag, and these were ligated onto the 3’ 
end of rat P2X2 to generate rP2X2-Thr-Myc-STS and rP2X2-Thr-Myc-LTS fusion constructs.  
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Figure 5.12 – Sequence alignment of gustatory receptors. The amino acid sequences of five diverse gustatory receptors (Gr64a, Gr64e, Gr5a, Gr32a and 
Gr43a) were aligned. Conserved residues are shaded in dark grey and amino acids which display similar properties are shaded in light grey. The start of 
the long targeting sequence (LTS) begins at residue 332 and is indicated by the red asterisk. The start of the short targeting sequence (STS) begins at 
residue 430 and is indicated by the blue asterisk.  
* 
* 
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The rP2X2-myc-LTS and rP2X2-myc-STS constructs were injected into Drosophila embryos to 
generate phiC31 mediated integration of transgenes on the third chromosome (attP2 site) 
(Markstein et al, 2008). Fly lines expressing the constructs under control of the C155 driver 
were obtained. However due to time constraints, it has not yet been possible to test the 
activity of rP2X2 in these fly lines. 
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5.4  Chapter 5 - Discussion 
5.4.1  P2X receptors form functional LGICs in Drosophila taste 
neurons 
rP2X2-GFP was shown to be functional in Drosophila under control of both the pan-neural 
C155-Gal4 and sugar neuron Gr5a-Gal4 drivers (Fig 5.6). Robust responses were elicited to ATP 
but not to ADP or the solvent TCC in rP2X2-GFP flies while GRNs in control flies did not respond 
to ATP (Fig 5.6).  
The basal number of action potentials elicited in response to TCC or ADP was higher in rP2X2-
GFP expressing flies compared to control flies. There are two possible reasons for this result. 
Firstly, there may be spontaneous ATP release in Drosophila causing activation of the 
receptors in the absence of exogenously applied ATP. Alternatively, the receptors may be 
undergoing a basal level of activation in the absence of ATP. To distinguish between these two 
possibilities, an enzyme such as apyrase (catalyses the hydrolysis of ATP to ADP and Pi (Smith 
et al, 2002)) could be co-applied to the sensillum with TCC to see if this reduces the basal level 
of responses. Additionally, a rP2X2 antagonist (such as suramin or PPADS) could be co-applied 
to the taste hair to ensure the increase in TCC response is as a result of the rP2X2-GFP 
activation. 
The response curve to ATP mediated by rP2X2-GFP under control of both the pan neural 
(C155-Gal4) and sugar neuron (Gr5a-Gal4) drivers showed a dose dependent increase. 
However, a higher concentration of ATP was required to activate the channel and a right-hand 
shift in the dose response curve was observed when compared to rP2X2 expressed in other 
systems (Fig 5.7). For example in HEK-293 cells the EC50 of rP2X2-GFP is 4.4 µM (Bobanovik et 
al, 2002) and in Xenopus oocytes the EC50 is approximately 15 µM (Khakh et al, 2001a). 
However the EC50 of rP2X2-GFP expressed in the Drosophila system was 147-206 µM. This 
rightward shift in ATP response could be as a result of the receptor not folding and functioning 
correctly in Drosophila. However, the P2X receptor is not exclusively localised to the tip of the 
dendrite where the stimulus enters the pore. One possible reason for the difference in ATP 
potency is that the taste sensillum pore is so small that the response is affected by the time 
required for the diffusion of ATP into the sensillum. In the time taken for the ATP to diffuse in 
to the sensillum, the neuron is adapting causing a shift in the dose response curve to the right. 
This could be investigated by removing the tip of the sensillum to make the access hole larger 
and seeing what effect this has on the ATP response. 
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The ATP response varies between different flies and sensilla. A histogram was generated that 
represents the frequency distribution of the ATP response in the sample of sensilla tested (Fig 
5.13). The frequency distribution appears to be multimodal. Two main peaks were observed 
between 40–99 and 120-199 action potentials. This indicates there may be at least two classes 
of sensilla responding to ATP at differing rates; one is less responsive to ATP with a peak of 40–
99 action potentials whereas the other is more responsive with a peak of 120–199 action 
potentials. This could be due to certain sensilla types acting as better hosts of the receptors. 
5.4.2  Using the taste system as a compound screening technique 
for rP2X2 receptors 
P2X2 receptors are major drug targets with roles in pain sensation, inflammation and hearing 
loss (Cockayne et al, 2005; Hunskaar and Hole, 1987; Xu and Huang, 2002; Yan et al, 2013). 
Selective, potent P2X2 agonists and antagonists could provide new therapies for a range of 
conditions. The taste system of Drosophila provides a novel medium throughput screening 
system for P2X2 agonists and holds the advantage of having the receptor expressed in a neural 
system.  
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Figure 5.13 – Variation of ATP responses in P2X2-GFP flies.  ATP responses were measured 
from each sensillum between 10 and 15 s after ATP application. The frequency of each block 
of action potential numbers is shown in this histogram. Two main peaks are observed at 50 – 
99 and 150 -199 action potentials. 
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In this thesis, an adenosine nucleotide library consisting of 80 compounds was tested on flies 
expressing rP2X2-GFP. Although nucleotides are not considered to have great therapeutic 
potential because of their central importance in many processes in the body, testing this 
library provides a proof of concept that the screen is feasible and a range of responses to the 
nucleotides were observed. In addition it allows us to speculate why certain adenosine 
nucleotides are able to activate P2X2 while others have no effect, giving insight into which 
parts of the ATP molecule are necessary for receptor activation. This information will help in 
the design of new and selective agonists and/or antagonists of P2X2. I chose to test the 
nucleotide library on flies expressing rP2X2-GFP under control of the C155-Gal4 driver rather 
than the Gr5a-Gal4 driver because responses to ATP were elicited in more than one neuron in 
Gr5a flies, suggesting that the driver is expressing rP2X2-GFP in other neurons as well as the 
sugar neurons. This is possibly due to leaky expression of the Gal4 driver rather than 
expression that is faithful to the endogenous localisation of Gr5a. 
5.4.3  Testing the adenosine nucleotide library 
The taste system of Drosophila has provided us with a novel platform for drug screening in 
search for new P2X2 agonists and antagonists. So far 80 adenosine nucleotides have 
successfully been tested using this system which elicited a large range of responses. Some of 
the nucleotides that displayed a response similar to ATP include 2F-ATP, ATPαS and ATPγS. 
Initially, only the compounds with 3 or more phosphate residues have been analysed due to 
the previously documented importance of the gamma phosphate in receptor activation 
(Hattori and Gouaux, 2012). A schematic of ATP is shown in Appendix IV noting the 
nomenclature of the various parts of the molecule used below. 
5.4.4  Changes to the phosphate groups 
Fig 5.11A shows that some modifications to the phosphate groups (shown in blue) of ATP can 
be tolerated by P2X2. ATPαS and ATPγS are ATP derivatives that contain a sulphide group in 
place of a hydroxyl group on either the α or γ phosphate respectively. Both ATPαS and ATPγS 
elicited responses similar to ATP in rP2X2-GFP flies with responses of 103% and 115% 
respectively. In the rP2X2 structural model based on the zfP2X4.1 crystal structure, the 
hydroxyl groups form hydrogen bonds with residues in the ligand binding site (see Fig 5.14B). 
This indicates that when these hydroxyl groups are replaced with sulphide groups, interactions 
can still be formed with the receptor and thus can still fully activate rP2X2. ATPαS and ATPγS 
have also been shown to activate P2X2 in other systems such as Xenopus oocytes using patch 
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clamping where ATPαS and ATPγS gave responses equivalent to 80% and 85% of the ATP 
response respectively (King et al, 1997). 
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affected activation.  
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Summary: 
• Substitutions to α and γ OH 
groups (ATPαS and ATPγS) 
tolerated and act as full agonists 
• Substitutions to either oxygen 
adjoining phosphate groups not 
tolerated and nucleotides do 
not activate P2X2. 
• Groups added to the end of the 
γ phosphate interfere with ATP 
binding and/or agonist activity. 
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Figure 5.14 – Model of rP2X2 ATP binding pocket. (A-C) Schematics showing position of ATP 
buried within the rP2X2 binding pocket, from angles which match schematics below. (D) The 
phosphate groups, shown in orange, are predicted to interact with residues from both adjacent 
subunits. (E) The ribose sugar, shown in cyan, is not predicted to interact with any rP2X2 residues. 
(F) The adenine ring, shown in blue, is predicted to interact with residues from one of the 
adjacent subunits. Dotted lines represent hydrogen bonds. (G-I) Testing the adenosine compound 
library on rP2X2 expressed in D. melanogaster, we summarised which residues appear to be 
important in channel activation. Positions where all ATP substitutions tested could be tolerated 
and gave full functional responses are circled in green. Positions where some, but not all, ATP 
substitutions tested could be tolerated and gave some functional responses are circled in yellow. 
At positions where any substitution gave rise to a molecule which could not activate P2X2 are 
circled in red. Nitrogen atoms are shown in blue, oxygen atoms are shown in red. 
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dAppCp and AppCp (also called β,γ-methylene-ATP) have an oxygen to methyl substitution 
joining the β and γ phosphate groups. dAppCp also lacks the ribose 2’ hydroxyl group. The 
oxygen substitution has a significant effect on channel function with responses for dAppCp and 
AppCp of 10.8% and 6.6% respectively. AppCp has been shown to be a partial agonist of rP2X2 
receptors before but with an EC50 >300 µM, it has a low potency (Liu et al, 2001). Therefore at 
a concentration of 100 µM it would be unlikely to activate the receptor in this system due to 
the rightward shift of the dose response curve. Similarly AppNp, where the same oxygen is 
substituted for an imido group, elicited a response of 6.2%. ApCpp (also called α,β-methylene-
ATP) has an oxygen to methyl substitution joining the α and β phosphates. This substitution 
also prevents receptor activation giving a response of 13.8%. This is in agreement with 
previous findings that suggested it is inactive at P2X2 receptors (Liu et al, 2001). This suggests 
that the oxygen atoms linking the phosphate groups together are vital for receptor activation. 
These oxygen atoms do not appear to be involved in the formation of interactions with the 
binding pocket in the rP2X2 structural model (Fig 5.14D). However alterations of these 
residues may lead to changes in the conformation of the phosphate groups, preventing critical 
interactions with the subunits. 
This agonist screen showed that the compounds AP3A, AP4A, AP5A and AP6A did not activate 
rP2X2 receptors with responses of 12%, 5.7%, 5% and 8.2% respectively. This is in contrast to 
previously published data that suggested AP4A is an agonist at rP2X2 expressed in Xenopus 
oocytes with an EC50 of 15.2 µM (Pintor et al, 1996; Wildman et al, 2002). However it is 
possible that the AP4A nucleotide was unstable and degraded to AMP and ATP and thus the 
effects seen in the past were due to activation by ATP. As the activity of AP4A has only been 
investigated in Xenopus oocytes, it would be useful to study its activity in other systems such 
as HEK-293 cells. The addition of another adenosine molecule and additional phosphate group 
to the ATP nucleotide increases the size of the agonist substantially and it seems unlikely the 
P2X receptor would be able to accommodate this but this would need to be further 
investigated. Other dinucleotide polyphosphates (AP5(8I)G, AP4T, AP5T, AP4(8I)G, AP4G, 
AP5U, AP5G, AP4U) did not activate rP2X2 with responses ranging from 10.7% to 22%. 
However, AP4, which has the addition of an extra phosphate group but no additional 
nucleoside, elicited partial activation of rP2X2-GFP with an average response of 31%. The 
rP2X2 homology model shows the gamma-phosphate group located at the edge of the binding 
pocket. As rP2X2 can still undergo partial activation by AP4, it is likely that the extra phosphate 
group lies outside the binding pocket (Fig 5.14A). 
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γ-[(6-aminohexyl)-imido]-ATP and γ-[(8-aminooctyl)-imido]-ATP have an aminohexyl-imido or 
aminooctyl-imido group attached the gamma phosphate of ATP. These nucleotides are inactive 
at rP2X2-GFP with responses of 11.2% and 6.5% of the ATP response respectively suggesting 
that, as with the diadenosine polyphosphates, the receptor cannot accommodate bulky 
additions to the end of the phosphate groups. Likewise, γ-aminophenyl-ATP has a 4-
aminophenyl group attached to the gamma phosphate and doesn’t activate the receptor with 
an average response of 13%. 
This data indicates that the addition of bulky groups to the end of the gamma phosphate of 
ATP prevent activation of the receptor despite the fact the gamma phosphate is located at the 
outside edge of the binding pocket (Fig 5.13G).  
5.4.5  Changes to the adenine ring 
Fig 5.11A shows that few alterations of the adenine ring of ATP (shown in red) can be tolerated 
by P2X2. N1-methyl-ATP contains a methyl group attached to the N1 position of the adenine 
ring of ATP. The addition of this group to ATP prevented the nucleotide from activating rP2X2 
in this system (17% of the ATP response). One possible explanation is that the methyl group is 
preventing the compound from accessing the binding pocket. Alternatively the compound may 
be accessing the binding pocket but the presence of the methyl group is preventing it from 
forming the hydrogen bond that is predicted to be formed between the N1 position of the 
adenine ring and the T184 residue of the adjacent subunit in the rP2X2 model (Fig 5.14F).  
2F-ATP is an ATP derivative with a fluorine to hydrogen substitution at position 2 of the 
adenine ring. 2F-ATP fully activated rP2X2 with an average response of 142%. In the rP2X2 
model, the hydrogen atom does not interact with the binding pocket (Fig 5.14F) suggesting 
that this substitution is unlikely to affect ATP forming interactions with the binding pocket and 
so 2F-ATP is still able to activate P2X2. 2F-ATP has not previously been tested on P2X2 
receptors making this nucleotide a novel agonist. However, 2-hydroxy-ATP, which has the 
addition of a hydroxyl group at position 2 of the adenine ring, does not activate rP2X2; it 
elicited an average response of 8.7% showing that it is not just the addition of the group that 
may affect binding but also the specific properties of the group are important for interactions 
with the binding pocket. The extra hydroxyl group in 2-hydroxyATP might be involved in the 
formation of hydrogen bonds with residues in the binding pocket with which ATP does not 
interact; this may in turn prevent activation. 
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N6-(6-amino)hexyl-dATP and N6-(6-amino)hexyl-ATP display a lower response than the TCC 
controls with average responses of 4% and 4.5% of the ATP response. A (6-amino)hexyl side 
group is added to the amino group at the 6th position of the adenine ring of ATP in these 
compounds. Additionally, N6-(6-amino)hexyl-dATP is lacking the 2’ hydroxyl group on the 
ribose sugar. The amino group at the 6th position of the adenine ring is predicted to form 2 
interactions with the T184 side chain of the adjacent P2X subunit in the rP2X2 homology 
model (Fig 5.14F). Consequently the addition of this bulky side chain may interfere with the 
formation of these hydrogen bonds and prevent channel opening or they may completely 
prevent the nucleotide from accessing the binding site as the adenine ring is buried deep in 
the binding pocket (Fig 5.14C). N6-(4-amino)butyl-ATP has an additional (4-amino)butyl group 
linked to the amino group at position 6 of the adenine ring. Similarly, the response to this 
compound does not differ largely from TCC (17%). Ɛ-ATP has an etheno group attached to the 
1st and 6th position of the adenine ring. This group prevents the nucleotide from activating the 
receptor with a response of 19.4%. N6-methyl-ATP holds a less bulky, methyl group attached 
to the amino group at position 6 of the adenine ring. This nucleotide gives a partial response of 
28.2% of the ATP response but with a large error of 21.3%, this makes it difficult to determine 
whether or not this compound is having an effect without further investigation. Mant-6-
methyl-ATP is the same as N6-methyl-ATP but with an additional mant group attached to the 
2’ or 3’ hydroxyl groups of the ribose sugar. This nucleotide gave an average response of 38.5% 
but with a large error of 21.5%, this also makes it difficult to determine what effect it has 
without further investigation. However, as both N6-methyl-ATP and mant-ATP give lower 
responses, mant-n6-methyl-ATP is unlikely to partially activate rP2X2. All these data indicate 
that additional groups at position 6 of the adenine ring cannot be accommodated and disrupt 
receptor activation (Fig 5.14I).  
7-Deaza-7I-dATP and 7-Deaza-7Br-dATP lack the 2’ hydroxyl group and have an iodine residue 
or bromine residues attached at position 7 of the adenine ring. These nucleotides gave 
responses of 10.2% and 11.4% respectively which are lower than the response of dATP (43.6%) 
indicating that the addition of iodine or bromine to position 7 of the adenine ring has a 
significant effect on agonist activity. However, the nitrogen atom at position 7 of the adenine 
ring in ATP is not predicted to form interactions with rP2X2 (Fig 5.14F). 
The nucleotide that gave the smallest response was 8-[(4-amino)butyl]-amino-ATP. This 
nucleotide has an additional amino group at position 8 of the adenine ring. The amino group is 
further attached to a butyl group and another amino group. 8-[(4-amino)butyl]-amino-ATP 
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gave a response of 2.7% of the ATP response which is 7.3% less than the control TCC response 
in rP2X2-GFP flies. This lower response is approximately equivalent to the basal response 
observed in control flies. I speculate that this compound might act as a rP2X2 antagonist and 
thus prevents basal channel opening either spontaneously or by competing with ATP released 
in the Drosophila taste sensillum. However, if 8-[(4-amino)butyl]-amino-ATP is acting as a 
competitive antagonist, the binding pocket must be able to accommodate the addition of the 
large side group to the 8 position of the adenine ring (Fig 5.14C). Further investigation would 
be required to determine whether or not this nucleotide is acting as an antagonist. 
8Br-dATP, 8Br-ATP and 8I-ATP have an additional bromine or iodine group attached to the 8th 
position of the adenine ring respectively. These nucleotides are inactive at rP2X2-GFP with 
responses of 20.9%, 5.8% and 11% of the ATP response for 8Br-dATP, 8Br-ATP and 8I-ATP 
respectively. The differences between responses for 8Br-dATP and 8Br-ATP are likely to be as a 
result of the large variation between flies with a great error of 13.6% for 8Br-dATP. In the 
rP2X2 model, the 8th position of the adenine ring does not appear to be involved in interacting 
with the binding pocket (Fig 5.14F). However these results suggest that even small additions at 
this position can have an effect on P2X2 activity suggesting that it may indeed interact with the 
receptor (Fig 5.14I).  
5.4.6  Changes to the ribose sugar 
Interestingly, the data from the nucleotide library indicates that any alteration to the ribose 
moiety of ATP has a significant effect on the ability of the nucleotide to activate P2X receptors 
(Fig 5.11A). Interestingly, no part of the ribose sugar is predicted to interact with the P2X2 
binding pocket in the rP2X2 structural model. This data indicates that conversely, most of the 
residues of the ribose sugar play a large role in receptor activation. DeoxyATP (dATP) lacks the 
2’ hydroxyl group on the ribose sugar moiety of ATP. dATP appears to retain some agonistic 
effects at rP2X2-GFP (43% of the ATP response) indicating that this hydroxyl group does not 
undergo significant interactions with the ATP binding pocket; this is in agreement with what is 
predicted in our rP2X2 homology model (Fig 5.14E). However when the 3’ hydroxyl group is 
removed from the ribose sugar (3’ dATP), there is a larger reduction in agonist potency with an 
average response of 23% of the ATP response. In addition upon removal of both the 2’ and 3’ 
hydroxyl groups (ddATP) the response is reduced further to approximately 16% of the ATP 
response. These results suggest the 3’ hydroxyl group is playing a role in ATP binding. However 
the homology model of the binding pocket does not show this residue interacting with any 
portion of the binding pocket (Fig 5.14E). The 2’ hydroxyl group is set in a different orientation 
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in ara-ATP; this nucleotide still partially activates the receptor with an average response of 
42.6%. Thus this suggests that changes to the 2’ hydroxyl group of ATP does not completely 
abolish receptor activation, but there is a decrease in agonist potency (Fig 5.14H). 
Mant dATP and Mant-ATP have a large O-(N-methyl-anthraniloyl) group attached to either the 
2’ or 3’ hydroxyl group of ATP. These nucleotides are inactive at rP2X2 with responses of 26% 
and 9.7% (differences are likely due to large error – 14.9% for Mant dATP). Similarly EDA-ATP 
has the addition of an O-(2-Aminoethyl-carbamoyl) group to either the 2’ or 3’ hydroxyl group 
of ATP and this addition prevents receptor activation with a response of 12.2%. TNP-ATP has 
the addition of a O-Trinitrophenyl-adenosine group to the 2’,3’ hydroxyl groups of ATP. TNP-
ATP does not activate rP2X2 with a response of 14.5%. However it has previously been shown 
to act as an antagonist at rP2X2 receptors (Virginio et al, 1998). Therefore bulky additions at 
the 2’ and 3’ positions of the ribose sugar cannot be tolerated and prevent activation. This is 
likely due to the nucleotides being unable to access the binding pocket, with the ribose sugar 
buried between the subunits (Fig 5.14B/H). 
5.4.7  P2X2 response to AMP and ADP derived nucleotides 
The compounds were separated into those with one (AMP derivatives), two (ADP derivatives) 
and three (ATP derivatives) phosphate groups to allow comparisons between individual groups 
to be made (Fig 5.11). Among the AMP derivatives, AMP was shown to elicit the lowest 
response (Fig 5.11C). Similarly, among the ADP derivatives, ADP was shown to elicit the lowest 
response (Fig 5.11B). This data indicates that any modification made to AMP or ADP enabled 
the nucleotide to elicit a higher P2X2 response. Thus this suggests that the P2X receptor has 
not only evolved specificity for ATP, but also evolved not to respond to the co-occurring 
species AMP and ADP. Whether the principle that receptors show these two modes of 
specificity –for the ligand and against co-occurring similar reaction products- holds true for 
other systems besides rat P2X2, remains to be investigated.    
5.4.8  Adenosine nucleotide library: Summary 
A range of responses were observed after testing the adenosine nucleotide library as potential 
agonists of rP2X2. 
Fig 5.15A shows a hypothetical response graph where none of the compounds, other than 
ATP, elicited a P2X2 response significantly different to the TCC control. In this situation, it 
could be concluded that every feature of the ATP molecule is critical for activation and thus 
plays a part in receptor activation. Fig 5.15C shows another hypothetical response graph 
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where the responses vary largely for the adenosine derivatives and many of them are able to 
partially or fully activate P2X2. In this situation, it could be concluded that there are many 
features of the ATP molecule that are not necessary for P2X2 activation and can be 
compromised without loss of agonist activity. The actual data (Fig 5.15B) shows an 
intermediate effect, but it is closer to what is observed in Fig 5.15A. This suggests that the 
majority of the changes to ATP could not be tolerated and are necessary for P2X2 activation.  
 
 
 
 
 
 
 
 
 
The nucleotide library screen has given a detailed insight into what is required for ATP to bind 
to and activate rP2X2 receptors. It is clear that the addition of large side groups to any part of 
the nucleotide has a significant effect on agonist activity. Altering the connecting residues 
between phosphate groups appears to have a notable effect on activation of rP2X2, in 
agreement with previous findings. This is in contrast to activity at other P2X receptors such as 
P2X1 and P2X5 (Wildman et al, 2002) indicating that the outer part of the binding pocket may 
differ in the different receptors. Substitutions of the phosphate hydroxyl groups to sulphide 
groups can be tolerated (ATPαS and ATPγS) indicating that the interactions made by the 
hydroxyl groups predicted in the rP2X2 model can either still be formed, or are not essential 
for receptor activation (Fig 5.14G). Further investigation is required to see what other 
substitutions can be tolerated.  
The ribose sugar possesses a 2’ and a 3’ hydroxyl group. Removal or alteration of the 2’ 
hydroxyl group does not completely prevent agonistic activity whereas the 3’ hydroxyl group 
seems to be of more importance for receptor activation. This suggests that, in contrast to what 
0 50 100 150 0 50 100 150
Figure 5.15 – Theoretical compound response profiles of P2X2. (A) Theoretical response 
profile for ATP; no other derivatives activated P2X2. (B) Actual response profile for adenosine 
nucleotide compound library tested. (C) Theoretical response profile for ATP if many factors 
were not critical for ATP activation.  
A B C 
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is predicted in the rP2X2 model, the 2’ and 3’ hydroxyl groups interact with the receptor. 
Addition of larger groups to the 2’ or 3’ position of the ribose sugar also disrupts agonist 
activity at P2X2. As the ribose sugar is buried within the binding pocket of the rP2X2 model (Fig 
5.14B), the additional groups may prevent the nucleotide from fitting in the binding pocket.  
Addition of large side groups to any part of the adenine ring prevents the nucleotide from 
activating the receptor. This part of the molecule is expected to be buried deep in the binding 
pocket in the homology model (Fig 5.14C) and so it is likely that with bulky side chains, the 
nucleotides cannot fit in the binding pocket. Interestingly, 2F-ATP acts as a potent agonist at 
rP2X2 whereas 2hydroxy-ATP has no agonistic activity. Additionally, 2MeSATP had a partial 
agonistic effect at rat P2X2 (39%). This compound has a methylthio group attached at position 
2 of the adenine ring. Therefore although hydrogen substitutions can be tolerated at this 
position, the properties of the group play a role in interacting with the binding pocket. This 
could be as a result of 2-hydroxyATP forming interactions with P2X2 that are not formed by 
ATP. This would suggest that, in agreement with the rP2X2 model, position 2 of the adenine 
ring does not play a role in receptor activation (Fig 5.14F). 
5.4.9  Problems faced with using the taste system as a compound-
screening system 
There are a number of problems faced when analysing this data, largely because of the large 
variation in responses observed between flies. For example, the TCC response in some flies can 
be as high as 50% of the ATP response where others may be 0% of the ATP response. Although 
we only used flies where the TCC response was 33% or less than the ATP response, this still 
allowed a large variation of responses for nucleotides which had no effect. As only 3 repeats 
were performed for each nucleotide, the error was large if one sensillum gave a high 
background response. In addition, some sensilla retained activity following ATP application in 
the absence of an agonist giving a high response even when the nucleotide had no activity. 
These problems account for the large errors observed with a number of nucleotides. To 
overcome these problems there are 2 main solutions; firstly with more time it would be 
necessary to test each nucleotide a minimum of 6 times to give more accurate results with less 
error. In addition, to account for the sensilla that retain activity after ATP application, TCC 
would be re-applied after ATP to ensure the neuron has returned to its basal state before 
testing the nucleotide of interest. 
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5.4.10  P2X2 expressed in other systems 
A number of other systems have been used for the expression of P2X2 receptors and the 
testing of compounds as potential agonists or antagonists of the receptor. In 1999, Grubb and 
Evans tested the effect of 2MeSATP, α,β-meATP, β,γ-meATP, UTP, TNP-ATP, suramin and 
PPADS on P2X2 receptors expressed in cultured adult rat dorsal root ganglion cells. They used 
whole-cell and outside-out patch clamp recordings to test the response of P2X2. In this system, 
reproducible responses to 10 µM ATP could only be obtained if a time gap of 4-5 minutes was 
given between agonist applications. To test the action of antagonistic compounds, they had to 
be presuperfused over the neuron and added to the superfusate that is applied to the cell. 
After application of suramin to a neuron, a time interval of 40 minutes was required before the 
baseline returned to control levels. During these experiments, the effects of 9 compounds 
were tested on P2X2 receptors over a lengthy time period due to the time intervals necessary 
between applications for levels to return to baseline. They concluded that 2MeSATP and α,β-
meATP were agonists and β,γ-meATP and UTP were ineffective at P2X2Rs. TNP-ATP, PPADS 
and suramin all had antagonistic effects (Grubb and Evans, 1999). 
Another expression system that has been used for P2X receptors is the Xenopus oocyte. Liu 
and colleagues, 2001, expressed P2X2 in Xenopus oocytes and tested the agonist activity of 
ATP, 2MeSATP, ATPγS, α,β-meATP, β,γ-meATP, AP5A and UTP using voltage clamp procedures. 
Using this method, the application of agonists were separated by a time gap of 20 minutes. 
They also tested PPADS, RB-2, Suramin, TNP-ATP and IP5I as antagonists at P2X2 which 
required a 1 minute pre-application, and were applied during agonist application. Their results 
showed that ATP, 2MeSATP and ATPγS acted as P2X2 agonists (EC50 values of 4.3, 6.9 and 8.4 
respectively). However in contrast to Grubb and Evans, 1999, (and in agreement with my 
results) they concluded that α,β-meATP was inactive at P2X2Rs. They also found that β,γ-
meATP, AP5A and UTP were ineffective at P2X2 receptors (Liu et al, 2001). 
The effect of adenine dinucleotides were also tested on P2X2 expressed in Xenopus oocytes. In 
this study by Pintor et al, the effects of AP2A, AP3A, AP4A, AP5A and AP6A were studied on 
P2X2. They concluded that AP4A had an EC50 of 15.2 µM, which was close to that of ATP (EC50 = 
3.7 µM). In addition, AP5A potentiated P2X2 responses to ATP, lowering the EC50 to 2.95 µM 
when co-applied (Pintor et al, 1996). 
King and colleagues (1997) investigated the effect of extracellular pH on the agonistic effects 
of various P2X2 agonists. Eighteen compounds were tested using voltage-clamp 
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electrophysiology on P2X2 expressed in Xenopus oocytes with results concluding that ATP, 2-
MeSATP, ATPγS and ATPαS acted as potent P2X2 agonists and CTP, BzATP, ADP, 2-MeSADP, 
ADPβS, AMP, α,β-meATP, β,γ-meATP, UTP, ITP, GTP, 2’-dATP, 3’-dATP and adenosine elicited 
little or no response. Under acidic conditions (pH 6.5 compared to pH 7.4), they noted that 
there was a 5-fold increase in ATP-affinity for all four agonists but no change in the order of 
potency (King et al, 1997). 
Baqi et al (2011) identified 2 selective P2X2 antagonists (PSB-1011 [IC50 – 79 nM] and PSB-
12011 [IC50 – 86 nM]) which blocked ATP mediated currents in Xenopus oocytes expressing 
P2X2 receptors.  In this study, a library of 59 anthraquinone derivatives of RB-2 were tested as 
antagonists using 2 electrode voltage-clamp electrophysiology (Baqi et al, 2011). 
Although Xenopus oocytes have proved effective in the past for testing compounds as 
potential agonists or antagonists of P2X2, there are some limitations to using this model; one 
of these is the recovery time required between repeated agonist applications. For these 
reasons, it would be difficult and time-consuming to use Xenopus oocytes to screen large 
compound libraries as potential agonists or antagonists of P2XRs and may explain why the 
above studies (Liu et al, 2001; Pintor et al, 1996; King et al, 1997) investigated only a small 
number of compounds (6 – 18 compounds), with the exception of Baqi et al (2011). The use of 
the Drosophila taste system as a novel drug screening system of P2XRs provides a much faster 
way of screening larger numbers of compounds with access to many sensilla per fly, meaning 
many compounds can be tested on each fly without significant time intervals between 
compounds. With 80 compounds having already been tested (Fig 5.5), this system can now be 
extended for the testing of other large compound libraries to help discover novel P2X2 drugs. 
In addition, if P2X2 receptors can be successfully localised to the tip of the taste sensilla, the 
responses can be recorded over a 2-3 second time period, as opposed to a 20-second time 
period, which will result in many more compounds being tested in a shorter length of time, 
improving the through-put of this system. In addition, it may reduce the response variations 
between flies, thus reducing the error. 
5.4.11  Conclusions 
rP2X2 is functional in the Drosophila taste system where responses are elicited in response to 
ATP in rP2X2-GFP expressing flies but not in control flies. However, the concentration of ATP 
required to activate the receptor is significantly higher than the concentration required to 
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activate P2X2 receptors in other systems. This could be as a result of the receptors position 
within the neuronal dendrites in the sensillum resulting in a time delay for activation.  
This system can also be used as a novel, medium through-put compound screening technique 
for drug discovery. By screening an adenosine nucleotide library consisting of 80 compounds, a 
P2X2 agonist was identified, 2F-ATP, which elicited higher responses that ATP at rP2X2 
receptors. This screen was also used to identify components of the ATP molecule that 
contribute to activation of rP2X2. It was shown that very few alterations to the ATP molecule 
were tolerated by P2X2 and the majority of the nucleotides did not activate the receptor. In 
particular, very few alterations to ribose gave nucleotides with activity at P2X2. However a few 
problems were faced using this system due to a large variation in response between flies. This 
made it difficult, in some cases, to establish if a partial response was real or as a result of this 
variation.   
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Chapter 6 – Final Discussion 
In this thesis, a protein expression system has been presented which covers two distinct 
aspects of biological research; protein expression for (i) purification and subsequent structural 
studies and (ii) a novel, medium-throughput drug-screening technique. Due to their relevance 
in many human diseases and conditions, P2X receptors and pannexin channels represent key 
drug targets (Tsuda et al, 2003; Le Feuvre et al, 2002; White et al, 2005; Greig et al, 2003; 
Wicki-Stordeur and Swayne, 2014; Penuela et al, 2013). Our successful expression of P2X2 and 
Panx channels in the eyes of Drosophila provides a method for the generation of material that 
may be suitable for future structure determination using TEM and single particle analysis, a 
technique that does not require a high yield of protein, and has the potential (as demonstrated 
for the LGIC TRPV1) to produce data of sufficient resolution to ‘solve’ the 3D-structure (Liao et 
al, 2013; Liao et al, 2014). However, the gel filtration data so far indicates that Panx1 may not 
be forming stable hexamers in Drosophila. This is in contrast to small-scale analysis of TEM 
images, whereby the approximate volume of each particle was calculated. Based on a number 
of assumptions, this analysis estimated the channel to be hexameric. More rigorous analysis is 
necessary to come to any definitive conclusions regarding the state of the pannexin channels. 
In addition, using the Drosophila taste system electrophysiology assay, we can ensure that the 
P2X receptor proteins that we are using for structural studies are correctly folded and 
functional, thus although the oligomeric state of P2X2 has not yet been studied in Drosophila, 
it is known that at least a portion is forming stable trimers due to its functional role in the taste 
system. 
 
During this project, the work in chapter 3 was undertaken prior to chapter 4 and 5. However 
the work in chapters 4 and 5 was performed concurrently. As a result, time constraints 
affected the final experiments and analysis for the final stages of both chapters; this included 
full analysis of rPanx1-GFP EM data and structural model building. In addition, testing the 
compound library in chapter 5 was performed at the very end of time course and thus each 
compound was only tested 3 times. Therefore although statistical analysis has been included 
for the adenosine library, this may explain why most differences among the responses were 
not statistically significant. The production of flies expressing P2X2-targeting sequence 
constructs was also hampered by time constraints at the end of the project. 
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6.1  Evaluation of Drosophila eyes as a membrane 
protein expression system 
There are many systems readily available to use for the heterologous expression of membrane 
proteins. However, each system displays a series of advantages and disadvantages with no 
solitary system providing an efficient universal expression system. 
6.1.1  Escherichia coli 
The most commonly used expression system for recombinant proteins is E. coli. However upon 
over-expression of membrane proteins in E. coli, they are often not folded correctly and form 
large aggregates in the form of inclusion bodies (Palmer and Wingfield, 2004). Although the 
formation of inclusion bodies allows for a high level of protein expression without causing host 
toxicity, the protein is often mis-folded and so is not useful for structural studies. 
Nevertheless, there have been a number of progressions that were designed to improve the 
use of E. coli as an expression system for membrane proteins. For example, mutant strains of 
E. coli were developed by selection from the BL21(DE3) strain, e.g. C41 and C43, that are more 
resistant to the toxicity caused by membrane protein over-expression. Although these strains 
allow expression of higher levels of membrane protein without toxic effects, the proteins are 
still aggregated into inclusion bodies (Miroux and Walker, 1996). Another mutant strain, 
Lemo21, was also developed from the BL21(DE3) strain. Lemo21 was engineered so that the 
activity of T7 RNA polymerase could be accurately controlled by T7 lysozyme which allows 
optimization of overexpression of any membrane protein (Wagner et al, 2008). The use of 
Mistic, a Bacillus subtilis protein that spontaneously associates with the inner membrane, 
bypassing the cellular translocon machinery, has also been investigated. Mistic has been used 
as an N-terminal fusion tag to membrane proteins in E. coli to facilitate targeting of the protein 
to the membrane, resulting in an increase in the protein yield (Roosild et al, 2005; Kefala et al, 
2007; Dvir and Choe, 2009). 
6.1.2  Insect cells 
Insect cells provide an alternative system for membrane protein over-expression that is better 
designed for the expression of eukaryotic proteins for a number of reasons including their 
ability to perform post-translational modifications such as glycosylation and the formation of 
disulphide bridges which are important for protein trafficking and structure respectively. 
Although the process of glycosylation in insect cells does not directly replicate that which is 
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noted in mammalian cells (i.e. No/little complex glycosylation), it is much closer to the natural 
modifications that occur in mammalian cells compared with bacterial or yeast systems (Rendic 
et al, 2008). In addition, the lack of complex glycosylation may prove to be an advantage in 
terms of protein structure determination as reducing complex glycosylation reduces protein 
heterogeneity and improves the formation of ordered crystals (Chang et al, 1993). However 
the respective yield of membrane protein produced in insect cells compared to E. coli is 
sufficiently lower, with many membrane proteins being produced at < 0.1% of the total 
membrane protein compared to 1 - 10 % in E. coli. This is increased even further in Mistic E. 
coli strains (3-20%) (Bernaudat et al, 2011).  
6.1.3  Mammalian cells 
Mammalian cells represent the most appropriate host for heterologous expression of 
mammalian membrane proteins as they possess all the machinery necessary to modify and 
traffic the proteins to the cell surface. However the addition of complex glycans to membrane 
proteins can often be deleterious for crystal formation and thus structure determination 
(Chang et al, 1993). In light of this, the GnTI- cell line was developed which lacks the tools to 
perform complex glycosylation and thus proteins only undergo core glycosylation (Reeves et 
al, 2002). A disadvantage of using mammalian cells is their higher cost to maintain than E. coli, 
yeast and insect cells. In addition they often produce low yields of heterologous membrane 
proteins (Gan et al, 2006; Allen et al, 2009).  
6.1.4  Cell free systems 
A relatively new system that is being developed for the rapid, efficient production of 
membrane proteins is a cell-free expression system. A cell-free expression system is an in vitro 
tool that consists of all the components required for the production and expression of proteins 
without the involvement of a live cell. Cell-free systems are useful for studying biological 
reactions because they minimize the other interactions that are found in a cell (Jackson et al, 
2004). The use of a cell-free system eliminates problems with cell toxicity and reduces 
problems with proteolytic degradation. In addition it is possible to supply high levels of 
cofactors, ligands etc into the reaction. One of the largest advantages of a cell free system is 
the ability to directly express membrane proteins into hydrophobic or membrane-mimetic 
environments such as detergents which may facilitate functional folding of the protein (Reckel 
et al, 2010). One example of the use of an E. coli cell-free system was for structural 
determination of the TM domains of three classes of E. coli histidine kinase receptors using 
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NMR analysis – ArcB, QSeC and KdpD at a resolution of 2.7 – 3.2 Å (Maslennikov et al, 2010). 
Recently, the crystal structure of diacylglycerol kinase, an integral membrane enzyme, was 
solved at a resolution of 2.28 Å using cell-free expression and crystallisation in lipid 
mesophases (Boland et al, 2014). Other structures solved using cell-free expression systems 
include Acetabularia rhodopsin II from marine alga at 3.2 Å (Wada et al, 2011), the E. coli EmrE 
multidrug transporter at a resolution of 4.5 Å (Chen et al, 2007) and an integral membrane 
enzyme diacylglycerol kinase at 2.28 Å (Boland et al, 2014). However, the number of 
membrane protein structures that have been solved using these systems remains extremely 
low. 
6.1.5  Drosophila melanogaster 
The main problems that are faced regarding heterologous expression of membrane proteins 
for structural studies are host toxicity, incorrect protein folding, protein heterogeneity and low 
expression yields and thus high costs to obtain high yields of protein. The use of Drosophila 
melanogaster as a membrane protein expression system overcomes many of these problems. 
It has been shown that expression of a number of membrane proteins can be tolerated by the 
Drosophila photoreceptor cells without any noteable effects on the fly itself. In addition, the 
expression levels of endogeneous rhodopsin do not seem to be affected (Panneels et al, 2011) 
which is important for the structural integrity of the rhabdomere (Kumar and Ready, 1995). 
Panneels and colleagues demonstrated that high yields of a number of different membrane 
proteins (a mixture of GPCRs, transporters and channels) could be obtained by expression in 
the fly eye under control of a GMR-Gal4 driver (0.2 – 0.4 mg per 10,000 flies) (see Table 4.1). In 
combination with the cheap cost of fly maintenance, this makes it viable to obtain enough 
protein for crystallization and structural studies. However, the data presented in this thesis 
show that the yield of purified rP2X2 and rPanx1 channels was much lower than that shown by 
Panneels et al for other membrane proteins. The low yields of rP2X2 and rPanx1 obtained 
(approx. 1 µg per 500 flies - Chapter 4) significantly hinders the use of this system for the 
production of enough protein for 3D-crystallization trials. However, it is possible that if the 
membrane protein extraction and purification procedures are fully optimized, the yield could 
be significantly improved. For example, protein may be lost during detergent solubilisation of 
the membranes (see section 6.2). Alternatively there are stages where some protein may be 
lost during purification including protein that doesn’t bind efficiently to the anion resin during 
ion exchange chromatography and protein that doesn’t bind to the nickel beads during IMAC. 
To improve binding of protein to the anion resin, the buffers need to be optimised to maximise 
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binding but in addition, a column with a larger binding capacity would ensure that all the 
protein is able to bind. Buffers and conditions such as temperature would also need to be 
optimised to ensure maximum binding of His-tagged protein to nickel beads. However, for 
more efficient protein purification, using an alternative tag for purification purposes such as 
the Strep-tag may provide a means of a one-step purification procedure and this would 
significantly reduce the amount of protein lost at various stages of the lengthy purification 
procedure. 
rP2X2 appeared to undergo high mannose glycosylation but no complex glycosylation in 
Drosophila; consequently, expression in this system overcomes the obstacle of the 
heterogeneous populations of protein that are often obtained with mammalian expression 
systems. Another significant advantage of using Drosophila as a host system of P2X receptors 
is the capacity to ensure that the protein is functional using electrophysiological recordings 
(chapter 5). As the protein is known to be functional, and responsive to its ligand, ATP, at least 
a proportion is correctly folded and targeted to the cell surface. Providing that the yield of 
protein can be significantly improved (see above), the fruit fly provides a promising new 
system for membrane protein expression. 
6.2  Detergent solubilisation of membrane proteins 
For the majority of structural studies of membrane proteins, it is vital that they are successfully 
reconstituted in a suitable detergent. Finding a detergent that can efficiently extract the 
protein from the membrane while maintaining it in a fully folded, functional state is a 
significant challenge. There are a large number of different types of detergents available; 
broadly classified into ionic detergents, non-ionic detergents and zwitterionic detergents. Ionic 
detergents, e.g. SDS, contain a charged head group and a hydrophobic hydrocarbon chain. 
Although ionic detergents tend to be very effective at removing and solubilising membrane 
proteins from the lipid bilayer, they are generally denaturing and are thus rarely useful for 
structural studies. Non-ionic detergents, e.g. DDM, consist of an uncharged head group and a 
hydrophobic hydrocarbon chain. Non-ionic detergents are often chosen to reconstitute 
membrane proteins for structural studies as they generally break protein-lipid interactions 
with little effect on protein-protein interactions, therefore they are usually non-denaturing. 
Zwitterionic detergents, e.g. CHAPS, have a net zero charge arising from both positive and 
negatively charged groups. Zwitterionic detergents are often used for structural studies but 
are can be more deactivating than non-ionic detergents (Seddon et al, 2004).  
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Generally, detergents with shorter alkyl chains are more disruptive to the membrane (Privé, 
2007). In addition, detergents that  form small micelles (e.g. n-octyl-β-D-glucoside or n-octyl-β-
D-maltoside) may not completely cover the hydrophobic regions of the membrane protein, 
thus causing protein aggregation. However, the small micelle size allows for more of the 
protein to be exposed to form protein-protein interactions which makes them more desirable 
for the formation of crystal-lattices (Gutmann et al, 2007). In light of this, a relatively large 
number of membrane protein structures have been solved using small micelle detergents. For 
example, 161 structures have been solved using n-octyl-β-D-glucoside (Membrane protein 
databank, accessed 27/09/14) (Raman et al, 2006). 
DDM, a non-ionic detergent with a 12-carbon hydrocarbon chain, is a particularly popular 
choice of detergent used for membrane protein solubilisation due to its ability to reconstitute 
many membrane proteins in their functional state; 150 structures have been published in the 
membrane protein databank using DDM for solubilsation (accessed 27/09/14). However, DDM 
forms large micelles which means less of the protein is exposed and able to form protein-
protein interactions, this can interfere with crystallisation; nevertheless it has been used 
successfully in a number of cases (Gutmann et al, 2007; Huang et al, 2003, Hattori and Gouaux, 
2012). Concentrations much higher than the CMC of DDM are required for protein 
solubilisation (i.e. DDM CMC = 0.009% but proteins are often solubilised in 1 – 4% DDM). This 
is often the case for long-chain detergents (Privé, 2007). DDM has been used for the 
solubilisation of a number of different P2X receptors (Sim et al, 2004; Mio et al, 2005; Mio et 
al, 2009; Kawate et al, 2009; Valente et al, 2011). The data in this thesis has also demonstrated 
its ability to solubilise hP2X4-GFP and zfP2X4-GFP from the membrane and potentially 
maintain their oligomeric structures (chapter 3). 
FC-12 is an zwitterionic detergent with a 12 carbon hydrocarbon tail and although efficient at 
membrane protein solubilisation, it is often denaturing. To date, only 3 crystal structures have 
determined in the presence of FC-12; the OmpF porin (3.8 Å) (Kefala et al, 2010), the zinc 
transporter YiiP (DDM was also present in the crystallisation sample) (Lu and Fu, 2007) and rat 
monoamine oxidase A (Ma et al, 2004). However, FC-12 has been commonly used in NMR 
studies (Raman et al, 2007). 
A study by Newstead and colleagues analysed the expression of 43 eukaryotic membrane 
proteins in S. cerevisae and showed that 70% of the well-expressed proteins were stable, 
correctly targeted and monodisperse in either DDM or FC-12 (Newstead et al, 2007). 
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Triton-X-100 is a non-ionic detergent that is often used in combination with a mild, non-
denaturing zwitterionic detergent such as 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS). 27 protein structures have been successfully solved in the 
presence of Triton (Membrane protein databank – accessed 27/09/14) (Kalipatnapu and 
Chattopadhyay, 2005). However, as Triton is not a homogeneous solution i.e. the length of the 
hydrophobic tail varies between molecules, it is not an ideal choice for crystallisation of 
membrane proteins. 
The choice of detergent for solubilisation of a membrane protein is extremely important and 
often complex screening is required to find a suitable detergent. As each protein is very 
different, each case is specific and there is no detergent that is suitable for the solubilisation of 
all membrane proteins. To improve the use of the Drosophila system for purification of 
membrane proteins, it would be useful to do a large detergent screen for both rPanx1 and 
rP2X2 to ensure they are being efficiently solubilised and importantly, not denatured. This will 
be important for maximising protein yield and maintaining structure for crystallisation. For the 
purification of rPanx1 for low resolution structural studies by Ambrosi et al, 2010, two 
detergents were used; Sarkosyl (N-Lauryl Sarkosine), an anionic detergent and Brij 58, a non-
ionic detergent (Ambrosi et al, 2010). DDM was used for the successful solubilisation of zfP2X4 
(Kawate et al, 2009) and DdP2XA (Valente et al, 2011) and thus was a logical choice for the 
solubilisation of rP2X2.  
However, the results in this thesis show that in the presence of DDM, purified rP2X2-GFP from 
HEK-293 cells does not appear to form stable trimers, though it is possible that the protein is 
forming trimers but with the dissociated GFP, they cannot be identified using FSEC. It is not 
known whether this is also the case in Drosophila as the protein has not yet been purified to a 
sufficient level to enable FSEC analysis of the protein. However it is unclear whether (i) P2X2 is 
not forming trimers in HEK-293 cells, (ii) DDM is not efficient for its solubilisation or (iii) the 
degradation of GFP makes it impossible to determine the oligomeric state of P2X2 using FSEC. 
To distinguish between these possibilities, it would be advantageous to perform a large-scale 
detergent screen to enable the identification of a detergent that can maintain the trimeric 
structure of P2X2. In addition, if DDM is not efficient at solubilising P2X2 from the membrane, 
it may be causing a reduction in the yield of P2X2. To decipher whether the peak observed is 
indeed that of free GFP, the purified protein could be separated by SDS PAGE and detected 
with a P2X2 antibody and a GFP antibody to see if the expected bands are observed. A small-
scale detergent screen was performed on rPanx1-GFP purified from both HEK-293 cells and 
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from Drosophila. This screen showed that the detergents FC-12 and Triton were efficient at 
extracting Panx1 channels from the membrane. FC-12 was chosen for solubilisation of Panx1 
due to the heterogeneous nature of Triton. However, FSEC results show that the majority of 
Panx1 protein formed dimeric units in the presence of DDM (HEK-293 cells) and FC-12 
(Drosophila). Although neither system appeared to assemble Panx1-GFP hexamers, it is also 
possible that both DDM and FC-12 disrupt the channel structure and cause dissociation of the 
subunits.  As with P2X2, to further investigate this, it would be useful to perform a large-scale 
detergent screen to identify a detergent that maintains the native protein structure.  
6.3  Evaluation of the Drosophila taste system as a 
compound-screening system 
Many systems have been developed that enable a library of compounds to be tested as novel 
agonists or antagonists of membrane proteins. Many of these systems use heterologous 
expression of membrane proteins in cell lines or Xenopus oocytes to test the compounds. The 
Drosophila taste system provides a novel, medium throughput drug screening method using 
electrophysiology that has the advantage of expressing the receptors in vivo. In addition, the 
fruit fly does not naturally express any known P2X receptors, P2Y receptors or Panx channels 
making it a useful system to study the exogenously expressed receptors in isolation. 
6.3.1  Calcium imaging techniques 
Calcium imaging techniques are commonly used as drug screening systems for P2X receptors. 
For example the selective P2X4 antagonists, PSB-12054 and PSB-12062, were discovered using 
calcium imaging techniques in 1321-N1 astrocytoma cells stably expressing the hP2X4 receptor 
(Hernandez-Olmos et al, 2012). Hernandez-Olmos and colleagues tested the activity of a 
number of phenoxazine and related acridone and bezoxazine derivatives on P2X4 receptors. 
This technique involves loading cells with a labelled calcium indicator (in this case, Fluo-4-AM) 
that exhibits an increase in fluorescence when bound to Ca2+. Upon activation of P2X4, calcium 
influx causes an increase in cell fluorescence and the activity of the receptor can be monitored. 
The calcium imaging technique can be performed in a number of different ways, one of which 
involves plating cells onto a 96 well plate; this technique allows relatively medium throughput 
compound screening as multiple compounds can be tested with each plate. However, although 
this technique is higher-throughput than other electrophysiology techniques (see section 6.3.2 
), it is much less sensitive (Wood et al, 2004). In addition, when testing the activity of P2X 
receptors using calcium imaging, it is essential that the cell does not express any endogenous 
P2X or P2Y receptors as they would cause an increase in intracellular calcium in response to 
185 
 
 
ATP, making it difficult to study the effects of the exogenously expressed protein. Commonly 
used cells such as HEK-293 cells cannot be used without first blocking the activity of the 
endogenous P2Y receptors. This can be done using an IP3 blocker such as 2-APB which 
prevents the release of calcium from intracellular stores (Maruyama et al, 1997). 
6.3.2  In vitro electrophysiology techniques 
Patch-clamp electrophysiology techniques have been commonly used to test the function and 
to characterize P2X receptors in cell culture e.g. in HEK cells (Li et al, 2008). Patch clamp 
recordings involve placing an electrode, with an open tip of about 1 µm, at the edge of the cell 
membrane using a micro-manipulator, creating a high-resistance seal with the cell. The 
electrode is filled with a solution with a similar composition to the cytoplasm and a silver wire 
responsible for recording the electric current is placed in contact with this solution. 
Compounds can then be added to the solution to investigate the activity of ion channels. 
Electrophysiology techniques can be used to test the activity of multiple compounds as 
potential P2X agonists or antagonists. For example Grubb and Evans tested the effect of 
various P2X agonists on P2X2 receptors using electrophysiological experiments in cultured 
adult rat dorsal root ganglion cells (Grubb and Evans, 1999). However the technique is 
technically challenging and relatively low throughput; to test multiple agonists/antagonists, 
lengthy time intervals were necessary between applications (see Section 5.4.10 for more 
details). In addition, run-down is a common problem faced when using the patch clamp 
technique on P2X receptors; the current amplitude decreases upon successive agonist 
applications (Lewis and Evans, 2000). These factors contribute to the relatively low throughput 
of this system; it is better used to fully characterise ‘hit’ compounds after they have been 
discovered using other screening protocols. 
Automated patch-clamp electrophysiology techniques have been developed that allow a more 
high-throughput approach for screening compounds (for example the PatchXpress 7000A is 
estimated to obtain 2,000 data points per day – Wood et al, 2004). The first step in the 
development of automated methods for patch-clamp of mammalian cells was the discovery 
that a planar substrate could replace a glass micropipette and thus a seal could be formed by 
bringing the cell to the substrate; this removed many of the difficult technical requirements 
and time consuming components associated with patch-clamp electrophysiology. Many of the 
devices that take advantage of this use multiwell plates so that multiple compounds can be 
screened simultaneously. However, there are problems associated with these systems. For 
example, a seal may not be formed in every single well, resulting in a success rate of <100% 
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and so data needs to be analysed carefully. In addition the machinery required to perform 
automated patch clamp electrophysiology is costly (Wood et al, 2004).  
6.3.3  Electrophysiology on Xenopus oocytes 
Xenopus oocytes represent a popular system used for the screening of compounds on the 
activity of P2X receptors with many of the key agonists and antagonists identified using this 
system (Pintor et al, 1996; King et al, 1997; Liu et al, 2001; Wildman et al, 2002; Baqi et al, 
2011). In addition, the recently identified P2X2 specific antagonists, PSB-12011 and PSB-1011 
were identified following a screen of anthraquinone derivatives on P2X2 expressed in Xenopus 
oocytes (Baqi et al, 2011). However the use of this system for compound screening is relatively 
low throughput. The advantages and disadvantages of using this system has been summarized 
in more detail in Section 5.4.10.  
6.3.4  The Drosophila taste system 
This thesis aims to highlight the potential use of the Drosophila taste system as a useful and 
novel method to screen the activity of compound libraries on P2X receptors. The data shows 
that the system can be used in this way as 80 compounds from an adenosine nucleotide library 
were tested on P2X2 expressed in the nervous system of Drosophila (chapter 5). Using this 
system, approximately 12 compounds were tested per day (with an n=3 for each compound). 
However, this number is likely to rise upon increased experience using the system. There was a 
large variation in response from the 80 compounds tested; specifically three compounds were 
highlighted that appear to be agonists of rP2X2 (2F-ATP, ATPαS and ATPγS). Although the latter 
two have already been characterized as P2X2 agonists (King et al, 1997; Liu et al, 2001), it was 
the first time 2F-ATP was demonstrated to be a rP2X2 agonist. The basal response to the 
solvent control, TCC, was significantly higher in flies expressing P2X2 compared with control 
flies. Possible reasons for this were that (i) P2X2 undergoes some activation in the absence of 
an agonist or (ii) there is some spontaneous ATP release in the fly resulting in channel 
activation (see section 5.3.1). A number of compounds (8-[(4-Amino)butyl]-amino-ATP, N6-(6-
Amino)hexyl-dATP, N6-(6-Amino)hexyl-ATP and AP5A) elicited a response substantially lower 
than that of  TCC. Thus one possibility, as previously mentioned, is that these compounds are 
acting as antagonists - blocking the activity of P2X2 and preventing any spontaneous channel 
opening. Although this needs to be further investigated to determine whether or not this is the 
case, it may represent the first system whereby compounds can be tested as agonists or 
antagonists in the same screening protocol.  
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However, there are still a number of problems to overcome for this system to be used as a 
medium throughput screening technique, including the large variation of responses observed 
between different flies which could result in false-positive results. The variation between 
sensilla may be as a result of the expression pattern of the receptors within the sensillum; thus 
if they can be localized to the tip of the sensillum, this may decrease the variation (see section 
5.3.3). In addition, once localized to the tip, each compound will only need to be applied for 2 -
3 seconds largely speeding up the process of compound screening and allowing the testing of 
an estimated 20-30 compounds per day (with an n=3 for each compound), making the system 
more viable for testing large numbers of compounds. These localization experiments are vitally 
important for the future of this system. 
6.4  Conclusions and future directions 
In this thesis, it has been shown that rP2X2-GFP and rPanx1-GFP can be expressed in both the 
Drosophila eye and nervous system under control of the Gal4-UAS system. rP2X2-GFP 
underwent high-mannose glycosylation in the fly (Fig 4.8) and was shown to be functional (Fig 
5.6) indicating that despite having no endogenous P2X receptors, the fly is capable of 
expressing, folding and trafficking functional P2X2 receptors. However, the conclusions 
regarding the state of rPanx1-GFP in the fly were less easily ascertained, as it did not appear to 
undergo N-linked glycosylation in the fly (Fig 4.8) and the function has not been tested. In 
addition, our gel filtration data indicated that rPanx1-GFP did not form stable hexamers in 
either HEK-293 cells or Drosophila eyes (Fig 4.14) suggesting either that hexamers are not the 
biologically functional unit of this protein, it may not be correctly folded or detergent 
solubilisation is inefficient. In contrast, TEM analysis indicated that the protein formed 
hexameric units in the Drosophila eye (Fig 4.17). However due to the assumptions made 
regarding the shape and density of the protein, this needs to be investigated in more details 
for any conclusive details on the state of rPanx1-GFP. Despite the low rP2X2 and rPanx1 
protein yields obtained following purification, if the protein is of sufficient quality, it may still 
be useful for low-resolution structural studies. In the future, it would be useful to add an 
alternative tag such as a Strep-tag to the receptors before expressing them in Drosophila, 
allowing purification via Streptactin, which may prove to be a more efficient purification 
technique in Drosophila and therefore provide a higher protein yield.  
The expression of rP2X2 in the nervous system of Drosophila also enabled its function to be 
tested. The data showed that flies expressing rP2X2 respond to ATP whereas control flies do 
not respond indicating that the channel is trafficked to the cell surface and folded in the 
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Drosophila taste system (Fig 5.6). An ATP dose response curve was generated for the response 
of flies expressing rP2X2 in both the nervous system (C155-Gal4) and the sugar neurons (Gr5a-
Gal4) (Fig 5.7). There was a dose-dependent increase in response to ATP, however, the ATP 
concentration required to activate rP2X2 was higher than what has been recorded in other 
systems, possibly due to the distribution of P2X2 in the sensillum. The function of rP2X2 in 
Drosophila led to the use of the Drosophila taste system as a new, medium-throughput system 
for screening of compound libraries, in a search for novel P2X2 agonists. The data in this thesis 
shows that large compound screens can be performed by expressing rP2X2 in the taste 
system. The response of rP2X2 to 80 adenosine nucleotides was investigated using the taste 
system. Three nucleotides were shown to activate P2X2 at similar levels to ATP; these were 
ATPγS, ATPαS and 2F-ATP. In addition to uncovering an unknown P2X2 agonist, 2F-ATP, it 
provided information on many of the molecular aspects of the ATP molecule that appear to be 
important for binding to rP2X2 (see section 5.4.3). For example, it appeared that any alteration 
to the ribose moiety caused a significant reduction in agonist potency, whereas some 
phosphate or adenine alterations could be tolerated. It was also noted that the receptor has 
not only evolved to respond to specifically to ATP, but has evolved to not respond to the 
commonly co-occurring molecules ADP and AMP (Fig 5.11). In the future this system could also 
be adapted to speed up the process of testing compounds by localizing the P2X2 receptors to 
the tip of the taste hair. In addition, other P2X receptors such as P2X1 and P2X3 could be 
expressed in this system in a search for novel agonists at these receptors.  
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 Appendix I – Standard curves 
 
 
 
 
  
Figure App. 1 – BSA standard curves - BSA standard curves (BSA concentration vs. 
absorbance at 595 nm) shown for Expedeon Bradford Ultra (top) and BioRad protein 
assay reagent (bottom). 
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Figure App. 2 – Gel filtration protein standards (A) Elution of BioRad gel filtration 
standards on Superdex200 columns. Peaks correspond to thyroglobulin, bovine γ-
globulin, chicken ovalbumin, equine myoglobin and vit B12 from left to right 
respectively. (B) Standard curve plotting LogMW of standard against elution volume. 
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Appendix II – Construct maps 
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Appendix III – Codon usage charts 
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Appendix IV – Adenosine nucleotide 
library 
This appendix lists the adenosine nucleotides that were tested for their effect on rat P2X2 
expressed Drosophila taste neurons. Eighty chemicals were obtained as a library (Cat. No. LIB-
101) from Jena Biosciences (Jena, Germany). Chemicals were >95% pure (HPLC) and racemic, if 
the derivative of ATP has additional chiral centers.  
 
The appendix is divided into derivatives of ATP (subdivided modifications of the ribose, 
adenine group, phosphate group moieties), derivatives of ADP and AMP, and a set of 
dinucleotides. Within divisions structures are organized by rank order of effectiveness on rat 
P2X2 as in Figure 5.8.  
 
 
 
 
 
 
 
 
 
 
 
 
The colour of bars in Figure 5.8 correspond to the modifications of ATP. I.e. ribose modifications 
are cyan, phosphate modifications are orange and adenine modifications are blue. 
Appendix content: 
Ribose modifications of ATP (Figure App. 3A-D) 
Adenine modifications of ATP (Figure App. 4A, B) 
Phosphate group modifications of ATP (Figure App. 5A, B) 
ADP derivatives (Figure App. 6A, B) 
AMP derivatives (Figure App. 7A, B) 
Dinucleotides (Figure App. 8A, B) 
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ATP derivatives with ribose modifications 
 
 
  
 
 
 
 
 
Figure App. 3A – Chemical structures of ATP derivatives with altered ribose moieties. ATP is 
shown in brown. Altered ribose groups are shown in cyan, altered adenine groups are 
shown in blue and altered phosphate groups are shown in orange. The response of each 
compound relative to ATP is shown (%) and are ordered respectively. 
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Figure App. 3B – Chemical structures of ATP derivatives with altered ribose moieties. 
Altered ribose groups are shown in cyan, altered adenine groups are shown in blue and 
altered phosphate groups are shown in orange. The response of each compound relative to 
ATP is shown (%) and are ordered respectively. 
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Figure App. 3C – Chemical structures of ATP derivatives with altered ribose moieties. 
Altered ribose groups are shown in cyan, altered adenine groups are shown in blue and 
altered phosphate groups are shown in orange. The response of each compound relative to 
ATP is shown (%) and are ordered respectively. 
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Figure App. 3D – Chemical structures of ATP derivatives with altered ribose moieties. Altered 
ribose groups are shown in cyan, altered adenine groups are shown in blue and altered 
phosphate groups are shown in orange. The response of each compound relative to ATP is 
shown (%) and are ordered respectively. 
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Adenine modifications of ATP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure App. 4A – ATP is shown in brown. Chemical structures of ATP derivatives with altered 
adenine moieties. Altered adenine groups are shown in blue. The response of each compound 
relative to ATP is shown (%) and are ordered respectively. 
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Figure App.4B – Chemical structures of ATP derivatives with altered adenine moieties. Altered 
adenine groups are shown in blue. The response of each compound relative to ATP is shown 
(%) and are ordered respectively. 
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ATP with altered phosphate groups 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure App. 5A – ATP is shown in brown. Chemical structures of ATP derivatives with altered 
phosphate groups. Altered phosphate groups are shown in orange, ribose alterations are 
shown in cyan. The response of each compound relative to ATP is shown (%) and are 
ordered respectively. 
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Figure App. 5B – Chemical structures of ATP derivatives with altered phosphate groups. 
Altered phosphate groups are shown in orange, ribose alterations are shown in cyan. The 
response of each compound relative to ATP is shown (%) and are ordered respectively. 
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ADP derivatives 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure App. 6A – ADP derivatives. Alterations to ribose are shown in cyan, altered adenine 
groups are shown in blue and altered phosphate groups are shown in orange. The response 
of each compound relative to ATP is shown (%) and are ordered respectively. 
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Figure App. 6B – ADP derivatives. Alterations to ribose are shown in cyan, altered adenine 
groups are shown in blue and altered phosphate groups are shown in orange. The response 
of each compound relative to ATP is shown (%) and are ordered respectively. 
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AMP derivatives 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure App. 7A – AMP derivatives. Alterations to ribose are shown in cyan, altered adenine 
groups are shown in blue and altered phosphate groups are shown in orange. The response 
of each compound relative to ATP is shown (%) and are ordered respectively. 
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Figure App. 7B – AMP derivatives. Alterations to ribose are shown in cyan, altered adenine 
groups are shown in blue and altered phosphate groups are shown in orange. The response 
of each compound relative to ATP is shown (%) and are ordered respectively. 
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Dinucleotides 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure App. 8A – Dinucleotides. Altered phosphate groups are shown in orange. The 
response of each compound relative to ATP is shown (%) and compounds are ordered 
respectively. 
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Figure App. 8B – Dinucleotides. Altered phosphate groups are shown in orange. The 
response of each compound relative to ATP is shown (%) and compounds are ordered 
respectively. 
 
224 
 
 
 References 
ABBRACCHIO M. P., BURNSTOCK G., 1994 Purinoceptors: Are there families of P2X and P2Y 
purinoceptors? Pharmacol. Ther. 64: 445–475. 
ABRAMOWSKI P., OGRODOWCZYK C., MARTIN R., PONGS O., 2014 A Truncation Variant of the Cation 
Channel P2RX5 Is Upregulated during T Cell Activation. PLoS One 9: e104692. 
ABU-QARN M., EICHLER J., SHARON N., 2008 Not just for Eukarya anymore: protein glycosylation in 
Bacteria and Archaea. Curr. Opin. Struct. Biol. 18: 544–50. 
ADAMS M. D., CELNIKER S. E., HOLT R. A., EVANS C. A., GOCAYNE J. D., AMANATIDES P. G., SCHERER S. 
E., LI P. W., HOSKINS R. A., GALLE R. F., GEORGE R. A., LEWIS S. E., RICHARDS S., ASHBURNER M., 
HENDERSON S. N., SUTTON G. G., WORTMAN J. R., YANDELL M. D., ZHANG Q., CHEN L. X., 
BRANDON R. C., ROGERS Y. H., BLAZEJ R. G., CHAMPE M., PFEIFFER B. D., WAN K. H., DOYLE C., 
BAXTER E. G., HELT G., NELSON C. R., GABOR G. L., ABRIL J. F., AGBAYANI A., AN H. J., ANDREWS-
PFANNKOCH C., BALDWIN D., BALLEW R. M., BASU A., BAXENDALE J., BAYRAKTAROGLU L., BEASLEY 
E. M., BEESON K. Y., BENOS P. V, BERMAN B. P., BHANDARI D., BOLSHAKOV S., BORKOVA D., 
BOTCHAN M. R., BOUCK J., BROKSTEIN P., BROTTIER P., BURTIS K. C., BUSAM D. A., BUTLER H., 
CADIEU E., CENTER A., CHANDRA I., CHERRY J. M., CAWLEY S., DAHLKE C., DAVENPORT L. B., DAVIES 
P., PABLOS B. DE, DELCHER A., DENG Z., MAYS A. D., DEW I., DIETZ S. M., DODSON K., DOUP L. E., 
DOWNES M., DUGAN-ROCHA S., DUNKOV B. C., DUNN P., DURBIN K. J., EVANGELISTA C. C., FERRAZ 
C., FERRIERA S., FLEISCHMANN W., FOSLER C., GABRIELIAN A. E., GARG N. S., GELBART W. M., 
GLASSER K., GLODEK A., GONG F., GORRELL J. H., GU Z., GUAN P., HARRIS M., HARRIS N. L., 
HARVEY D., HEIMAN T. J., HERNANDEZ J. R., HOUCK J., HOSTIN D., HOUSTON K. A., HOWLAND T. J., 
WEI M. H., IBEGWAM C., JALALI M., KALUSH F., KARPEN G. H., KE Z., KENNISON J. A., KETCHUM K. 
A., KIMMEL B. E., KODIRA C. D., KRAFT C., KRAVITZ S., KULP D., LAI Z., LASKO P., LEI Y., LEVITSKY A. 
A., LI J., LI Z., LIANG Y., LIN X., LIU X., MATTEI B., MCINTOSH T. C., MCLEOD M. P., MCPHERSON 
D., MERKULOV G., MILSHINA N. V, MOBARRY C., MORRIS J., MOSHREFI A., MOUNT S. M., MOY M., 
MURPHY B., MURPHY L., MUZNY D. M., NELSON D. L., NELSON D. R., NELSON K. A., NIXON K., 
NUSSKERN D. R., PACLEB J. M., PALAZZOLO M., PITTMAN G. S., PAN S., POLLARD J., PURI V., REESE 
M. G., REINERT K., REMINGTON K., SAUNDERS R. D., SCHEELER F., SHEN H., SHUE B. C., SIDÉN-
KIAMOS I., SIMPSON M., SKUPSKI M. P., SMITH T., SPIER E., SPRADLING A. C., STAPLETON M., 
STRONG R., SUN E., SVIRSKAS R., TECTOR C., TURNER R., VENTER E., WANG A. H., WANG X., WANG 
Z. Y., WASSARMAN D. A., WEINSTOCK G. M., WEISSENBACH J., WILLIAMS S. M., WOODAGET, 
WORLEY K. C., WU D., YANG S., YAO Q. A., YE J., YEH R. F., ZAVERI J. S., ZHAN M., ZHANG G., 
ZHAO Q., ZHENG L., ZHENG X. H., ZHONG F. N., ZHONG W., ZHOU X., ZHU S., ZHU X., SMITH H. O., 
GIBBS R. A., MYERS E. W., RUBIN G. M., VENTER J. C., 2000 The genome sequence of 
Drosophila melanogaster. Science 287: 2185–95. 
ALBERTS B., JOHNSON A., LEWIS J., RAFF M., ROBERTS K., WALTER P., 2002 Ion Channels and the 
Electrical Properties of Membranes. 
ALLEN S. J., RIBEIRO S., HORUK R., HANDEL T. M., 2009 Expression, purification and in vitro 
functional reconstitution of the chemokine receptor CCR1. Protein Expr. Purif. 66: 73–81. 
225 
 
 
ALLSOPP R. C., EVANS R. J., 2011 The intracellular amino terminus plays a dominant role in 
desensitization of ATP-gated P2X receptor ion channels. J. Biol. Chem. 286: 44691–701. 
ALLSOPP R. C., FARMER L. K., FRYATT A. G., EVANS R. J., 2013 P2X receptor chimeras highlight roles 
of the amino terminus to partial agonist efficacy, the carboxyl terminus to recovery from 
desensitization, and independent regulation of channel transitions. J. Biol. Chem. 288: 
21412–21. 
AMBROSI C., GASSMANN O., PRANSKEVICH J. N., BOASSA D., SMOCK A., WANG J., DAHL G., STEINEM C., 
SOSINSKY G. E., 2010 Pannexin1 and Pannexin2 channels show quaternary similarities to 
connexons and different oligomerization numbers from each other. J Biol Chem 285: 
24420–24431. 
AN H. J., GIP P., KIM J., WU S., PARK K. W., MCVAUGH C. T., SCHAFFER D. V, BERTOZZI C. R., LEBRILLA C. 
B., 2012 Extensive determination of glycan heterogeneity reveals an unusual abundance 
of high mannose glycans in enriched plasma membranes of human embryonic stem cells. 
Mol. Cell. Proteomics 11: M111.010660. 
ANDREWS S. P., MASON J. S., HURRELL E., CONGREVE M., 2014 Structure-based drug design of 
chromone antagonists of the adenosine A2A receptor. Medchemcomm 5: 571. 
ANTONIO L. S., STEWART A. P., VARANDA W. A., EDWARDSON J. M., 2014 Identification of 
P2X2/P2X4/P2X6 heterotrimeric receptors using atomic force microscopy (AFM) imaging. 
FEBS Lett. 588: 2125–8. 
ARDISSONE V., RADAELLI E., ZARATIN P., ARDIZZONE M., LADEL C., GATTORNO M., MARTINI A., GRASSI F., 
TRAGGIAI E., 2011 Pharmacologic P2X purinergic receptor antagonism in the treatment of 
collagen-induced arthritis. Arthritis Rheum. 63: 3323–32. 
ARINAMINPATHY Y., KHURANA E., ENGELMAN D. M., GERSTEIN M. B., 2009 Computational analysis of 
membrane proteins: the largest class of drug targets. Drug Discov. Today 14: 1130–5. 
BAO L., LOCOVEI S., DAHL G., 2004 Pannexin membrane channels are mechanosensitive conduits 
for ATP. FEBS Lett. 572: 65–8. 
BAQI Y., HAUSMANN R., ROSEFORT C., RETTINGER J., SCHMALZING G., MÜLLER C. E., 2011 Discovery of 
potent competitive antagonists and positive modulators of the P2X2 receptor. J. Med. 
Chem. 54: 817–30. 
BARANOVA A., IVANOV D., PETRASH N., PESTOVA A., SKOBLOV M., KELMANSON I., SHAGIN D., NAZARENKO 
S., GERAYMOVYCH E., LITVIN O., TIUNOVA A., BORN T. L., USMAN N., STAROVEROV D., LUKYANOV 
S., PANCHIN Y., 2004 The mammalian pannexin family is homologous to the invertebrate 
innexin gap junction proteins. Genomics 83: 706–716. 
BARDEN N., HARVEY M., GAGNÉ B., SHINK E., TREMBLAY M., RAYMOND C., LABBÉ M., VILLENEUVE A., 
ROCHETTE D., BORDELEAU L., STADLER H., HOLSBOER F., MÜLLER-MYHSOK B., 2006 Analysis of 
single nucleotide polymorphisms in genes in the chromosome 12Q24.31 region points to 
P2RX7 as a susceptibility gene to bipolar affective disorder. Am. J. Med. Genet. B. 
Neuropsychiatr. Genet. 141B: 374–82. 
226 
 
 
BARRERA N. P., ORMOND S. J., HENDERSON R. M., MURRELL-LAGNADO R. D., EDWARDSON J. M., 2005 
Atomic force microscopy imaging demonstrates that P2X2 receptors are trimers but that 
P2X6 receptor subunits do not oligomerize. J. Biol. Chem. 280: 10759–65. 
BARRERA N. P., HENDERSON R. M., MURRELL-LAGNADO R. D., EDWARDSON J. M., 2007 The 
stoichiometry of P2X2/6 receptor heteromers depends on relative subunit expression 
levels. Biophys. J. 93: 505–12. 
BATEMAN J. R., LEE A. M., WU C., 2006 Site-specific transformation of Drosophila via phiC31 
integrase-mediated cassette exchange. Genetics 173: 769–77. 
BAUMANN K., ADELANTADO N., LANG C., MATTANOVICH D., FERRER P., 2011 Protein trafficking, 
ergosterol biosynthesis and membrane physics impact recombinant protein secretion in 
Pichia pastoris. Microb. Cell Fact. 10: 93. 
BENHAM C. D., TSIEN R. W., A novel receptor-operated Ca2+-permeable channel activated by 
ATP in smooth muscle. Nature 328: 275–8. 
BENTON R., DAHANUKAR A., 2011 Electrophysiological recording from Drosophila taste sensilla. 
Cold Spring Harb Protoc 2011: 839–850. 
BERNAUDAT F., FRELET-BARRAND A., POCHON N., DEMENTIN S., HIVIN P., BOUTIGNY S., RIOUX J.-B., SALVI 
D., SEIGNEURIN-BERNY D., RICHAUD P., JOYARD J., PIGNOL D., SABATY M., DESNOS T., PEBAY-
PEYROULA E., DARROUZET E., VERNET T., ROLLAND N., 2011 Heterologous expression of 
membrane proteins: choosing the appropriate host. PLoS One 6: e29191. 
BINDA C., NEWTON-VINSON P., HUBÁLEK F., EDMONDSON D. E., MATTEVI A., 2002 Structure of human 
monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat. 
Struct. Biol. 9: 22–6. 
BINDA C., LI M., HUBALEK F., RESTELLI N., EDMONDSON D. E., MATTEVI A., 2003 Insights into the 
mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution 
crystal structures. Proc. Natl. Acad. Sci. U. S. A. 100: 9750–5. 
BISCHOF J., MAEDA R. K., HEDIGER M., KARCH F., BASLER K., 2007 An optimized transgenesis system 
for Drosophila using germ-line-specific phiC31 integrases. Proc. Natl. Acad. Sci. U. S. A. 
104: 3312–7. 
BO X., JIANG L.-H., WILSON H. L., KIM M., BURNSTOCK G., SURPRENANT A., NORTH R. A., 2003 
Pharmacological and biophysical properties of the human P2X5 receptor. Mol. 
Pharmacol. 63: 1407–16. 
BOASSA D., AMBROSI C., QIU F., DAHL G., GAIETTA G., SOSINSKY G., 2007 Pannexin1 channels contain 
a glycosylation site that targets the hexamer to the plasma membrane. J. Biol. Chem. 282: 
31733–43. 
BOASSA D., QIU F., DAHL G., SOSINSKY G., 2008 Trafficking dynamics of glycosylated pannexin 1 
proteins. Cell Commun. Adhes. 15: 119–32. 
227 
 
 
BOBANOVIC L. K., ROYLE S. J., MURRELL-LAGNADO R. D., 2002 P2X receptor trafficking in neurons is 
subunit specific. J. Neurosci. 22: 4814–24. 
BODIN P., BURNSTOCK G., 2001 Evidence that release of adenosine triphosphate from endothelial 
cells during increased shear stress is vesicular. J. Cardiovasc. Pharmacol. 38: 900–8. 
BODNAR M., WANG H., RIEDEL T., HINTZE S., KATO E., FALLAH G., GRÖGER-ARNDT H., GINIATULLIN R., 
GROHMANN M., HAUSMANN R., SCHMALZING G., ILLES P., RUBINI P., 2011 Amino acid residues 
constituting the agonist binding site of the human P2X3 receptor. J. Biol. Chem. 286: 
2739–49. 
BOLAND C., LI D., SHAH S. T. A., HABERSTOCK S., DÖTSCH V., BERNHARD F., CAFFREY M., 2014 Cell-free 
expression and in meso crystallisation of an integral membrane kinase for structure 
determination. Cell. Mol. Life Sci. 
BONIFACINO J. S., DELL’ANGELICA E. C., SPRINGER T. A., 2001 Immunoprecipitation. Curr. Protoc. 
Protein Sci. Chapter 9: Unit 9.8. 
BORNHORST J. A., FALKE J. J., 2000 Purification of proteins using polyhistidine affinity tags. 
Methods Enzymol. 326: 245–54. 
BOUÉ-GRABOT E., ARCHAMBAULT V., SÉGUÉLA P., 2000 A protein kinase C site highly conserved in 
P2X subunits controls the desensitization kinetics of P2X(2) ATP-gated channels. J. Biol. 
Chem. 275: 10190–5. 
BRACEY M. H., HANSON M. A., MASUDA K. R., STEVENS R. C., CRAVATT B. F., 2002 Structural 
adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science 
298: 1793–6. 
BRAND A. H., PERRIMON N., 1993 Targeted gene expression as a means of altering cell fates and 
generating dominant phenotypes. Development 118: 401–15. 
BRAUN K., RETTINGER J., GANSO M., KASSACK M., HILDEBRANDT C., ULLMANN H., NICKEL P., SCHMALZING 
G., LAMBRECHT G., 2001 NF449: a subnanomolar potency antagonist at recombinant rat 
P2X1 receptors. Naunyn. Schmiedebergs. Arch. Pharmacol. 364: 285–90. 
BRAY S., AMREIN H., 2003 A putative Drosophila pheromone receptor expressed in male-specific 
taste neurons is required for efficient courtship. Neuron 39: 1019–29. 
BRETSCHER M. S., 1972 Asymmetrical lipid bilayer structure for biological membranes. Nat. New 
Biol. 236: 11–2. 
BROTHERTON-PLEISS C. E., DILLON M. P., FORD A. P. D. W., GEVER J. R., CARTER D. S., GLEASON S. K., 
LIN C. J., MOORE A. G., THOMPSON A. W., VILLA M., ZHAI Y., 2010 Discovery and optimization 
of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist. Bioorg. Med. 
Chem. Lett. 20: 1031–6. 
BUELL G., LEWIS C., COLLO G., NORTH R. A., SURPRENANT A., 1996 An antagonist-insensitive P2X 
receptor expressed in epithelia and brain. EMBO J. 15: 55–62. 
228 
 
 
BURDA P., AEBI M., 1999 The dolichol pathway of N-linked glycosylation. Biochim. Biophys. Acta 
1426: 239–57. 
BURNSTOCK G., CAMPBELL G., SATCHELL D., SMYTHE A., 1970 Evidence that adenosine triphosphate 
or a related nucleotide is the transmitter substance released by non-adrenergic inhibitory 
nerves in the gut. Br. J. Pharmacol. 40: 668–88. 
BURNSTOCK G., KENNEDY C., 1985 Is there a basis for distinguishing two types of P2-
purinoceptor? Gen. Pharmacol. 16: 433–40. 
BURNSTOCK G., 2006 Purinergic signalling--an overview. Novartis Found. Symp. 276: 26–48; 
discussion 48–57, 275–81. 
BURNSTOCK G., 2007 Purine and pyrimidine receptors. Cell. Mol. Life Sci. 64: 1471–83. 
BURNSTOCK G., VERKHRATSKY A., 2010 Long-term (trophic) purinergic signalling: purinoceptors 
control cell proliferation, differentiation and death. Cell Death Dis. 1: e9. 
BURROUGHS A. M., IYER L. M., ARAVIND L., 2012 The natural history of ubiquitin and ubiquitin-
related domains. Front. Biosci. (Landmark Ed. 17: 1433–60. 
CAMPOS A. R., GROSSMAN D., WHITE K., 1985 Mutant alleles at the locus elav in Drosophila 
melanogaster lead to nervous system defects. A developmental-genetic analysis. J. 
Neurogenet. 2: 197–218. 
CAMPOS A. R., ROSEN D. R., ROBINOW S. N., WHITE K., 1987 Molecular analysis of the locus elav in 
Drosophila melanogaster: a gene whose embryonic expression is neural specific. EMBO J. 
6: 425–31. 
CAO L., YOUNG M. T., BROOMHEAD H. E., FOUNTAIN S. J., NORTH R. A., 2007 Thr339-to-serine 
substitution in rat P2X2 receptor second transmembrane domain causes constitutive 
opening and indicates a gating role for Lys308. J. Neurosci. 27: 12916–23. 
CARPENTER E. P., BEIS K., CAMERON A. D., IWATA S., 2008 Overcoming the challenges of membrane 
protein crystallography. Curr. Opin. Struct. Biol. 18: 581–6. 
CHANG V. T., CRISPIN M., ARICESCU A. R., HARVEY D. J., NETTLESHIP J. E., FENNELLY J. A., YU C., BOLES K. 
S., EVANS E. J., STUART D. I., DWEK R. A., JONES E. Y., OWENS R. J., DAVIS S. J., 2007 
Glycoprotein structural genomics: solving the glycosylation problem. Structure 15: 267–
73. 
CHATAIGNEAU T., LEMOINE D., GRUTTER T., 2013 Exploring the ATP-binding site of P2X receptors. 
Front. Cell. Neurosci. 7: 273. 
CHAUDHARY S., PAK J. E., GRUSWITZ F., SHARMA V., STROUD R. M., 2012 Overexpressing human 
membrane proteins in stably transfected and clonal human embryonic kidney 293S cells. 
Nat. Protoc. 7: 453–66. 
229 
 
 
CHAUMONT S., JIANG L.-H., PENNA A., NORTH R. A., RASSENDREN F., 2004 Identification of a 
trafficking motif involved in the stabilization and polarization of P2X receptors. J. Biol. 
Chem. 279: 29628–38. 
CHEKENI F. B., ELLIOTT M. R., SANDILOS J. K., WALK S. F., KINCHEN J. M., LAZAROWSKI E. R., ARMSTRONG 
A. J., PENUELA S., LAIRD D. W., SALVESEN G. S., ISAKSON B. E., BAYLISS D. A., RAVICHANDRAN K. S., 
2010 Pannexin 1 channels mediate “find-me” signal release and membrane permeability 
during apoptosis. Nature 467: 863–867. 
CHEN C. C., AKOPIAN A. N., SIVILOTTI L., COLQUHOUN D., BURNSTOCK G., WOOD J. N., 1995 A P2X 
purinoceptor expressed by a subset of sensory neurons. Nature 377: 428–31. 
CHEN Y.-J., PORNILLOS O., LIEU S., MA C., CHEN A. P., CHANG G., 2007 X-ray structure of EmrE 
supports dual topology model. Proc. Natl. Acad. Sci. U. S. A. 104: 18999–9004. 
CHESSELL I. P., MICHEL A. D., HUMPHREY P. P., 1998 Effects of antagonists at the human 
recombinant P2X7 receptor. Br. J. Pharmacol. 124: 1314–20. 
CHONG S., MONTELLO G. E., ZHANG A., CANTOR E. J., LIAO W., XU M. Q., BENNER J., 1998 Utilizing the 
C-terminal cleavage activity of a protein splicing element to purify recombinant proteins 
in a single chromatographic step. Nucleic Acids Res. 26: 5109–15. 
CIEŚLA J., FRĄCZYK T., RODE W., 2011 Phosphorylation of basic amino acid residues in proteins: 
important but easily missed. Acta Biochim. Pol. 58: 137–48. 
CLARK A. G., EISEN M. B., SMITH D. R., BERGMAN C. M., OLIVER B., MARKOW T. A., KAUFMAN T. C., 
KELLIS M., GELBART W., IYER V. N., POLLARD D. A., SACKTON T. B., LARRACUENTE A. M., SINGH N. 
D., ABAD J. P., ABT D. N., ADRYAN B., AGUADE M., AKASHI H., ANDERSON W. W., AQUADRO C. F., 
ARDELL D. H., ARGUELLO R., ARTIERI C. G., BARBASH D. A., BARKER D., BARSANTI P., BATTERHAM P., 
BATZOGLOU S., BEGUN D., BHUTKAR A., BLANCO E., BOSAK S. A., BRADLEY R. K., BRAND A. D., 
BRENT M. R., BROOKS A. N., BROWN R. H., BUTLIN R. K., CAGGESE C., CALVI B. R., BERNARDO DE 
CARVALHO A., CASPI A., CASTREZANA S., CELNIKER S. E., CHANG J. L., CHAPPLE C., CHATTERJI S., 
CHINWALLA A., CIVETTA A., CLIFTON S. W., COMERON J. M., COSTELLO J. C., COYNE J. A., DAUB J., 
DAVID R. G., DELCHER A. L., DELEHAUNTY K., DO C. B., EBLING H., EDWARDS K., EICKBUSH T., 
EVANS J. D., FILIPSKI A., FINDEISS S., FREYHULT E., FULTON L., FULTON R., GARCIA A. C. L., 
GARDINER A., GARFIELD D. A., GARVIN B. E., GIBSON G., GILBERT D., GNERRE S., GODFREY J., GOOD 
R., GOTEA V., GRAVELY B., GREENBERG A. J., GRIFFITHS-JONES S., GROSS S., GUIGO R., GUSTAFSON 
E. A., HAERTY W., HAHN M. W., HALLIGAN D. L., HALPERN A. L., HALTER G. M., HAN M. V, HEGER 
A., HILLIER L., HINRICHS A. S., HOLMES I., HOSKINS R. A., HUBISZ M. J., HULTMARK D., HUNTLEY M. 
A., JAFFE D. B., JAGADEESHAN S., JECK W. R., JOHNSON J., JONES C. D., JORDAN W. C., KARPEN G. 
H., KATAOKA E., KEIGHTLEY P. D., KHERADPOUR P., KIRKNESS E. F., KOERICH L. B., KRISTIANSEN K., 
KUDRNA D., KULATHINAL R. J., KUMAR S., KWOK R., LANDER E., LANGLEY C. H., LAPOINT R., 
LAZZARO B. P., LEE S.-J., LEVESQUE L., LI R., LIN C.-F., LIN M. F., LINDBLAD-TOH K., LLOPART A., 
LONG M., LOW L., LOZOVSKY E., LU J., LUO M., MACHADO C. A., MAKALOWSKI W., MARZO M., 
MATSUDA M., MATZKIN L., MCALLISTER B., MCBRIDE C. S., MCKERNAN B., MCKERNAN K., 
MENDEZ-LAGO M., MINX P., MOLLENHAUER M. U., MONTOOTH K., MOUNT S. M., MU X., MYERS 
E., NEGRE B., NEWFELD S., NIELSEN R., NOOR M. A. F., O’GRADY P., PACHTER L., PAPACEIT M., 
PARISI M. J., PARISI M., PARTS L., PEDERSEN J. S., PESOLE G., PHILLIPPY A. M., PONTING C. P., POP 
M., PORCELLI D., POWELL J. R., PROHASKA S., PRUITT K., PUIG M., QUESNEVILLE H., RAM K. R., 
RAND D., RASMUSSEN M. D., REED L. K., REENAN R., REILY A., REMINGTON K. A., RIEGER T. T., 
230 
 
 
RITCHIE M. G., ROBIN C., ROGERS Y.-H., ROHDE C., ROZAS J., RUBENFIELD M. J., RUIZ A., RUSSO S., 
SALZBERG S. L., SANCHEZ-GRACIA A., SARANGA D. J., SATO H., SCHAEFFER S. W., SCHATZ M. C., 
SCHLENKE T., SCHWARTZ R., SEGARRA C., SINGH R. S., SIROT L., SIROTA M., SISNEROS N. B., SMITH 
C. D., SMITH T. F., SPIETH J., STAGE D. E., STARK A., STEPHAN W., STRAUSBERG R. L., STREMPEL S., 
STURGILL D., SUTTON G., SUTTON G. G., TAO W., TEICHMANN S., TOBARI Y. N., TOMIMURA Y., 
TSOLAS J. M., VALENTE V. L. S., VENTER E., VENTER J. C., VICARIO S., VIEIRA F. G., VILELLA A. J., 
VILLASANTE A., WALENZ B., WANG J., WASSERMAN M., WATTS T., WILSON D., WILSON R. K., WING 
R. A., WOLFNER M. F., WONG A., WONG G. K.-S., WU C.-I., WU G., YAMAMOTO D., YANG H.-P., 
YANG S.-P., YORKE J. A., YOSHIDA K., ZDOBNOV E., ZHANG P., ZHANG Y., ZIMIN A. V, BALDWIN J., 
ABDOUELLEIL A., ABDULKADIR J., ABEBE A., ABERA B., ABREU J., ACER S. C., AFTUCK L., ALEXANDER 
A., AN P., ANDERSON E., ANDERSON S., ARACHI H., AZER M., BACHANTSANG P., BARRY A., BAYUL T., 
BERLIN A., BESSETTE D., BLOOM T., BLYE J., BOGUSLAVSKIY L., BONNET C., BOUKHGALTER B., 
BOURZGUI I., BROWN A., CAHILL P., CHANNER S., CHESHATSANG Y., CHUDA L., CITROEN M., 
COLLYMORE A., COOKE P., COSTELLO M., D’ACO K., DAZA R., HAAN G. DE, DEGRAY S., DEMASO C., 
DHARGAY N., DOOLEY K., DOOLEY E., DORICENT M., DORJE P., DORJEE K., DUPES A., ELONG R., FALK 
J., FARINA A., FARO S., FERGUSON D., FISHER S., FOLEY C. D., FRANKE A., FRIEDRICH D., GADBOIS L., 
GEARIN G., GEARIN C. R., GIANNOUKOS G., GOODE T., GRAHAM J., GRANDBOIS E., GREWAL S., 
GYALTSEN K., HAFEZ N., HAGOS B., HALL J., HENSON C., HOLLINGER A., HONAN T., HUARD M. D., 
HUGHES L., HURHULA B., HUSBY M. E., KAMAT A., KANGA B., KASHIN S., KHAZANOVICH D., KISNER 
P., LANCE K., LARA M., LEE W., LENNON N., LETENDRE F., LEVINE R., LIPOVSKY A., LIU X., LIU J., LIU 
S., LOKYITSANG T., LOKYITSANG Y., LUBONJA R., LUI A., MACDONALD P., MAGNISALIS V., MARU K., 
MATTHEWS C., MCCUSKER W., MCDONOUGH S., MEHTA T., MELDRIM J., MENEUS L., MIHAI O., 
MIHALEV A., MIHOVA T., MITTELMAN R., MLENGA V., MONTMAYEUR A., MULRAIN L., NAVIDI A., 
NAYLOR J., NEGASH T., NGUYEN T., NGUYEN N., NICOL R., NORBU C., NORBU N., NOVOD N., 
O’NEILL B., OSMAN S., MARKIEWICZ E., OYONO O. L., PATTI C., PHUNKHANG P., PIERRE F., PRIEST 
M., RAGHURAMAN S., REGE F., REYES R., RISE C., ROGOV P., ROSS K., RYAN E., SETTIPALLI S., SHEA 
T., SHERPA N., SHI L., SHIH D., SPARROW T., SPAULDING J., STALKER J., STANGE-THOMANN N., 
STAVROPOULOS S., STONE C., STRADER C., TESFAYE S., THOMSON T., THOULUTSANG Y., 
THOULUTSANG D., TOPHAM K., TOPPING I., TSAMLA T., VASSILIEV H., VO A., WANGCHUK T., 
WANGDI T., WEIAND M., WILKINSON J., WILSON A., YADAV S., YOUNG G., YU Q., ZEMBEK L., 
ZHONG D., ZIMMER A., ZWIRKO Z., ALVAREZ P., BROCKMAN W., BUTLER J., CHIN C., GRABHERR M., 
KLEBER M., MAUCELI E., MACCALLUM I., 2007 Evolution of genes and genomes on the 
Drosophila phylogeny. Nature 450: 203–18. 
CLARKE S., 1993 Protein methylation. Curr. Opin. Cell Biol. 5: 977–83. 
CLYNE P. J., WARR C. G., CARLSON J. R., 2000 Candidate taste receptors in Drosophila. Science 
287: 1830–4. 
COCKAYNE D. A., DUNN P. M., ZHONG Y., RONG W., HAMILTON S. G., KNIGHT G. E., RUAN H.-Z., MA B., 
YIP P., NUNN P., MCMAHON S. B., BURNSTOCK G., FORD A. P. D. W., 2005 P2X2 knockout mice 
and P2X2/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in 
mediating multiple sensory effects of ATP. J. Physiol. 567: 621–39. 
CODDOU C., YAN Z., OBSIL T., HUIDOBRO-TORO J. P., STOJILKOVIC S. S., 2011 Activation and regulation 
of purinergic P2X receptor channels. Pharmacol. Rev. 63: 641–83. 
COMPAN V., ULMANN L., STELMASHENKO O., CHEMIN J., CHAUMONT S., RASSENDREN F., 2012 P2X2 and 
P2X5 subunits define a new heteromeric receptor with P2X7-like properties. J. Neurosci. 
32: 4284–96. 
231 
 
 
CONGREVE M., ANDREWS S. P., DORÉ A. S., HOLLENSTEIN K., HURRELL E., LANGMEAD C. J., MASON J. S., 
NG I. W., TEHAN B., ZHUKOV A., WEIR M., MARSHALL F. H., 2012 Discovery of 1,2,4-triazine 
derivatives as adenosine A(2A) antagonists using structure based drug design. J. Med. 
Chem. 55: 1898–903. 
CROSS B. C. S., HIGH S., 2009 Dissecting the physiological role of selective transmembrane-
segment retention at the ER translocon. J. Cell Sci. 122: 1768–77. 
DAHANUKAR A., FOSTER K., GOES VAN NATERS W. M. VAN DER, CARLSON J. R., 2001 A Gr receptor is 
required for response to the sugar trehalose in taste neurons of Drosophila. Nat. 
Neurosci. 4: 1182–6. 
DAHANUKAR A., LEI Y.-T., KWON J. Y., CARLSON J. R., 2007 Two Gr genes underlie sugar reception in 
Drosophila. Neuron 56: 503–16. 
DAMER S., NIEBEL B., CZECHE S., NICKEL P., ARDANUY U., SCHMALZING G., RETTINGER J., MUTSCHLER E., 
LAMBRECHT G., 1998 NF279: a novel potent and selective antagonist of P2X receptor-
mediated responses. Eur. J. Pharmacol. 350: R5–6. 
DANDO R., ROPER S. D., 2009 Cell-to-cell communication in intact taste buds through ATP 
signalling from pannexin 1 gap junction hemichannels. J. Physiol. 587: 5899–906. 
DAVIES M. G., BERKOWITZ D. E., HAGEN P. O., 1995 Constitutive nitric oxide synthase is expressed 
and nitric oxide-mediated relaxation is preserved in retrieved human aortocoronary vein 
grafts. J. Surg. Res. 58: 732–8. 
DEISENHOFER J., EPP O., MIKI K., HUBER R., MICHEL H., 1985 Structure of the protein subunits in the 
photosynthetic reaction centre of Rhodopseudomonas viridis at 3Å resolution. Nature 
318: 618–24. 
DEVASAHAYAM M., 2007 Factors affecting the expression of recombinant glycoproteins. Indian J. 
Med. Res. 126: 22–7. 
DIAZ-HERNANDEZ M., COX J. A., MIGITA K., HAINES W., EGAN T. M., VOIGT M. M., 2002 Cloning and 
characterization of two novel zebrafish P2X receptor subunits. Biochem. Biophys. Res. 
Commun. 295: 849–53. 
DIAZ-HERNANDEZ J. I., GOMEZ-VILLAFUERTES R., LEÓN-OTEGUI M., HONTECILLAS-PRIETO L., PUERTO A. 
DEL, TREJO J. L., LUCAS J. J., GARRIDO J. J., GUALIX J., MIRAS-PORTUGAL M. T., DIAZ-HERNANDEZ 
M., 2012 In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer’s disease through 
GSK3β and secretases. Neurobiol. Aging 33: 1816–28. 
DING S., SACHS F., 1999 Ion permeation and block of P2X(2) purinoceptors: single channel 
recordings. J. Membr. Biol. 172: 215–23. 
DONNELLY-ROBERTS D. L., NAMOVIC M. T., HAN P., JARVIS M. F., 2009 Mammalian P2X7 receptor 
pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors. Br. J. 
Pharmacol. 157: 1203–14. 
232 
 
 
DOROGHAZI J. R., JU K.-S., BROWN D. W., LABEDA D. P., DENG Z., METCALF W. W., CHEN W., PRICE N. 
P. J., 2011 Genome sequences of three tunicamycin-producing Streptomyces Strains, S. 
chartreusis NRRL 12338, S. chartreusis NRRL 3882, and S. lysosuperificus ATCC 31396. J. 
Bacteriol. 193: 7021–2. 
DUCKWITZ W., HAUSMANN R., ASCHRAFI A., SCHMALZING G., 2006 P2X5 subunit assembly requires 
scaffolding by the second transmembrane domain and a conserved aspartate. J. Biol. 
Chem. 281: 39561–72. 
DUFFY J. B., 2000 GAL4 system in Drosophila: a fly geneticist’s Swiss army knife. Genesis 34: 1–
15. 
DUNIPACE L., MEISTER S., MCNEALY C., AMREIN H., 2001 Spatially restricted expression of 
candidate taste receptors in the Drosophila gustatory system. Curr. Biol. 11: 822–835. 
DUTZLER R., CAMPBELL E. B., CADENE M., CHAIT B. T., MACKINNON R., 2002 X-ray structure of a ClC 
chloride channel at 3.0 A reveals the molecular basis of anion selectivity. Nature 415: 
287–94. 
DUTZLER R., CAMPBELL E. B., MACKINNON R., 2003 Gating the selectivity filter in ClC chloride 
channels. Science 300: 108–12. 
DVIR H., CHOE S., 2009 Bacterial expression of a eukaryotic membrane protein in fusion to 
various Mistic orthologs. Protein Expr. Purif. 68: 28–33. 
DYKE M. W. VAN, SIRITO M., SAWADOGO M., 1992 Single-step purification of bacterially expressed 
polypeptides containing an oligo-histidine domain. Gene 111: 99–104. 
EARL J. B., BRITT S. G., 2006 Expression of Drosophila rhodopsins during photoreceptor cell 
differentiation: insights into R7 and R8 cell subtype commitment. Gene Expr. Patterns 6: 
687–94. 
ECCLES J. C., 1964 The Physiology of Synapses. Elsevier Science. 
EGAN T. M., HAINES W. R., VOIGT M. M., 1998 A domain contributing to the ion channel of ATP-
gated P2X2 receptors identified by the substituted cysteine accessibility method. J. 
Neurosci. 18: 2350–9. 
ENNION S., HAGAN S., EVANS R. J., 2000 The role of positively charged amino acids in ATP 
recognition by human P2X(1) receptors. J. Biol. Chem. 275: 29361–7. 
ENNION S. J., EVANS R. J., 2002 Conserved cysteine residues in the extracellular loop of the 
human P2X(1) receptor form disulfide bonds and are involved in receptor trafficking to 
the cell surface. Mol. Pharmacol. 61: 303–11. 
ERHARDT J. A., PILLARISETTI K., TOOMEY J. R., 2003 Potentiation of platelet activation through the 
stimulation of P2X1 receptors. J. Thromb. Haemost. 1: 2626–35. 
233 
 
 
ERHARDT A., LUCAE S., UNSCHULD P. G., ISING M., KERN N., SALYAKINA D., LIEB R., UHR M., BINDER E. 
B., KECK M. E., MÜLLER-MYHSOK B., HOLSBOER F., 2007 Association of polymorphisms in 
P2RX7 and CaMKKb with anxiety disorders. J. Affect. Disord. 101: 159–68. 
ERICKSON J., NEIDHART D. J., VANDRIE J., KEMPF D. J., WANG X. C., NORBECK D. W., PLATTNER J. J., 
RITTENHOUSE J. W., TURON M., WIDEBURG N., 1990 Design, activity, and 2.8 A crystal 
structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science 249: 527–33. 
EVANS R. J., LEWIS C., BUELL G., VALERA S., NORTH R. A., SURPRENANT A., 1995 Pharmacological 
characterization of heterologously expressed ATP-gated cation channels (P2x 
purinoceptors). Mol. Pharmacol. 48: 178–83. 
FERGUSON A. D., MCKEEVER B. M., XU S., WISNIEWSKI D., MILLER D. K., YAMIN T.-T., SPENCER R. H., 
CHU L., UJJAINWALLA F., CUNNINGHAM B. R., EVANS J. F., BECKER J. W., 2007 Crystal structure 
of inhibitor-bound human 5-lipoxygenase-activating protein. Science 317: 510–2. 
FERRARI D., PIZZIRANI C., GULINELLI S., CALLEGARI G., CHIOZZI P., IDZKO M., PANTHER E., VIRGILIO F. DI, 
2007 Modulation of P2X7 receptor functions by polymyxin B: crucial role of the 
hydrophobic tail of the antibiotic molecule. Br. J. Pharmacol. 150: 445–54. 
FEUVRE R. A. LE, BROUGH D., IWAKURA Y., TAKEDA K., ROTHWELL N. J., 2002 Priming of macrophages 
with lipopolysaccharide potentiates P2X7-mediated cell death via a caspase-1-dependent 
mechanism, independently of cytokine production. J. Biol. Chem. 277: 3210–8. 
FINGER T. E., DANILOVA V., BARROWS J., BARTEL D. L., VIGERS A. J., STONE L., HELLEKANT G., KINNAMON 
S. C., 2005 ATP signaling is crucial for communication from taste buds to gustatory 
nerves. Science 310: 1495–9. 
FISCHER J. A., GINIGER E., MANIATIS T., PTASHNE M., 1988 GAL4 activates transcription in 
Drosophila. Nature 332: 853–6. 
FISCHER H., POLIKARPOV I., CRAIEVICH A. F., 2004 Average protein density is a molecular-weight-
dependent function. Protein Sci. 13: 2825–8. 
FISCHER W., ZADORI Z., KULLNICK Y., GRÖGER-ARNDT H., FRANKE H., WIRKNER K., ILLES P., MAGER P. P., 
2007 Conserved lysin and arginin residues in the extracellular loop of P2X(3) receptors 
are involved in agonist binding. Eur. J. Pharmacol. 576: 7–17. 
FOUNTAIN S. J., BURNSTOCK G., 2009 An evolutionary history of P2X receptors. Purinergic Signal. 
5: 269–72. 
FREEMAN M., 2002 A fly’s eye view of EGF receptor signalling. EMBO J. 21: 6635–42. 
FREEMAN WH, 2000 Protein Glycosylation in the ER and Golgi Complex. 
FRICK A., ERIKSSON U. K., MATTIA F. DE, OBERG F., HEDFALK K., NEUTZE R., GRIP W. J. DE, DEEN P. M. T., 
TÖRNROTH-HORSEFIELD S., 2014 X-ray structure of human aquaporin 2 and its implications 
for nephrogenic diabetes insipidus and trafficking. Proc. Natl. Acad. Sci. U. S. A. 111: 
6305–10. 
234 
 
 
GADSBY D. C., 2009 Ion channels versus ion pumps: the principal difference, in principle. Nat. 
Rev. Mol. Cell Biol. 10: 344–52. 
GAN L., ALEXANDER J. M., WITTELSBERGER A., THOMAS B., ROSENBLATT M., 2006 Large-scale 
purification and characterization of human parathyroid hormone-1 receptor stably 
expressed in HEK293S GnTI- cells. Protein Expr. Purif. 47: 296–302. 
GARAVITO R. M., FERGUSON-MILLER S., 2001 Detergents as tools in membrane biochemistry. J. 
Biol. Chem. 276: 32403–6. 
GARCIA-GUZMAN M., STÜHMER W., SOTO F., 1997 Molecular characterization and pharmacological 
properties of the human P2X3 purinoceptor. Brain Res. Mol. Brain Res. 47: 59–66. 
GARGETT C. E., WILEY J. S., 1997 The isoquinoline derivative KN-62 a potent antagonist of the 
P2Z-receptor of human lymphocytes. Br. J. Pharmacol. 120: 1483–90. 
GEEST M. VAN, LOLKEMA J. S., 2000 Membrane topology and insertion of membrane proteins: 
search for topogenic signals. Microbiol. Mol. Biol. Rev. 64: 13–33. 
GEHI R., SHAO Q., LAIRD D. W., 2011 Pathways regulating the trafficking and turnover of 
pannexin1 protein and the role of the C-terminal domain. J. Biol. Chem. 286: 27639–53. 
GORDON J. L., 1986 Extracellular ATP: effects, sources and fate. Biochem. J. 233: 309–19. 
GREENSPAN R. J., FERVEUR J. F., 2000 Courtship in Drosophila. Annu. Rev. Genet. 34: 205–232. 
GREIG A. V. H., LINGE C., HEALY V., LIM P., CLAYTON E., RUSTIN M. H. A., MCGROUTHER D. A., 
BURNSTOCK G., 2003 Expression of purinergic receptors in non-melanoma skin cancers and 
their functional roles in A431 cells. J. Invest. Dermatol. 121: 315–27. 
GROTH A. C., FISH M., NUSSE R., CALOS M. P., 2004 Construction of transgenic Drosophila by using 
the site-specific integrase from phage phiC31. Genetics 166: 1775–82. 
GRUBB B. D., EVANS R. J., 1999 Characterization of cultured dorsal root ganglion neuron P2X 
receptors. Eur. J. Neurosci. 11: 149–154. 
GRUENINGER-LEITCH F., D’ARCY A., D’ARCY B., CHÈNE C., 1996 Deglycosylation of proteins for 
crystallization using recombinant fusion protein glycosidases. Protein Sci. 5: 2617–22. 
GRUSWITZ F., CHAUDHARY S., HO J. D., SCHLESSINGER A., PEZESHKI B., HO C.-M., SALI A., WESTHOFF C. 
M., STROUD R. M., 2010 Function of human Rh based on structure of RhCG at 2.1 A. Proc. 
Natl. Acad. Sci. U. S. A. 107: 9638–43. 
GU J. G., MACDERMOTT A. B., 1997 Activation of ATP P2X receptors elicits glutamate release 
from sensory neuron synapses. Nature 389: 749–53. 
GU B. J., ZHANG W. Y., BENDALL L. J., CHESSELL I. P., BUELL G. N., WILEY J. S., 2000 Expression of 
P2X(7) purinoceptors on human lymphocytes and monocytes: evidence for nonfunctional 
P2X(7) receptors. Am J Physiol Cell Physiol 279: C1189–97. 
235 
 
 
GUARENTE L., YOCUM R. R., GIFFORD P., 1982 A GAL10-CYC1 hybrid yeast promoter identifies the 
GAL4 regulatory region as an upstream site. Proc. Natl. Acad. Sci. U. S. A. 79: 7410–4. 
GUDIPATY L., HUMPHREYS B. D., BUELL G., DUBYAK G. R., 2001 Regulation of P2X(7) nucleotide 
receptor function in human monocytes by extracellular ions and receptor density. Am J 
Physiol Cell Physiol 280: C943–53. 
GUTMANN D. A. P., MIZOHATA E., NEWSTEAD S., FERRANDON S., POSTIS V., XIA X., HENDERSON P. J. F., 
VEEN H. W. VAN, BYRNE B., 2007 A high-throughput method for membrane protein 
solubility screening: the ultracentrifugation dispersity sedimentation assay. Protein Sci. 
16: 1422–8. 
HAGEL L., 2001 Gel-filtration chromatography. Curr. Protoc. Mol. Biol. Chapter 10: Unit 10.9. 
HARDIE R. C., RAGHU P., 2001 Visual transduction in Drosophila. Nature 413: 186–93. 
HARDIE R. C., 2001 Phototransduction in Drosophila melanogaster. J. Exp. Biol. 204: 3403–9. 
HASSAINE G., DELUZ C., GRASSO L., WYSS R., TOL M. B., HOVIUS R., GRAFF A., STAHLBERG H., TOMIZAKI 
T., DESMYTER A., MOREAU C., LI X.-D., POITEVIN F., VOGEL H., NURY H., 2014 X-ray structure of 
the mouse serotonin 5-HT3 receptor. Nature 512: 276–281. 
HATTORI M., GOUAUX E., 2012 Molecular mechanism of ATP binding and ion channel activation 
in P2X receptors. Nature 485: 207–12. 
HAYDEN J. D., BROWN L. R., GUNAWARDENA H. P., PERKOWSKI E. F., CHEN X., BRAUNSTEIN M., 2013 
Reversible acetylation regulates acetate and propionate metabolism in Mycobacterium 
smegmatis. Microbiology 159: 1986–99. 
HECHLER B., LENAIN N., MARCHESE P., VIAL C., HEIM V., FREUND M., CAZENAVE J.-P., CATTANEO M., 
RUGGERI Z. M., EVANS R., GACHET C., 2003 A role of the fast ATP-gated P2X1 cation channel 
in thrombosis of small arteries in vivo. J. Exp. Med. 198: 661–7. 
HEFTI M. H., VUGT-VAN DER TOORN C. J. VAN, DIXON R., VERVOORT J., 2001 A novel purification 
method for histidine-tagged proteins containing a thrombin cleavage site. Anal. Biochem. 
295: 180–5. 
HEJJAS K., SZEKELY A., DOMOTOR E., HALMAI Z., BALOGH G., SCHILLING B., SAROSI A., FALUDI G., SASVARI-
SZEKELY M., NEMODA Z., 2009 Association between depression and the Gln460Arg 
polymorphism of P2RX7 gene: a dimensional approach. Am. J. Med. Genet. B. 
Neuropsychiatr. Genet. 150B: 295–9. 
HELENIUS A., AEBI M., 2004 Roles of N-linked glycans in the endoplasmic reticulum. Annu. Rev. 
Biochem. 73: 1019–49. 
HERNANDEZ-OLMOS V., ABDELRAHMAN A., EL-TAYEB A., FREUDENDAHL D., WEINHAUSEN S., MÜLLER C. E., 
2012 N-substituted phenoxazine and acridone derivatives: structure-activity relationships 
of potent P2X4 receptor antagonists. J. Med. Chem. 55: 9576–88. 
236 
 
 
HIROI M., MEUNIER N., MARION-POLL F., TANIMURA T., 2004 Two antagonistic gustatory receptor 
neurons responding to sweet-salty and bitter taste in Drosophila. J Neurobiol 61: 333–
342. 
HODGSON E. S., LETTVIN J. Y., ROEDER K. D., 1955 Physiology of a primary chemoreceptor unit. 
Science 122: 417–8. 
HOLTON F. A., HOLTON P., 1954 The capillary dilator substances in dry powders of spinal roots; a 
possible role of adenosine triphosphate in chemical transmission from nerve endings. J. 
Physiol. 126: 124–140. 
HOLTON P., 1959 The liberation of adenosine triphosphate on antidromic stimulation of 
sensory nerves. J. Physiol. 145: 494–504. 
HONORE P., DONNELLY-ROBERTS D., NAMOVIC M. T., HSIEH G., ZHU C. Z., MIKUSA J. P., HERNANDEZ G., 
ZHONG C., GAUVIN D. M., CHANDRAN P., HARRIS R., MEDRANO A. P., CARROLL W., MARSH K., 
SULLIVAN J. P., FALTYNEK C. R., JARVIS M. F., 2006 A-740003 [N-(1-{[(cyanoimino)(5-
quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-
dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-
dependently reduces neuropathic pain in the rat. J. Pharmacol. Exp. Ther. 319: 1376–85. 
HU B., SENKLER C., YANG A., SOTO F., LIANG B. T., 2002 P2X4 receptor is a glycosylated cardiac 
receptor mediating a positive inotropic response to ATP. J. Biol. Chem. 277: 15752–7. 
HU A., ZHANG W., WANG Z., 2010 Functional feedback from mushroom bodies to antennal lobes 
in the Drosophila olfactory pathway. Proc. Natl. Acad. Sci. U. S. A. 107: 10262–7. 
HUANG Y., LEMIEUX M. J., SONG J., AUER M., WANG D.-N., 2003 Structure and mechanism of the 
glycerol-3-phosphate transporter from Escherichia coli. Science 301: 616–20. 
HUANG Y. A., STONE L. M., PEREIRA E., YANG R., KINNAMON J. C., DVORYANCHIKOV G., CHAUDHARI N., 
FINGER T. E., KINNAMON S. C., ROPER S. D., 2011 Knocking out P2X receptors reduces 
transmitter secretion in taste buds. J. Neurosci. 31: 13654–61. 
HUDLICKA O., BROWN M., EGGINTON S., 1992 Angiogenesis in skeletal and cardiac muscle. Physiol. 
Rev. 72: 369–417. 
HÜLSMANN M., NICKEL P., KASSACK M., SCHMALZING G., LAMBRECHT G., MARKWARDT F., 2003 NF449, 
a novel picomolar potency antagonist at human P2X1 receptors. Eur. J. Pharmacol. 470: 
1–7. 
HUNSKAAR S., HOLE K., 1987 The formalin test in mice: dissociation between inflammatory and 
non-inflammatory pain. Pain 30: 103–14. 
ICHIMIYA T., MANYA H., OHMAE Y., YOSHIDA H., TAKAHASHI K., UEDA R., ENDO T., NISHIHARA S., 2004 
The twisted abdomen phenotype of Drosophila POMT1 and POMT2 mutants coincides 
with their heterophilic protein O-mannosyltransferase activity. J. Biol. Chem. 279: 42638–
47. 
237 
 
 
INOUE M., TERADA T., OKUDA M., INUI K.-I., 2005 Regulation of human peptide transporter 1 
(PEPT1) in gastric cancer cells by anticancer drugs. Cancer Lett. 230: 72–80. 
ISHIMOTO H., TAKAHASHI K., UEDA R., TANIMURA T., 2005 G-protein gamma subunit 1 is required 
for sugar reception in Drosophila. EMBO J. 24: 3259–65. 
ISONO K., MORITA H., 2010 Molecular and cellular designs of insect taste receptor system. Front. 
Cell. Neurosci. 4: 20. 
ITZSTEIN M. VON, WU W. Y., KOK G. B., PEGG M. S., DYASON J. C., JIN B., PHAN T. VAN, SMYTHE M. L., 
WHITE H. F., OLIVER S. W., 1993 Rational design of potent sialidase-based inhibitors of 
influenza virus replication. Nature 363: 418–23. 
JAAKOLA V.-P., GRIFFITH M. T., HANSON M. A., CHEREZOV V., CHIEN E. Y. T., LANE J. R., IJZERMAN A. P., 
STEVENS R. C., 2008 The 2.6 angstrom crystal structure of a human A2A adenosine 
receptor bound to an antagonist. Science 322: 1211–7. 
JACKSON A. M., BOUTELL J., COOLEY N., HE M., 2004 Cell-free protein synthesis for proteomics. 
Brief. Funct. Genomic. Proteomic. 2: 308–19. 
JANKNECHT R., MARTYNOFF G. DE, LOU J., HIPSKIND R. A., NORDHEIM A., STUNNENBERG H. G., 1991 
Rapid and efficient purification of native histidine-tagged protein expressed by 
recombinant vaccinia virus. Proc. Natl. Acad. Sci. U. S. A. 88: 8972–6. 
JANKNECHT R., NORDHEIM A., 1992 Affinity purification of histidine-tagged proteins transiently 
produced in HeLa cells. Gene 121: 321–4. 
JARVIS M. F., BIANCHI B., UCHIC J. T., CARTMELL J., LEE C.-H., WILLIAMS M., FALTYNEK C., 2004 [3H]A-
317491, a novel high-affinity non-nucleotide antagonist that specifically labels human 
P2X2/3 and P2X3 receptors. J. Pharmacol. Exp. Ther. 310: 407–16. 
JENNINGS B. H., 2011 Drosophila – a versatile model in biology & medicine. Mater. Today 14: 
190–195. 
JENTSCH T. J., HÜBNER C. A., FUHRMANN J. C., 2004 Ion channels: function unravelled by 
dysfunction. Nat. Cell Biol. 6: 1039–47. 
JIANG L. H., MACKENZIE A. B., NORTH R. A., SURPRENANT A., 2000a Brilliant blue G selectively blocks 
ATP-gated rat P2X(7) receptors. Mol. Pharmacol. 58: 82–8. 
JIANG L. H., RASSENDREN F., SURPRENANT A., NORTH R. A., 2000b Identification of amino acid 
residues contributing to the ATP-binding site of a purinergic P2X receptor. J. Biol. Chem. 
275: 34190–6. 
JIANG R., LEMOINE D., MARTZ A., TALY A., GONIN S., PRADO DE CARVALHO L., SPECHT A., GRUTTER T., 
2011 Agonist trapped in ATP-binding sites of the P2X2 receptor. Proc. Natl. Acad. Sci. U. 
S. A. 108: 9066–71. 
238 
 
 
JIAO Y., MOON S. J., MONTELL C., 2007 A Drosophila gustatory receptor required for the 
responses to sucrose, glucose, and maltose identified by mRNA tagging. Proc. Natl. Acad. 
Sci. U. S. A. 104: 14110–5. 
JIMENEZ-PACHECO A., MESURET G., SANZ-RODRIGUEZ A., TANAKA K., MOONEY C., CONROY R., MIRAS-
PORTUGAL M. T., DIAZ-HERNANDEZ M., HENSHALL D. C., ENGEL T., 2013 Increased neocortical 
expression of the P2X7 receptor after status epilepticus and anticonvulsant effect of P2X7 
receptor antagonist A-438079. Epilepsia 54: 1551–61. 
JOHNSON E. C., PAK W. L., 1986 Electrophysiological study of Drosophila rhodopsin mutants. J. 
Gen. Physiol. 88: 651–73. 
JONES C. A., CHESSELL I. P., SIMON J., BARNARD E. A., MILLER K. J., MICHEL A. D., HUMPHREY P. P., 2000 
Functional characterization of the P2X(4) receptor orthologues. Br. J. Pharmacol. 129: 
388–94. 
JONES C. A., VIAL C., SELLERS L. A., HUMPHREY P. P. A., EVANS R. J., CHESSELL I. P., 2004 Functional 
regulation of P2X6 receptors by N-linked glycosylation: identification of a novel alpha 
beta-methylene ATP-sensitive phenotype. Mol. Pharmacol. 65: 979–85. 
JONES S., EVANS R. J., MAHAUT-SMITH M. P., 2014 Ca2+ influx through P2X1 receptors amplifies 
P2Y1 receptor-evoked Ca2+ signaling and ADP-evoked platelet aggregation. Mol. 
Pharmacol. 86: 243–51. 
JUNG K.-Y., MOON H. D., LEE G. E., LIM H.-H., PARK C.-S., KIM Y.-C., 2007 Structure-activity 
relationship studies of spinorphin as a potent and selective human P2X(3) receptor 
antagonist. J. Med. Chem. 50: 4543–7. 
KACZMAREK-HÁJEK K., LÖRINCZI E., HAUSMANN R., NICKE A., 2012 Molecular and functional 
properties of P2X receptors--recent progress and persisting challenges. Purinergic Signal. 
8: 375–417. 
KAIN P., BADSHA F., HUSSAIN S. M., NAIR A., HASAN G., RODRIGUES V., 2010 Mutants in phospholipid 
signaling attenuate the behavioral response of adult Drosophila to trehalose. Chem. 
Senses 35: 663–73. 
KALIPATNAPU S., CHATTOPADHYAY A., 2005 Membrane protein solubilization: recent advances and 
challenges in solubilization of serotonin1A receptors. IUBMB Life 57: 505–12. 
KARAKAS E., FURUKAWA H., 2014 Crystal structure of a heterotetrameric NMDA receptor ion 
channel. Science 344: 992–7. 
KASLOW D. C., SHILOACH J., 1994 Production, purification and immunogenicity of a malaria 
transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using 
nickel-NTA agarose. Biotechnology. (N. Y). 12: 494–9. 
KATOH T., TIEMEYER M., 2013 The N’s and O's of Drosophila glycoprotein glycobiology. 
Glycoconj. J. 30: 57–66. 
239 
 
 
KAWATE T., MICHEL J. C., BIRDSONG W. T., GOUAUX E., 2009 Crystal structure of the ATP-gated 
P2X(4) ion channel in the closed state. Nature 460: 592–8. 
KEFALA G., KWIATKOWSKI W., ESQUIVIES L., MASLENNIKOV I., CHOE S., 2007 Application of Mistic to 
improving the expression and membrane integration of histidine kinase receptors from 
Escherichia coli. J. Struct. Funct. Genomics 8: 167–72. 
KEW J., DAVIES C., 2010 Ion Channels: From Structure to Function. Oxford University Press. 
KHAKH B. S., BURNSTOCK G., KENNEDY C., KING B. F., NORTH R. A., SÉGUÉLA P., VOIGT M., HUMPHREY P. 
P., 2001a International union of pharmacology. XXIV. Current status of the nomenclature 
and properties of P2X receptors and their subunits. Pharmacol. Rev. 53: 107–18. 
KHAKH B. S., SMITH W. B., CHIU C. S., JU D., DAVIDSON N., LESTER H. A., 2001b Activation-
dependent changes in receptor distribution and dendritic morphology in hippocampal 
neurons expressing P2X2-green fluorescent protein receptors. Proc. Natl. Acad. Sci. U. S. 
A. 98: 5288–93. 
KHAKH B. S., NORTH R. A., 2006 P2X receptors as cell-surface ATP sensors in health and disease. 
Nature 442: 527–32. 
KING B. F., WILDMAN S. S., ZIGANSHINA L. E., PINTOR J., BURNSTOCK G., 1997 Effects of extracellular 
pH on agonism and antagonism at a recombinant P2X2 receptor. Br. J. Pharmacol. 121: 
1445–53. 
KING B. F., LIU M., PINTOR J., GUALIX J., MIRAS-PORTUGAL M. T., BURNSTOCK G., 1999 Diinosine 
pentaphosphate (IP5I) is a potent antagonist at recombinant rat P2X1 receptors. Br. J. 
Pharmacol. 128: 981–8. 
KLAPPERSTÜCK M., BÜTTNER C., NICKEL P., SCHMALZING G., LAMBRECHT G., MARKWARDT F., 2000 
Antagonism by the suramin analogue NF279 on human P2X(1) and P2X(7) receptors. Eur. 
J. Pharmacol. 387: 245–52. 
KOTNIS S., BINGHAM B., VASILYEV D. V, MILLER S. W., BAI Y., YEOLA S., CHANDA P. K., BOWLBY M. R., 
KAFTAN E. J., SAMAD T. A., WHITESIDE G. T., 2010 Genetic and functional analysis of human 
P2X5 reveals a distinct pattern of exon 10 polymorphism with predominant expression of 
the nonfunctional receptor isoform. Mol. Pharmacol. 77: 953–60. 
KOTO M., TANOUYE M. A., FERRUS A., THOMAS J. B., WYMAN R. J., 1981 The morphology of the 
cervical giant fiber neuron of Drosophila. Brain Res. 221: 213–7. 
KRACUN S., CHAPTAL V., ABRAMSON J., KHAKH B. S., 2010 Gated access to the pore of a P2X 
receptor: structural implications for closed-open transitions. J. Biol. Chem. 285: 10110–
21. 
KRAMER J. M., STAVELEY B. E., 2003 GAL4 causes developmental defects and apoptosis when 
expressed in the developing eye of Drosophila melanogaster. Genet. Mol. Res. 2: 43–7. 
KUCENAS S., LI Z., COX J. A., EGAN T. M., VOIGT M. M., 2003 Molecular characterization of the 
zebrafish P2X receptor subunit gene family. Neuroscience 121: 935–45. 
240 
 
 
KUMAR J. P., READY D. F., 1995 Rhodopsin plays an essential structural role in Drosophila 
photoreceptor development. Development 121: 4359–70. 
KUUSINEN A., ARVOLA M., OKER-BLOM C., KEINÄNEN K., 1995 Purification of recombinant GluR-D 
glutamate receptor produced in Sf21 insect cells. Eur. J. Biochem. 233: 720–6. 
LABASI J. M., PETRUSHOVA N., DONOVAN C., MCCURDY S., LIRA P., PAYETTE M. M., BRISSETTE W., WICKS 
J. R., AUDOLY L., GABEL C. A., 2002 Absence of the P2X7 receptor alters leukocyte function 
and attenuates an inflammatory response. J. Immunol. 168: 6436–45. 
LAMBRECHT G., FRIEBE T., GRIMM U., WINDSCHEIF U., BUNGARDT E., HILDEBRANDT C., BÄUMERT H. G., 
SPATZ-KÜMBEL G., MUTSCHLER E., 1992 PPADS, a novel functionally selective antagonist of 
P2 purinoceptor-mediated responses. Eur. J. Pharmacol. 217: 217–9. 
LAMPING E., MONK B. C., NIIMI K., HOLMES A. R., TSAO S., TANABE K., NIIMI M., UEHARA Y., CANNON R. 
D., 2007 Characterization of three classes of membrane proteins involved in fungal azole 
resistance by functional hyperexpression in Saccharomyces cerevisiae. Eukaryot. Cell 6: 
1150–65. 
LAUGHON A., GESTELAND R. F., 1984 Primary structure of the Saccharomyces cerevisiae GAL4 
gene. Mol. Cell. Biol. 4: 260–7. 
LÊ K. T., PAQUET M., NOUEL D., BABINSKI K., SÉGUÉLA P., 1997 Primary structure and expression of 
a naturally truncated human P2X ATP receptor subunit from brain and immune system. 
FEBS Lett. 418: 195–9. 
LEBON G., WARNE T., EDWARDS P. C., BENNETT K., LANGMEAD C. J., LESLIE A. G. W., TATE C. G., 2011 
Agonist-bound adenosine A2A receptor structures reveal common features of GPCR 
activation. Nature 474: 521–5. 
LECKER S. H., GOLDBERG A. L., MITCH W. E., 2006 Protein degradation by the ubiquitin-
proteasome pathway in normal and disease states. J. Am. Soc. Nephrol. 17: 1807–19. 
LEDERKREMER G. Z., 2009 Glycoprotein folding, quality control and ER-associated degradation. 
Curr. Opin. Struct. Biol. 19: 515–23. 
LEE Y., MOON S. J., MONTELL C., 2009 Multiple gustatory receptors required for the caffeine 
response in Drosophila. Proc. Natl. Acad. Sci. U. S. A. 106: 4495–500. 
LEE C.-H., LÜ W., MICHEL J. C., GOEHRING A., DU J., SONG X., GOUAUX E., 2014 NMDA receptor 
structures reveal subunit arrangement and pore architecture. Nature 511: 191–197. 
LEMMON M. A., SCHLESSINGER J., 2010 Cell signaling by receptor tyrosine kinases. Cell 141: 1117–
34. 
LENERTZ L. Y., WANG Z., GUADARRAMA A., HILL L. M., GAVALA M. L., BERTICS P. J., 2010 Mutation of 
putative N-linked glycosylation sites on the human nucleotide receptor P2X7 reveals a 
key residue important for receptor function. Biochemistry 49: 4611–9. 
241 
 
 
LEWIS C., NEIDHART S., HOLY C., NORTH R. A., BUELL G., SURPRENANT A., 1995 Coexpression of P2X2 
and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons. 
Nature 377: 432–5. 
LEWIS C. J., EVANS R. J., 2000 Lack of run-down of smooth muscle P2X receptor currents 
recorded with the amphotericin permeabilized patch technique, physiological and 
pharmacological characterization of the properties of mesenteric artery P2X receptor ion 
channels. Br. J. Pharmacol. 131: 1659–66. 
LI F., GUO N., MA Y., NING B., WANG Y., KOU L., 2014 Inhibition of P2X4 suppresses joint 
inflammation and damage in collagen-induced arthritis. Inflammation 37: 146–53. 
LIAO M., CAO E., JULIUS D., CHENG Y., 2013 Structure of the TRPV1 ion channel determined by 
electron cryo-microscopy. Nature 504: 107–12. 
LIAO M., CAO E., JULIUS D., CHENG Y., 2014 Single particle electron cryo-microscopy of a 
mammalian ion channel. Curr. Opin. Struct. Biol. 27C: 1–7. 
LICHTY J. J., MALECKI J. L., AGNEW H. D., MICHELSON-HOROWITZ D. J., TAN S., 2005 Comparison of 
affinity tags for protein purification. Protein Expr. Purif. 41: 98–105. 
LIMA S. Q., MIESENBÖCK G., 2005 Remote control of behavior through genetically targeted 
photostimulation of neurons. Cell 121: 141–52. 
LIN D. M., GOODMAN C. S., 1994 Ectopic and increased expression of Fasciclin II alters 
motoneuron growth cone guidance. Neuron 13: 507–23. 
LIU M., KING B. F., DUNN P. M., RONG W., TOWNSEND-NICHOLSON A., BURNSTOCK G., 2001 
Coexpression of P2X(3) and P2X(2) receptor subunits in varying amounts generates 
heterogeneous populations of P2X receptors that evoke a spectrum of agonist responses 
comparable to that seen in sensory neurons. J. Pharmacol. Exp. Ther. 296: 1043–50. 
LODISH H., BERK A., ZIPURSKY S. L., MATSUDAIRA P., BALTIMORE D., DARNELL J., 2000 Membrane 
Proteins. 
LOHMAN A. W., WEAVER J. L., BILLAUD M., SANDILOS J. K., GRIFFITHS R., STRAUB A. C., PENUELA S., 
LEITINGER N., LAIRD D. W., BAYLISS D. A., ISAKSON B. E., 2012 S-nitrosylation inhibits pannexin 
1 channel function. J. Biol. Chem. 287: 39602–12. 
LU M., FU D., 2007 Structure of the zinc transporter YiiP. Science 317: 1746–8. 
LUCAE S., SALYAKINA D., BARDEN N., HARVEY M., GAGNÉ B., LABBÉ M., BINDER E. B., UHR M., PAEZ-
PEREDA M., SILLABER I., ISING M., BRÜCKL T., LIEB R., HOLSBOER F., MÜLLER-MYHSOK B., 2006 
P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major 
depressive disorder. Hum. Mol. Genet. 15: 2438–45. 
LYNCH K. J., TOUMA E., NIFORATOS W., KAGE K. L., BURGARD E. C., BIESEN T. VAN, KOWALUK E. A., 
JARVIS M. F., 1999 Molecular and functional characterization of human P2X(2) receptors. 
Mol. Pharmacol. 56: 1171–81. 
242 
 
 
MA J., YOSHIMURA M., YAMASHITA E., NAKAGAWA A., ITO A., TSUKIHARA T., 2004 Structure of rat 
monoamine oxidase A and its specific recognitions for substrates and inhibitors. J. Mol. 
Biol. 338: 103–14. 
MA W., HUI H., PELEGRIN P., SURPRENANT A., 2009 Pharmacological characterization of pannexin-
1 currents expressed in mammalian cells. J. Pharmacol. Exp. Ther. 328: 409–18. 
MACAULEY-PATRICK S., FAZENDA M. L., MCNEIL B., HARVEY L. M., 2005 Heterologous protein 
production using the Pichia pastoris expression system. Yeast 22: 249–70. 
MAEDA S., NAKAGAWA S., SUGA M., YAMASHITA E., OSHIMA A., FUJIYOSHI Y., TSUKIHARA T., 2009 
Structure of the connexin 26 gap junction channel at 3.5 A resolution. Nature 458: 597–
602. 
MAHAUT-SMITH M. P., JONES S., EVANS R. J., 2011 The P2X1 receptor and platelet function. 
Purinergic Signal. 7: 341–56. 
MALEY F., TRIMBLE R. B., TARENTINO A. L., PLUMMER T. H., 1989 Characterization of glycoproteins 
and their associated oligosaccharides through the use of endoglycosidases. Anal. 
Biochem. 180: 195–204. 
MANDAL S., MOUDGIL M., MANDAL S. K., 2009 Rational drug design. Eur. J. Pharmacol. 625: 90–
100. 
MARKSTEIN M., PITSOULI C., VILLALTA C., CELNIKER S. E., PERRIMON N., 2008 Exploiting position 
effects and the gypsy retrovirus insulator to engineer precisely expressed transgenes. 
Nat. Genet. 40: 476–83. 
MARQUEZ-KLAKA B., RETTINGER J., BHARGAVA Y., EISELE T., NICKE A., 2007 Identification of an 
intersubunit cross-link between substituted cysteine residues located in the putative ATP 
binding site of the P2X1 receptor. J. Neurosci. 27: 1456–66. 
MARQUEZ-KLAKA B., RETTINGER J., NICKE A., 2009 Inter-subunit disulfide cross-linking in 
homomeric and heteromeric P2X receptors. Eur. Biophys. J. 38: 329–38. 
MARUYAMA T., KANAJI T., NAKADE S., KANNO T., MIKOSHIBA K., 1997 2APB, 2-aminoethoxydiphenyl 
borate, a membrane-penetrable modulator of Ins(1,4,5)P3-induced Ca2+ release. J. 
Biochem. 122: 498–505. 
MASLENNIKOV I., KLAMMT C., HWANG E., KEFALA G., OKAMURA M., ESQUIVIES L., MÖRS K., GLAUBITZ C., 
KWIATKOWSKI W., JEON Y. H., CHOE S., 2010 Membrane domain structures of three classes 
of histidine kinase receptors by cell-free expression and rapid NMR analysis. Proc. Natl. 
Acad. Sci. U. S. A. 107: 10902–7. 
MIGITA K., HAINES W. R., VOIGT M. M., EGAN T. M., 2001 Polar residues of the second 
transmembrane domain influence cation permeability of the ATP-gated P2X(2) receptor. 
J. Biol. Chem. 276: 30934–41. 
MILLER P. S., ARICESCU A. R., 2014 Crystal structure of a human GABAA receptor. Nature 512: 
270–275. 
243 
 
 
MINSKAIA E., RYAN M. D., 2013 Protein coexpression using FMDV 2A: effect of “linker” residues. 
Biomed Res. Int. 2013: 291730. 
MIO K., KUBO Y., OGURA T., YAMAMOTO T., SATO C., 2005 Visualization of the trimeric P2X2 
receptor with a crown-capped extracellular domain. Biochem. Biophys. Res. Commun. 
337: 998–1005. 
MIO K., OGURA T., YAMAMOTO T., HIROAKI Y., FUJIYOSHI Y., KUBO Y., SATO C., 2009 Reconstruction of 
the P2X(2) receptor reveals a vase-shaped structure with lateral tunnels above the 
membrane. Structure 17: 266–75. 
MIROUX B., WALKER J. E., 1996 Over-production of proteins in Escherichia coli: mutant hosts that 
allow synthesis of some membrane proteins and globular proteins at high levels. J. Mol. 
Biol. 260: 289–98. 
MIRZABEKOV T., BANNERT N., FARZAN M., HOFMANN W., KOLCHINSKY P., WU L., WYATT R., SODROSKI J., 
1999 Enhanced expression, native purification, and characterization of CCR5, a principal 
HIV-1 coreceptor. J. Biol. Chem. 274: 28745–50. 
MITCHELL B. K., ITAGAKI H., RIVET M. P., 1999 Peripheral and central structures involved in insect 
gustation. Microsc. Res. Tech. 47: 401–15. 
MOHANTY A. K., WIENER M. C., 2004 Membrane protein expression and production: effects of 
polyhistidine tag length and position. Protein Expr. Purif. 33: 311–25. 
MONTELL C., 2009 A taste of the Drosophila gustatory receptors. Curr Opin Neurobiol 19: 345–
353. 
MOREMEN K. W., TIEMEYER M., NAIRN A. V, 2012 Vertebrate protein glycosylation: diversity, 
synthesis and function. Nat. Rev. Mol. Cell Biol. 13: 448–62. 
MORTH J. P., PEDERSEN B. P., TOUSTRUP-JENSEN M. S., SØRENSEN T. L.-M., PETERSEN J., ANDERSEN J. P., 
VILSEN B., NISSEN P., 2007 Crystal structure of the sodium-potassium pump. Nature 450: 
1043–9. 
MÜLLER B. A., 2009 Imatinib and its successors--how modern chemistry has changed drug 
development. Curr. Pharm. Des. 15: 120–33. 
MULRYAN K., GITTERMAN D. P., LEWIS C. J., VIAL C., LECKIE B. J., COBB A. L., BROWN J. E., CONLEY E. C., 
BUELL G., PRITCHARD C. A., EVANS R. J., 2000 Reduced vas deferens contraction and male 
infertility in mice lacking P2X1 receptors. Nature 403: 86–9. 
MURGIA M., HANAU S., PIZZO P., RIPPA M., VIRGILIO F. DI, 1993 Oxidized ATP. An irreversible 
inhibitor of the macrophage purinergic P2Z receptor. J. Biol. Chem. 268: 8199–203. 
MUS-VETEAU I., 2010 Heterologous expression of membrane proteins for structural analysis. 
Methods Mol. Biol. 601: 1–16. 
NAGAE M., YAMAGUCHI Y., 2012 Function and 3D Structure of the N-Glycans on Glycoproteins. 
Int. J. Mol. Sci. 13: 8398–429. 
244 
 
 
NEER E. J., 1995 Heterotrimeric C proteins: Organizers of transmembrane signals. Cell 80: 249–
257. 
NELSON D. W., GREGG R. J., KORT M. E., PEREZ-MEDRANO A., VOIGHT E. A., WANG Y., GRAYSON G., 
NAMOVIC M. T., DONNELLY-ROBERTS D. L., NIFORATOS W., HONORE P., JARVIS M. F., FALTYNEK C. 
R., CARROLL W. A., 2006 Structure-activity relationship studies on a series of novel, 
substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. J. Med. Chem. 49: 3659–66. 
NEWBOLT A., STOOP R., VIRGINIO C., SURPRENANT A., NORTH R. A., BUELL G., RASSENDREN F., 1998 
Membrane topology of an ATP-gated ion channel (P2X receptor). J. Biol. Chem. 273: 
15177–82. 
NEWSTEAD S., KIM H., HEIJNE G. VON, IWATA S., DREW D., 2007 High-throughput fluorescent-based 
optimization of eukaryotic membrane protein overexpression and purification in 
Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U. S. A. 104: 13936–41. 
NÖRENBERG W., ILLES P., 2000 Neuronal P2X receptors: localisation and functional properties. 
Naunyn. Schmiedebergs. Arch. Pharmacol. 362: 324–39. 
NORTH R. A., 2002 Molecular physiology of P2X receptors. Physiol. Rev. 82: 1013–67. 
NORTH R. A., JARVIS M. F., 2013 P2X receptors as drug targets. Mol. Pharmacol. 83: 759–69. 
ORMOND S. J., BARRERA N. P., QURESHI O. S., HENDERSON R. M., EDWARDSON J. M., MURRELL-LAGNADO 
R. D., 2006 An uncharged region within the N terminus of the P2X6 receptor inhibits its 
assembly and exit from the endoplasmic reticulum. Mol. Pharmacol. 69: 1692–700. 
OTT C. M., LINGAPPA V. R., 2002 Integral membrane protein biosynthesis: why topology is hard 
to predict. J. Cell Sci. 115: 2003–9. 
PALCZEWSKI K., KUMASAKA T., HORI T., BEHNKE C. A., MOTOSHIMA H., FOX B. A., TRONG I. LE, TELLER D. 
C., OKADA T., STENKAMP R. E., YAMAMOTO M., MIYANO M., 2000 Crystal structure of 
rhodopsin: A G protein-coupled receptor. Science 289: 739–45. 
PALCZEWSKI K., 2006 G protein-coupled receptor rhodopsin. Annu. Rev. Biochem. 75: 743–67. 
PALMER E., FREEMAN T., 2004 Investigation into the use of C- and N-terminal GFP fusion proteins 
for subcellular localization studies using reverse transfection microarrays. Comp. Funct. 
Genomics 5: 342–53. 
PALMER I., WINGFIELD P. T., 2004 Preparation and extraction of insoluble (inclusion-body) 
proteins from Escherichia coli. Curr. Protoc. Protein Sci. Chapter 6: Unit 6.3. 
PANCHIN Y., KELMANSON I., MATZ M., LUKYANOV K., USMAN N., LUKYANOV S., 2000 A ubiquitous 
family of putative gap junction molecules. Curr Biol 10: R473–4. 
PANNEELS V., KOCK I., KRIJNSE-LOCKER J., REZGAOUI M., SINNING I., 2011 Drosophila photoreceptor 
cells exploited for the production of eukaryotic membrane proteins: receptors, 
transporters and channels. PLoS One 6: e18478. 
245 
 
 
PEDERSEN B. P., BUCH-PEDERSEN M. J., MORTH J. P., PALMGREN M. G., NISSEN P., 2007 Crystal 
structure of the plasma membrane proton pump. Nature 450: 1111–4. 
PELEGRIN P., SURPRENANT A., 2006 Pannexin-1 mediates large pore formation and interleukin-
1beta release by the ATP-gated P2X7 receptor. EMBO J 25: 5071–5082. 
PELEGRIN P., SURPRENANT A., 2007 Pannexin-1 couples to maitotoxin- and nigericin-induced 
interleukin-1beta release through a dye uptake-independent pathway. J. Biol. Chem. 282: 
2386–94. 
PELEGRIN P., SURPRENANT A., 2009 The P2X(7) receptor-pannexin connection to dye uptake and 
IL-1beta release. Purinergic Signal 5: 129–137. 
PENUELA S., BHALLA R., GONG X.-Q., COWAN K. N., CELETTI S. J., COWAN B. J., BAI D., SHAO Q., LAIRD 
D. W., 2007 Pannexin 1 and pannexin 3 are glycoproteins that exhibit many distinct 
characteristics from the connexin family of gap junction proteins. J. Cell Sci. 120: 3772–
83. 
PENUELA S., BHALLA R., NAG K., LAIRD D. W., 2009 Glycosylation regulates pannexin intermixing 
and cellular localization. Mol Biol Cell 20: 4313–4323. 
PENUELA S., GEHI R., LAIRD D. W., 2012 The biochemistry and function of pannexin channels. 
Biochim Biophys Acta 1828: 15–22. 
PENUELA S., GEHI R., LAIRD D. W., 2013 The biochemistry and function of pannexin channels. 
Biochim. Biophys. Acta 1828: 15–22. 
PFEIFFER B. D., NGO T.-T. B., HIBBARD K. L., MURPHY C., JENETT A., TRUMAN J. W., RUBIN G. M., 2010 
Refinement of tools for targeted gene expression in Drosophila. Genetics 186: 735–55. 
PICHAUD F., DESPLAN C., 2001 A new visualization approach for identifying mutations that affect 
differentiation and organization of the Drosophila ommatidia. Development 128: 815–26. 
PIERRE SE, PONTING L, STEFANCSIK R M. P. ST., 2014 FlyBase 102 - advanced approaches to 
interrogating FlyBase. Nucleic Acids Res. 42(D1)D780-D788. 
PINTOR J., KING B. F., MIRAS-PORTUGAL M. T., BURNSTOCK G., 1996 Selectivity and activity of 
adenine dinucleotides at recombinant P2X2 and P2Y1 purinoceptors. Br. J. Pharmacol. 
119: 1006–12. 
PRIVÉ G. G., 2007 Detergents for the stabilization and crystallization of membrane proteins. 
Methods 41: 388–97. 
QURESHI O. S., PARAMASIVAM A., YU J. C. H., MURRELL-LAGNADO R. D., 2007 Regulation of P2X4 
receptors by lysosomal targeting, glycan protection and exocytosis. J. Cell Sci. 120: 3838–
49. 
RADFORD K. M., VIRGINIO C., SURPRENANT A., NORTH R. A., KAWASHIMA E., 1997 Baculovirus 
expression provides direct evidence for heteromeric assembly of P2X2 and P2X3 
receptors. J. Neurosci. 17: 6529–33. 
246 
 
 
RALEVIC V., BURNSTOCK G., 1998 Receptors for purines and pyrimidines. Pharmacol. Rev. 50: 
413–92. 
RAMAN P., CHEREZOV V., CAFFREY M., 2006 The Membrane Protein Data Bank. Cell. Mol. Life Sci. 
63: 36–51. 
RAMJEESINGH M., HUAN L. J., GARAMI E., BEAR C. E., 1999 Novel method for evaluation of the 
oligomeric structure of membrane proteins. Biochem. J. 342 ( Pt 1: 119–23. 
RASSENDREN F., BUELL G., NEWBOLT A., NORTH R. A., SURPRENANT A., 1997 Identification of amino 
acid residues contributing to the pore of a P2X receptor. EMBO J. 16: 3446–54. 
RECKEL S., SOBHANIFAR S., DURST F., LÖHR F., SHIROKOV V. A., DÖTSCH V., BERNHARD F., 2010 
Strategies for the cell-free expression of membrane proteins. Methods Mol. Biol. 607: 
187–212. 
REES D. C., DEANTONIO L., EISENBERG D., 1989 Hydrophobic organization of membrane proteins. 
Science 245: 510–3. 
REITER L. T., POTOCKI L., CHIEN S., GRIBSKOV M., BIER E., 2001 A systematic analysis of human 
disease-associated gene sequences in Drosophila melanogaster. Genome Res. 11: 1114–
25. 
RENDIĆ D., WILSON I. B. H., PASCHINGER K., 2008 The Glycosylation Capacity of Insect Cells. Croat. 
Chem. Acta 81: 7–21. 
RETTINGER J., SCHMALZING G., DAMER S., MÜLLER G., NICKEL P., LAMBRECHT G., 2000a The suramin 
analogue NF279 is a novel and potent antagonist selective for the P2X1 receptor. 
Neuropharmacology 39: 2044–2053. 
RETTINGER J., ASCHRAFI A., SCHMALZING G., 2000b  Roles of individual N-glycans for ATP potency 
and expression of the rat P2X1 receptor. J. Biol. Chem. 275: 33542–7. 
RETTINGER J., BRAUN K., HOCHMANN H., KASSACK M. U., ULLMANN H., NICKEL P., SCHMALZING G., 
LAMBRECHT G., 2005 Profiling at recombinant homomeric and heteromeric rat P2X 
receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor 
antagonist. Neuropharmacology 48: 461–8. 
RICHARDS S., LIU Y., BETTENCOURT B. R., HRADECKY P., LETOVSKY S., NIELSEN R., THORNTON K., HUBISZ 
M. J., CHEN R., MEISEL R. P., COURONNE O., HUA S., SMITH M. A., ZHANG P., LIU J., BUSSEMAKER 
H. J., BATENBURG M. F. VAN, HOWELLS S. L., SCHERER S. E., SODERGREN E., MATTHEWS B. B., 
CROSBY M. A., SCHROEDER A. J., ORTIZ-BARRIENTOS D., RIVES C. M., METZKER M. L., MUZNY D. 
M., SCOTT G., STEFFEN D., WHEELER D. A., WORLEY K. C., HAVLAK P., DURBIN K. J., EGAN A., GILL 
R., HUME J., MORGAN M. B., MINER G., HAMILTON C., HUANG Y., WALDRON L., VERDUZCO D., 
CLERC-BLANKENBURG K. P., DUBCHAK I., NOOR M. A. F., ANDERSON W., WHITE K. P., CLARK A. G., 
SCHAEFFER S. W., GELBART W., WEINSTOCK G. M., GIBBS R. A., 2005 Comparative genome 
sequencing of Drosophila pseudoobscura: chromosomal, gene, and cis-element 
evolution. Genome Res. 15: 1–18. 
247 
 
 
ROBERTS J. A., EVANS R. J., 2007 Cysteine substitution mutants give structural insight and identify 
ATP binding and activation sites at P2X receptors. J. Neurosci. 27: 4072–82. 
ROBERTS J. A., DIGBY H. R., KARA M., AJOUZ S. EL, SUTCLIFFE M. J., EVANS R. J., 2008 Cysteine 
substitution mutagenesis and the effects of methanethiosulfonate reagents at P2X2 and 
P2X4 receptors support a core common mode of ATP action at P2X receptors. J. Biol. 
Chem. 283: 20126–36. 
ROBERTSON H. M., WARR C. G., CARLSON J. R., 2003 Molecular evolution of the insect 
chemoreceptor gene superfamily in Drosophila melanogaster. Proc Natl Acad Sci U S A 
100 Suppl : 14537–14542. 
ROBINSON L. E., MURRELL-LAGNADO R. D., 2013 The trafficking and targeting of P2X receptors. 
Front Cell Neurosci 7: 233. 
ROGER S., MEI Z.-Z., BALDWIN J. M., DONG L., BRADLEY H., BALDWIN S. A., SURPRENANT A., JIANG L.-H., 
2010 Single nucleotide polymorphisms that were identified in affective mood disorders 
affect ATP-activated P2X7 receptor functions. J. Psychiatr. Res. 44: 347–55. 
ROLF M. G., BREARLEY C. A., MAHAUT-SMITH M. P., 2001 Platelet shape change evoked by 
selective activation of P2X1 purinoceptors with alpha,beta-methylene ATP. Thromb. 
Haemost. 85: 303–8. 
ROMANOV R. A., BYSTROVA M. F., ROGACHEVSKAYA O. A., SADOVNIKOV V. B., SHESTOPALOV V. I., 
KOLESNIKOV S. S., 2012 The ATP permeability of pannexin 1 channels in a heterologous 
system and in mammalian taste cells is dispensable. J. Cell Sci. 125: 5514–23. 
ROOSILD T. P., GREENWALD J., VEGA M., CASTRONOVO S., RIEK R., CHOE S., 2005 NMR structure of 
Mistic, a membrane-integrating protein for membrane protein expression. Science 307: 
1317–21. 
ROYLE S. J., BOBANOVIĆ L. K., MURRELL-LAGNADO R. D., 2002 Identification of a non-canonical 
tyrosine-based endocytic motif in an ionotropic receptor. J. Biol. Chem. 277: 35378–85. 
ROYLE S. J., QURESHI O. S., BOBANOVIĆ L. K., EVANS P. R., OWEN D. J., MURRELL-LAGNADO R. D., 2005 
Non-canonical YXXGPhi endocytic motifs: recognition by AP2 and preferential utilization 
in P2X4 receptors. J. Cell Sci. 118: 3073–80. 
RUBIO M. E., SOTO F., 2001 Distinct Localization of P2X receptors at excitatory postsynaptic 
specializations. J. Neurosci. 21: 641–53. 
SAMWAYS D. S. K., KHAKH B. S., DUTERTRE S., EGAN T. M., 2011 Preferential use of unobstructed 
lateral portals as the access route to the pore of human ATP-gated ion channels (P2X 
receptors). Proc. Natl. Acad. Sci. U. S. A. 108: 13800–5. 
SAMWAYS D. S. K., KHAKH B. S., EGAN T. M., 2012 Allosteric modulation of Ca2+ flux in ligand-
gated cation channel (P2X4) by actions on lateral portals. J. Biol. Chem. 287: 7594–602. 
SANDILOS J. K., BAYLISS D. A., 2012 Physiological mechanisms for the modulation of pannexin 1 
channel activity. J. Physiol. 590: 6257–66. 
248 
 
 
SANZ J. M., CHIOZZI P., FERRARI D., COLAIANNA M., IDZKO M., FALZONI S., FELLIN R., TRABACE L., 
VIRGILIO F. DI, 2009 Activation of microglia by amyloid {beta} requires P2X7 receptor 
expression. J. Immunol. 182: 4378–85. 
SATO K., PELLEGRINO M., NAKAGAWA T., NAKAGAWA T., VOSSHALL L. B., TOUHARA K., 2008 Insect 
olfactory receptors are heteromeric ligand-gated ion channels. Nature 452: 1002–6. 
SATO K., TANAKA K., TOUHARA K., 2011 Sugar-regulated cation channel formed by an insect 
gustatory receptor. Proc. Natl. Acad. Sci. U. S. A. 108: 11680–5. 
SCHMIDT T. G., SKERRA A., 1994 One-step affinity purification of bacterially produced proteins by 
means of the “Strep tag” and immobilized recombinant core streptavidin. J. Chromatogr. 
A 676: 337–45. 
SCHWEISGUTH F., NERO P., POSAKONY J. W., 1994 The sequence similarity of the Drosophila 
suppressor of hairless protein to the integrase domain has no functional significance in 
vivo. Dev. Biol. 166: 812–4. 
SCOTT K., BRADY R., CRAVCHIK A., MOROZOV P., RZHETSKY A., ZUKER C., AXEL R., 2001 A 
chemosensory gene family encoding candidate gustatory and olfactory receptors in 
Drosophila. Cell 104: 661–73. 
SEDDON A. M., CURNOW P., BOOTH P. J., 2004 Membrane proteins, lipids and detergents: not just 
a soap opera. Biochim. Biophys. Acta 1666: 105–17. 
SELLIER M.-J., REEB P., MARION-POLL F., 2011 Consumption of bitter alkaloids in Drosophila 
melanogaster in multiple-choice test conditions. Chem. Senses 36: 323–34. 
SILVERMAN W. R., RIVERO VACCARI J. P. DE, LOCOVEI S., QIU F., CARLSSON S. K., SCEMES E., KEANE R. W., 
DAHL G., 2009 The pannexin 1 channel activates the inflammasome in neurons and 
astrocytes. J. Biol. Chem. 284: 18143–51. 
SIM J. A., YOUNG M. T., SUNG H.-Y., NORTH R. A., SURPRENANT A., 2004 Reanalysis of P2X7 receptor 
expression in rodent brain. J. Neurosci. 24: 6307–14. 
SKUBE S. B., CHAVERRI J. M., GOODSON H. V, 2010 Effect of GFP tags on the localization of EB1 and 
EB1 fragments in vivo. Cytoskeleton (Hoboken). 67: 1–12. 
SMITH T. M., HICKS-BERGER C. A., KIM S., KIRLEY T. L., 2002 Cloning, expression, and 
characterization of a soluble calcium-activated nucleotidase, a human enzyme belonging 
to a new family of extracellular nucleotidases. Arch. Biochem. Biophys. 406: 105–15. 
SOBOLEVSKY A. I., ROSCONI M. P., GOUAUX E., 2009 X-ray structure, symmetry and mechanism of 
an AMPA-subtype glutamate receptor. Nature 462: 745–56. 
SOTO F., LAMBRECHT G., NICKEL P., STÜHMER W., BUSCH A. E., 1999 Antagonistic properties of the 
suramin analogue NF023 at heterologously expressed P2X receptors. 
Neuropharmacology 38: 141–9. 
249 
 
 
STEVENS T. J., ARKIN I. T., 2000 Do more complex organisms have a greater proportion of 
membrane proteins in their genomes? Proteins 39: 417–20. 
STOCKER R. F., 2004 Taste perception: Drosophila - a model of good taste. Curr Biol 14: R560–1. 
STOKES L., JIANG L.-H., ALCARAZ L., BENT J., BOWERS K., FAGURA M., FURBER M., MORTIMORE M., 
LAWSON M., THEAKER J., LAURENT C., BRADDOCK M., SURPRENANT A., 2006 Characterization of 
a selective and potent antagonist of human P2X(7) receptors, AZ11645373. Br. J. 
Pharmacol. 149: 880–7. 
STOKES L., SCURRAH K., ELLIS J. A., CROMER B. A., SKARRATT K. K., GU B. J., HARRAP S. B., WILEY J. S., 
2011 A loss-of-function polymorphism in the human P2X4 receptor is associated with 
increased pulse pressure. Hypertension 58: 1086–92. 
SURPRENANT A., RASSENDREN F., KAWASHIMA E., NORTH R. A., BUELL G., 1996 The cytolytic P2Z 
receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 272: 735–8. 
SWAYNE L. A., SORBARA C. D., BENNETT S. A., 2010 Pannexin 2 is expressed by postnatal 
hippocampal neural progenitors and modulates neuronal commitment. J Biol Chem 285: 
24977–24986. 
TATE C. G., 2001 Overexpression of mammalian integral membrane proteins for structural 
studies. FEBS Lett. 504: 94–8. 
TAVOULARIS S., SCAZZOCCHIO C., SOPHIANOPOULOU V., 2001 Functional expression and cellular 
localization of a green fluorescent protein-tagged proline transporter in Aspergillus 
nidulans. Fungal Genet. Biol. 33: 115–25. 
TAYLOR A. L., SCHWIEBERT L. M., SMITH J. J., KING C., JONES J. R., SORSCHER E. J., SCHWIEBERT E. M., 
1999 Epithelial P2X purinergic receptor channel expression and function. J. Clin. Invest. 
104: 875–84. 
TERPE K., 2003 Overview of tag protein fusions: from molecular and biochemical fundamentals 
to commercial systems. Appl. Microbiol. Biotechnol. 60: 523–33. 
THORNE N., CHROMEY C., BRAY S., AMREIN H., 2004 Taste perception and coding in Drosophila. 
Curr Biol 14: 1065–1079. 
THORPE H. M., SMITH M. C., 1998 In vitro site-specific integration of bacteriophage DNA 
catalyzed by a recombinase of the resolvase/invertase family. Proc. Natl. Acad. Sci. U. S. 
A. 95: 5505–10. 
TONDI D., POWERS R. A., CASELLI E., NEGRI M. C., BLÁZQUEZ J., COSTI M. P., SHOICHET B. K., 2001 
Structure-based design and in-parallel synthesis of inhibitors of AmpC beta-lactamase. 
Chem. Biol. 8: 593–611. 
TORRES G. E., EGAN T. M., VOIGT M. M., 1998 N-Linked glycosylation is essential for the 
functional expression of the recombinant P2X2 receptor. Biochemistry 37: 14845–51. 
250 
 
 
TOTH-ZSAMBOKI E., OURY C., CORNELISSEN H., VOS R. DE, VERMYLEN J., HOYLAERTS M. F., 2003 P2X1-
mediated ERK2 activation amplifies the collagen-induced platelet secretion by enhancing 
myosin light chain kinase activation. J. Biol. Chem. 278: 46661–7. 
TSUDA M., SHIGEMOTO-MOGAMI Y., KOIZUMI S., MIZOKOSHI A., KOHSAKA S., SALTER M. W., INOUE K., 
2003 P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. 
Nature 424: 778–83. 
UENO K., KOHATSU S., CLAY C., FORTE M., ISONO K., KIDOKORO Y., 2006 Gsalpha is involved in sugar 
perception in Drosophila melanogaster. J. Neurosci. 26: 6143–52. 
UNWIN N., 2005 Refined structure of the nicotinic acetylcholine receptor at 4A resolution. J. 
Mol. Biol. 346: 967–89. 
URSU D., EBERT P., LANGRON E., RUBLE C., MUNSIE L., ZOU W., FIJAL B., QIAN Y.-W., MCNEARNEY T. A., 
MOGG A., GRUBISHA O., MERCHANT K., SHER E., 2014 Gain and loss of function of P2X7 
receptors: mechanisms, pharmacology and relevance to diabetic neuropathic pain. Mol. 
Pain 10: 37. 
VACCA F., GIUSTIZIERI M., CIOTTI M. T., MERCURI N. B., VOLONTÉ C., 2009 Rapid constitutive and 
ligand-activated endocytic trafficking of P2X receptor. J. Neurochem. 109: 1031–41. 
VACCA F., D’AMBROSI N., NESTOLA V., AMADIO S., GIUSTIZIERI M., CUCCHIARONI M. L., TOZZI A., VELLUZ 
M. C., MERCURI N. B., VOLONTÉ C., 2011 N-Glycans mutations rule oligomeric assembly and 
functional expression of P2X3 receptor for extracellular ATP. Glycobiology 21: 634–43. 
VALENTE M., WATTERSON S. J., PARKER M. D., FORD R. C., YOUNG M. T., 2011 Expression, 
purification, electron microscopy, N-glycosylation mutagenesis and molecular modeling 
of human P2X4 and Dictyostelium discoideum P2XA. Biochim. Biophys. Acta 1808: 2859–
66. 
VALERA S., HUSSY N., EVANS R. J., ADAMI N., NORTH R. A., SURPRENANT A., BUELL G., 1994 A new class 
of ligand-gated ion channel defined by P2x receptor for extracellular ATP. Nature 371: 
516–9. 
VIRGILIO F. DI, FERRARI D., ADINOLFI E., 2009 P2X(7): a growth-promoting receptor-implications 
for cancer. Purinergic Signal. 5: 251–6. 
VIRGINIO C., ROBERTSON G., SURPRENANT A., NORTH R. A., 1998 Trinitrophenyl-substituted 
nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 
receptors. Mol. Pharmacol. 53: 969–73. 
VULCHANOVA L., ARVIDSSON U., RIEDL M., WANG J., BUELL G., SURPRENANT A., NORTH R. A., ELDE R., 
1996 Differential distribution of two ATP-gated channels (P2X receptors) determined by 
immunocytochemistry. Proc. Natl. Acad. Sci. U. S. A. 93: 8063–7. 
WADA T., SHIMONO K., KIKUKAWA T., HATO M., SHINYA N., KIM S. Y., KIMURA-SOMEYA T., SHIROUZU M., 
TAMOGAMI J., MIYAUCHI S., JUNG K.-H., KAMO N., YOKOYAMA S., 2011 Crystal structure of the 
eukaryotic light-driven proton-pumping rhodopsin, Acetabularia rhodopsin II, from 
marine alga. J. Mol. Biol. 411: 986–98. 
251 
 
 
WAGNER S., KLEPSCH M. M., SCHLEGEL S., APPEL A., DRAHEIM R., TARRY M., HÖGBOM M., WIJK K. J. 
VAN, SLOTBOOM D. J., PERSSON J. O., GIER J.-W. DE, 2008 Tuning Escherichia coli for 
membrane protein overexpression. Proc. Natl. Acad. Sci. U. S. A. 105: 14371–6. 
WALDRON J. B., SAWYNOK J., 2004 Peripheral P2X receptors and nociception: interactions with 
biogenic amine systems. Pain 110: 79–89. 
WALKER J. E., SARASTE M., RUNSWICK M. J., GAY N. J., 1982 Distantly related sequences in the 
alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring 
enzymes and a common nucleotide binding fold. EMBO J. 1: 945–51. 
WANG Z., SINGHVI A., KONG P., SCOTT K., 2004a Taste representations in the Drosophila brain. 
Cell 117: 981–991. 
WANG Z., SINGHVI A., KONG P., SCOTT K., 2004b Taste representations in the Drosophila brain. 
Cell 117: 981–91. 
WANG H., ELFERICH J., GOUAUX E., 2012 Structures of LeuT in bicelles define conformation and 
substrate binding in a membrane-like context. Nat. Struct. Mol. Biol. 19: 212–9. 
WATANABE T., ITO Y., YAMADA T., HASHIMOTO M., SEKINE S., TANAKA H., 1994 The roles of the C-
terminal domain and type III domains of chitinase A1 from Bacillus circulans WL-12 in 
chitin degradation. J. Bacteriol. 176: 4465–72. 
WEISS L. A., DAHANUKAR A., KWON J. Y., BANERJEE D., CARLSON J. R., 2011 The molecular and 
cellular basis of bitter taste in Drosophila. Neuron 69: 258–72. 
WEN H., EVANS R. J., 2009 Regions of the amino terminus of the P2X receptor required for 
modification by phorbol ester and mGluR1alpha receptors. J. Neurochem. 108: 331–40. 
WEWERS M. D., SARKAR A., 2009 P2X(7) receptor and macrophage function. Purinergic Signal. 5: 
189–95. 
WHITE N., BUTLER P. E. M., BURNSTOCK G., 2005 Human melanomas express functional P2 X(7) 
receptors. Cell Tissue Res. 321: 411–8. 
WHITE N., BURNSTOCK G., 2006 P2 receptors and cancer. Trends Pharmacol. Sci. 27: 211–7. 
WHITE C. W., CHOONG Y.-T., SHORT J. L., EXINTARIS B., MALONE D. T., ALLEN A. M., EVANS R. J., 
VENTURA S., 2013 Male contraception via simultaneous knockout of α1A-adrenoceptors 
and P2X1-purinoceptors in mice. Proc. Natl. Acad. Sci. U. S. A. 110: 20825–30. 
WICHER D., SCHÄFER R., BAUERNFEIND R., STENSMYR M. C., HELLER R., HEINEMANN S. H., HANSSON B. S., 
2008 Drosophila odorant receptors are both ligand-gated and cyclic-nucleotide-activated 
cation channels. Nature 452: 1007–11. 
WICKI-STORDEUR L. E., SWAYNE L. A., 2014 The emerging Pannexin 1 signalome: a new nexus 
revealed? Front. Cell. Neurosci. 7: 287. 
252 
 
 
WILDMAN S. S., BROWN S. G., KING B. F., BURNSTOCK G., 1999 Selectivity of diadenosine 
polyphosphates for rat P2X receptor subunits. Eur. J. Pharmacol. 367: 119–23. 
WILDMAN S. S., BROWN S. G., RAHMAN M., NOEL C. A., CHURCHILL L., BURNSTOCK G., UNWIN R. J., KING 
B. F., 2002 Sensitization by extracellular Ca(2+) of rat P2X(5) receptor and its 
pharmacological properties compared with rat P2X(1). Mol. Pharmacol. 62: 957–66. 
WILKINSON W. J., JIANG L.-H., SURPRENANT A., NORTH R. A., 2006 Role of ectodomain lysines in the 
subunits of the heteromeric P2X2/3 receptor. Mol. Pharmacol. 70: 1159–63. 
WILLEMSEN N. M., HITCHEN E. M., BODETTI T. J., APOLLONI A., WARRILOW D., PILLER S. C., HARRICH D., 
2006 Protein methylation is required to maintain optimal HIV-1 infectivity. Retrovirology 
3: 92. 
WISOTSKY Z., MEDINA A., FREEMAN E., DAHANUKAR A., 2011 Evolutionary differences in food 
preference rely on Gr64e, a receptor for glycerol. Nat. Neurosci. 14: 1534–41. 
WOLF C., ROSEFORT C., FALLAH G., KASSACK M. U., HAMACHER A., BODNAR M., WANG H., ILLES P., KLESS 
A., BAHRENBERG G., SCHMALZING G., HAUSMANN R., 2011 Molecular determinants of potent 
P2X2 antagonism identified by functional analysis, mutagenesis, and homology docking. 
Mol. Pharmacol. 79: 649–61. 
WOOD C., WILLIAMS C., WALDRON G. J., 2004 Patch clamping by numbers. Drug Discov. Today 9: 
434–41. 
WORTHINGTON R. A., SMART M. L., GU B. J., WILLIAMS D. A., PETROU S., WILEY J. S., BARDEN J. A., 
2002 Point mutations confer loss of ATP-induced human P2X(7) receptor function. FEBS 
Lett. 512: 43–6. 
WU J., HOLSTEIN J. D., UPADHYAY G., LIN D.-T., CONWAY S., MULLER E., LECHLEITER J. D., 2007 
Purinergic receptor-stimulated IP3-mediated Ca2+ release enhances neuroprotection by 
increasing astrocyte mitochondrial metabolism during aging. J. Neurosci. 27: 6510–20. 
WUU J. J., SWARTZ J. R., 2008 High yield cell-free production of integral membrane proteins 
without refolding or detergents. Biochim. Biophys. Acta 1778: 1237–50. 
XU G.-Y., HUANG L.-Y. M., 2002 Peripheral inflammation sensitizes P2X receptor-mediated 
responses in rat dorsal root ganglion neurons. J. Neurosci. 22: 93–102. 
YAMAMOTO K., SOKABE T., MATSUMOTO T., YOSHIMURA K., SHIBATA M., OHURA N., FUKUDA T., SATO T., 
SEKINE K., KATO S., ISSHIKI M., FUJITA T., KOBAYASHI M., KAWAMURA K., MASUDA H., KAMIYA A., 
ANDO J., 2006 Impaired flow-dependent control of vascular tone and remodeling in P2X4-
deficient mice. Nat. Med. 12: 133–7. 
YAN D., ZHU Y., WALSH T., XIE D., YUAN H., SIRMACI A., FUJIKAWA T., WONG A. C. Y., LOH T. L., DU L., 
GRATI M., VLAJKOVIC S. M., BLANTON S., RYAN A. F., CHEN Z.-Y., THORNE P. R., KACHAR B., TEKIN 
M., ZHAO H.-B., HOUSLEY G. D., KING M.-C., LIU X. Z., 2013 Mutation of the ATP-gated P2X(2) 
receptor leads to progressive hearing loss and increased susceptibility to noise. Proc. 
Natl. Acad. Sci. U. S. A. 110: 2228–33. 
253 
 
 
YANG C.-H., BELAWAT P., HAFEN E., JAN L. Y., JAN Y.-N., 2008 Drosophila egg-laying site selection 
as a system to study simple decision-making processes. Science 319: 1679–83. 
YAO K. M., WHITE K., 1994 Neural specificity of elav expression: defining a Drosophila promoter 
for directing expression to the nervous system. J. Neurochem. 63: 41–51. 
YAO Z., MACARA A. M., LELITO K. R., MINOSYAN T. Y., SHAFER O. T., 2012 Analysis of functional 
neuronal connectivity in the Drosophila brain. J. Neurophysiol. 108: 684–96. 
YEN M. R., SAIER  JR. M. H., 2007 Gap junctional proteins of animals: the innexin/pannexin 
superfamily. Prog Biophys Mol Biol 94: 5–14. 
YOUNG M. T., ZHANG Y.-H., CAO L., BROOMHEAD H., JIANG L.-H., 2008 Role of the domain 
encompassing Arg304-Ile328 in rat P2X2 receptor conformation revealed by alterations in 
complex glycosylation at Asn298. Biochem. J. 416: 137–43. 
ZEMKOVA H., HE M.-L., KOSHIMIZU T., STOJILKOVIC S. S., 2004 Identification of ectodomain regions 
contributing to gating, deactivation, and resensitization of purinergic P2X receptors. J. 
Neurosci. 24: 6968–78. 
ZEMKOVA H., YAN Z., LIANG Z., JELINKOVA I., TOMIC M., STOJILKOVIC S. S., 2007 Role of aromatic and 
charged ectodomain residues in the P2X(4) receptor functions. J. Neurochem. 102: 1139–
50. 
ZHANG J., YUN J., SHANG Z., ZHANG X., PAN B., 2009 Design and optimization of a linker for fusion 
protein construction. Prog. Nat. Sci. 19: 1197–1200. 
ZHANG J., ZHANG K., GAO Z.-G., PAOLETTA S., ZHANG D., HAN G. W., LI T., MA L., ZHANG W., MÜLLER 
C. E., YANG H., JIANG H., CHEREZOV V., KATRITCH V., JACOBSON K. A., STEVENS R. C., WU B., ZHAO 
Q., 2014 Agonist-bound structure of the human P2Y12 receptor. Nature 509: 119–22. 
ZHAO X., LI G., LIANG S., 2013 Several Affinity Tags Commonly Used in Chromatographic 
Purification. J. Anal. Methods Chem. 2013: 581093. 
ZIMMER M., 2002 Green fluorescent protein (GFP): applications, structure, and related 
photophysical behavior. Chem. Rev. 102: 759–81. 
ZIMMERMANN H., 2000 Extracellular metabolism of ATP and other nucleotides. Naunyn. 
Schmiedebergs. Arch. Pharmacol. 362: 299–309. 
ZUKER C. S., 1996 The biology of vision of Drosophila. Proc. Natl. Acad. Sci. U. S. A. 93: 571–6. 
  
254 
 
 
 
Publications 
Grimes L.M., Young M.T., (2014) Purinergic P2X receptors: structural and functional 
features depicted by X-ray and molecular modelling studies. Curr. Med. Chem. (accepted; in 
press) 
